%autism-novel	autism-known(SFARI)	evidence
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
ACPT	GRIN2B	1-GoPubMed-related-GO->GO:0016595[glutamate binding], 1-FACTA-related-disease->UMLS:C0012734[Disruptive Behavior Disorders],
ACPT	BAIAP2	1-FACTA-related-disease->UMLS:C1263846[Attention Deficit Disorder with Hyperactivity],
ACPT	SYNGAP1	1-FACTA-related-disease->UMLS:C0008074[Child Development Disorders, Pervasive],
ACPT	ALDH5A1	2-GoPubMed-related-disease->mesh:6948[Hyperkinesis],mesh:4832[Epilepsy, Absence],
ACPT	NRCAM	1-FACTA-related-disease->UMLS:C0600104[Compulsive Behavior],
ACPT	NBEA	2-GoPubMed-related-disease->mesh:7806[Language Disorders],mesh:3147[Communication Disorders],
ACPT	APBA2	1-FACTA-related-disease->UMLS:C0008074[Child Development Disorders, Pervasive],
ACPT	FOXP2	3-GoPubMed-related-disease->mesh:7806[Language Disorders],mesh:3147[Communication Disorders],mesh:4410[Dyslexia], 1-FACTA-related-drug->DrugBank:APRD00280[Frontal],
ACPT	NDNL2	2-GoPubMed-related-disease->mesh:7806[Language Disorders],mesh:3147[Communication Disorders],
ACPT	NRXN1	1-GoPubMed-related-disease->mesh:7806[Language Disorders], 1-FACTA-related-disease->UMLS:C0008074[Child Development Disorders, Pervasive],
ACPT	ROBO1	4-GoPubMed-related-disease->mesh:4410[Dyslexia],mesh:7859[Learning Disorders],mesh:7806[Language Disorders],mesh:3147[Communication Disorders],
ACPT	TPH2	1-GoPubMed-related-disease->mesh:6948[Hyperkinesis], 1-FACTA-related-disease->UMLS:C1263846[Attention Deficit Disorder with Hyperactivity], 1-FACTA-related-drug->DrugBank:APRD00280[Frontal],
ACPT	CACNA1G	2-GoPubMed-related-disease->mesh:4832[Epilepsy, Absence],mesh:4829[Epilepsy, Generalized], 1-FACTA-related-drug->DrugBank:EXPT01467[Forskolin],
ACPT	SLC1A1	2-GoPubMed-related-GO->GO:0016595[glutamate binding],GO:0016597[amino acid binding], 2-FACTA-related-disease->UMLS:C0008074[Child Development Disorders, Pervasive],UMLS:C0600104[Compulsive Behavior], 1-FACTA-related-drug->DrugBank:APRD00280[Frontal],
ACPT	HTR7	1-FACTA-related-disease->UMLS:C1263846[Attention Deficit Disorder with Hyperactivity], 1-FACTA-related-drug->DrugBank:APRD00657[Ritalin],
ACPT	DISC1	3-FACTA-related-drug->DrugBank:APRD00280[Frontal],DrugBank:EXPT01467[Forskolin],DrugBank:EXPT00494[Alanine],
ADRA2A	ALDH5A1	1-GoPubMed-related-disease->mesh:6948[Hyperkinesis], 1-FACTA-related-disease->UMLS:C1849843[HPA], 2-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00631[Gel],
ADRA2A	FLT1	3-FACTA-related-drug->DrugBank:EXPT00572[Asn],DrugBank:APRD00174[Clonidine],DrugBank:BIOD00057[Fragment],
ADRA2A	PIK3CG	4-FACTA-related-gene->HUMANGGP:025566[PIK3CG],HUMANGGP:042457[Platelet endothelial aggregation receptor 1],HUMANGGP:035544[MRVI1],HUMANGGP:010542[JMJD1C],
ADRA2A	DAB1	1-GoPubMed-related-disease->mesh:6972[Hypertelorism], 3-FACTA-related-drug->DrugBank:EXPT00572[Asn],DrugBank:BIOD00057[Fragment],DrugBank:APRD00631[Gel],
ADRA2A	KCNJ10	2-FACTA-related-drug->DrugBank:APRD00174[Clonidine],DrugBank:BIOD00057[Fragment],
ADRA2A	EN2	3-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00450[Norepinephrine],DrugBank:APRD00631[Gel],
ADRA2A	TPH2	1-GoPubMed-related-disease->mesh:6948[Hyperkinesis], 1-FACTA-related-disease->UMLS:C1263846[Attention Deficit Disorder with Hyperactivity], 2-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:APRD00450[Norepinephrine],
ADRA2A	GRIN2B	1-GoPubMed-related-disease->mesh:12798[Sialorrhea], 4-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:EXPT00572[Asn],DrugBank:BIOD00057[Fragment],DrugBank:APRD00631[Gel], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
ADRA2A	HTR7	2-GoPubMed-related-GO->GO:0008227[G-protein coupled amine receptor activity],GO:0004930[G-protein coupled receptor activity], 2-FACTA-related-disease->UMLS:C0040517[Tourette Syndrome],UMLS:C1263846[Attention Deficit Disorder with Hyperactivity], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
ADRA2A	DPP6	1-FACTA-related-disease->UMLS:C0751265[learning disability],
ADRA2A	NRXN1	2-GoPubMed-related-disease->mesh:5879[Tourette Syndrome],mesh:13981[Tic Disorders],
ADRA2A	BAIAP2	1-FACTA-related-disease->UMLS:C1263846[Attention Deficit Disorder with Hyperactivity], 1-FACTA-related-drug->DrugBank:APRD00631[Gel],
ADRA2A	EGR2	3-FACTA-related-drug->DrugBank:APRD00674[DEX],DrugBank:APRD00423[Sterol],DrugBank:BIOD00057[Fragment],
ADRA2A	HTR2A	3-GoPubMed-related-GO->GO:0004937[alpha1-adrenergic receptor activity],GO:0008227[G-protein coupled amine receptor activity],GO:0004930[G-protein coupled receptor activity], 1-FACTA-related-gene->HUMANGGP:028713[PAPLN], 1-FACTA-related-disease->UMLS:C0036337[schizoaffective disorder], 3-FACTA-related-drug->DrugBank:APRD00685[Mirtazapine],DrugBank:APRD01072[HCH],DrugBank:BIOD00057[Fragment], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
ADRA2A	HTR1B	1-GoPubMed-related-gene->1816[DRD5], 2-GoPubMed-related-GO->GO:0008227[G-protein coupled amine receptor activity],GO:0004930[G-protein coupled receptor activity], 1-FACTA-related-disease->UMLS:C1263846[Attention Deficit Disorder with Hyperactivity], 3-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:BIOD00057[Fragment],DrugBank:APRD00450[Norepinephrine], 2-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],reactome:REACT_19231[],
ADRA2A	CNTNAP2	2-GoPubMed-related-disease->mesh:5879[Tourette Syndrome],mesh:13981[Tic Disorders], 2-FACTA-related-disease->UMLS:C0454651[specific language impairment],UMLS:C0040517[Tourette Syndrome], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
ADRA2A	IMMP2L	2-GoPubMed-related-disease->mesh:5879[Tourette Syndrome],mesh:13981[Tic Disorders], 2-FACTA-related-disease->UMLS:C0040517[Tourette Syndrome],UMLS:C0751265[learning disability],
ADRA2A	WNT2	1-FACTA-related-disease->UMLS:C0454651[specific language impairment], 2-FACTA-related-drug->DrugBank:EXPT00572[Asn],DrugBank:BIOD00057[Fragment],
ADRA2A	ADRB2	1-GoPubMed-related-disease->mesh:3655[Decerebrate State], 3-FACTA-related-gene->HUMANGGP:039243[ADRA1B],HUMANGGP:011331[ADRA1C],HUMANGGP:016527[SLC8A1], 5-FACTA-related-drug->DrugBank:APRD00674[DEX],DrugBank:APRD01072[HCH],DrugBank:BIOD00057[Fragment],DrugBank:APRD00423[Sterol],DrugBank:EXPT01027[Glycerol],
ADRA2A	DRD3	1-GoPubMed-related-gene->1816[DRD5], 1-FACTA-related-gene->HUMANGGP:011331[ADRA1C], 4-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:BIOD00057[Fragment],DrugBank:APRD00450[Norepinephrine],DrugBank:APRD00631[Gel],
ADRA2A	AUTS2	2-GoPubMed-related-disease->mesh:5879[Tourette Syndrome],mesh:13981[Tic Disorders], 2-FACTA-related-disease->UMLS:C0036337[schizoaffective disorder],UMLS:C0040517[Tourette Syndrome],
ADRA2A	JMJD1C	4-FACTA-related-gene->HUMANGGP:010542[JMJD1C],HUMANGGP:042457[Platelet endothelial aggregation receptor 1],HUMANGGP:035544[MRVI1],HUMANGGP:025566[PIK3CG],
ADRA2A	ITGB3	1-GoPubMed-related-gene->81027[TUBB1], 1-FACTA-related-disease->UMLS:C1849843[HPA], 2-FACTA-related-drug->DrugBank:APRD00669[PFA],DrugBank:BIOD00057[Fragment],
ADRA2C	SLC9A9	1-FACTA-related-gene->HUMANGGP:031659[SLC6A2], 1-FACTA-related-disease->UMLS:C1263846[Attention Deficit Disorder with Hyperactivity], 1-FACTA-related-drug->DrugBank:APRD01072[HCH],
ADRA2C	SLC9A6	2-GoPubMed-related-GO->GO:0004937[alpha1-adrenergic receptor activity],GO:0004936[alpha-adrenergic receptor activity], 1-GoPubMed-related-disease->mesh:2303[Cardiac Output, Low],
ADRA2C	AUTS2	1-GoPubMed-related-gene->2560[GABRB1], 2-GoPubMed-related-disease->mesh:5879[Tourette Syndrome],mesh:13981[Tic Disorders], 1-FACTA-related-gene->HUMANGGP:004123[GABRB1], 1-FACTA-related-disease->UMLS:C0040517[Tourette Syndrome],
ADRA2C	NTRK3	3-FACTA-related-drug->DrugBank:EXPT01467[Forskolin],DrugBank:APRD00340[Reserpine],DrugBank:APRD00450[Norepinephrine],
ADRA2C	NLGN3	2-GoPubMed-related-disease->mesh:19970[Cocaine-Related Disorders],mesh:7859[Learning Disorders],
ADRA2C	GRIN2B	2-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:BIOD00057[Fragment], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
ADRA2C	OXTR	2-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:EXPT01467[Forskolin], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
ADRA2C	TPH2	2-GoPubMed-related-disease->mesh:6948[Hyperkinesis],mesh:19970[Cocaine-Related Disorders], 1-FACTA-related-disease->UMLS:C1263846[Attention Deficit Disorder with Hyperactivity], 2-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:APRD00450[Norepinephrine],
ADRA2C	BAIAP2	1-FACTA-related-disease->UMLS:C1263846[Attention Deficit Disorder with Hyperactivity],
ADRA2C	HTR7	2-GoPubMed-related-GO->GO:0008227[G-protein coupled amine receptor activity],GO:0004930[G-protein coupled receptor activity], 2-FACTA-related-disease->UMLS:C0040517[Tourette Syndrome],UMLS:C1263846[Attention Deficit Disorder with Hyperactivity], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
ADRA2C	IMMP2L	3-GoPubMed-related-disease->mesh:5879[Tourette Syndrome],mesh:13981[Tic Disorders],mesh:20323[Tics], 1-FACTA-related-disease->UMLS:C0040517[Tourette Syndrome],
ADRA2C	CNTNAP2	3-GoPubMed-related-disease->mesh:5879[Tourette Syndrome],mesh:13981[Tic Disorders],mesh:20323[Tics], 1-FACTA-related-disease->UMLS:C0040517[Tourette Syndrome], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
ADRA2C	NRXN1	2-GoPubMed-related-disease->mesh:5879[Tourette Syndrome],mesh:13981[Tic Disorders],
ADRA2C	CHRNA7	2-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:BIOD00057[Fragment], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
ADRA2C	EN2	2-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00450[Norepinephrine],
ADRA2C	HTR3A	1-FACTA-related-disease->UMLS:C0040517[Tourette Syndrome], 2-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:APRD00450[Norepinephrine],
ADRA2C	HTR2A	3-GoPubMed-related-GO->GO:0004937[alpha1-adrenergic receptor activity],GO:0008227[G-protein coupled amine receptor activity],GO:0004930[G-protein coupled receptor activity], 3-FACTA-related-disease->UMLS:C1840994[HBB],UMLS:C1840993[HBB],UMLS:C1840958[HBB], 3-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:BIOD00057[Fragment],DrugBank:APRD00340[Reserpine], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
ADRA2C	HTR1B	2-GoPubMed-related-GO->GO:0008227[G-protein coupled amine receptor activity],GO:0004930[G-protein coupled receptor activity], 2-FACTA-related-gene->HUMANGGP:024926[DRD5],HUMANGGP:031659[SLC6A2], 1-FACTA-related-disease->UMLS:C1263846[Attention Deficit Disorder with Hyperactivity], 3-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:BIOD00057[Fragment],DrugBank:APRD00450[Norepinephrine], 2-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],reactome:REACT_19231[],
ADRA2C	ALDH5A1	1-GoPubMed-related-disease->mesh:6948[Hyperkinesis], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
ADRA2C	MAOA	1-GoPubMed-related-disease->mesh:20230[Serotonin Syndrome], 3-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:BIOD00057[Fragment],DrugBank:APRD00450[Norepinephrine],
ADRA2C	ADRB2	2-FACTA-related-gene->HUMANGGP:008161[ADRB3],HUMANGGP:011331[ADRA1C], 3-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:BIOD00057[Fragment],DrugBank:EXPT01467[Forskolin],
ADRA2C	DRD3	2-FACTA-related-gene->HUMANGGP:011331[ADRA1C],HUMANGGP:024926[DRD5], 3-FACTA-related-disease->UMLS:C1840958[HBB],UMLS:C1840993[HBB],UMLS:C1840994[HBB], 3-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:BIOD00057[Fragment],DrugBank:APRD00450[Norepinephrine],
ADRA2C	NLGN4X	3-GoPubMed-related-disease->mesh:7859[Learning Disorders],mesh:5879[Tourette Syndrome],mesh:20323[Tics],
ADRA2C	GABRB1	4-FACTA-related-gene->HUMANGGP:004123[GABRB1],HUMANGGP:003403[ADRA2C],HUMANGGP:024653[HYD1],HUMANGGP:013695[IDUA], 1-FACTA-related-disease->UMLS:C0020179[Huntington's disease], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
ADRA2C	TDO2	2-GoPubMed-related-disease->mesh:20230[Serotonin Syndrome],mesh:5879[Tourette Syndrome], 2-FACTA-related-gene->HUMANGGP:003403[ADRA2C],HUMANGGP:024926[DRD5], 3-FACTA-related-disease->UMLS:C0040517[Tourette Syndrome],UMLS:C1263846[Attention Deficit Disorder with Hyperactivity],UMLS:C1260899[DBA],
ADRA2C	MED12	1-FACTA-related-disease->UMLS:C0004930[Behavior Disorders], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
ADRB3	MBD1	1-FACTA-related-drug->DrugBank:APRD00530[Portal],
ADRB3	HTR1B	2-GoPubMed-related-GO->GO:0008227[G-protein coupled amine receptor activity],GO:0004930[G-protein coupled receptor activity], 4-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00530[Portal],DrugBank:EXPT00494[Alanine],DrugBank:APRD00450[Norepinephrine], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
ADRB3	HSD11B1	3-FACTA-related-gene->HUMANGGP:011799[GHRL],HUMANGGP:017427[SHC1],HUMANGGP:007089[GJA4], 4-FACTA-related-disease->UMLS:C1862639[APOA1],UMLS:C0206081[hyperandrogenism],UMLS:C0032460[polycystic ovary syndrome],UMLS:C0948265[metabolic syndrome],
ADRB3	DISC1	3-FACTA-related-drug->DrugBank:BIOD00060[IL-1ra],DrugBank:BIOD00057[Fragment],DrugBank:EXPT00494[Alanine],
ADRB3	ADRB2	5-GoPubMed-related-GO->GO:0004941[beta2-adrenergic receptor activity],GO:0040009[regulation of growth rate],GO:0004939[beta-adrenergic receptor activity],GO:0004940[beta1-adrenergic receptor activity],GO:0015052[beta3-adrenergic receptor activity], 4-FACTA-related-gene->HUMANGGP:039243[ADRA1B],HUMANGGP:008161[ADRB3],HUMANGGP:020893[ADRA1A],HUMANGGP:016527[SLC8A1], 2-FACTA-related-disease->UMLS:C0268138[XPD],UMLS:C0282488[interstitial cystitis], 3-FACTA-related-drug->DrugBank:APRD00553[Albuterol],DrugBank:BIOD00060[IL-1ra],DrugBank:BIOD00057[Fragment],
ADRB3	NRP2	1-FACTA-related-disease->UMLS:C0282488[interstitial cystitis], 1-FACTA-related-drug->DrugBank:APRD01015[Histamine],
ADRB3	MAOA	4-FACTA-related-drug->DrugBank:APRD00499[AraC],DrugBank:BIOD00057[Fragment],DrugBank:APRD00450[Norepinephrine],DrugBank:APRD00530[Portal],
ADRB3	MTHFR	2-FACTA-related-gene->HUMANGGP:036941[adrenergic, beta-3-, receptor],HUMANGGP:006455[cholesteryl ester transfer protein, plasma], 2-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:BIOD00060[IL-1ra],
ADRB3	ERBB4	1-FACTA-related-drug->DrugBank:BIOD00060[IL-1ra], 2-pathway->kegg:path:hsa04144[Endocytosis],kegg:path:hsa04020[Calcium signaling pathway],
ADRB3	NPAS2	2-FACTA-related-drug->DrugBank:APRD00530[Portal],DrugBank:EXPT00494[Alanine],
ADRB3	EN2	1-GoPubMed-related-GO->GO:0004939[beta-adrenergic receptor activity], 2-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00450[Norepinephrine],
ADRB3	ALOX5AP	3-FACTA-related-drug->DrugBank:APRD00553[Albuterol],DrugBank:BIOD00057[Fragment],DrugBank:APRD01015[Histamine],
ADRB3	TPH2	2-FACTA-related-drug->DrugBank:APRD00530[Portal],DrugBank:APRD00450[Norepinephrine],
ADRB3	ATP2B2	1-FACTA-related-drug->DrugBank:BIOD00057[Fragment], 2-pathway->kegg:path:hsa04970[Salivary secretion],kegg:path:hsa04020[Calcium signaling pathway],
ADRB3	HTR7	2-GoPubMed-related-GO->GO:0008227[G-protein coupled amine receptor activity],GO:0004930[G-protein coupled receptor activity], 1-FACTA-related-disease->UMLS:C0282488[interstitial cystitis], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment], 3-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],kegg:path:hsa04020[Calcium signaling pathway],reactome:REACT_19327[],
ADRB3	KCNMA1	1-GoPubMed-related-gene->10242[KCNMB2], 1-GoPubMed-related-disease->mesh:53202[Urinary Incontinence, Urge], 2-FACTA-related-drug->DrugBank:APRD00530[Portal],DrugBank:APRD01015[Histamine], 1-pathway->kegg:path:hsa04970[Salivary secretion],
ALCAM	NTRK1	1-FACTA-related-gene->HUMANGGP:021114[GOLGA5], 4-FACTA-related-drug->DrugBank:BIOD00052[p75],DrugBank:APRD00627[Progesterone],DrugBank:APRD00506[Spectrum],DrugBank:APRD00631[Gel],
ALCAM	NLGN3	1-pathway->kegg:path:hsa04514[Cell adhesion molecules (CAMs)],
ALCAM	NLGN1	1-FACTA-related-disease->UMLS:C0001511[Adhesion], 1-pathway->kegg:path:hsa04514[Cell adhesion molecules (CAMs)],
ALCAM	GRPR	3-GoPubMed-related-disease->mesh:1063[Appendiceal Neoplasms],mesh:2430[Cecal Neoplasms],mesh:15831[Osteochondroma], 2-FACTA-related-drug->DrugBank:APRD00627[Progesterone],DrugBank:APRD00631[Gel],
ALCAM	NRP2	2-GoPubMed-related-disease->mesh:2804[Chondroblastoma],mesh:15831[Osteochondroma],
ALCAM	CNTNAP2	1-FACTA-related-drug->DrugBank:APRD00506[Spectrum], 1-pathway->kegg:path:hsa04514[Cell adhesion molecules (CAMs)],
ALCAM	DHCR7	4-FACTA-related-drug->DrugBank:BIOD00052[p75],DrugBank:BIOD00035[CSF],DrugBank:APRD00627[Progesterone],DrugBank:APRD00506[Spectrum],
ALCAM	CTNNA3	1-GoPubMed-related-gene->1496[CTNNA2], 1-FACTA-related-drug->DrugBank:BIOD00035[CSF],
ALCAM	NRXN2	1-FACTA-related-disease->UMLS:C0001511[Adhesion], 1-pathway->kegg:path:hsa04514[Cell adhesion molecules (CAMs)],
ALCAM	NRXN1	1-pathway->kegg:path:hsa04514[Cell adhesion molecules (CAMs)],
ALCAM	CD44	3-GoPubMed-related-GO->GO:0043854[cyclic nucleotide-gated mechanosensitive ion channel activity],GO:0043855[cyclic nucleotide-gated ion channel activity],GO:0008381[mechanically-gated ion channel activity], 1-GoPubMed-related-disease->mesh:15838[Chondromatosis, Synovial], 3-FACTA-related-drug->DrugBank:APRD00328[Selectin],DrugBank:BIOD00082[IL-2],DrugBank:BIOD00017[IFN-gamma],
ALCAM	RPS6KA2	5-FACTA-related-gene->HUMANGGP:006284[RPS6KA2],HUMANGGP:014823[VCAN],HUMANGGP:038143[SDC4],HUMANGGP:018018[DUSP16],HUMANGGP:000545[CD166], 2-FACTA-related-drug->DrugBank:BIOD00018[Menotropins],DrugBank:APRD00627[Progesterone],
ALCAM	DAB1	3-FACTA-related-disease->UMLS:C1521924[Ganglioglioma],UMLS:C0206716[ganglioglioma],UMLS:C0001511[Adhesion], 2-FACTA-related-drug->DrugBank:APRD00627[Progesterone],DrugBank:APRD00631[Gel],
ALCAM	HMGN1	4-FACTA-related-drug->DrugBank:BIOD00018[Menotropins],DrugBank:APRD00396[Estrogens],DrugBank:APRD00627[Progesterone],DrugBank:APRD00631[Gel],
ALCAM	NLGN4X	1-FACTA-related-drug->DrugBank:APRD00506[Spectrum], 1-pathway->kegg:path:hsa04514[Cell adhesion molecules (CAMs)],
ALCAM	PTGS2	2-FACTA-related-drug->DrugBank:BIOD00018[Menotropins],DrugBank:APRD00627[Progesterone],
ALDH3A2	NSD1	1-FACTA-related-disease->UMLS:C0424605[developmental delay], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum], 1-pathway->kegg:path:hsa00310[Lysine degradation],
ALDH3A2	CNTNAP2	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
ALDH3A2	CACNA1G	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
ALDH3A2	NTRK1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
ALDH3A2	CHD7	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
ALDH3A2	NPAS2	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
ALDH3A2	FABP5	2-GoPubMed-related-GO->GO:0033561[regulation of water loss via skin],GO:0060361[flight], 1-GoPubMed-related-disease->mesh:17453[Dermatitis, Irritant],
ALDH3A2	HOXB1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
ALDH3A2	ALDH5A1	2-GoPubMed-related-gene->4329[ALDH6A1],219[ALDH1B1], 1-GoPubMed-related-GO->GO:0004030[aldehyde dehydrogenase [NAD(P)+] activity], 5-FACTA-related-gene->HUMANGGP:034633[ALDH5A1],HUMANGGP:020284[ALDH4A1],HUMANGGP:042427[ALDH6A1],HUMANGGP:017519[ALDH3A2],HUMANGGP:000911[ALDH3A1], 2-FACTA-related-disease->UMLS:C0268528[hyperprolinemia],UMLS:C0424605[developmental delay], 1-pathway->kegg:path:hsa01100[Metabolic pathways],
ALDH3A2	NLGN4X	1-GoPubMed-related-disease->mesh:7057[Ichthyosis], 3-FACTA-related-disease->UMLS:C0020758[ichthyosis],UMLS:C0020757[ichthyosis],UMLS:C0917816[mental retardation], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
ALDH3A2	DHCR7	1-FACTA-related-disease->UMLS:C0917816[mental retardation], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum], 1-pathway->kegg:path:hsa01100[Metabolic pathways],
ALDH3A2	CA6	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
ALDH3A2	AHI1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
ALDH3A2	PITX1	1-FACTA-related-drug->DrugBank:APRD00201[GEO],
ALDH3A2	TH	1-FACTA-related-disease->UMLS:C1858142[LI3],
ALDH3A2	PON1	1-GoPubMed-related-disease->mesh:18489[Space Motion Sickness],
ALDH3A2	CADM1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
ALDH3A2	ANKRD11	1-GoPubMed-related-disease->mesh:3963[Diaper Rash], 1-FACTA-related-disease->UMLS:C0917816[mental retardation],
APBA1	FOXP2	1-FACTA-related-drug->DrugBank:APRD00280[Frontal],
APBA1	DRD3	2-FACTA-related-gene->HUMANGGP:007874[DRD3],HUMANGGP:024926[DRD5], 1-FACTA-related-drug->DrugBank:APRD00280[Frontal],
APBA1	TDO2	1-FACTA-related-gene->HUMANGGP:024926[DRD5], 2-FACTA-related-disease->UMLS:C0004352[autism],UMLS:C0036341[schizophrenia], 1-FACTA-related-drug->DrugBank:APRD00280[Frontal],
APBA1	RELN	3-GoPubMed-related-GO->GO:0001784[phosphotyrosine binding],GO:0045309[protein phosphorylated amino acid binding],GO:0051219[phosphoprotein binding], 1-FACTA-related-drug->DrugBank:APRD00280[Frontal],
APBA1	HMGN1	1-FACTA-related-disease->UMLS:C0002622[amnesia],
APBA1	SYNGAP1	3-FACTA-related-disease->UMLS:C0004352[autism],UMLS:C0009241[Cognition Disorders],UMLS:C0036341[schizophrenia],
APBA1	DISC1	1-FACTA-related-disease->UMLS:C0036341[schizophrenia], 1-FACTA-related-drug->DrugBank:APRD00280[Frontal],
APBA1	SLC1A1	1-FACTA-related-disease->UMLS:C0004352[autism], 1-FACTA-related-drug->DrugBank:APRD00280[Frontal],
APBA1	ADSL	1-GoPubMed-related-disease->mesh:18253[Adenoma, Villous],
APBA1	CTNNA3	2-FACTA-related-disease->UMLS:C0002395[Alzheimer's disease],UMLS:C0497327[dementia],
APBA1	ANKRD11	4-FACTA-related-disease->UMLS:C0004352[autism],UMLS:C0338656[cognitive impairment],UMLS:C0009241[Cognition Disorders],UMLS:C0027651[tumor],
APBA1	CNTNAP2	3-GoPubMed-related-gene->85445[CNTNAP4],80262[C16orf70],79937[CNTNAP3], 1-GoPubMed-related-GO->GO:0050126[N-carbamoylputrescine amidase activity], 1-FACTA-related-disease->UMLS:C0004352[autism],
APBA1	GABRA4	2-FACTA-related-disease->UMLS:C0004352[autism],UMLS:C0002622[amnesia],
APBA1	CACNA1G	1-GoPubMed-related-gene->321[APBA2], 4-GoPubMed-related-GO->GO:0044027[hypermethylation of CpG island],GO:0003908[methylated-DNA-[protein]-cysteine S-methyltransferase activity],GO:0008172[S-methyltransferase activity],GO:0044026[DNA hypermethylation], 2-GoPubMed-related-disease->mesh:53842[Microsatellite Instability],mesh:42822[Genomic Instability], 1-FACTA-related-gene->HUMANGGP:031986[MINT2],
APBA1	RIMS3	3-FACTA-related-disease->UMLS:C0004352[autism],UMLS:C0036341[schizophrenia],UMLS:C0027651[tumor],
APBA1	APBA2	4-GoPubMed-related-gene->9413[FAM189A2],23359[FAM189A1],9546[APBA3],8913[CACNA1G], 10-GoPubMed-related-GO->GO:0001784[phosphotyrosine binding],GO:0045309[protein phosphorylated amino acid binding],GO:0051219[phosphoprotein binding],GO:0003908[methylated-DNA-[protein]-cysteine S-methyltransferase activity],GO:0042982[amyloid precursor protein metabolic process],GO:0008172[S-methyltransferase activity],GO:0044027[hypermethylation of CpG island],GO:0016079[synaptic vesicle exocytosis],GO:0044026[DNA hypermethylation],GO:0048489[synaptic vesicle transport], 4-GoPubMed-related-disease->mesh:53842[Microsatellite Instability],mesh:3111[Colonic Polyps],mesh:7417[Intestinal Polyps],mesh:42822[Genomic Instability], 2-FACTA-related-gene->HUMANGGP:036411[APBA2],HUMANGGP:031986[MINT2], 3-FACTA-related-disease->UMLS:C0004352[autism],UMLS:C0002395[Alzheimer's disease],UMLS:C0036341[schizophrenia],
ARHGEF6	OPHN1	3-GoPubMed-related-gene->5063[PAK3],7592[ZNF41],11141[IL1RAPL1], 9-GoPubMed-related-GO->GO:0005100[Rho GTPase activator activity],GO:0005089[Rho guanyl-nucleotide exchange factor activity],GO:0005099[Ras GTPase activator activity],GO:0005088[Ras guanyl-nucleotide exchange factor activity],GO:0005092[GDP-dissociation inhibitor activity],GO:0048489[synaptic vesicle transport],GO:0005085[guanyl-nucleotide exchange factor activity],GO:0005083[small GTPase regulator activity],GO:0005096[GTPase activator activity], 4-GoPubMed-related-disease->mesh:38901[Mental Retardation, X-Linked],mesh:5600[Fragile X Syndrome],mesh:8607[Mental Retardation],mesh:40181[Genetic Diseases, X-Linked], 8-FACTA-related-gene->HUMANGGP:039910[OPHN1],HUMANGGP:007783[ARHGEF6],HUMANGGP:020388[TM4SF2],HUMANGGP:002027[RPS6KA3],HUMANGGP:040636[FTSJ1],HUMANGGP:028523[FACL4],HUMANGGP:015143[DLG3],HUMANGGP:027462[ZNF41], 5-FACTA-related-disease->UMLS:C1136249[Mental Retardation, X-Linked],UMLS:C1845055[ATRX],UMLS:C1859974[FGD1],UMLS:C0917816[mental retardation],UMLS:C0016667[Fragile X Syndrome],
ARHGEF6	NTNG1	4-GoPubMed-related-disease->mesh:38901[Mental Retardation, X-Linked],mesh:8607[Mental Retardation],mesh:40181[Genetic Diseases, X-Linked],mesh:20271[Heredodegenerative Disorders, Nervous System], 2-FACTA-related-disease->UMLS:C0917816[mental retardation],UMLS:C0025362[Mental Retardation],
ARHGEF6	RFWD2	1-GoPubMed-related-GO->GO:0005085[guanyl-nucleotide exchange factor activity], 2-GoPubMed-related-disease->mesh:24182[Uniparental Disomy],mesh:9630[Nondisjunction, Genetic],
ARHGEF6	TSPAN7	6-GoPubMed-related-gene->24140[FTSJ1],7592[ZNF41],11141[IL1RAPL1],4983[OPHN1],79659[DYNC2H1],5063[PAK3], 6-GoPubMed-related-GO->GO:0005092[GDP-dissociation inhibitor activity],GO:0005089[Rho guanyl-nucleotide exchange factor activity],GO:0048489[synaptic vesicle transport],GO:0005088[Ras guanyl-nucleotide exchange factor activity],GO:0005083[small GTPase regulator activity],GO:0005085[guanyl-nucleotide exchange factor activity], 2-GoPubMed-related-disease->mesh:38901[Mental Retardation, X-Linked],mesh:5600[Fragile X Syndrome], 1-FACTA-related-gene->HUMANGGP:020388[TM4SF2], 3-FACTA-related-disease->UMLS:C1136249[Mental Retardation, X-Linked],UMLS:C0917816[mental retardation],UMLS:C0025362[Mental Retardation],
ARHGEF6	IL1RAPL2	1-GoPubMed-related-gene->11141[IL1RAPL1], 3-GoPubMed-related-disease->mesh:38901[Mental Retardation, X-Linked],mesh:8607[Mental Retardation],mesh:40181[Genetic Diseases, X-Linked], 1-FACTA-related-gene->HUMANGGP:007566[IL1RAPL1], 3-FACTA-related-disease->UMLS:C1136249[Mental Retardation, X-Linked],UMLS:C0917816[mental retardation],UMLS:C0025362[Mental Retardation],
ARHGEF6	IL1RAPL1	3-GoPubMed-related-gene->7592[ZNF41],24140[FTSJ1],4983[OPHN1], 6-GoPubMed-related-GO->GO:0048489[synaptic vesicle transport],GO:0005092[GDP-dissociation inhibitor activity],GO:0005089[Rho guanyl-nucleotide exchange factor activity],GO:0005088[Ras guanyl-nucleotide exchange factor activity],GO:0005083[small GTPase regulator activity],GO:0005085[guanyl-nucleotide exchange factor activity], 3-GoPubMed-related-disease->mesh:38901[Mental Retardation, X-Linked],mesh:5600[Fragile X Syndrome],mesh:8607[Mental Retardation], 6-FACTA-related-gene->HUMANGGP:007566[IL1RAPL1],HUMANGGP:040636[FTSJ1],HUMANGGP:015143[DLG3],HUMANGGP:027462[ZNF41],HUMANGGP:034035[PQBP1],HUMANGGP:007783[ARHGEF6], 4-FACTA-related-disease->UMLS:C1136249[Mental Retardation, X-Linked],UMLS:C1845055[ATRX],UMLS:C0917816[mental retardation],UMLS:C0016667[Fragile X Syndrome],
ARHGEF6	DLGAP2	4-GoPubMed-related-disease->mesh:5600[Fragile X Syndrome],mesh:25064[Sex Chromosome Disorders],mesh:38901[Mental Retardation, X-Linked],mesh:8607[Mental Retardation], 2-FACTA-related-disease->UMLS:C0917816[mental retardation],UMLS:C0025362[Mental Retardation],
ARHGEF6	NLGN4X	1-GoPubMed-related-gene->7592[ZNF41], 2-GoPubMed-related-GO->GO:0005092[GDP-dissociation inhibitor activity],GO:0005083[small GTPase regulator activity], 9-FACTA-related-gene->HUMANGGP:006914[ZNF81],HUMANGGP:040636[FTSJ1],HUMANGGP:015143[DLG3],HUMANGGP:027462[ZNF41],HUMANGGP:007783[ARHGEF6],HUMANGGP:020388[TM4SF2],HUMANGGP:028523[FACL4],HUMANGGP:039910[OPHN1],HUMANGGP:002027[RPS6KA3], 4-FACTA-related-disease->UMLS:C1859974[FGD1],UMLS:C1136249[Mental Retardation, X-Linked],UMLS:C0917816[mental retardation],UMLS:C0025362[Mental Retardation],
ARHGEF6	ARX	5-GoPubMed-related-gene->24140[FTSJ1],11141[IL1RAPL1],7592[ZNF41],347344[ZNF81],4983[OPHN1], 2-GoPubMed-related-GO->GO:0005092[GDP-dissociation inhibitor activity],GO:0048489[synaptic vesicle transport], 1-GoPubMed-related-disease->mesh:38901[Mental Retardation, X-Linked], 7-FACTA-related-gene->HUMANGGP:007783[ARHGEF6],HUMANGGP:039910[OPHN1],HUMANGGP:002027[RPS6KA3],HUMANGGP:020388[TM4SF2],HUMANGGP:040636[FTSJ1],HUMANGGP:028523[FACL4],HUMANGGP:015143[DLG3], 1-FACTA-related-disease->UMLS:C1136249[Mental Retardation, X-Linked],
ARHGEF6	SLC6A8	1-GoPubMed-related-gene->7592[ZNF41], 2-GoPubMed-related-GO->GO:0005092[GDP-dissociation inhibitor activity],GO:0005083[small GTPase regulator activity], 8-FACTA-related-gene->HUMANGGP:039910[OPHN1],HUMANGGP:002027[RPS6KA3],HUMANGGP:007783[ARHGEF6],HUMANGGP:020388[TM4SF2],HUMANGGP:040636[FTSJ1],HUMANGGP:028523[FACL4],HUMANGGP:015143[DLG3],HUMANGGP:027462[ZNF41], 4-FACTA-related-disease->UMLS:C1136249[Mental Retardation, X-Linked],UMLS:C1845055[ATRX],UMLS:C0917816[mental retardation],UMLS:C0016667[Fragile X Syndrome],
ARHGEF6	RAB39B	4-GoPubMed-related-disease->mesh:38901[Mental Retardation, X-Linked],mesh:40181[Genetic Diseases, X-Linked],mesh:8607[Mental Retardation],mesh:20271[Heredodegenerative Disorders, Nervous System], 3-FACTA-related-disease->UMLS:C1136249[Mental Retardation, X-Linked],UMLS:C0917816[mental retardation],UMLS:C0025362[Mental Retardation],
ARHGEF6	AGTR2	2-GoPubMed-related-gene->7592[ZNF41],24140[FTSJ1], 8-FACTA-related-gene->HUMANGGP:007783[ARHGEF6],HUMANGGP:020388[TM4SF2],HUMANGGP:040636[FTSJ1],HUMANGGP:039910[OPHN1],HUMANGGP:028523[FACL4],HUMANGGP:002027[RPS6KA3],HUMANGGP:015143[DLG3],HUMANGGP:027462[ZNF41], 2-FACTA-related-disease->UMLS:C1845055[ATRX],UMLS:C1136249[Mental Retardation, X-Linked],
ARHGEF6	FGD1	4-GoPubMed-related-gene->7592[ZNF41],347344[ZNF81],24140[FTSJ1],11141[IL1RAPL1], 6-GoPubMed-related-GO->GO:0005089[Rho guanyl-nucleotide exchange factor activity],GO:0005088[Ras guanyl-nucleotide exchange factor activity],GO:0005085[guanyl-nucleotide exchange factor activity],GO:0046847[filopodium assembly],GO:0030035[microspike assembly],GO:0005083[small GTPase regulator activity], 9-FACTA-related-gene->HUMANGGP:006914[ZNF81],HUMANGGP:040636[FTSJ1],HUMANGGP:015143[DLG3],HUMANGGP:027462[ZNF41],HUMANGGP:007783[ARHGEF6],HUMANGGP:020388[TM4SF2],HUMANGGP:039910[OPHN1],HUMANGGP:028523[FACL4],HUMANGGP:002027[RPS6KA3], 2-FACTA-related-disease->UMLS:C1859974[FGD1],UMLS:C1136249[Mental Retardation, X-Linked], 2-pathway->kegg:path:hsa04810[Regulation of actin cytoskeleton],nci_nature_pid:Regulation_of_CDC42_activity[],
ARHGEF6	NLGN3	2-GoPubMed-related-GO->GO:0005092[GDP-dissociation inhibitor activity],GO:0005083[small GTPase regulator activity], 3-GoPubMed-related-disease->mesh:5600[Fragile X Syndrome],mesh:25064[Sex Chromosome Disorders],mesh:8607[Mental Retardation], 6-FACTA-related-gene->HUMANGGP:040636[FTSJ1],HUMANGGP:015143[DLG3],HUMANGGP:027462[ZNF41],HUMANGGP:007783[ARHGEF6],HUMANGGP:020388[TM4SF2],HUMANGGP:039910[OPHN1], 4-FACTA-related-disease->UMLS:C1845055[ATRX],UMLS:C0016667[Fragile X Syndrome],UMLS:C0015923[Fetal Alcohol Syndrome],UMLS:C0917816[mental retardation],
ARHGEF6	RPL10	2-GoPubMed-related-disease->mesh:24182[Uniparental Disomy],mesh:9630[Nondisjunction, Genetic], 2-FACTA-related-disease->UMLS:C1136249[Mental Retardation, X-Linked],UMLS:C0917816[mental retardation],
ARHGEF6	SYN1	2-GoPubMed-related-gene->347344[ZNF81],7592[ZNF41], 1-GoPubMed-related-GO->GO:0005092[GDP-dissociation inhibitor activity], 4-FACTA-related-gene->HUMANGGP:006914[ZNF81],HUMANGGP:027462[ZNF41],HUMANGGP:040636[FTSJ1],HUMANGGP:015143[DLG3], 3-FACTA-related-disease->UMLS:C1845055[ATRX],UMLS:C1136249[Mental Retardation, X-Linked],UMLS:C0016667[Fragile X Syndrome],
ASCL1	GTF2I	1-FACTA-related-drug->DrugBank:APRD00256[Valproic Acid],
ASCL1	HOXA1	2-GoPubMed-related-disease->mesh:7040[Hypoventilation],mesh:18243[Teratocarcinoma], 4-FACTA-related-drug->DrugBank:APRD00017[Tretinoin],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00256[Valproic Acid],DrugBank:EXPT02079[lysine],
ASCL1	RELN	1-FACTA-related-disease->UMLS:C0220620[GCT], 3-FACTA-related-drug->DrugBank:APRD00256[Valproic Acid],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
ASCL1	NRCAM	1-GoPubMed-related-gene->27097[TAF5L], 3-FACTA-related-gene->HUMANGGP:035843[NRCAM],HUMANGGP:013454[PHF20],HUMANGGP:033100[TAF5L],
ASCL1	NRXN1	2-FACTA-related-disease->UMLS:C1739393[Hopkins syndrome],UMLS:C0028043[nicotine addiction], 1-FACTA-related-drug->DrugBank:APRD00256[Valproic Acid],
ASCL1	TBX1	3-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:EXPT02079[lysine],
ASCL1	HTR3A	2-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:APRD00450[Norepinephrine],
ASCL1	EN2	1-GoPubMed-related-GO->GO:0005112[Notch binding], 3-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00450[Norepinephrine],
ASCL1	HTR1B	2-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:APRD00450[Norepinephrine],
ASCL1	DLX2	4-FACTA-related-drug->DrugBank:APRD00504[ID2],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:EXPT02079[lysine],
ASCL1	DISC1	1-GoPubMed-related-disease->mesh:7644[Keratosis Follicularis], 1-FACTA-related-drug->DrugBank:EXPT02079[lysine],
ASCL1	ALDH5A1	1-GoPubMed-related-disease->mesh:20182[Sleep Apnea, Central],
ASCL1	BAIAP2	1-GoPubMed-related-gene->63974[NEUROD6], 1-FACTA-related-gene->HUMANGGP:006897[NEUROD6], 1-FACTA-related-drug->DrugBank:APRD00504[ID2],
ASCL1	SCN2A	4-FACTA-related-drug->DrugBank:EXPT02079[lysine],DrugBank:APRD00256[Valproic Acid],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
ASCL1	UBE3A	1-FACTA-related-disease->UMLS:C1739393[Hopkins syndrome], 1-FACTA-related-drug->DrugBank:APRD00256[Valproic Acid],
ASCL1	MECP2	1-GoPubMed-related-GO->GO:0003360[brainstem development], 1-FACTA-related-disease->UMLS:C1739393[Hopkins syndrome], 3-FACTA-related-drug->DrugBank:APRD00504[ID2],DrugBank:EXPT02079[lysine],DrugBank:APRD00256[Valproic Acid],
AVPR1B	NLGN4Y	1-GoPubMed-related-gene->57502[NLGN4X], 1-FACTA-related-disease->UMLS:C0236792[Asperger Syndrome],
AVPR1B	NLGN4X	2-GoPubMed-related-GO->GO:0060134[prepulse inhibition],GO:0001964[startle response], 1-FACTA-related-gene->HUMANGGP:038063[AVPR1B], 2-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0236792[Asperger Syndrome], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
AVPR1B	TPH2	1-FACTA-related-gene->HUMANGGP:042269[CRHBP], 1-FACTA-related-disease->UMLS:C0525045[Mood Disorders], 1-FACTA-related-drug->DrugBank:APRD00530[Portal],
AVPR1B	KCNMA1	1-FACTA-related-disease->UMLS:C0233639[Autism], 1-FACTA-related-drug->DrugBank:APRD00530[Portal], 1-pathway->kegg:path:hsa04270[Vascular smooth muscle contraction],
AVPR1B	HTR1B	1-FACTA-related-drug->DrugBank:APRD00530[Portal], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
AVPR1B	CADM1	1-FACTA-related-disease->UMLS:C0233639[Autism], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
AVPR1B	CREBBP	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
AVPR1B	NSD1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
AVPR1B	CA6	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
AVPR1B	MBD1	1-FACTA-related-disease->UMLS:C0233639[Autism], 1-FACTA-related-drug->DrugBank:APRD00530[Portal],
AVPR1B	CNTNAP2	2-GoPubMed-related-GO->GO:0022831[narrow pore, gated channel activity],GO:0022842[narrow pore channel activity], 1-FACTA-related-disease->UMLS:C0233639[Autism], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
AVPR1B	CHD7	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
AVPR1B	CACNA1G	1-FACTA-related-disease->UMLS:C0233639[Autism], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum], 1-pathway->kegg:path:hsa04020[Calcium signaling pathway],
AVPR1B	MAOA	1-FACTA-related-gene->HUMANGGP:026425[MAOB], 1-FACTA-related-drug->DrugBank:APRD00530[Portal],
AVPR1B	PTGS2	1-GoPubMed-related-disease->mesh:4412[Dysmenorrhea],
AVPR1B	IL1RAPL2	1-FACTA-related-disease->UMLS:C0236792[Asperger Syndrome],
AVPR1B	NTRK1	2-FACTA-related-gene->HUMANGGP:009070[NTRK1],HUMANGGP:038063[AVPR1B], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
AVPR1B	NPAS2	1-FACTA-related-disease->UMLS:C0233639[Autism], 3-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00530[Portal],
AVPR1B	CHRNA7	1-GoPubMed-related-GO->GO:0022831[narrow pore, gated channel activity], 2-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],kegg:path:hsa04020[Calcium signaling pathway],
AVPR1B	HOXB1	1-GoPubMed-related-gene->3198[HOXA1], 1-FACTA-related-gene->HUMANGGP:025411[HOXA1], 1-FACTA-related-disease->UMLS:C0236792[Asperger Syndrome], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
AVPR1B	HOXA1	1-GoPubMed-related-GO->GO:0004708[MAP kinase kinase activity], 2-FACTA-related-gene->HUMANGGP:025411[HOXA1],HUMANGGP:038063[AVPR1B], 2-FACTA-related-disease->UMLS:C0236792[Asperger Syndrome],UMLS:C0233639[Autism], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
AVPR1B	SHANK3	1-GoPubMed-related-gene->57502[NLGN4X], 2-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0236792[Asperger Syndrome], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
AVPR1B	RBMS3	1-FACTA-related-disease->UMLS:C0001807[aggression],
AVPR1B	OXTR	1-GoPubMed-related-gene->552[AVPR1A], 3-GoPubMed-related-disease->mesh:7752[Obstetric Labor, Premature],mesh:4412[Dysmenorrhea],mesh:17699[Pelvic Pain], 1-FACTA-related-gene->HUMANGGP:038063[AVPR1B], 2-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0236792[Asperger Syndrome], 4-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],reactome:REACT_18283[],kegg:path:hsa04020[Calcium signaling pathway],reactome:REACT_17041[],
AVPR1B	DHCR7	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
BPHL	CHD7	3-FACTA-related-drug->DrugBank:EXPT02079[lysine],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
BPHL	MYO1A	2-FACTA-related-drug->DrugBank:EXPT00573[Aspartic Acid],DrugBank:APRD00631[Gel],
BPHL	CA6	3-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00631[Gel],
BPHL	CDH9	2-GoPubMed-related-GO->GO:0003823[antigen binding],GO:0005488[binding], 5-GoPubMed-related-disease->mesh:2292[Carcinoma, Renal Cell],mesh:7680[Kidney Neoplasms],mesh:14571[Urologic Neoplasms],mesh:5355[Fibrosis],mesh:2277[Carcinoma],
BPHL	AHI1	3-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00631[Gel],
BPHL	CREBBP	3-FACTA-related-drug->DrugBank:EXPT02079[lysine],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
BPHL	HEPACAM	1-GoPubMed-related-gene->1462[VCAN], 1-FACTA-related-disease->UMLS:C0007134[renal cell carcinoma],
BPHL	FBXO40	1-GoPubMed-related-disease->mesh:1284[Atrophy],
BPHL	NTRK1	4-FACTA-related-drug->DrugBank:EXPT02079[lysine],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00631[Gel],
BPHL	NPAS2	3-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00631[Gel],
BPHL	HOXB1	4-FACTA-related-drug->DrugBank:EXPT02079[lysine],DrugBank:APRD00506[Spectrum],DrugBank:APRD00631[Gel],DrugBank:APRD00552[Spectrum],
BPHL	CNTNAP2	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
BPHL	ALDH5A1	2-GoPubMed-related-gene->4329[ALDH6A1],55856[ACOT13], 1-FACTA-related-gene->HUMANGGP:042427[ALDH6A1], 1-FACTA-related-drug->DrugBank:APRD00631[Gel],
BPHL	NSD1	3-FACTA-related-drug->DrugBank:EXPT02079[lysine],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
BPHL	GRIP1	1-FACTA-related-drug->DrugBank:APRD00263[Ganciclovir],
BPHL	MKL2	1-GoPubMed-related-disease->mesh:1284[Atrophy], 3-FACTA-related-disease->UMLS:C0018799[heart disease],UMLS:C0007097[carcinoma],UMLS:C0006826[cancer],
BPHL	GRID2	2-GoPubMed-related-GO->GO:0003823[antigen binding],GO:0005488[binding],
BPHL	PLN	1-FACTA-related-gene->HUMANGGP:033470[biphenyl hydrolase-like],
CACNB4	DMD	3-pathway->kegg:path:hsa05410[Hypertrophic cardiomyopathy (HCM)],kegg:path:hsa05414[Dilated cardiomyopathy],kegg:path:hsa05412[Arrhythmogenic right ventricular cardiomyopathy (ARVC)],
CACNB4	CACNA1F	4-GoPubMed-related-GO->GO:0007416[synapse assembly],GO:0050808[synapse organization],GO:0043062[extracellular structure organization],GO:0015267[channel activity], 1-FACTA-related-disease->UMLS:C0270862[hemiplegic migraine], 6-pathway->kegg:path:hsa05410[Hypertrophic cardiomyopathy (HCM)],kegg:path:hsa04010[MAPK signaling pathway],kegg:path:hsa05414[Dilated cardiomyopathy],kegg:path:hsa05412[Arrhythmogenic right ventricular cardiomyopathy (ARVC)],kegg:path:hsa04260[Cardiac muscle contraction],reactome:REACT_18312[],
CACNB4	AHI1	1-FACTA-related-drug->DrugBank:APRD00552[Spectrum],
CACNB4	CACNA1D	2-GoPubMed-related-disease->mesh:15624[Lambert-Eaton Myasthenic Syndrome],mesh:20361[Paraneoplastic Syndromes, Nervous System], 6-pathway->kegg:path:hsa05410[Hypertrophic cardiomyopathy (HCM)],kegg:path:hsa04010[MAPK signaling pathway],kegg:path:hsa05414[Dilated cardiomyopathy],kegg:path:hsa05412[Arrhythmogenic right ventricular cardiomyopathy (ARVC)],kegg:path:hsa04260[Cardiac muscle contraction],reactome:REACT_18312[],
CACNB4	CADM1	1-GoPubMed-related-GO->GO:0004385[guanylate kinase activity], 1-FACTA-related-drug->DrugBank:APRD00552[Spectrum],
CACNB4	TNIP2	2-GoPubMed-related-disease->mesh:15419[Spastic Paraplegia, Hereditary],mesh:4831[Epilepsies, Myoclonic],
CACNB4	CHRNA7	1-GoPubMed-related-GO->GO:0022831[narrow pore, gated channel activity], 3-GoPubMed-related-disease->mesh:20190[Myoclonic Epilepsy, Juvenile],mesh:17034[Epilepsy, Frontal Lobe],mesh:4831[Epilepsies, Myoclonic], 1-FACTA-related-gene->HUMANGGP:008639[CHRNA1], 2-FACTA-related-disease->UMLS:C0270853[juvenile myoclonic epilepsy],UMLS:C0014548[Epilepsy, Generalized],
CACNB4	SCN1A	3-GoPubMed-related-GO->GO:0022831[narrow pore, gated channel activity],GO:0022842[narrow pore channel activity],GO:0007416[synapse assembly], 4-GoPubMed-related-disease->mesh:3294[Seizures, Febrile],mesh:4831[Epilepsies, Myoclonic],mesh:20190[Myoclonic Epilepsy, Juvenile],mesh:4832[Epilepsy, Absence], 1-FACTA-related-drug->DrugBank:APRD00552[Spectrum],
CACNB4	SLC4A10	1-GoPubMed-related-disease->mesh:17034[Epilepsy, Frontal Lobe], 1-FACTA-related-disease->UMLS:C0014544[epilepsy],
CACNB4	NTRK1	1-FACTA-related-drug->DrugBank:APRD00552[Spectrum], 1-pathway->kegg:path:hsa04010[MAPK signaling pathway],
CACNB4	NLGN4X	3-GoPubMed-related-GO->GO:0007416[synapse assembly],GO:0050808[synapse organization],GO:0043062[extracellular structure organization], 1-FACTA-related-disease->UMLS:C0014544[epilepsy], 1-FACTA-related-drug->DrugBank:APRD00552[Spectrum],
CACNB4	CACNA1G	2-GoPubMed-related-disease->mesh:4832[Epilepsy, Absence],mesh:20190[Myoclonic Epilepsy, Juvenile], 3-FACTA-related-disease->UMLS:C0270862[hemiplegic migraine],UMLS:C0270853[juvenile myoclonic epilepsy],UMLS:C0014553[Epilepsy, Absence], 1-FACTA-related-drug->DrugBank:APRD00552[Spectrum], 2-pathway->kegg:path:hsa04010[MAPK signaling pathway],reactome:REACT_18312[],
CACNB4	CACNA1C	1-GoPubMed-related-GO->GO:0004385[guanylate kinase activity], 1-FACTA-related-gene->HUMANGGP:002682[CACNB2], 1-FACTA-related-disease->UMLS:C0270862[hemiplegic migraine], 6-pathway->kegg:path:hsa05410[Hypertrophic cardiomyopathy (HCM)],kegg:path:hsa04010[MAPK signaling pathway],kegg:path:hsa05414[Dilated cardiomyopathy],kegg:path:hsa05412[Arrhythmogenic right ventricular cardiomyopathy (ARVC)],kegg:path:hsa04260[Cardiac muscle contraction],reactome:REACT_18312[],
CACNB4	ITGB7	3-pathway->kegg:path:hsa05410[Hypertrophic cardiomyopathy (HCM)],kegg:path:hsa05414[Dilated cardiomyopathy],kegg:path:hsa05412[Arrhythmogenic right ventricular cardiomyopathy (ARVC)],
CACNB4	ITGB3	1-GoPubMed-related-GO->GO:0042615[CD154 receptor binding], 3-pathway->kegg:path:hsa05410[Hypertrophic cardiomyopathy (HCM)],kegg:path:hsa05414[Dilated cardiomyopathy],kegg:path:hsa05412[Arrhythmogenic right ventricular cardiomyopathy (ARVC)],
CACNB4	ITGA4	3-pathway->kegg:path:hsa05410[Hypertrophic cardiomyopathy (HCM)],kegg:path:hsa05414[Dilated cardiomyopathy],kegg:path:hsa05412[Arrhythmogenic right ventricular cardiomyopathy (ARVC)],
CACNB4	SLC9A6	1-FACTA-related-disease->UMLS:C0028738[nystagmus], 1-pathway->kegg:path:hsa04260[Cardiac muscle contraction],
CACNB4	CACNA1H	4-GoPubMed-related-disease->mesh:4832[Epilepsy, Absence],mesh:20190[Myoclonic Epilepsy, Juvenile],mesh:3294[Seizures, Febrile],mesh:4831[Epilepsies, Myoclonic], 4-FACTA-related-disease->UMLS:C0014553[Epilepsy, Absence],UMLS:C0014548[Epilepsy, Generalized],UMLS:C0270853[juvenile myoclonic epilepsy],UMLS:C0014544[epilepsy], 2-pathway->kegg:path:hsa04010[MAPK signaling pathway],reactome:REACT_18312[],
CACNB4	CNTNAP2	2-GoPubMed-related-GO->GO:0022831[narrow pore, gated channel activity],GO:0022842[narrow pore channel activity], 1-FACTA-related-drug->DrugBank:APRD00552[Spectrum],
CACNG2	NBEA	1-GoPubMed-related-GO->GO:0043495[protein anchor], 1-FACTA-related-disease->UMLS:C0260662[Hearing Disorders],
CACNG2	TDO2	2-FACTA-related-disease->UMLS:C0005586[Bipolar Disorder],UMLS:C0036341[schizophrenia], 1-FACTA-related-drug->DrugBank:APRD00280[Frontal],
CACNG2	CACNA1F	4-GoPubMed-related-GO->GO:0007268[synaptic transmission],GO:0050808[synapse organization],GO:0019226[transmission of nerve impulse],GO:0043062[extracellular structure organization], 1-GoPubMed-related-disease->mesh:53447[Channelopathies], 5-pathway->kegg:path:hsa05410[Hypertrophic cardiomyopathy (HCM)],kegg:path:hsa04010[MAPK signaling pathway],kegg:path:hsa05414[Dilated cardiomyopathy],kegg:path:hsa05412[Arrhythmogenic right ventricular cardiomyopathy (ARVC)],kegg:path:hsa04260[Cardiac muscle contraction],
CACNG2	CACNA1D	5-pathway->kegg:path:hsa05410[Hypertrophic cardiomyopathy (HCM)],kegg:path:hsa04010[MAPK signaling pathway],kegg:path:hsa05414[Dilated cardiomyopathy],kegg:path:hsa05412[Arrhythmogenic right ventricular cardiomyopathy (ARVC)],kegg:path:hsa04260[Cardiac muscle contraction],
CACNG2	RELN	1-FACTA-related-drug->DrugBank:APRD00280[Frontal],
CACNG2	DISC1	2-FACTA-related-disease->UMLS:C0036341[schizophrenia],UMLS:C0005586[Bipolar Disorder], 1-FACTA-related-drug->DrugBank:APRD00280[Frontal],
CACNG2	DMD	3-pathway->kegg:path:hsa05410[Hypertrophic cardiomyopathy (HCM)],kegg:path:hsa05414[Dilated cardiomyopathy],kegg:path:hsa05412[Arrhythmogenic right ventricular cardiomyopathy (ARVC)],
CACNG2	SLC9A6	1-pathway->kegg:path:hsa04260[Cardiac muscle contraction],
CACNG2	CACNA1G	2-GoPubMed-related-disease->mesh:4832[Epilepsy, Absence],mesh:4829[Epilepsy, Generalized], 1-FACTA-related-disease->UMLS:C0014553[Epilepsy, Absence], 1-pathway->kegg:path:hsa04010[MAPK signaling pathway],
CACNG2	ITGB7	2-FACTA-related-disease->UMLS:C0001511[Adhesion],UMLS:C0006826[cancer], 3-pathway->kegg:path:hsa05410[Hypertrophic cardiomyopathy (HCM)],kegg:path:hsa05414[Dilated cardiomyopathy],kegg:path:hsa05412[Arrhythmogenic right ventricular cardiomyopathy (ARVC)],
CACNG2	CACNA1C	1-GoPubMed-related-disease->mesh:53447[Channelopathies], 1-FACTA-related-disease->UMLS:C0005586[Bipolar Disorder], 5-pathway->kegg:path:hsa05410[Hypertrophic cardiomyopathy (HCM)],kegg:path:hsa04010[MAPK signaling pathway],kegg:path:hsa05414[Dilated cardiomyopathy],kegg:path:hsa05412[Arrhythmogenic right ventricular cardiomyopathy (ARVC)],kegg:path:hsa04260[Cardiac muscle contraction],
CACNG2	SYNGAP1	1-GoPubMed-related-GO->GO:0050877[neurological system process], 3-GoPubMed-related-disease->mesh:9461[Neurologic Manifestations],mesh:12816[Signs and Symptoms],mesh:9422[Nervous System Diseases], 1-FACTA-related-disease->UMLS:C0036341[schizophrenia],
CACNG2	NTNG1	1-GoPubMed-related-GO->GO:0060074[synapse maturation], 2-GoPubMed-related-disease->mesh:12640[Seizures],mesh:4827[Epilepsy], 3-FACTA-related-disease->UMLS:C0036341[schizophrenia],UMLS:C0005586[Bipolar Disorder],UMLS:C0014544[epilepsy],
CACNG2	SLC1A1	1-FACTA-related-drug->DrugBank:APRD00280[Frontal],
CACNG2	CACNA1H	4-GoPubMed-related-disease->mesh:4832[Epilepsy, Absence],mesh:4829[Epilepsy, Generalized],mesh:53447[Channelopathies],mesh:4827[Epilepsy], 2-FACTA-related-disease->UMLS:C0014553[Epilepsy, Absence],UMLS:C0014544[epilepsy], 1-pathway->kegg:path:hsa04010[MAPK signaling pathway],
CACNG2	FOXP2	1-FACTA-related-drug->DrugBank:APRD00280[Frontal],
CACNG2	SHANK2	1-GoPubMed-related-gene->85358[SHANK3], 1-FACTA-related-drug->DrugBank:APRD00280[Frontal],
CAMK2A	DISC1	1-GoPubMed-related-GO->GO:0016358[dendrite development], 2-FACTA-related-disease->UMLS:C0036341[schizophrenia],UMLS:C0005586[Bipolar Disorder], 2-FACTA-related-drug->DrugBank:APRD00280[Frontal],DrugBank:BIOD00057[Fragment],
CAMK2A	CREBBP	2-GoPubMed-related-disease->mesh:12415[Rubinstein-Taybi Syndrome],mesh:4413[Dysostoses], 5-pathway->kegg:path:hsa04916[Melanogenesis],kegg:path:hsa04310[Wnt signaling pathway],kegg:path:hsa05152[Tuberculosis],nci_nature_pid:IFN-gamma_pathway[],kegg:path:hsa04720[Long-term potentiation],
CAMK2A	NSD1	2-GoPubMed-related-gene->84254[CAMKK1],10645[CAMKK2], 1-GoPubMed-related-GO->GO:0004683[calmodulin-dependent protein kinase activity], 1-GoPubMed-related-disease->mesh:12415[Rubinstein-Taybi Syndrome],
CAMK2A	MED12	1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
CAMK2A	MECP2	1-GoPubMed-related-disease->mesh:12415[Rubinstein-Taybi Syndrome], 1-FACTA-related-drug->DrugBank:APRD00280[Frontal],
CAMK2A	PTGS2	1-FACTA-related-gene->HUMANGGP:033431[prostaglandin-endoperoxide synthase 2],
CAMK2A	PLCD1	1-FACTA-related-drug->DrugBank:BIOD00057[Fragment], 1-pathway->kegg:path:hsa04020[Calcium signaling pathway],
CAMK2A	LRRC1	1-FACTA-related-disease->UMLS:C0014544[epilepsy], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
CAMK2A	MAOA	3-FACTA-related-drug->DrugBank:APRD00753[Flurbiprofen],DrugBank:BIOD00057[Fragment],DrugBank:APRD00280[Frontal],
CAMK2A	SLC1A1	1-FACTA-related-drug->DrugBank:APRD00280[Frontal],
CAMK2A	SHANK3	1-GoPubMed-related-gene->10369[CACNG2], 2-GoPubMed-related-GO->GO:0048813[dendrite morphogenesis],GO:0016358[dendrite development], 2-FACTA-related-drug->DrugBank:APRD00280[Frontal],DrugBank:BIOD00057[Fragment],
CAMK2A	APBA2	1-FACTA-related-gene->HUMANGGP:031986[MINT2], 1-FACTA-related-disease->UMLS:C0036341[schizophrenia],
CAMK2A	RELN	1-FACTA-related-drug->DrugBank:APRD00280[Frontal],
CAMK2A	FOXP2	2-FACTA-related-drug->DrugBank:APRD00280[Frontal],DrugBank:BIOD00057[Fragment],
CAMK2A	OXTR	1-FACTA-related-drug->DrugBank:APRD00753[Flurbiprofen], 1-pathway->kegg:path:hsa04020[Calcium signaling pathway],
CAMK2A	GABRB1	3-GoPubMed-related-GO->GO:0016934[extracellular-glycine-gated chloride channel activity],GO:0016933[extracellular-glycine-gated ion channel activity],GO:0005237[inhibitory extracellular ligand-gated ion channel activity], 1-FACTA-related-disease->UMLS:C0005586[Bipolar Disorder], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
CAMK2A	TPH2	2-GoPubMed-related-disease->mesh:6948[Hyperkinesis],mesh:11180[Postmortem Changes], 2-FACTA-related-disease->UMLS:C1269683[major depression],UMLS:C0812393[suicide], 1-FACTA-related-drug->DrugBank:APRD00280[Frontal],
CAMK2A	ATP2B2	1-GoPubMed-related-GO->GO:0005516[calmodulin binding], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment], 1-pathway->kegg:path:hsa04020[Calcium signaling pathway],
CD109	NTRK1	3-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00631[Gel],
CD109	NPAS2	1-GoPubMed-related-disease->mesh:12892[Sleep Deprivation], 3-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00631[Gel],
CD109	HOXB1	3-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00631[Gel],DrugBank:APRD00552[Spectrum],
CD109	ITGB3	1-GoPubMed-related-GO->GO:0043863[4-hydroxy-2-ketopimelate aldolase activity], 1-GoPubMed-related-disease->mesh:5331[Fetomaternal Transfusion], 1-FACTA-related-disease->UMLS:C1849843[HPA], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
CD109	AHI1	2-GoPubMed-related-GO->GO:0001578[microtubule bundle formation],GO:0046876[3,4-didehydroretinal binding], 3-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00631[Gel],
CD109	SYNE1	3-GoPubMed-related-gene->9754[STARD8],11074[TRIM31],26038[CHD5], 3-FACTA-related-gene->HUMANGGP:001444[SYNE1],HUMANGGP:004013[LGR6],HUMANGGP:022787[CHD5], 1-FACTA-related-disease->UMLS:C0403592[CAN],
CD109	CREBBP	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
CD109	DHCR7	3-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
CD109	NFIA	2-GoPubMed-related-disease->mesh:12892[Sleep Deprivation],mesh:18287[Carcinoma, Large Cell],
CD109	CADM1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
CD109	CA6	3-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00631[Gel],
CD109	CHD7	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
CD109	CAMTA1	1-GoPubMed-related-gene->26038[CHD5], 1-FACTA-related-gene->HUMANGGP:022787[CHD5],
CD109	SHANK3	3-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
CD109	CNTNAP2	3-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
CD109	HRAS	1-GoPubMed-related-gene->54922[RASIP1], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
CEP290	CNTNAP2	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
CEP290	HTR1B	1-FACTA-related-drug->DrugBank:APRD00530[Portal],
CEP290	AHI1	4-GoPubMed-related-gene->200894[ARL13B],57545[CC2D2A],91147[TMEM67],23322[RPGRIP1L], 3-GoPubMed-related-GO->GO:0007099[centriole replication],GO:0042384[cilium assembly],GO:0060271[cilium morphogenesis], 5-GoPubMed-related-disease->mesh:17689[Polydactyly],mesh:21782[Multicystic Dysplastic Kidney],mesh:4677[Encephalocele],mesh:9123[Muscle Hypotonia],mesh:20788[Bardet-Biedl Syndrome], 6-FACTA-related-gene->HUMANGGP:022096[AHI1],HUMANGGP:019523[JBTS6],HUMANGGP:003757[CC2D2A],HUMANGGP:023286[RPGRIP1L],HUMANGGP:019521[CEP290],HUMANGGP:009937[MKS1], 11-FACTA-related-disease->UMLS:C1853153[JBTS6],UMLS:C1846357[MKS3],UMLS:C0431399[Joubert syndrome],UMLS:C1848526[PCH2],UMLS:C0687120[Nephronophthisis],UMLS:C1847013[NPHP4],UMLS:C0349653[CDG Ia],UMLS:C1510460[OFD1],UMLS:C0022679[renal cyst],UMLS:C0339527[LCA],UMLS:C0752166[Bardet-Biedl syndrome], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
CEP290	SHANK3	2-GoPubMed-related-disease->mesh:9123[Muscle Hypotonia],mesh:3103[Coloboma], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
CEP290	CREBBP	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
CEP290	NLGN4X	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
CEP290	NTRK1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
CEP290	CADM1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
CEP290	NPAS2	3-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00530[Portal],
CEP290	HOXB1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
CEP290	CACNA1G	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
CEP290	DHCR7	2-GoPubMed-related-disease->mesh:17689[Polydactyly],mesh:17880[Limb Deformities, Congenital], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
CEP290	NSD1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
CEP290	MBD1	1-FACTA-related-drug->DrugBank:APRD00530[Portal],
CEP290	FOXG1	1-FACTA-related-drug->DrugBank:APRD00530[Portal],
CEP290	CHD7	1-GoPubMed-related-disease->mesh:3103[Coloboma], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
CHI3L1	NSD1	3-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00080[Freeze],
CHI3L1	KCNMA1	1-GoPubMed-related-gene->84417[C2orf40], 1-FACTA-related-drug->DrugBank:APRD00631[Gel],
CHI3L1	DHCR7	1-FACTA-related-disease->UMLS:C0263541[Founder], 4-FACTA-related-drug->DrugBank:APRD00627[Progesterone],DrugBank:APRD00506[Spectrum],DrugBank:APRD00080[Freeze],DrugBank:APRD00552[Spectrum],
CHI3L1	NRP2	1-GoPubMed-related-gene->223117[SEMA3D], 3-GoPubMed-related-GO->GO:0030247[polysaccharide binding],GO:0001871[pattern binding],GO:0005125[cytokine activity], 1-FACTA-related-disease->UMLS:C0238478[TEC],
CHI3L1	CREBBP	3-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00627[Progesterone],
CHI3L1	AHI1	3-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00631[Gel],
CHI3L1	ALOX5AP	2-GoPubMed-related-gene->526[ATP6V1B2],7805[LAPTM5], 2-FACTA-related-disease->UMLS:C0158168[villonodular synovitis],UMLS:C0039106[Synovitis, Pigmented Villonodular],
CHI3L1	HRAS	2-FACTA-related-gene->HUMANGGP:030554[PLEKHA8],HUMANGGP:019184[FAM46A], 1-FACTA-related-drug->DrugBank:APRD00627[Progesterone],
CHI3L1	CA6	3-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00631[Gel],
CHI3L1	CNTNAP2	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
CHI3L1	DCX	3-FACTA-related-gene->HUMANGGP:003561[C20orf42],HUMANGGP:012891[GALNT13],HUMANGGP:015105[RNF135], 1-FACTA-related-drug->DrugBank:APRD00106[Norplant],
CHI3L1	CTTNBP2	5-FACTA-related-gene->HUMANGGP:019471[CTTNBP2],HUMANGGP:003561[C20orf42],HUMANGGP:012891[GALNT13],HUMANGGP:015105[RNF135],HUMANGGP:037959[CHI3L1], 2-FACTA-related-disease->UMLS:C1336751[PLAT],UMLS:C0017636[glioblastoma], 1-FACTA-related-drug->DrugBank:APRD00106[Norplant],
CHI3L1	NTRK1	4-FACTA-related-drug->DrugBank:APRD00627[Progesterone],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00631[Gel],
CHI3L1	NPAS2	3-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00631[Gel],
CHI3L1	HOXB1	5-FACTA-related-drug->DrugBank:BIOD00030[Urokinase],DrugBank:APRD00506[Spectrum],DrugBank:APRD00631[Gel],DrugBank:APRD00552[Spectrum],DrugBank:APRD00627[Progesterone],
CHI3L1	F13A1	2-FACTA-related-disease->UMLS:C0795800[trisomy 1q],UMLS:C1852996[COL2A1], 2-FACTA-related-drug->DrugBank:BIOD00030[Urokinase],DrugBank:APRD00631[Gel],
CHRM2	PLCD1	1-GoPubMed-related-GO->GO:0004703[G-protein coupled receptor kinase activity], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment], 1-pathway->kegg:path:hsa04020[Calcium signaling pathway],
CHRM2	LRRC1	1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
CHRM2	MARK1	1-FACTA-related-disease->UMLS:C1332347[ADH],
CHRM2	OPRM1	2-GoPubMed-related-GO->GO:0043279[response to alkaloid],GO:0035094[response to nicotine], 1-GoPubMed-related-disease->mesh:6556[Heroin Dependence], 2-FACTA-related-gene->HUMANGGP:016831[PDYN],HUMANGGP:034085[CHRM1], 2-FACTA-related-disease->UMLS:C1510472[drug addiction],UMLS:C0019337[Heroin Dependence], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment], 2-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],reactome:REACT_19231[],
CHRM2	SLC1A1	1-FACTA-related-disease->UMLS:C0149654[conduct disorder], 1-FACTA-related-drug->DrugBank:APRD00280[Frontal],
CHRM2	CHRNA7	1-GoPubMed-related-disease->mesh:14029[Tobacco Use Disorder], 1-FACTA-related-gene->HUMANGGP:034085[CHRM1], 1-FACTA-related-disease->UMLS:C0028043[nicotine addiction], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment], 2-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],kegg:path:hsa04020[Calcium signaling pathway],
CHRM2	FOXP2	2-FACTA-related-drug->DrugBank:APRD00280[Frontal],DrugBank:BIOD00057[Fragment],
CHRM2	ATP2B2	1-FACTA-related-drug->DrugBank:BIOD00057[Fragment], 1-pathway->kegg:path:hsa04020[Calcium signaling pathway],
CHRM2	HTR3A	3-FACTA-related-gene->HUMANGGP:014538[HTR3A],HUMANGGP:036176[SLC29A1],HUMANGGP:020893[ADRA1A], 3-FACTA-related-disease->UMLS:C0233523[antisocial behavior],UMLS:C1510472[drug addiction],UMLS:C0019337[Heroin Dependence],
CHRM2	HTR1B	1-FACTA-related-disease->UMLS:C0233523[antisocial behavior], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment], 2-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],reactome:REACT_19231[],
CHRM2	GABRB1	1-GoPubMed-related-gene->2555[GABRA2], 1-GoPubMed-related-disease->mesh:437[Alcoholism], 1-FACTA-related-gene->HUMANGGP:023025[GABRA2], 3-FACTA-related-disease->UMLS:C1332347[ADH],UMLS:C0001973[Alcoholism],UMLS:C0003431[Antisocial Personality Disorder], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
CHRM2	GABRA4	1-GoPubMed-related-gene->2555[GABRA2], 2-GoPubMed-related-disease->mesh:14029[Tobacco Use Disorder],mesh:437[Alcoholism], 1-FACTA-related-gene->HUMANGGP:023025[GABRA2], 3-FACTA-related-disease->UMLS:C0028043[nicotine addiction],UMLS:C1510472[drug addiction],UMLS:C0525045[Mood Disorders], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
CHRM2	TDO2	3-FACTA-related-disease->UMLS:C1510472[drug addiction],UMLS:C1269683[major depression],UMLS:C0001973[Alcoholism], 1-FACTA-related-drug->DrugBank:APRD00280[Frontal],
CHRM2	SLC6A4	1-FACTA-related-disease->UMLS:C0233523[antisocial behavior], 2-FACTA-related-drug->DrugBank:APRD00280[Frontal],DrugBank:BIOD00057[Fragment],
CHRM2	RELN	1-GoPubMed-related-disease->mesh:2828[Choristoma], 1-FACTA-related-drug->DrugBank:APRD00280[Frontal],
CHRM2	SLC9A9	2-FACTA-related-gene->HUMANGGP:020893[ADRA1A],HUMANGGP:039570[GRIN2A],
CHRNA4	SCN2A	3-GoPubMed-related-disease->mesh:20936[Epilepsy, Benign Neonatal],mesh:3294[Seizures, Febrile],mesh:53447[Channelopathies], 1-FACTA-related-gene->HUMANGGP:036212[CHRNB], 4-FACTA-related-disease->UMLS:C0220669[Benign Familial Neonatal Convulsions],UMLS:C0270851[Epilepsy, Benign Neonatal],UMLS:C1720983[Channelopathies],UMLS:C0270850[IGE], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
CHRNA4	SCN1A	4-GoPubMed-related-GO->GO:0022831[narrow pore, gated channel activity],GO:0022842[narrow pore channel activity],GO:0050893[sensory processing],GO:0051899[membrane depolarization], 5-GoPubMed-related-disease->mesh:3294[Seizures, Febrile],mesh:20936[Epilepsy, Benign Neonatal],mesh:20190[Myoclonic Epilepsy, Juvenile],mesh:53447[Channelopathies],mesh:4832[Epilepsy, Absence], 1-FACTA-related-gene->HUMANGGP:036212[CHRNB], 1-FACTA-related-disease->UMLS:C0220669[Benign Familial Neonatal Convulsions], 2-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:EXPT00573[Aspartic Acid],
CHRNA4	GRIN2B	2-GoPubMed-related-GO->GO:0004972[N-methyl-D-aspartate selective glutamate receptor activity],GO:0004970[ionotropic glutamate receptor activity], 1-FACTA-related-disease->UMLS:C0028043[nicotine addiction], 3-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:BIOD00057[Fragment],DrugBank:APRD00631[Gel], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
CHRNA4	CACNA1G	2-GoPubMed-related-disease->mesh:4832[Epilepsy, Absence],mesh:20190[Myoclonic Epilepsy, Juvenile], 1-FACTA-related-disease->UMLS:C0270853[juvenile myoclonic epilepsy],
CHRNA4	CACNA1H	5-GoPubMed-related-disease->mesh:4832[Epilepsy, Absence],mesh:20936[Epilepsy, Benign Neonatal],mesh:20190[Myoclonic Epilepsy, Juvenile],mesh:53447[Channelopathies],mesh:3294[Seizures, Febrile], 1-FACTA-related-disease->UMLS:C0270853[juvenile myoclonic epilepsy],
CHRNA4	EN2	3-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00450[Norepinephrine],DrugBank:APRD00631[Gel],
CHRNA4	ALDH5A1	2-GoPubMed-related-disease->mesh:4832[Epilepsy, Absence],mesh:20190[Myoclonic Epilepsy, Juvenile], 1-FACTA-related-disease->UMLS:C0270853[juvenile myoclonic epilepsy], 2-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00631[Gel],
CHRNA4	SLC1A1	2-GoPubMed-related-GO->GO:0004972[N-methyl-D-aspartate selective glutamate receptor activity],GO:0004970[ionotropic glutamate receptor activity], 2-FACTA-related-drug->DrugBank:EXPT00573[Aspartic Acid],DrugBank:APRD00280[Frontal],
CHRNA4	CHRNA7	7-GoPubMed-related-gene->1142[CHRNB3],55584[CHRNA9],8973[CHRNA6],57053[CHRNA10],1135[CHRNA2],1141[CHRNB2],1138[CHRNA5], 4-GoPubMed-related-GO->GO:0050893[sensory processing],GO:0050000[chromosome localization],GO:0051640[organelle localization],GO:0022831[narrow pore, gated channel activity], 4-GoPubMed-related-disease->mesh:20190[Myoclonic Epilepsy, Juvenile],mesh:20936[Epilepsy, Benign Neonatal],mesh:14029[Tobacco Use Disorder],mesh:17034[Epilepsy, Frontal Lobe], 5-FACTA-related-gene->HUMANGGP:017687[CHRNA6],HUMANGGP:036210[CHRNB1],HUMANGGP:002476[CHRNB2],HUMANGGP:028113[CHRNA5],HUMANGGP:036604[CHRNB4], 4-FACTA-related-disease->UMLS:C0270851[Epilepsy, Benign Neonatal],UMLS:C0270853[juvenile myoclonic epilepsy],UMLS:C0085541[Epilepsy, Frontal Lobe],UMLS:C0028043[nicotine addiction], 2-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:BIOD00057[Fragment], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
CHRNA4	FOXP2	1-FACTA-related-disease->UMLS:C1838601[RP11], 2-FACTA-related-drug->DrugBank:APRD00280[Frontal],DrugBank:BIOD00057[Fragment],
CHRNA4	MYO1A	2-FACTA-related-drug->DrugBank:EXPT00573[Aspartic Acid],DrugBank:APRD00631[Gel],
CHRNA4	OXTR	2-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:APRD00396[Estrogens], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
CHRNA4	SLC4A10	1-GoPubMed-related-GO->GO:0022857[transmembrane transporter activity], 1-GoPubMed-related-disease->mesh:17034[Epilepsy, Frontal Lobe], 1-FACTA-related-disease->UMLS:C0085541[Epilepsy, Frontal Lobe],
CHRNA4	TPH2	1-GoPubMed-related-GO->GO:0005484[SNAP receptor activity], 1-GoPubMed-related-disease->mesh:14029[Tobacco Use Disorder], 1-FACTA-related-gene->HUMANGGP:012079[GFOD1], 4-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:APRD00280[Frontal],DrugBank:APRD00396[Estrogens],DrugBank:APRD00450[Norepinephrine],
CHRNA4	HTR3A	2-GoPubMed-related-GO->GO:0022831[narrow pore, gated channel activity],GO:0022842[narrow pore channel activity], 2-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:APRD00450[Norepinephrine],
CHRNA4	HTR1B	1-GoPubMed-related-GO->GO:0005484[SNAP receptor activity], 4-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:BIOD00057[Fragment],DrugBank:EXPT00494[Alanine],DrugBank:APRD00450[Norepinephrine], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
CHRNA4	RAI1	1-FACTA-related-disease->UMLS:C0752287[Sleep Disorders, Intrinsic], 1-FACTA-related-drug->DrugBank:APRD00631[Gel],
CHRNA4	GABRB1	1-FACTA-related-drug->DrugBank:BIOD00057[Fragment], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
CHRNA4	GABRA4	1-GoPubMed-related-gene->1142[CHRNB3], 2-GoPubMed-related-GO->GO:0007268[synaptic transmission],GO:0019226[transmission of nerve impulse], 1-GoPubMed-related-disease->mesh:14029[Tobacco Use Disorder], 1-FACTA-related-gene->HUMANGGP:028113[CHRNA5], 1-FACTA-related-disease->UMLS:C0028043[nicotine addiction], 1-FACTA-related-drug->DrugBank:APRD00631[Gel], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
CHRNA4	DISC1	5-FACTA-related-drug->DrugBank:APRD00280[Frontal],DrugBank:EXPT00573[Aspartic Acid],DrugBank:BIOD00057[Fragment],DrugBank:EXPT00494[Alanine],DrugBank:APRD00631[Gel],
CHRNA5	FGD1	1-FACTA-related-drug->DrugBank:APRD00627[Progesterone],
CHRNA5	BZRAP1	2-GoPubMed-related-disease->mesh:437[Alcoholism],mesh:19966[Substance-Related Disorders],
CHRNA5	CHRNA7	6-GoPubMed-related-gene->1142[CHRNB3],55584[CHRNA9],8973[CHRNA6],57053[CHRNA10],1135[CHRNA2],1141[CHRNB2], 3-GoPubMed-related-GO->GO:0050000[chromosome localization],GO:0051640[organelle localization],GO:0008134[transcription factor binding], 2-GoPubMed-related-disease->mesh:14029[Tobacco Use Disorder],mesh:17034[Epilepsy, Frontal Lobe], 5-FACTA-related-gene->HUMANGGP:017687[CHRNA6],HUMANGGP:036210[CHRNB1],HUMANGGP:002476[CHRNB2],HUMANGGP:028113[CHRNA5],HUMANGGP:036604[CHRNB4], 3-FACTA-related-disease->UMLS:C0085541[Epilepsy, Frontal Lobe],UMLS:C0036337[schizoaffective disorder],UMLS:C0028043[nicotine addiction], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
CHRNA5	MED12	1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
CHRNA5	SLC4A10	1-GoPubMed-related-disease->mesh:17034[Epilepsy, Frontal Lobe], 1-FACTA-related-disease->UMLS:C0085541[Epilepsy, Frontal Lobe],
CHRNA5	PLCD1	1-FACTA-related-disease->UMLS:C0242379[lung cancer], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
CHRNA5	LRRC1	1-GoPubMed-related-GO->GO:0051641[cellular localization], 1-GoPubMed-related-disease->mesh:4827[Epilepsy], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
CHRNA5	NLGN3	1-GoPubMed-related-disease->mesh:19970[Cocaine-Related Disorders], 2-FACTA-related-disease->UMLS:C0600427[cocaine addiction],UMLS:C0236736[Cocaine-Related Disorders],
CHRNA5	NLGN1	1-GoPubMed-related-disease->mesh:19970[Cocaine-Related Disorders], 2-FACTA-related-disease->UMLS:C0600427[cocaine addiction],UMLS:C0236736[Cocaine-Related Disorders],
CHRNA5	MARK1	2-FACTA-related-disease->UMLS:C0040336[Tobacco Use Disorder],UMLS:C0007131[non-small cell lung cancer],
CHRNA5	OPRM1	1-GoPubMed-related-gene->1135[CHRNA2], 2-FACTA-related-disease->UMLS:C0600427[cocaine addiction],UMLS:C0038586[substance use disorders], 2-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00627[Progesterone], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
CHRNA5	GABRB1	1-GoPubMed-related-disease->mesh:437[Alcoholism], 1-FACTA-related-disease->UMLS:C0036337[schizoaffective disorder], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
CHRNA5	GABRA4	1-GoPubMed-related-gene->1142[CHRNB3], 4-GoPubMed-related-disease->mesh:14029[Tobacco Use Disorder],mesh:19966[Substance-Related Disorders],mesh:437[Alcoholism],mesh:4828[Epilepsies, Partial], 2-FACTA-related-gene->HUMANGGP:042295[KCNJ6],HUMANGGP:028113[CHRNA5], 3-FACTA-related-disease->UMLS:C0028043[nicotine addiction],UMLS:C0036337[schizoaffective disorder],UMLS:C0040336[Tobacco Use Disorder], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
CHRNA5	PDZD4	3-GoPubMed-related-disease->mesh:8175[Lung Neoplasms],mesh:12142[Respiratory Tract Neoplasms],mesh:13899[Thoracic Neoplasms],
CHRNA5	LAMB1	1-GoPubMed-related-GO->GO:0050000[chromosome localization], 2-FACTA-related-disease->UMLS:C0600427[cocaine addiction],UMLS:C0236736[Cocaine-Related Disorders], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
CHRNA5	NRXN1	1-GoPubMed-related-disease->mesh:14029[Tobacco Use Disorder], 2-FACTA-related-disease->UMLS:C0028043[nicotine addiction],UMLS:C0040336[Tobacco Use Disorder],
CHRNA5	CNTN4	1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
CHRNB2	DISC1	2-FACTA-related-drug->DrugBank:APRD00280[Frontal],DrugBank:BIOD00057[Fragment],
CHRNB2	CACNA1C	2-GoPubMed-related-disease->mesh:53447[Channelopathies],mesh:20385[Myokymia],
CHRNB2	SCN2A	3-GoPubMed-related-disease->mesh:20936[Epilepsy, Benign Neonatal],mesh:3294[Seizures, Febrile],mesh:53447[Channelopathies], 2-FACTA-related-gene->HUMANGGP:020586[SCN1B],HUMANGGP:023447[GABRA1], 2-FACTA-related-disease->UMLS:C0270851[Epilepsy, Benign Neonatal],UMLS:C0270850[IGE], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
CHRNB2	SLC1A1	1-FACTA-related-drug->DrugBank:APRD00280[Frontal],
CHRNB2	SCN1A	2-GoPubMed-related-GO->GO:0022831[narrow pore, gated channel activity],GO:0022842[narrow pore channel activity], 3-GoPubMed-related-disease->mesh:3294[Seizures, Febrile],mesh:20936[Epilepsy, Benign Neonatal],mesh:53447[Channelopathies], 1-FACTA-related-gene->HUMANGGP:020586[SCN1B], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
CHRNB2	ATP2B2	1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
CHRNB2	PLCD1	1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
CHRNB2	CACNA1H	3-GoPubMed-related-disease->mesh:20936[Epilepsy, Benign Neonatal],mesh:53447[Channelopathies],mesh:3294[Seizures, Febrile],
CHRNB2	LRRC1	3-GoPubMed-related-GO->GO:0003774[motor activity],GO:0017111[nucleoside-triphosphatase activity],GO:0051641[cellular localization], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
CHRNB2	GABRB1	1-FACTA-related-gene->HUMANGGP:023447[GABRA1], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
CHRNB2	GABRA4	1-GoPubMed-related-gene->1142[CHRNB3], 3-GoPubMed-related-GO->GO:0007268[synaptic transmission],GO:0019226[transmission of nerve impulse],GO:0050877[neurological system process], 1-GoPubMed-related-disease->mesh:14029[Tobacco Use Disorder], 2-FACTA-related-gene->HUMANGGP:023447[GABRA1],HUMANGGP:028113[CHRNA5], 2-FACTA-related-disease->UMLS:C0028043[nicotine addiction],UMLS:C0040336[Tobacco Use Disorder], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
CHRNB2	RAI1	1-FACTA-related-disease->UMLS:C0752287[Sleep Disorders, Intrinsic],
CHRNB2	CHRNA7	5-GoPubMed-related-gene->1142[CHRNB3],55584[CHRNA9],8973[CHRNA6],57053[CHRNA10],1135[CHRNA2], 3-GoPubMed-related-GO->GO:0050000[chromosome localization],GO:0051640[organelle localization],GO:0022831[narrow pore, gated channel activity], 3-GoPubMed-related-disease->mesh:20936[Epilepsy, Benign Neonatal],mesh:14029[Tobacco Use Disorder],mesh:17034[Epilepsy, Frontal Lobe], 5-FACTA-related-gene->HUMANGGP:002240[CHRNA7],HUMANGGP:017687[CHRNA6],HUMANGGP:002476[CHRNB2],HUMANGGP:028113[CHRNA5],HUMANGGP:036604[CHRNB4], 3-FACTA-related-disease->UMLS:C0270851[Epilepsy, Benign Neonatal],UMLS:C0085541[Epilepsy, Frontal Lobe],UMLS:C0028043[nicotine addiction], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
CHRNB2	SLC4A10	1-GoPubMed-related-GO->GO:0022857[transmembrane transporter activity], 1-GoPubMed-related-disease->mesh:17034[Epilepsy, Frontal Lobe], 1-FACTA-related-disease->UMLS:C0085541[Epilepsy, Frontal Lobe],
CHRNB2	FOXP2	2-FACTA-related-drug->DrugBank:APRD00280[Frontal],DrugBank:BIOD00057[Fragment],
CHRNB2	NRXN1	1-GoPubMed-related-disease->mesh:14029[Tobacco Use Disorder], 2-FACTA-related-disease->UMLS:C0028043[nicotine addiction],UMLS:C0040336[Tobacco Use Disorder],
CHRNB3	ARHGAP15	1-GoPubMed-related-GO->GO:0005488[binding],
CHRNB3	CDH8	1-GoPubMed-related-GO->GO:0005488[binding],
CHRNB3	BZRAP1	1-GoPubMed-related-GO->GO:0005488[binding], 1-GoPubMed-related-disease->mesh:19966[Substance-Related Disorders], 1-FACTA-related-disease->UMLS:C0004352[autism],
CHRNB3	SLC4A10	1-GoPubMed-related-disease->mesh:17034[Epilepsy, Frontal Lobe], 1-FACTA-related-disease->UMLS:C0085541[Epilepsy, Frontal Lobe],
CHRNB3	GPR139	1-GoPubMed-related-GO->GO:0005488[binding],
CHRNB3	SCN1A	4-GoPubMed-related-disease->mesh:4831[Epilepsies, Myoclonic],mesh:20190[Myoclonic Epilepsy, Juvenile],mesh:4829[Epilepsy, Generalized],mesh:4832[Epilepsy, Absence], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
CHRNB3	PLCD1	1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
CHRNB3	LRRC1	2-GoPubMed-related-GO->GO:0051641[cellular localization],GO:0005488[binding], 4-GoPubMed-related-disease->mesh:20190[Myoclonic Epilepsy, Juvenile],mesh:4831[Epilepsies, Myoclonic],mesh:4830[Epilepsy, Tonic-Clonic],mesh:4829[Epilepsy, Generalized], 1-FACTA-related-disease->UMLS:C0270853[juvenile myoclonic epilepsy], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
CHRNB3	NLGN1	1-GoPubMed-related-GO->GO:0005488[binding], 1-FACTA-related-disease->UMLS:C0004352[autism],
CHRNB3	PCDH19	2-GoPubMed-related-disease->mesh:4831[Epilepsies, Myoclonic],mesh:12640[Seizures], 2-FACTA-related-disease->UMLS:C0014550[Epilepsies, Myoclonic],UMLS:C0004352[autism],
CHRNB3	ALDH5A1	2-GoPubMed-related-disease->mesh:4832[Epilepsy, Absence],mesh:20190[Myoclonic Epilepsy, Juvenile], 2-FACTA-related-disease->UMLS:C0270853[juvenile myoclonic epilepsy],UMLS:C0014549[Epilepsy, Tonic-Clonic], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
CHRNB3	SEMA5A	1-GoPubMed-related-GO->GO:0005488[binding], 2-FACTA-related-disease->UMLS:C0014550[Epilepsies, Myoclonic],UMLS:C0004352[autism], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
CHRNB3	RBMS3	1-GoPubMed-related-GO->GO:0005488[binding],
CHRNB3	CHRNA7	7-GoPubMed-related-gene->55584[CHRNA9],8973[CHRNA6],57053[CHRNA10],1135[CHRNA2],1141[CHRNB2],1138[CHRNA5],5533[PPP3CC], 2-GoPubMed-related-GO->GO:0050000[chromosome localization],GO:0051640[organelle localization], 4-GoPubMed-related-disease->mesh:20190[Myoclonic Epilepsy, Juvenile],mesh:14029[Tobacco Use Disorder],mesh:17034[Epilepsy, Frontal Lobe],mesh:4831[Epilepsies, Myoclonic], 6-FACTA-related-gene->HUMANGGP:002240[CHRNA7],HUMANGGP:017687[CHRNA6],HUMANGGP:036210[CHRNB1],HUMANGGP:002476[CHRNB2],HUMANGGP:028113[CHRNA5],HUMANGGP:036604[CHRNB4], 3-FACTA-related-disease->UMLS:C0270853[juvenile myoclonic epilepsy],UMLS:C0085541[Epilepsy, Frontal Lobe],UMLS:C0028043[nicotine addiction], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
CHRNB3	NLGN4Y	1-GoPubMed-related-GO->GO:0005488[binding], 1-FACTA-related-disease->UMLS:C0004352[autism],
CHRNB3	GRID2	1-GoPubMed-related-GO->GO:0005488[binding],
CHRNB3	NBEA	1-GoPubMed-related-GO->GO:0005488[binding], 1-FACTA-related-disease->UMLS:C0004352[autism],
CHRNE	HTR1B	2-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00530[Portal], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
CHRNE	CNTNAP2	3-GoPubMed-related-GO->GO:0022831[narrow pore, gated channel activity],GO:0022842[narrow pore channel activity],GO:0008037[cell recognition], 3-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
CHRNE	CADM1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
CHRNE	SHANK3	1-GoPubMed-related-disease->mesh:9123[Muscle Hypotonia], 1-FACTA-related-disease->UMLS:C0236792[Asperger Syndrome], 3-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
CHRNE	CHD7	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
CHRNE	NSD1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
CHRNE	MBD1	1-FACTA-related-drug->DrugBank:APRD00530[Portal],
CHRNE	NPAS2	3-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00530[Portal],
CHRNE	HOXB1	1-FACTA-related-disease->UMLS:C0236792[Asperger Syndrome], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
CHRNE	NLGN4X	1-FACTA-related-disease->UMLS:C0236792[Asperger Syndrome], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
CHRNE	GABRB1	1-FACTA-related-drug->DrugBank:BIOD00057[Fragment], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
CHRNE	GABRA4	3-GoPubMed-related-GO->GO:0004707[MAP kinase activity],GO:0004702[receptor signaling protein serine/threonine kinase activity],GO:0005057[receptor signaling protein activity], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
CHRNE	IL1RAPL2	1-FACTA-related-disease->UMLS:C0236792[Asperger Syndrome],
CHRNE	NRCAM	1-FACTA-related-disease->UMLS:C0751882[Myasthenic Syndromes, Congenital],
CHRNE	DHCR7	1-FACTA-related-disease->UMLS:C0263541[Founder], 3-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
CHRNE	CACNA1D	2-GoPubMed-related-disease->mesh:15624[Lambert-Eaton Myasthenic Syndrome],mesh:20361[Paraneoplastic Syndromes, Nervous System],
CHRNE	CHRNA7	1-GoPubMed-related-GO->GO:0022831[narrow pore, gated channel activity], 2-FACTA-related-gene->HUMANGGP:036210[CHRNB1],HUMANGGP:008639[CHRNA1], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
CHRNE	CREBBP	1-FACTA-related-disease->UMLS:C0175699[SCS], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
CHRNE	AHI1	1-GoPubMed-related-disease->mesh:9123[Muscle Hypotonia], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
CLN8	NTRK1	3-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00631[Gel],
CLN8	NLGN4X	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
CLN8	NPAS2	3-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00631[Gel],
CLN8	HOXB1	3-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00631[Gel],DrugBank:APRD00552[Spectrum],
CLN8	HOXA1	4-FACTA-related-drug->DrugBank:EXPT01468[Folic Acid],DrugBank:APRD00506[Spectrum],DrugBank:APRD00631[Gel],DrugBank:APRD00552[Spectrum],
CLN8	DHCR7	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
CLN8	CREBBP	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
CLN8	NSD1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
CLN8	CADM1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
CLN8	RFWD2	2-GoPubMed-related-disease->mesh:24182[Uniparental Disomy],mesh:9630[Nondisjunction, Genetic],
CLN8	CNTNAP2	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
CLN8	CACNA1G	1-GoPubMed-related-disease->mesh:4832[Epilepsy, Absence], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
CLN8	CHD7	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
CLN8	PCDH19	1-GoPubMed-related-disease->mesh:9207[Myoclonus],
CLN8	SLC25A12	1-GoPubMed-related-disease->mesh:14855[Wallerian Degeneration],
CLN8	AHI1	3-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00631[Gel],
CSTB	HOXB1	3-FACTA-related-drug->DrugBank:APRD00017[Tretinoin],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00256[Valproic Acid],
CSTB	GTF2I	2-FACTA-related-drug->DrugBank:APRD00256[Valproic Acid],DrugBank:BIOD00057[Fragment],
CSTB	NRP2	1-GoPubMed-related-disease->mesh:8204[Lymphangiosarcoma], 1-FACTA-related-disease->UMLS:C0270853[juvenile myoclonic epilepsy],
CSTB	CHRNA7	3-GoPubMed-related-disease->mesh:20190[Myoclonic Epilepsy, Juvenile],mesh:20936[Epilepsy, Benign Neonatal],mesh:4831[Epilepsies, Myoclonic], 1-FACTA-related-disease->UMLS:C0270853[juvenile myoclonic epilepsy], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
CSTB	EN2	3-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:BIOD00057[Fragment],
CSTB	RELN	3-FACTA-related-drug->DrugBank:APRD00256[Valproic Acid],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
CSTB	NRXN2	1-FACTA-related-drug->DrugBank:APRD00256[Valproic Acid],
CSTB	SCN2A	1-GoPubMed-related-disease->mesh:20936[Epilepsy, Benign Neonatal], 4-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00256[Valproic Acid],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
CSTB	SCN1A	1-GoPubMed-related-GO->GO:0008138[protein tyrosine/serine/threonine phosphatase activity], 4-GoPubMed-related-disease->mesh:4831[Epilepsies, Myoclonic],mesh:20936[Epilepsy, Benign Neonatal],mesh:20190[Myoclonic Epilepsy, Juvenile],mesh:20192[Lafora Disease], 2-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00623[ROC],
CSTB	TBX1	2-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
CSTB	EGR2	4-FACTA-related-drug->DrugBank:APRD00256[Valproic Acid],DrugBank:BIOD00057[Fragment],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
CSTB	PCDH19	2-GoPubMed-related-disease->mesh:4831[Epilepsies, Myoclonic],mesh:9207[Myoclonus], 1-FACTA-related-disease->UMLS:C0014550[Epilepsies, Myoclonic],
CSTB	UBE3A	1-FACTA-related-disease->UMLS:C0085859[Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy], 2-FACTA-related-drug->DrugBank:APRD00256[Valproic Acid],DrugBank:BIOD00057[Fragment],
CSTB	PARK2	2-GoPubMed-related-disease->mesh:20192[Lafora Disease],mesh:20191[Myoclonic Epilepsies, Progressive], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
CSTB	NFIA	2-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
CSTB	LRRC1	2-GoPubMed-related-disease->mesh:20190[Myoclonic Epilepsy, Juvenile],mesh:4831[Epilepsies, Myoclonic], 1-FACTA-related-disease->UMLS:C0270853[juvenile myoclonic epilepsy], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
CSTB	CACNA1H	3-GoPubMed-related-disease->mesh:20936[Epilepsy, Benign Neonatal],mesh:20190[Myoclonic Epilepsy, Juvenile],mesh:4831[Epilepsies, Myoclonic], 1-FACTA-related-disease->UMLS:C0270853[juvenile myoclonic epilepsy],
CYFIP1	SLC25A12	1-GoPubMed-related-disease->mesh:9123[Muscle Hypotonia], 3-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0004352[autism],UMLS:C0008074[Child Development Disorders, Pervasive],
CYFIP1	UBE2H	2-GoPubMed-related-disease->mesh:17204[Angelman Syndrome],mesh:25063[Chromosome Disorders], 2-FACTA-related-disease->UMLS:C0162635[Angelman syndrome],UMLS:C0004352[autism],
CYFIP1	SLC1A1	5-FACTA-related-disease->UMLS:C0028768[obsessive-compulsive disorder],UMLS:C0008074[Child Development Disorders, Pervasive],UMLS:C0233639[Autism],UMLS:C0600104[Compulsive Behavior],UMLS:C0004352[autism],
CYFIP1	DLGAP2	1-GoPubMed-related-GO->GO:0016791[phosphatase activity], 4-GoPubMed-related-disease->mesh:5600[Fragile X Syndrome],mesh:25064[Sex Chromosome Disorders],mesh:8607[Mental Retardation],mesh:25063[Chromosome Disorders], 4-FACTA-related-disease->UMLS:C0008074[Child Development Disorders, Pervasive],UMLS:C0233639[Autism],UMLS:C0004352[autism],UMLS:C0917816[mental retardation],
CYFIP1	RPL10	2-GoPubMed-related-disease->mesh:24182[Uniparental Disomy],mesh:9630[Nondisjunction, Genetic], 3-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0004352[autism],UMLS:C0917816[mental retardation], 1-FACTA-related-drug->DrugBank:APRD00631[Gel],
CYFIP1	SHANK2	1-GoPubMed-related-disease->mesh:5600[Fragile X Syndrome], 4-FACTA-related-disease->UMLS:C0008074[Child Development Disorders, Pervasive],UMLS:C0004352[autism],UMLS:C1855900[HCG],UMLS:C0917816[mental retardation],
CYFIP1	APBA2	1-GoPubMed-related-disease->mesh:17204[Angelman Syndrome], 4-FACTA-related-disease->UMLS:C0008074[Child Development Disorders, Pervasive],UMLS:C1855900[HCG],UMLS:C0004352[autism],UMLS:C0917816[mental retardation],
CYFIP1	OPHN1	3-GoPubMed-related-disease->mesh:5600[Fragile X Syndrome],mesh:8607[Mental Retardation],mesh:9123[Muscle Hypotonia], 3-FACTA-related-disease->UMLS:C0917816[mental retardation],UMLS:C0036857[severe mental retardation],UMLS:C0016667[Fragile X Syndrome],
CYFIP1	NRCAM	3-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0600104[Compulsive Behavior],UMLS:C0004352[autism],
CYFIP1	ATP10A	5-GoPubMed-related-disease->mesh:17204[Angelman Syndrome],mesh:11218[Prader-Willi Syndrome],mesh:24182[Uniparental Disomy],mesh:9630[Nondisjunction, Genetic],mesh:25063[Chromosome Disorders], 3-FACTA-related-disease->UMLS:C0162635[Angelman syndrome],UMLS:C0004352[autism],UMLS:C0917816[mental retardation],
CYFIP1	MCPH1	1-GoPubMed-related-GO->GO:0016791[phosphatase activity], 1-FACTA-related-drug->DrugBank:APRD00631[Gel],
CYFIP1	FMR1	3-GoPubMed-related-gene->123720[WHAMM],151556[GPR155],390535[GOLGA8E], 4-GoPubMed-related-GO->GO:0050658[RNA transport],GO:0051236[establishment of RNA localization],GO:0050657[nucleic acid transport],GO:0006403[RNA localization], 4-GoPubMed-related-disease->mesh:5600[Fragile X Syndrome],mesh:25064[Sex Chromosome Disorders],mesh:25063[Chromosome Disorders],mesh:8607[Mental Retardation], 3-FACTA-related-gene->HUMANGGP:029883[JAKMIP1],HUMANGGP:018529[GPR155],HUMANGGP:009997[CYFIP1], 1-FACTA-related-disease->UMLS:C0016667[Fragile X Syndrome], 1-FACTA-related-drug->DrugBank:APRD00631[Gel],
CYFIP1	SLC9A9	2-GoPubMed-related-disease->mesh:17204[Angelman Syndrome],mesh:25063[Chromosome Disorders],
CYFIP1	SLC9A6	1-GoPubMed-related-disease->mesh:17204[Angelman Syndrome], 4-FACTA-related-disease->UMLS:C0162635[Angelman syndrome],UMLS:C0036857[severe mental retardation],UMLS:C0917816[mental retardation],UMLS:C0004352[autism],
CYFIP1	NDNL2	5-GoPubMed-related-GO->GO:0004066[asparagine synthase (glutamine-hydrolyzing) activity],GO:0016884[carbon-nitrogen ligase activity, with glutamine as amido-N-donor],GO:0007417[central nervous system development],GO:0016879[ligase activity, forming carbon-nitrogen bonds],GO:0016874[ligase activity], 4-GoPubMed-related-disease->mesh:17204[Angelman Syndrome],mesh:11218[Prader-Willi Syndrome],mesh:25063[Chromosome Disorders],mesh:8607[Mental Retardation], 1-FACTA-related-disease->UMLS:C0004352[autism],
CYFIP1	NRXN1	2-GoPubMed-related-disease->mesh:5600[Fragile X Syndrome],mesh:8607[Mental Retardation], 6-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0008074[Child Development Disorders, Pervasive],UMLS:C0036857[severe mental retardation],UMLS:C0004352[autism],UMLS:C1855900[HCG],UMLS:C0917816[mental retardation],
DFFB	CNTNAP2	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
DFFB	SHANK3	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
DFFB	NSD1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
DFFB	AHI1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
DFFB	MBD4	1-GoPubMed-related-disease->mesh:1926[Brain Death],
DFFB	NLGN4X	1-GoPubMed-related-GO->GO:0005092[GDP-dissociation inhibitor activity], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
DFFB	CREBBP	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
DFFB	CAMTA1	1-GoPubMed-related-gene->55966[AJAP1], 1-FACTA-related-gene->HUMANGGP:001285[TNFRSF25], 5-FACTA-related-disease->UMLS:C1521891[Oligodendroglioma],UMLS:C0028945[Oligodendroglioma],UMLS:C1524043[Neuroblastoma],UMLS:C0700095[Neuroblastoma],UMLS:C0027819[neuroblastoma],
DFFB	NTRK1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum], 1-pathway->kegg:path:hsa04210[Apoptosis],
DFFB	HOXB1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
DFFB	SLC9A6	1-GoPubMed-related-disease->mesh:2303[Cardiac Output, Low],
DFFB	CA6	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
DFFB	DHCR7	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
DFFB	CADM1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
DFFB	CACNA1G	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
DFFB	CHD7	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
DLG3	OPHN1	3-GoPubMed-related-gene->266678[MRX81],641339[ZNF674],55998[NXF5], 8-GoPubMed-related-GO->GO:0060997[dendritic spine morphogenesis],GO:0060996[dendritic spine development],GO:0048813[dendrite morphogenesis],GO:0015881[creatine transport],GO:0016358[dendrite development],GO:0005089[Rho guanyl-nucleotide exchange factor activity],GO:0005092[GDP-dissociation inhibitor activity],GO:0048489[synaptic vesicle transport], 4-GoPubMed-related-disease->mesh:38921[Coffin-Lowry Syndrome],mesh:5146[Facial Asymmetry],mesh:38901[Mental Retardation, X-Linked],mesh:5600[Fragile X Syndrome], 8-FACTA-related-gene->HUMANGGP:039910[OPHN1],HUMANGGP:007783[ARHGEF6],HUMANGGP:020388[TM4SF2],HUMANGGP:002027[RPS6KA3],HUMANGGP:040636[FTSJ1],HUMANGGP:028523[FACL4],HUMANGGP:015143[DLG3],HUMANGGP:027462[ZNF41], 5-FACTA-related-disease->UMLS:C1136249[Mental Retardation, X-Linked],UMLS:C1845055[ATRX],UMLS:C1859974[FGD1],UMLS:C0917816[mental retardation],UMLS:C0016667[Fragile X Syndrome],
DLG3	NRCAM	1-FACTA-related-disease->UMLS:C0233639[Autism], 1-pathway->reactome:REACT_22329[],
DLG3	SUCLG2	1-FACTA-related-drug->DrugBank:APRD00631[Gel],
DLG3	FOXG1	1-GoPubMed-related-GO->GO:0050175[phenylalanine dehydrogenase activity], 1-FACTA-related-disease->UMLS:C0683322[intellectual impairment],
DLG3	TSPAN7	1-GoPubMed-related-gene->54328[GPR173], 3-GoPubMed-related-GO->GO:0005092[GDP-dissociation inhibitor activity],GO:0005089[Rho guanyl-nucleotide exchange factor activity],GO:0048489[synaptic vesicle transport], 2-GoPubMed-related-disease->mesh:38901[Mental Retardation, X-Linked],mesh:5600[Fragile X Syndrome], 1-FACTA-related-gene->HUMANGGP:020388[TM4SF2], 2-FACTA-related-disease->UMLS:C1136249[Mental Retardation, X-Linked],UMLS:C0917816[mental retardation],
DLG3	ATRX	1-GoPubMed-related-GO->GO:0050175[phenylalanine dehydrogenase activity], 2-GoPubMed-related-disease->mesh:8265[Macrostomia],mesh:38921[Coffin-Lowry Syndrome], 3-FACTA-related-gene->HUMANGGP:039910[OPHN1],HUMANGGP:002027[RPS6KA3],HUMANGGP:007783[ARHGEF6], 2-FACTA-related-disease->UMLS:C1845055[ATRX],UMLS:C1136249[Mental Retardation, X-Linked], 1-FACTA-related-drug->DrugBank:APRD00631[Gel],
DLG3	NLGN4X	1-GoPubMed-related-gene->641339[ZNF674], 2-GoPubMed-related-GO->GO:0042043[neurexin binding],GO:0005092[GDP-dissociation inhibitor activity], 10-FACTA-related-gene->HUMANGGP:014727[NLGN3],HUMANGGP:006914[ZNF81],HUMANGGP:040636[FTSJ1],HUMANGGP:015143[DLG3],HUMANGGP:027462[ZNF41],HUMANGGP:007783[ARHGEF6],HUMANGGP:020388[TM4SF2],HUMANGGP:028523[FACL4],HUMANGGP:039910[OPHN1],HUMANGGP:002027[RPS6KA3], 5-FACTA-related-disease->UMLS:C1859974[FGD1],UMLS:C1136249[Mental Retardation, X-Linked],UMLS:C0233639[Autism],UMLS:C0026351[moderate mental retardation],UMLS:C0917816[mental retardation],
DLG3	CREBBP	1-GoPubMed-related-gene->170261[ZCCHC12], 1-GoPubMed-related-disease->mesh:5660[Funnel Chest],
DLG3	SLC6A8	3-GoPubMed-related-GO->GO:0015881[creatine transport],GO:0042043[neurexin binding],GO:0005092[GDP-dissociation inhibitor activity], 1-GoPubMed-related-disease->mesh:38921[Coffin-Lowry Syndrome], 8-FACTA-related-gene->HUMANGGP:039910[OPHN1],HUMANGGP:002027[RPS6KA3],HUMANGGP:007783[ARHGEF6],HUMANGGP:020388[TM4SF2],HUMANGGP:040636[FTSJ1],HUMANGGP:028523[FACL4],HUMANGGP:015143[DLG3],HUMANGGP:027462[ZNF41], 5-FACTA-related-disease->UMLS:C1136249[Mental Retardation, X-Linked],UMLS:C1845055[ATRX],UMLS:C0917816[mental retardation],UMLS:C0026351[moderate mental retardation],UMLS:C0016667[Fragile X Syndrome],
DLG3	FGD1	1-GoPubMed-related-GO->GO:0005089[Rho guanyl-nucleotide exchange factor activity], 1-GoPubMed-related-disease->mesh:5146[Facial Asymmetry], 9-FACTA-related-gene->HUMANGGP:006914[ZNF81],HUMANGGP:040636[FTSJ1],HUMANGGP:015143[DLG3],HUMANGGP:027462[ZNF41],HUMANGGP:007783[ARHGEF6],HUMANGGP:020388[TM4SF2],HUMANGGP:039910[OPHN1],HUMANGGP:028523[FACL4],HUMANGGP:002027[RPS6KA3], 2-FACTA-related-disease->UMLS:C1859974[FGD1],UMLS:C1136249[Mental Retardation, X-Linked],
DLG3	AGTR2	9-FACTA-related-gene->HUMANGGP:007783[ARHGEF6],HUMANGGP:020388[TM4SF2],HUMANGGP:040636[FTSJ1],HUMANGGP:039910[OPHN1],HUMANGGP:028523[FACL4],HUMANGGP:002027[RPS6KA3],HUMANGGP:015143[DLG3],HUMANGGP:027462[ZNF41],HUMANGGP:014727[NLGN3], 2-FACTA-related-disease->UMLS:C1845055[ATRX],UMLS:C1136249[Mental Retardation, X-Linked],
DLG3	SYN1	2-GoPubMed-related-gene->54328[GPR173],8552[INE1], 2-GoPubMed-related-GO->GO:0042043[neurexin binding],GO:0005092[GDP-dissociation inhibitor activity], 4-FACTA-related-gene->HUMANGGP:006914[ZNF81],HUMANGGP:027462[ZNF41],HUMANGGP:040636[FTSJ1],HUMANGGP:015143[DLG3], 3-FACTA-related-disease->UMLS:C1845055[ATRX],UMLS:C1136249[Mental Retardation, X-Linked],UMLS:C0016667[Fragile X Syndrome], 1-FACTA-related-drug->DrugBank:APRD00631[Gel],
DLG3	ARX	4-GoPubMed-related-GO->GO:0015881[creatine transport],GO:0042043[neurexin binding],GO:0005092[GDP-dissociation inhibitor activity],GO:0048489[synaptic vesicle transport], 3-GoPubMed-related-disease->mesh:6832[Hydranencephaly],mesh:38921[Coffin-Lowry Syndrome],mesh:38901[Mental Retardation, X-Linked], 7-FACTA-related-gene->HUMANGGP:007783[ARHGEF6],HUMANGGP:039910[OPHN1],HUMANGGP:002027[RPS6KA3],HUMANGGP:020388[TM4SF2],HUMANGGP:040636[FTSJ1],HUMANGGP:028523[FACL4],HUMANGGP:015143[DLG3], 1-FACTA-related-disease->UMLS:C1136249[Mental Retardation, X-Linked],
DLG3	PARK2	1-GoPubMed-related-gene->158787[RIBC1], 1-FACTA-related-drug->DrugBank:APRD00631[Gel],
DLG3	TBC1D4	1-FACTA-related-drug->DrugBank:APRD00631[Gel],
DLG3	NLGN3	2-GoPubMed-related-GO->GO:0042043[neurexin binding],GO:0005092[GDP-dissociation inhibitor activity], 1-GoPubMed-related-disease->mesh:5600[Fragile X Syndrome], 7-FACTA-related-gene->HUMANGGP:014727[NLGN3],HUMANGGP:040636[FTSJ1],HUMANGGP:015143[DLG3],HUMANGGP:027462[ZNF41],HUMANGGP:007783[ARHGEF6],HUMANGGP:020388[TM4SF2],HUMANGGP:039910[OPHN1], 5-FACTA-related-disease->UMLS:C1845055[ATRX],UMLS:C0233639[Autism],UMLS:C0016667[Fragile X Syndrome],UMLS:C0917816[mental retardation],UMLS:C0041341[tuberous sclerosis],
DLG3	IL1RAPL2	2-GoPubMed-related-disease->mesh:12729[Sex Chromosome Aberrations],mesh:38901[Mental Retardation, X-Linked], 2-FACTA-related-disease->UMLS:C1136249[Mental Retardation, X-Linked],UMLS:C0917816[mental retardation],
DLG3	IL1RAPL1	4-GoPubMed-related-GO->GO:0008887[glycerate kinase activity],GO:0048489[synaptic vesicle transport],GO:0005092[GDP-dissociation inhibitor activity],GO:0005089[Rho guanyl-nucleotide exchange factor activity], 4-GoPubMed-related-disease->mesh:38921[Coffin-Lowry Syndrome],mesh:38901[Mental Retardation, X-Linked],mesh:12729[Sex Chromosome Aberrations],mesh:5600[Fragile X Syndrome], 6-FACTA-related-gene->HUMANGGP:040636[FTSJ1],HUMANGGP:006428[DLG2],HUMANGGP:015143[DLG3],HUMANGGP:027462[ZNF41],HUMANGGP:034035[PQBP1],HUMANGGP:007783[ARHGEF6], 5-FACTA-related-disease->UMLS:C1136249[Mental Retardation, X-Linked],UMLS:C1845055[ATRX],UMLS:C0917816[mental retardation],UMLS:C0016667[Fragile X Syndrome],UMLS:C0233639[Autism],
DLX5	MECP2	1-GoPubMed-related-GO->GO:0008327[methyl-CpG binding], 1-GoPubMed-related-disease->mesh:15518[Rett Syndrome], 3-FACTA-related-disease->UMLS:C0035372[Rett syndrome],UMLS:C1136249[Mental Retardation, X-Linked],UMLS:C0162635[Angelman syndrome], 4-FACTA-related-drug->DrugBank:APRD00504[ID2],DrugBank:APRD00953[ETS],DrugBank:APRD00280[Frontal],DrugBank:BIOD00001[DNase I],
DLX5	HDAC4	6-FACTA-related-drug->DrugBank:APRD00764[Orphan],DrugBank:APRD00369[ROS],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:EXPT01467[Forskolin],DrugBank:APRD00627[Progesterone],
DLX5	DLX6	3-GoPubMed-related-gene->1746[DLX2],1745[DLX1],7979[SHFM1], 5-GoPubMed-related-GO->GO:0008327[methyl-CpG binding],GO:0030900[forebrain development],GO:0060173[limb development],GO:0048736[appendage development],GO:0001649[osteoblast differentiation], 7-GoPubMed-related-disease->mesh:6228[Hand Deformities, Congenital],mesh:38062[Upper Extremity Deformities, Congenital],mesh:5532[Foot Deformities, Congenital],mesh:38061[Lower Extremity Deformities, Congenital],mesh:6226[Hand Deformities],mesh:848[Anodontia],mesh:15518[Rett Syndrome], 5-FACTA-related-gene->HUMANGGP:036672[DLX5],HUMANGGP:004062[SHFM1],HUMANGGP:034360[DLX2],HUMANGGP:015560[DLX1],HUMANGGP:014649[DLX3], 6-FACTA-related-disease->UMLS:C1857344[SHFM1D],UMLS:C1834571[DYT11],UMLS:C0410422[OCM],UMLS:C0035372[Rett syndrome],UMLS:C0158646[cleft lip/palate],UMLS:C0497552[Nervous System Malformations], 2-FACTA-related-drug->DrugBank:BIOD00001[DNase I],DrugBank:APRD00140[Tretinoin], 1-pathway->nci_nature_pid:Validated_transcriptional_targets_of_deltaNp63_isoforms[],
DLX5	MBD4	1-GoPubMed-related-GO->GO:0008327[methyl-CpG binding], 1-GoPubMed-related-disease->mesh:15518[Rett Syndrome], 1-FACTA-related-disease->UMLS:C0035372[Rett syndrome],
DLX5	MBD1	1-GoPubMed-related-GO->GO:0008327[methyl-CpG binding], 2-GoPubMed-related-disease->mesh:15518[Rett Syndrome],mesh:6226[Hand Deformities], 2-FACTA-related-disease->UMLS:C0035372[Rett syndrome],UMLS:C0233639[Autism],
DLX5	AUTS2	2-FACTA-related-gene->HUMANGGP:001496[AUTS2],HUMANGGP:036672[DLX5], 2-FACTA-related-disease->UMLS:C1846330[AUTS2],UMLS:C0233639[Autism],
DLX5	GABRB1	1-GoPubMed-related-gene->26053[AUTS2], 1-FACTA-related-gene->HUMANGGP:001496[AUTS2], 2-FACTA-related-disease->UMLS:C1846330[AUTS2],UMLS:C0233639[Autism],
DLX5	DLX2	2-GoPubMed-related-gene->1745[DLX1],1750[DLX6], 3-GoPubMed-related-GO->GO:0060173[limb development],GO:0048736[appendage development],GO:0030900[forebrain development], 2-GoPubMed-related-disease->mesh:5532[Foot Deformities, Congenital],mesh:38061[Lower Extremity Deformities, Congenital], 3-FACTA-related-gene->HUMANGGP:034360[DLX2],HUMANGGP:015560[DLX1],HUMANGGP:014649[DLX3], 4-FACTA-related-disease->UMLS:C1136249[Mental Retardation, X-Linked],UMLS:C0266463[lissencephaly],UMLS:C0233639[Autism],UMLS:C0497552[Nervous System Malformations], 4-FACTA-related-drug->DrugBank:APRD00504[ID2],DrugBank:APRD00140[Tretinoin],DrugBank:BIOD00001[DNase I],DrugBank:APRD00017[Tretinoin],
DLX5	NTNG1	1-GoPubMed-related-disease->mesh:15518[Rett Syndrome], 1-FACTA-related-disease->UMLS:C0035372[Rett syndrome],
DLX5	FOXP2	5-GoPubMed-related-GO->GO:0042043[neurexin binding],GO:0022833[mechanically gated channel activity],GO:0043854[cyclic nucleotide-gated mechanosensitive ion channel activity],GO:0043855[cyclic nucleotide-gated ion channel activity],GO:0008381[mechanically-gated ion channel activity], 1-FACTA-related-disease->UMLS:C1846330[AUTS2], 1-FACTA-related-drug->DrugBank:APRD00280[Frontal],
DLX5	RELN	1-GoPubMed-related-GO->GO:0042043[neurexin binding], 1-GoPubMed-related-disease->mesh:16142[Holoprosencephaly], 4-FACTA-related-disease->UMLS:C0266463[lissencephaly],UMLS:C0233639[Autism],UMLS:C0497552[Nervous System Malformations],UMLS:C1136249[Mental Retardation, X-Linked], 4-FACTA-related-drug->DrugBank:BIOD00001[DNase I],DrugBank:APRD00280[Frontal],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
DLX5	GNAS	1-GoPubMed-related-GO->GO:0008757[S-adenosylmethionine-dependent methyltransferase activity], 1-FACTA-related-disease->UMLS:C1272677[MEST], 6-FACTA-related-drug->DrugBank:APRD00134[Activin],DrugBank:BIOD00001[DNase I],DrugBank:EXPT01467[Forskolin],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00627[Progesterone],
DLX5	FOXG1	1-GoPubMed-related-GO->GO:0030900[forebrain development], 1-GoPubMed-related-disease->mesh:15518[Rett Syndrome], 2-FACTA-related-disease->UMLS:C0035372[Rett syndrome],UMLS:C1855792[CIE], 1-FACTA-related-drug->DrugBank:APRD00627[Progesterone],
DLX5	PITX1	1-GoPubMed-related-gene->9096[TBX18], 2-GoPubMed-related-GO->GO:0060173[limb development],GO:0048736[appendage development], 5-FACTA-related-drug->DrugBank:APRD00134[Activin],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00396[Estrogens],DrugBank:APRD00627[Progesterone],
DLX5	RAPGEF4	2-GoPubMed-related-gene->1745[DLX1],1746[DLX2],
DLX5	EN2	1-GoPubMed-related-disease->mesh:16142[Holoprosencephaly], 3-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0497552[Nervous System Malformations],UMLS:C1855792[CIE], 2-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
DLX5	DLX1	2-GoPubMed-related-gene->1746[DLX2],1750[DLX6], 2-GoPubMed-related-GO->GO:0060173[limb development],GO:0048736[appendage development], 2-GoPubMed-related-disease->mesh:5532[Foot Deformities, Congenital],mesh:38061[Lower Extremity Deformities, Congenital], 2-FACTA-related-gene->HUMANGGP:015560[DLX1],HUMANGGP:034360[DLX2], 2-FACTA-related-disease->UMLS:C0162635[Angelman syndrome],UMLS:C0497552[Nervous System Malformations], 3-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:BIOD00001[DNase I],DrugBank:APRD00017[Tretinoin],
DLX5	IMMP2L	1-GoPubMed-related-gene->26053[AUTS2], 1-GoPubMed-related-disease->mesh:15518[Rett Syndrome], 1-FACTA-related-gene->HUMANGGP:001496[AUTS2], 3-FACTA-related-disease->UMLS:C1846330[AUTS2],UMLS:C0233639[Autism],UMLS:C0035372[Rett syndrome],
DLX5	SLC1A1	1-FACTA-related-gene->HUMANGGP:042167[SLC38A4], 1-FACTA-related-disease->UMLS:C0233639[Autism], 4-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00280[Frontal],DrugBank:APRD00627[Progesterone],
DLX5	PCDH19	1-GoPubMed-related-disease->mesh:15518[Rett Syndrome], 2-FACTA-related-disease->UMLS:C1136249[Mental Retardation, X-Linked],UMLS:C0035372[Rett syndrome],
DRD1	DISC1	1-GoPubMed-related-gene->63915[MUTED], 4-GoPubMed-related-GO->GO:0042420[dopamine catabolic process],GO:0042424[catecholamine catabolic process],GO:0019614[catechol catabolic process],GO:0034313[diol catabolic process], 1-FACTA-related-gene->HUMANGGP:036486[SYNGR1], 5-FACTA-related-drug->DrugBank:APRD00280[Frontal],DrugBank:BIOD00057[Fragment],DrugBank:EXPT02079[lysine],DrugBank:EXPT00494[Alanine],DrugBank:APRD00631[Gel],
DRD1	TPH2	3-GoPubMed-related-gene->9145[SYNGR1],23316[CUX2],57132[CHMP1B], 1-GoPubMed-related-GO->GO:0005484[SNAP receptor activity], 2-GoPubMed-related-disease->mesh:14029[Tobacco Use Disorder],mesh:6556[Heroin Dependence], 4-FACTA-related-gene->HUMANGGP:036486[SYNGR1],HUMANGGP:014007[CUX2],HUMANGGP:022732[NAPG],HUMANGGP:010722[GRM4], 3-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:APRD00280[Frontal],DrugBank:APRD00450[Norepinephrine],
DRD1	NRXN1	3-GoPubMed-related-disease->mesh:14029[Tobacco Use Disorder],mesh:5879[Tourette Syndrome],mesh:13981[Tic Disorders],
DRD1	HTR2A	1-GoPubMed-related-gene->63915[MUTED], 1-FACTA-related-gene->HUMANGGP:036486[SYNGR1], 5-FACTA-related-disease->UMLS:C1840994[HBB],UMLS:C1840993[HBB],UMLS:C1840958[HBB],UMLS:C0392702[abnormal involuntary movements],UMLS:C0600241[heroin abuse], 2-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:BIOD00057[Fragment],
DRD1	HTR1B	1-GoPubMed-related-gene->1816[DRD5], 1-GoPubMed-related-GO->GO:0005484[SNAP receptor activity], 1-FACTA-related-gene->HUMANGGP:024926[DRD5], 3-FACTA-related-disease->UMLS:C1851920[DRD],UMLS:C0338480[common migraine],UMLS:C0001956[alcohol use disorder], 4-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:BIOD00057[Fragment],DrugBank:EXPT00494[Alanine],DrugBank:APRD00450[Norepinephrine],
DRD1	CNTNAP2	3-GoPubMed-related-disease->mesh:5879[Tourette Syndrome],mesh:12148[Restless Legs Syndrome],mesh:13981[Tic Disorders], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
DRD1	PCDH9	1-FACTA-related-gene->HUMANGGP:024970[PCDH9], 1-FACTA-related-disease->UMLS:C0019556[Hip Dysplasia, Canine],
DRD1	SLC9A9	2-FACTA-related-gene->HUMANGGP:035830[ARRB2],HUMANGGP:020893[ADRA1A], 1-FACTA-related-drug->DrugBank:APRD01072[HCH],
DRD1	AUTS2	3-GoPubMed-related-disease->mesh:12148[Restless Legs Syndrome],mesh:5879[Tourette Syndrome],mesh:13981[Tic Disorders],
DRD1	GRIN2B	1-GoPubMed-related-disease->mesh:430[Alcohol Withdrawal Delirium], 4-FACTA-related-gene->HUMANGGP:010722[GRM4],HUMANGGP:036486[SYNGR1],HUMANGGP:014007[CUX2],HUMANGGP:022732[NAPG], 1-FACTA-related-disease->UMLS:C1851920[DRD], 4-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:BIOD00057[Fragment],DrugBank:EXPT02079[lysine],DrugBank:APRD00631[Gel],
DRD1	DRD3	1-GoPubMed-related-gene->1816[DRD5], 3-GoPubMed-related-GO->GO:0042417[dopamine metabolic process],GO:0033736[L-lysine 6-oxidase activity],GO:0005484[SNAP receptor activity], 3-FACTA-related-gene->HUMANGGP:007874[DRD3],HUMANGGP:023786[DRD1],HUMANGGP:024926[DRD5], 5-FACTA-related-disease->UMLS:C1851920[DRD],UMLS:C0392702[abnormal involuntary movements],UMLS:C1840958[HBB],UMLS:C1840993[HBB],UMLS:C1840994[HBB], 7-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:BIOD00057[Fragment],DrugBank:APRD00531[Apomorphine],DrugBank:APRD00280[Frontal],DrugBank:APRD00084[Ascorbic Acid],DrugBank:APRD00450[Norepinephrine],DrugBank:APRD00631[Gel],
DRD1	OPRM1	1-GoPubMed-related-disease->mesh:6556[Heroin Dependence], 1-FACTA-related-gene->HUMANGGP:035830[ARRB2], 1-FACTA-related-disease->UMLS:C0600241[heroin abuse], 3-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:EXPT02079[lysine],DrugBank:EXPT00494[Alanine],
DRD1	ADRB2	2-FACTA-related-gene->HUMANGGP:039243[ADRA1B],HUMANGGP:020893[ADRA1A], 2-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:BIOD00057[Fragment],
DRD1	EN2	1-GoPubMed-related-disease->mesh:17689[Polydactyly], 3-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00450[Norepinephrine],DrugBank:APRD00631[Gel],
DRD1	IMMP2L	3-GoPubMed-related-disease->mesh:5879[Tourette Syndrome],mesh:12148[Restless Legs Syndrome],mesh:13981[Tic Disorders],
DRD1	FOXP2	1-GoPubMed-related-disease->mesh:13342[Stuttering], 2-FACTA-related-drug->DrugBank:APRD00280[Frontal],DrugBank:BIOD00057[Fragment],
DRD1	RBFOX1	2-GoPubMed-related-disease->mesh:12148[Restless Legs Syndrome],mesh:5879[Tourette Syndrome],
DRD4	GRIN2B	1-GoPubMed-related-disease->mesh:19969[Amphetamine-Related Disorders], 2-FACTA-related-disease->UMLS:C1851920[DRD],UMLS:C0029121[oppositional defiant disorder], 4-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:BIOD00057[Fragment],DrugBank:APRD01322[Potassium Chloride],DrugBank:APRD00631[Gel],
DRD4	MBD1	3-FACTA-related-drug->DrugBank:APRD00326[Factor II],DrugBank:APRD00530[Portal],DrugBank:APRD00631[Gel],
DRD4	NPAS2	3-FACTA-related-drug->DrugBank:APRD00326[Factor II],DrugBank:APRD00530[Portal],DrugBank:APRD00631[Gel],
DRD4	OPRM1	1-GoPubMed-related-GO->GO:0004952[dopamine receptor activity], 3-GoPubMed-related-disease->mesh:9293[Opioid-Related Disorders],mesh:6556[Heroin Dependence],mesh:19969[Amphetamine-Related Disorders], 1-FACTA-related-gene->HUMANGGP:035830[ARRB2], 2-FACTA-related-disease->UMLS:C0028047[Nicotine withdrawal],UMLS:C0600241[heroin abuse], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
DRD4	MAOA	2-GoPubMed-related-GO->GO:0004952[dopamine receptor activity],GO:0001591[dopamine receptor activity, coupled via Gi/Go], 1-FACTA-related-disease->UMLS:C1851920[DRD], 7-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:APRD00753[Flurbiprofen],DrugBank:BIOD00057[Fragment],DrugBank:APRD00450[Norepinephrine],DrugBank:APRD00530[Portal],DrugBank:APRD00280[Frontal],DrugBank:BIOD00035[CSF],
DRD4	CNTNAP2	3-GoPubMed-related-disease->mesh:5879[Tourette Syndrome],mesh:13981[Tic Disorders],mesh:20323[Tics], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
DRD4	IMMP2L	3-GoPubMed-related-disease->mesh:5879[Tourette Syndrome],mesh:13981[Tic Disorders],mesh:20323[Tics],
DRD4	TDO2	1-GoPubMed-related-disease->mesh:5879[Tourette Syndrome], 2-FACTA-related-gene->HUMANGGP:003403[ADRA2C],HUMANGGP:024926[DRD5], 1-FACTA-related-disease->UMLS:C1263846[Attention Deficit Disorder with Hyperactivity], 2-FACTA-related-drug->DrugBank:APRD00280[Frontal],DrugBank:APRD00631[Gel],
DRD4	FOXG1	1-FACTA-related-drug->DrugBank:APRD00530[Portal],
DRD4	HRAS	3-FACTA-related-disease->UMLS:C1840993[HBB],UMLS:C1840994[HBB],UMLS:C1840958[HBB], 2-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:BIOD00039[Secretin],
DRD4	BAIAP2	1-FACTA-related-disease->UMLS:C1263846[Attention Deficit Disorder with Hyperactivity], 1-FACTA-related-drug->DrugBank:APRD00631[Gel],
DRD4	OXTR	2-FACTA-related-drug->DrugBank:APRD00753[Flurbiprofen],DrugBank:APRD01072[HCH],
DRD4	NRXN1	3-GoPubMed-related-disease->mesh:14029[Tobacco Use Disorder],mesh:5879[Tourette Syndrome],mesh:13981[Tic Disorders],
DRD4	ADRB2	1-FACTA-related-gene->HUMANGGP:011331[ADRA1C], 2-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:BIOD00057[Fragment],
DRD4	HTR2A	1-GoPubMed-related-disease->mesh:19969[Amphetamine-Related Disorders], 4-FACTA-related-disease->UMLS:C1840994[HBB],UMLS:C1840993[HBB],UMLS:C1840958[HBB],UMLS:C0600241[heroin abuse], 3-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:BIOD00057[Fragment],DrugBank:APRD00530[Portal],
DRD4	HTR1B	1-GoPubMed-related-gene->1816[DRD5], 1-GoPubMed-related-GO->GO:0005484[SNAP receptor activity], 1-FACTA-related-gene->HUMANGGP:024926[DRD5], 2-FACTA-related-disease->UMLS:C1851920[DRD],UMLS:C1263846[Attention Deficit Disorder with Hyperactivity], 5-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:BIOD00057[Fragment],DrugBank:APRD00530[Portal],DrugBank:BIOD00035[CSF],DrugBank:APRD00450[Norepinephrine],
DRD4	TPH2	1-GoPubMed-related-GO->GO:0005484[SNAP receptor activity], 3-GoPubMed-related-disease->mesh:6948[Hyperkinesis],mesh:14029[Tobacco Use Disorder],mesh:6556[Heroin Dependence], 1-FACTA-related-disease->UMLS:C1263846[Attention Deficit Disorder with Hyperactivity], 5-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:APRD00530[Portal],DrugBank:APRD00280[Frontal],DrugBank:APRD00450[Norepinephrine],DrugBank:BIOD00035[CSF],
DRD4	ALDH5A1	1-GoPubMed-related-disease->mesh:6948[Hyperkinesis], 3-FACTA-related-drug->DrugBank:BIOD00035[CSF],DrugBank:BIOD00057[Fragment],DrugBank:APRD00631[Gel],
DRD4	DRD3	5-GoPubMed-related-gene->1812[DRD1],83855[KLF16],1816[DRD5],8677[STX10],1813[DRD2], 10-GoPubMed-related-GO->GO:0035240[dopamine binding],GO:0032099[negative regulation of appetite],GO:0032096[negative regulation of response to food],GO:0032105[negative regulation of response to extracellular stimulus],GO:0032108[negative regulation of response to nutrient levels],GO:0043178[alcohol binding],GO:0032095[regulation of response to food],GO:0042417[dopamine metabolic process],GO:0018933[nicotine metabolic process],GO:0005484[SNAP receptor activity], 5-FACTA-related-gene->HUMANGGP:007874[DRD3],HUMANGGP:011331[ADRA1C],HUMANGGP:023786[DRD1],HUMANGGP:024926[DRD5],HUMANGGP:008234[DRD2], 5-FACTA-related-disease->UMLS:C1851920[DRD],UMLS:C0036351[residual schizophrenia],UMLS:C1840958[HBB],UMLS:C1840993[HBB],UMLS:C1840994[HBB], 6-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:BIOD00057[Fragment],DrugBank:APRD00530[Portal],DrugBank:APRD00280[Frontal],DrugBank:APRD00450[Norepinephrine],DrugBank:APRD00631[Gel],
DRD4	HTR7	1-GoPubMed-related-disease->mesh:14029[Tobacco Use Disorder], 1-FACTA-related-disease->UMLS:C1263846[Attention Deficit Disorder with Hyperactivity], 2-FACTA-related-drug->DrugBank:APRD00657[Ritalin],DrugBank:BIOD00057[Fragment],
DRD4	NLGN4X	2-GoPubMed-related-disease->mesh:5879[Tourette Syndrome],mesh:20323[Tics],
DRD4	GABRA4	1-GoPubMed-related-gene->2561[GABRB2], 1-GoPubMed-related-disease->mesh:14029[Tobacco Use Disorder], 2-FACTA-related-drug->DrugBank:APRD01322[Potassium Chloride],DrugBank:APRD00631[Gel],
DRD4	SLC6A4	1-GoPubMed-related-disease->mesh:19969[Amphetamine-Related Disorders], 1-FACTA-related-gene->HUMANGGP:032072[SLC6A3], 5-FACTA-related-disease->UMLS:C1851920[DRD],UMLS:C0206042[FFI],UMLS:C1840958[HBB],UMLS:C1840993[HBB],UMLS:C1840994[HBB], 5-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:APRD00530[Portal],DrugBank:APRD00280[Frontal],DrugBank:APRD00450[Norepinephrine],DrugBank:BIOD00057[Fragment],
DRP2	CHD7	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
DRP2	CNTNAP2	4-GoPubMed-related-GO->GO:0047801[L-cysteine:2-oxoglutarate aminotransferase activity],GO:0019228[regulation of action potential in neuron],GO:0001508[regulation of action potential],GO:0003840[gamma-glutamyltransferase activity], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
DRP2	FOXP2	1-FACTA-related-drug->DrugBank:APRD00280[Frontal],
DRP2	IL1RAPL2	4-GoPubMed-related-disease->mesh:20388[Muscular Dystrophy, Duchenne],mesh:40181[Genetic Diseases, X-Linked],mesh:9136[Muscular Dystrophies],mesh:20966[Muscular Disorders, Atrophic], 1-FACTA-related-disease->UMLS:C1138434[Genetic Diseases, X-Linked],
DRP2	NSD1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
DRP2	FOXG1	1-FACTA-related-drug->DrugBank:APRD00530[Portal],
DRP2	AHI1	3-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00631[Gel],
DRP2	CREBBP	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
DRP2	SLC1A1	1-FACTA-related-drug->DrugBank:APRD00280[Frontal],
DRP2	DHCR7	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
DRP2	DMD	1-GoPubMed-related-gene->7402[UTRN], 5-GoPubMed-related-disease->mesh:20388[Muscular Dystrophy, Duchenne],mesh:9137[Muscular Dystrophy, Animal],mesh:9136[Muscular Dystrophies],mesh:20966[Muscular Disorders, Atrophic],mesh:40181[Genetic Diseases, X-Linked], 2-FACTA-related-disease->UMLS:C0013264[Duchenne muscular dystrophy],UMLS:C0026850[Muscular Dystrophies],
DRP2	SHANK3	1-GoPubMed-related-gene->26047[CNTNAP2], 3-FACTA-related-drug->DrugBank:APRD00280[Frontal],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
DRP2	RELN	2-FACTA-related-drug->DrugBank:APRD00280[Frontal],DrugBank:APRD00631[Gel],
DRP2	CA6	3-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00631[Gel],
DRP2	NTRK1	3-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00631[Gel],
DRP2	HOXB1	1-GoPubMed-related-disease->mesh:2607[Charcot-Marie-Tooth Disease], 2-FACTA-related-disease->UMLS:C0741036[PNS],UMLS:C0007959[Charcot-Marie-Tooth Disease], 3-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00631[Gel],DrugBank:APRD00552[Spectrum],
DRP2	TPH2	2-FACTA-related-drug->DrugBank:APRD00530[Portal],DrugBank:APRD00280[Frontal],
EMX2	RAI1	1-GoPubMed-related-disease->mesh:9123[Muscle Hypotonia], 4-FACTA-related-drug->DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00631[Gel],
EMX2	CDKL5	1-GoPubMed-related-GO->GO:0030900[forebrain development], 3-GoPubMed-related-disease->mesh:13036[Spasms, Infantile],mesh:4829[Epilepsy, Generalized],mesh:9123[Muscle Hypotonia], 2-FACTA-related-disease->UMLS:C0036857[severe mental retardation],UMLS:C1843916[LIS1],
EMX2	NSD1	4-FACTA-related-drug->DrugBank:APRD00162[MRC],DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
EMX2	DCX	3-GoPubMed-related-disease->mesh:20828[Pseudobulbar Palsy],mesh:13036[Spasms, Infantile],mesh:14402[Tuberous Sclerosis], 1-FACTA-related-gene->HUMANGGP:027188[XLIS], 5-FACTA-related-disease->UMLS:C1848199[XLIS],UMLS:C1843916[LIS1],UMLS:C0266463[lissencephaly],UMLS:C0266483[pachygyria],UMLS:C0497552[Nervous System Malformations], 2-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
EMX2	NTRK1	5-FACTA-related-drug->DrugBank:BIOD00052[p75],DrugBank:APRD00953[ETS],DrugBank:APRD00627[Progesterone],DrugBank:APRD00691[Estradiol],DrugBank:APRD00631[Gel],
EMX2	DLX2	1-GoPubMed-related-GO->GO:0030900[forebrain development], 2-FACTA-related-disease->UMLS:C0266463[lissencephaly],UMLS:C0497552[Nervous System Malformations], 5-FACTA-related-drug->DrugBank:BIOD00052[p75],DrugBank:APRD00140[Tretinoin],DrugBank:BIOD00001[DNase I],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00631[Gel],
EMX2	HOXA1	1-FACTA-related-disease->UMLS:C0497552[Nervous System Malformations], 8-FACTA-related-drug->DrugBank:APRD00017[Tretinoin],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00700[Medroxyprogesterone Acetate],DrugBank:EXPT01468[Folic Acid],DrugBank:APRD00627[Progesterone],DrugBank:APRD00631[Gel],DrugBank:APRD00691[Estradiol],
EMX2	ARX	2-GoPubMed-related-GO->GO:0007405[neuroblast proliferation],GO:0030900[forebrain development], 3-GoPubMed-related-disease->mesh:13036[Spasms, Infantile],mesh:4829[Epilepsy, Generalized],mesh:20828[Pseudobulbar Palsy], 1-FACTA-related-gene->HUMANGGP:034445[RAB3GAP1], 2-FACTA-related-disease->UMLS:C1848199[XLIS],UMLS:C0266463[lissencephaly], 2-FACTA-related-drug->DrugBank:BIOD00052[p75],DrugBank:APRD00140[Tretinoin],
EMX2	CA6	5-FACTA-related-drug->DrugBank:APRD00162[MRC],DrugBank:BIOD00001[DNase I],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00631[Gel],
EMX2	MEF2C	2-FACTA-related-disease->UMLS:C0410174[Fukuyama congenital muscular dystrophy],UMLS:C0036857[severe mental retardation], 4-FACTA-related-drug->DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00627[Progesterone],DrugBank:APRD00140[Tretinoin],
EMX2	DISC1	2-FACTA-related-disease->UMLS:C1843916[LIS1],UMLS:C0266463[lissencephaly], 4-FACTA-related-drug->DrugBank:BIOD00052[p75],DrugBank:APRD00280[Frontal],DrugBank:APRD00627[Progesterone],DrugBank:APRD00631[Gel],
EMX2	EN2	1-GoPubMed-related-gene->85416[ZIC5], 2-FACTA-related-disease->UMLS:C0236970[Alcohol-Induced Disorders],UMLS:C0497552[Nervous System Malformations], 4-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00631[Gel],
EMX2	DLX6	2-GoPubMed-related-gene->10668[CGRRF1],8545[CGGBP1], 1-GoPubMed-related-GO->GO:0030900[forebrain development], 1-GoPubMed-related-disease->mesh:18240[Endodermal Sinus Tumor], 2-FACTA-related-gene->HUMANGGP:002915[HOXB5],HUMANGGP:013660[SORBS1], 2-FACTA-related-disease->UMLS:C0497552[Nervous System Malformations],UMLS:C0036857[severe mental retardation], 2-FACTA-related-drug->DrugBank:BIOD00001[DNase I],DrugBank:APRD00140[Tretinoin],
EMX2	FOXP2	1-GoPubMed-related-gene->2016[EMX1], 1-FACTA-related-drug->DrugBank:APRD00280[Frontal],
EMX2	RELN	3-GoPubMed-related-disease->mesh:20828[Pseudobulbar Palsy],mesh:14402[Tuberous Sclerosis],mesh:13036[Spasms, Infantile], 1-FACTA-related-gene->HUMANGGP:034445[RAB3GAP1], 7-FACTA-related-disease->UMLS:C1848199[XLIS],UMLS:C1843916[LIS1],UMLS:C0266483[pachygyria],UMLS:C0266463[lissencephaly],UMLS:C0266484[schizencephaly],UMLS:C0497552[Nervous System Malformations],UMLS:C0033790[pseudobulbar palsy], 5-FACTA-related-drug->DrugBank:BIOD00001[DNase I],DrugBank:APRD00280[Frontal],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00631[Gel],
EMX2	LAMB1	1-GoPubMed-related-GO->GO:0001656[metanephros development], 7-FACTA-related-drug->DrugBank:APRD00700[Medroxyprogesterone Acetate],DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00140[Tretinoin],DrugBank:BIOD00001[DNase I],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00691[Estradiol],DrugBank:APRD00631[Gel],
EMX2	FOXG1	1-GoPubMed-related-GO->GO:0030900[forebrain development], 1-FACTA-related-disease->UMLS:C0036857[severe mental retardation], 2-FACTA-related-drug->DrugBank:APRD00162[MRC],DrugBank:APRD00627[Progesterone],
EN1	NFIA	2-FACTA-related-disease->UMLS:C0497552[Nervous System Malformations],UMLS:C0153640[Cerebellum], 2-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
EN1	GRIP1	3-FACTA-related-drug->DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00263[Ganciclovir],
EN1	DLX6	1-FACTA-related-disease->UMLS:C0497552[Nervous System Malformations], 2-FACTA-related-drug->DrugBank:BIOD00001[DNase I],DrugBank:APRD00140[Tretinoin],
EN1	DCX	1-FACTA-related-disease->UMLS:C0497552[Nervous System Malformations], 4-FACTA-related-drug->DrugBank:APRD00106[Norplant],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00263[Ganciclovir],DrugBank:APRD00017[Tretinoin],
EN1	PITX1	1-GoPubMed-related-disease->mesh:4480[Ectromelia], 1-FACTA-related-gene->HUMANGGP:023475[EVX1], 3-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00627[Progesterone],
EN1	RELN	2-FACTA-related-disease->UMLS:C0497552[Nervous System Malformations],UMLS:C0265210[Weaver], 4-FACTA-related-drug->DrugBank:BIOD00001[DNase I],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00631[Gel],
EN1	GNAS	1-GoPubMed-related-disease->mesh:11556[Pseudopseudohypoparathyroidism], 2-FACTA-related-disease->UMLS:C0033806[pseudohypoparathyroidism],UMLS:C0033835[Pseudopseudohypoparathyroidism], 5-FACTA-related-drug->DrugBank:BIOD00001[DNase I],DrugBank:BIOD00057[Fragment],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00627[Progesterone],
EN1	DLX1	1-FACTA-related-gene->HUMANGGP:015295[GSX2], 1-FACTA-related-disease->UMLS:C0497552[Nervous System Malformations], 3-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:BIOD00001[DNase I],DrugBank:APRD00017[Tretinoin],
EN1	EN2	3-GoPubMed-related-gene->2636[GBX1],2637[GBX2],56751[BARHL1], 2-GoPubMed-related-GO->GO:0008039[synaptic target recognition],GO:0008038[neuron recognition], 2-GoPubMed-related-disease->mesh:46151[Lingual Thyroid],mesh:50033[Thyroid Dysgenesis], 7-FACTA-related-gene->HUMANGGP:033836[EN2],HUMANGGP:003993[ESG2],HUMANGGP:017730[EN1],HUMANGGP:007238[ESG1],HUMANGGP:033838[Engrailed-2],HUMANGGP:002869[BARHL1],HUMANGGP:037747[GBX2], 4-FACTA-related-disease->UMLS:C0220603[pediatric brain tumor],UMLS:C0431399[Joubert syndrome],UMLS:C0497552[Nervous System Malformations],UMLS:C0795864[SMS], 6-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:BIOD00057[Fragment],DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00450[Norepinephrine],DrugBank:APRD00631[Gel],
EN1	HDAC4	1-FACTA-related-gene->HUMANGGP:012592[STK25], 3-FACTA-related-disease->UMLS:C0265218[NLS],UMLS:C0795864[SMS],UMLS:C0033806[pseudohypoparathyroidism], 4-FACTA-related-drug->DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00627[Progesterone],
EN1	RAI1	1-FACTA-related-disease->UMLS:C0795864[SMS], 4-FACTA-related-drug->DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00631[Gel],
EN1	MARK1	2-FACTA-related-drug->DrugBank:APRD01322[Potassium Chloride],DrugBank:APRD00631[Gel],
EN1	HOXA1	1-GoPubMed-related-gene->2636[GBX1], 1-FACTA-related-gene->HUMANGGP:023475[EVX1], 1-FACTA-related-disease->UMLS:C0497552[Nervous System Malformations], 5-FACTA-related-drug->DrugBank:APRD00017[Tretinoin],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00627[Progesterone],DrugBank:APRD00631[Gel],
EN1	F13A1	4-FACTA-related-drug->DrugBank:APRD00362[Retinoic Acid],DrugBank:BIOD00057[Fragment],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00631[Gel],
EN1	TBX1	4-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00627[Progesterone],DrugBank:APRD00631[Gel],
EN1	DLX2	1-FACTA-related-gene->HUMANGGP:015295[GSX2], 2-FACTA-related-disease->UMLS:C0268503[OAR],UMLS:C0497552[Nervous System Malformations], 4-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:BIOD00001[DNase I],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00631[Gel],
EN1	GRIN2B	1-FACTA-related-disease->UMLS:C0178417[anhedonia], 4-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD01322[Potassium Chloride],DrugBank:APRD00627[Progesterone],DrugBank:APRD00631[Gel],
FGF8	FMR1	4-FACTA-related-drug->DrugBank:APRD00264[Bayer],DrugBank:APRD00256[Valproic Acid],DrugBank:BIOD00001[DNase I],DrugBank:EXPT01467[Forskolin],
FGF8	RELN	1-GoPubMed-related-disease->mesh:16142[Holoprosencephaly], 4-FACTA-related-drug->DrugBank:APRD00256[Valproic Acid],DrugBank:BIOD00001[DNase I],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
FGF8	GNAS	7-FACTA-related-drug->DrugBank:APRD00134[Activin],DrugBank:APRD00326[Factor II],DrugBank:BIOD00001[DNase I],DrugBank:EXPT01467[Forskolin],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00627[Progesterone],
FGF8	CACNA1G	6-FACTA-related-drug->DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00326[Factor II],DrugBank:APRD00017[Tretinoin],DrugBank:EXPT00514[Amiloride],DrugBank:APRD00790[Amiloride],DrugBank:EXPT01467[Forskolin], 1-pathway->kegg:path:hsa04010[MAPK signaling pathway],
FGF8	CHD7	2-GoPubMed-related-disease->mesh:2754[Choanal Atresia],mesh:17436[Kallmann Syndrome], 4-FACTA-related-disease->UMLS:C1563720[KAL2],UMLS:C0162809[Kallmann's syndrome],UMLS:C0271623[Hypogonadotropic hypogonadism],UMLS:C0012236[DiGeorge Syndrome], 1-FACTA-related-drug->DrugBank:BIOD00001[DNase I],
FGF8	PITX1	1-GoPubMed-related-disease->mesh:25962[Septo-Optic Dysplasia], 3-FACTA-related-disease->UMLS:C0496842[Pituitary gland],UMLS:C0496901[Pituitary gland],UMLS:C0496944[Pituitary gland], 4-FACTA-related-drug->DrugBank:APRD00134[Activin],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00627[Progesterone],
FGF8	EGR2	7-FACTA-related-drug->DrugBank:APRD00953[ETS],DrugBank:APRD00326[Factor II],DrugBank:APRD00256[Valproic Acid],DrugBank:BIOD00001[DNase I],DrugBank:EXPT01467[Forskolin],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
FGF8	NLGN4X	1-GoPubMed-related-disease->mesh:17436[Kallmann Syndrome], 1-FACTA-related-disease->UMLS:C0162809[Kallmann's syndrome],
FGF8	JMJD1C	1-FACTA-related-gene->HUMANGGP:000310[JMJD1B],
FGF8	MECP2	4-FACTA-related-drug->DrugBank:APRD00953[ETS],DrugBank:APRD00256[Valproic Acid],DrugBank:APRD00326[Factor II],DrugBank:BIOD00001[DNase I],
FGF8	DLX2	4-FACTA-related-drug->DrugBank:BIOD00052[p75],DrugBank:APRD00140[Tretinoin],DrugBank:BIOD00001[DNase I],DrugBank:APRD00017[Tretinoin],
FGF8	TTN	3-FACTA-related-drug->DrugBank:EXPT00514[Amiloride],DrugBank:APRD00790[Amiloride],DrugBank:APRD00326[Factor II],
FGF8	NTRK1	1-FACTA-related-gene->HUMANGGP:000310[JMJD1B], 3-FACTA-related-drug->DrugBank:BIOD00052[p75],DrugBank:APRD00953[ETS],DrugBank:APRD00627[Progesterone], 2-pathway->kegg:path:hsa05200[Pathways in cancer],kegg:path:hsa04010[MAPK signaling pathway],
FGF8	HOXB1	1-FACTA-related-disease->UMLS:C0012236[DiGeorge Syndrome], 5-FACTA-related-drug->DrugBank:APRD00017[Tretinoin],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00256[Valproic Acid],DrugBank:APRD00627[Progesterone],
FGF8	EN2	2-GoPubMed-related-gene->2637[GBX2],56751[BARHL1], 4-GoPubMed-related-GO->GO:0021903[rostrocaudal neural tube patterning],GO:0030917[midbrain-hindbrain boundary development],GO:0021532[neural tube patterning],GO:0046875[ephrin receptor binding], 1-GoPubMed-related-disease->mesh:16142[Holoprosencephaly], 3-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00362[Retinoic Acid],
FGF8	CD44	1-FACTA-related-disease->UMLS:C1864968[DFNB51],
FKRP	SHANK3	1-GoPubMed-related-GO->GO:0016301[kinase activity], 1-GoPubMed-related-disease->mesh:9123[Muscle Hypotonia], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
FKRP	AHI1	1-GoPubMed-related-disease->mesh:9123[Muscle Hypotonia], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
FKRP	CREBBP	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
FKRP	NLGN4X	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
FKRP	NTRK1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
FKRP	NPAS2	3-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:EXPT00494[Alanine],
FKRP	HOXB1	3-FACTA-related-drug->DrugBank:EXPT00494[Alanine],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
FKRP	DHCR7	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
FKRP	MEF2C	1-GoPubMed-related-disease->mesh:49288[Muscular Dystrophies, Limb-Girdle], 1-FACTA-related-disease->UMLS:C0410174[Fukuyama congenital muscular dystrophy],
FKRP	CA6	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
FKRP	NSD1	1-GoPubMed-related-disease->mesh:8260[Macroglossia], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
FKRP	CADM1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
FKRP	MYO1A	1-FACTA-related-drug->DrugBank:EXPT00573[Aspartic Acid],
FKRP	CHD7	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
FKRP	FBXO40	4-GoPubMed-related-disease->mesh:49288[Muscular Dystrophies, Limb-Girdle],mesh:9136[Muscular Dystrophies],mesh:20966[Muscular Disorders, Atrophic],mesh:9135[Muscular Diseases], 1-FACTA-related-disease->UMLS:C0686353[limb-girdle muscular dystrophy],
FKRP	CNTNAP2	1-GoPubMed-related-GO->GO:0001764[neuron migration], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
FOXE1	AHI1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
FOXE1	CADM1	1-GoPubMed-related-gene->121643[FOXN4], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
FOXE1	NLGN4X	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
FOXE1	NTRK1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
FOXE1	NPAS2	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
FOXE1	HOXB1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
FOXE1	DLX2	1-GoPubMed-related-GO->GO:0003677[DNA binding], 1-FACTA-related-disease->UMLS:C0016632[Fox], 2-FACTA-related-drug->DrugBank:APRD00504[ID2],DrugBank:BIOD00001[DNase I],
FOXE1	HOXA1	2-GoPubMed-related-disease->mesh:2754[Choanal Atresia],mesh:16569[Blepharophimosis], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
FOXE1	ARNT2	3-GoPubMed-related-disease->mesh:2972[Cleft Palate],mesh:7569[Jaw Abnormalities],mesh:19767[Maxillofacial Abnormalities],
FOXE1	CHD7	1-GoPubMed-related-disease->mesh:2754[Choanal Atresia], 3-FACTA-related-disease->UMLS:C1535927[HHS],UMLS:C0265354[CHARGE association],UMLS:C0158646[cleft lip/palate], 3-FACTA-related-drug->DrugBank:BIOD00001[DNase I],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
FOXE1	NSD1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
FOXE1	BAIAP2	1-FACTA-related-drug->DrugBank:APRD00504[ID2],
FOXE1	ESRRB	1-FACTA-related-drug->DrugBank:BIOD00001[DNase I],
FOXE1	CNTNAP2	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
FOXE1	FOXP2	6-GoPubMed-related-gene->27023[FOXB1],286380[FOXD4L3],116113[FOXP4],22887[FOXJ3],200350[FOXD4L1],121643[FOXN4], 1-GoPubMed-related-GO->GO:0003677[DNA binding], 1-GoPubMed-related-disease->mesh:16569[Blepharophimosis], 6-FACTA-related-gene->HUMANGGP:026116[FOXD4L3],HUMANGGP:004581[FOXP4],HUMANGGP:033853[MLLT7],HUMANGGP:023561[FOXD4L1],HUMANGGP:006514[FOXN2],HUMANGGP:040868[FOXO6], 1-FACTA-related-disease->UMLS:C0016632[Fox],
FOXE1	FOXP1	5-GoPubMed-related-gene->27023[FOXB1],286380[FOXD4L3],116113[FOXP4],22887[FOXJ3],200350[FOXD4L1], 1-GoPubMed-related-GO->GO:0004996[thyroid-stimulating hormone receptor activity], 1-GoPubMed-related-disease->mesh:16569[Blepharophimosis], 4-FACTA-related-gene->HUMANGGP:026116[FOXD4L3],HUMANGGP:004581[FOXP4],HUMANGGP:033853[MLLT7],HUMANGGP:023561[FOXD4L1], 1-FACTA-related-disease->UMLS:C0016632[Fox],
FOXE1	CREBBP	3-FACTA-related-drug->DrugBank:BIOD00001[DNase I],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
FOXE1	FOXG1	7-GoPubMed-related-gene->27023[FOXB1],286380[FOXD4L3],22887[FOXJ3],116113[FOXP4],200350[FOXD4L1],121643[FOXN4],100132074[FOXO6], 10-FACTA-related-gene->HUMANGGP:026116[FOXD4L3],HUMANGGP:023561[FOXD4L1],HUMANGGP:033853[MLLT7],HUMANGGP:006514[FOXN2],HUMANGGP:040868[FOXO6],HUMANGGP:022781[FOXN4],HUMANGGP:004581[FOXP4],HUMANGGP:005137[FOXK1],HUMANGGP:034707[FOXR1],HUMANGGP:023562[FOXD4], 2-FACTA-related-disease->UMLS:C0016632[Fox],UMLS:C1535927[HHS],
FOXE1	DLX6	1-GoPubMed-related-GO->GO:0003677[DNA binding], 1-FACTA-related-disease->UMLS:C0158646[cleft lip/palate], 1-FACTA-related-drug->DrugBank:BIOD00001[DNase I],
FOXF1	FOXG1	6-GoPubMed-related-gene->27023[FOXB1],286380[FOXD4L3],22887[FOXJ3],116113[FOXP4],200350[FOXD4L1],121643[FOXN4], 5-FACTA-related-gene->HUMANGGP:026116[FOXD4L3],HUMANGGP:023561[FOXD4L1],HUMANGGP:033853[MLLT7],HUMANGGP:006514[FOXN2],HUMANGGP:017016[FOXF2],
FOXF1	NF1	1-GoPubMed-related-GO->GO:0043871[delta1-piperideine-6-carboxylate dehydrogenase activity], 2-FACTA-related-drug->DrugBank:BIOD00001[DNase I],DrugBank:APRD00017[Tretinoin], 1-pathway->nci_nature_pid:FOXA2_and_FOXA3_transcription_factor_networks[],
FOXF1	PITX1	3-FACTA-related-drug->DrugBank:APRD00134[Activin],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
FOXF1	DAB1	3-GoPubMed-related-disease->mesh:6972[Hypertelorism],mesh:3394[Craniofacial Dysostosis],mesh:2972[Cleft Palate], 1-FACTA-related-disease->UMLS:C0221355[macrocephaly],
FOXF1	EN2	2-FACTA-related-disease->UMLS:C0206655[Rhabdomyosarcoma, Alveolar],UMLS:C0026106[mild mental retardation], 2-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
FOXF1	RELN	3-FACTA-related-drug->DrugBank:BIOD00001[DNase I],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
FOXF1	SYN1	1-GoPubMed-related-GO->GO:0005484[SNAP receptor activity], 1-FACTA-related-disease->UMLS:C0221355[macrocephaly], 1-FACTA-related-drug->DrugBank:APRD00953[ETS],
FOXF1	DHCR7	1-GoPubMed-related-disease->mesh:3616[Dandy-Walker Syndrome], 1-FACTA-related-disease->UMLS:C0026351[moderate mental retardation], 1-FACTA-related-drug->DrugBank:BIOD00001[DNase I],
FOXF1	DCX	1-GoPubMed-related-gene->9832[JAKMIP2], 1-GoPubMed-related-GO->GO:0043871[delta1-piperideine-6-carboxylate dehydrogenase activity], 1-FACTA-related-gene->HUMANGGP:008518[JAKMIP2], 2-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
FOXF1	DLX2	4-FACTA-related-drug->DrugBank:APRD00504[ID2],DrugBank:APRD00140[Tretinoin],DrugBank:BIOD00001[DNase I],DrugBank:APRD00017[Tretinoin],
FOXF1	DLX1	3-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:BIOD00001[DNase I],DrugBank:APRD00017[Tretinoin],
FOXF1	SHANK3	1-GoPubMed-related-disease->mesh:3103[Coloboma], 2-FACTA-related-disease->UMLS:C0221355[macrocephaly],UMLS:C0026106[mild mental retardation],
FOXF1	FGD1	2-GoPubMed-related-disease->mesh:6972[Hypertelorism],mesh:3394[Craniofacial Dysostosis], 1-FACTA-related-disease->UMLS:C0221355[macrocephaly],
FOXF1	BAIAP2	1-FACTA-related-drug->DrugBank:APRD00504[ID2],
FOXF1	NRCAM	1-GoPubMed-related-gene->9832[JAKMIP2], 1-GoPubMed-related-GO->GO:0043871[delta1-piperideine-6-carboxylate dehydrogenase activity], 1-FACTA-related-gene->HUMANGGP:008518[JAKMIP2], 2-FACTA-related-disease->UMLS:C0206655[Rhabdomyosarcoma, Alveolar],UMLS:C0206656[embryonal rhabdomyosarcoma],
FOXF1	NFIA	1-FACTA-related-disease->UMLS:C0221355[macrocephaly], 2-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
FOXF1	ABAT	1-GoPubMed-related-gene->9832[JAKMIP2], 1-GoPubMed-related-GO->GO:0043871[delta1-piperideine-6-carboxylate dehydrogenase activity], 2-FACTA-related-gene->HUMANGGP:008518[JAKMIP2],HUMANGGP:034649[FOXF1], 2-FACTA-related-disease->UMLS:C0206655[Rhabdomyosarcoma, Alveolar],UMLS:C0206656[embryonal rhabdomyosarcoma],
FOXF1	FOXP1	6-GoPubMed-related-gene->27023[FOXB1],286380[FOXD4L3],116113[FOXP4],22887[FOXJ3],200350[FOXD4L1],2306[FOXD2], 3-FACTA-related-gene->HUMANGGP:026116[FOXD4L3],HUMANGGP:033853[MLLT7],HUMANGGP:023561[FOXD4L1], 1-FACTA-related-drug->DrugBank:APRD00953[ETS],
FOXF1	DLX6	2-FACTA-related-drug->DrugBank:BIOD00001[DNase I],DrugBank:APRD00140[Tretinoin],
FOXL2	WNT2	4-FACTA-related-drug->DrugBank:APRD00433[Methyltestosterone],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00691[Estradiol],DrugBank:APRD00396[Estrogens],
FOXL2	ST7	3-FACTA-related-drug->DrugBank:APRD00433[Methyltestosterone],DrugBank:APRD00631[Gel],DrugBank:EXPT00494[Alanine],
FOXL2	ATRX	1-GoPubMed-related-disease->mesh:7829[Laryngostenosis], 2-FACTA-related-drug->DrugBank:EXPT02079[lysine],DrugBank:APRD00631[Gel],
FOXL2	HMGN1	1-FACTA-related-disease->UMLS:C0018054[Gonadal Dysgenesis, 46,XY], 5-FACTA-related-drug->DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00017[Tretinoin],DrugBank:EXPT02079[lysine],DrugBank:APRD00396[Estrogens],DrugBank:APRD00631[Gel],
FOXL2	CA6	4-FACTA-related-drug->DrugBank:APRD00017[Tretinoin],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00631[Gel],
FOXL2	ARNT2	3-FACTA-related-drug->DrugBank:APRD00396[Estrogens],DrugBank:APRD00691[Estradiol],DrugBank:APRD00631[Gel],
FOXL2	FOXG1	7-GoPubMed-related-gene->27023[FOXB1],286380[FOXD4L3],22887[FOXJ3],116113[FOXP4],200350[FOXD4L1],121643[FOXN4],100132074[FOXO6], 6-FACTA-related-gene->HUMANGGP:026116[FOXD4L3],HUMANGGP:023561[FOXD4L1],HUMANGGP:033853[MLLT7],HUMANGGP:006514[FOXN2],HUMANGGP:040868[FOXO6],HUMANGGP:022781[FOXN4], 1-FACTA-related-drug->DrugBank:EXPT02079[lysine],
FOXL2	FGD1	1-GoPubMed-related-disease->mesh:1763[Blepharoptosis],
FOXL2	NTRK1	5-FACTA-related-drug->DrugBank:EXPT02079[lysine],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00691[Estradiol],DrugBank:APRD00631[Gel],
FOXL2	NPAS2	4-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:EXPT00494[Alanine],DrugBank:APRD00631[Gel],
FOXL2	HOXB1	1-GoPubMed-related-GO->GO:0050254[rhodopsin kinase activity], 7-FACTA-related-drug->DrugBank:APRD00017[Tretinoin],DrugBank:APRD00362[Retinoic Acid],DrugBank:EXPT02079[lysine],DrugBank:EXPT00494[Alanine],DrugBank:APRD00506[Spectrum],DrugBank:APRD00631[Gel],DrugBank:APRD00552[Spectrum],
FOXL2	HOXA1	1-GoPubMed-related-disease->mesh:16569[Blepharophimosis], 8-FACTA-related-drug->DrugBank:APRD00017[Tretinoin],DrugBank:APRD00362[Retinoic Acid],DrugBank:EXPT02079[lysine],DrugBank:EXPT00494[Alanine],DrugBank:APRD00506[Spectrum],DrugBank:APRD00631[Gel],DrugBank:APRD00552[Spectrum],DrugBank:APRD00691[Estradiol],
FOXL2	EGR2	1-GoPubMed-related-disease->mesh:20331[Mobius Syndrome], 1-FACTA-related-drug->DrugBank:APRD00017[Tretinoin],
FOXL2	MCPH1	1-GoPubMed-related-disease->mesh:16569[Blepharophimosis], 2-FACTA-related-disease->UMLS:C0265202[Seckel syndrome],UMLS:C0265237[blepharophimosis-ptosis-epicanthus inversus syndrome], 1-FACTA-related-drug->DrugBank:APRD00631[Gel],
FOXL2	FOXP2	6-GoPubMed-related-gene->27023[FOXB1],286380[FOXD4L3],116113[FOXP4],22887[FOXJ3],200350[FOXD4L1],121643[FOXN4], 1-GoPubMed-related-disease->mesh:16569[Blepharophimosis], 5-FACTA-related-gene->HUMANGGP:026116[FOXD4L3],HUMANGGP:033853[MLLT7],HUMANGGP:023561[FOXD4L1],HUMANGGP:006514[FOXN2],HUMANGGP:040868[FOXO6],
FOXL2	FOXP1	5-GoPubMed-related-gene->27023[FOXB1],286380[FOXD4L3],116113[FOXP4],22887[FOXJ3],200350[FOXD4L1], 1-GoPubMed-related-disease->mesh:16569[Blepharophimosis], 3-FACTA-related-gene->HUMANGGP:026116[FOXD4L3],HUMANGGP:033853[MLLT7],HUMANGGP:023561[FOXD4L1], 2-FACTA-related-drug->DrugBank:APRD00396[Estrogens],DrugBank:APRD00691[Estradiol],
FOXL2	NIPBL	1-GoPubMed-related-disease->mesh:1763[Blepharoptosis],
FOXL2	NSD1	1-FACTA-related-disease->UMLS:C0751156[FRAXA], 5-FACTA-related-drug->DrugBank:EXPT02079[lysine],DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
FOXL2	AHI1	1-GoPubMed-related-GO->GO:0008792[arginine decarboxylase activity], 3-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00631[Gel],
FOXL2	PITX1	1-GoPubMed-related-GO->GO:0004760[serine-pyruvate transaminase activity], 2-FACTA-related-disease->UMLS:C0154208[ovarian dysfunction],UMLS:C1522297[Granulosa Cell Tumor], 4-FACTA-related-drug->DrugBank:APRD00134[Activin],DrugBank:APRD00017[Tretinoin],DrugBank:EXPT02079[lysine],DrugBank:APRD00396[Estrogens],
FOXQ1	SLC1A1	3-FACTA-related-drug->DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
FOXQ1	DAB1	2-GoPubMed-related-GO->GO:0030228[lipoprotein receptor activity],GO:0008034[lipoprotein binding], 1-GoPubMed-related-disease->mesh:6972[Hypertelorism], 1-FACTA-related-disease->UMLS:C0221355[macrocephaly],
FOXQ1	EN2	1-FACTA-related-disease->UMLS:C0026106[mild mental retardation], 3-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00362[Retinoic Acid],
FOXQ1	SHANK3	1-GoPubMed-related-disease->mesh:3103[Coloboma], 2-FACTA-related-disease->UMLS:C0221355[macrocephaly],UMLS:C0026106[mild mental retardation],
FOXQ1	DCTN5	2-GoPubMed-related-disease->mesh:3616[Dandy-Walker Syndrome],mesh:5124[Eye Abnormalities],
FOXQ1	FOXP1	6-GoPubMed-related-gene->27023[FOXB1],286380[FOXD4L3],116113[FOXP4],22887[FOXJ3],200350[FOXD4L1],2306[FOXD2], 1-GoPubMed-related-GO->GO:0030225[macrophage differentiation], 1-GoPubMed-related-disease->mesh:16569[Blepharophimosis], 4-FACTA-related-gene->HUMANGGP:026116[FOXD4L3],HUMANGGP:004581[FOXP4],HUMANGGP:033853[MLLT7],HUMANGGP:023561[FOXD4L1], 1-FACTA-related-disease->UMLS:C0016632[Fox],
FOXQ1	DLX1	2-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
FOXQ1	FOXG1	8-GoPubMed-related-gene->27023[FOXB1],286380[FOXD4L3],22887[FOXJ3],116113[FOXP4],200350[FOXD4L1],121643[FOXN4],100132074[FOXO6],2299[FOXI1], 12-FACTA-related-gene->HUMANGGP:026116[FOXD4L3],HUMANGGP:023561[FOXD4L1],HUMANGGP:033853[MLLT7],HUMANGGP:006514[FOXN2],HUMANGGP:040868[FOXO6],HUMANGGP:022781[FOXN4],HUMANGGP:004581[FOXP4],HUMANGGP:005137[FOXK1],HUMANGGP:034707[FOXR1],HUMANGGP:023562[FOXD4],HUMANGGP:020398[FOXN3],HUMANGGP:017016[FOXF2], 1-FACTA-related-disease->UMLS:C0016632[Fox],
FOXQ1	FGD1	2-GoPubMed-related-disease->mesh:6972[Hypertelorism],mesh:1763[Blepharoptosis], 1-FACTA-related-disease->UMLS:C0221355[macrocephaly],
FOXQ1	FOXP2	6-GoPubMed-related-gene->27023[FOXB1],286380[FOXD4L3],116113[FOXP4],22887[FOXJ3],200350[FOXD4L1],121643[FOXN4], 2-GoPubMed-related-GO->GO:0003677[DNA binding],GO:0003676[nucleic acid binding], 1-GoPubMed-related-disease->mesh:16569[Blepharophimosis], 6-FACTA-related-gene->HUMANGGP:026116[FOXD4L3],HUMANGGP:004581[FOXP4],HUMANGGP:033853[MLLT7],HUMANGGP:023561[FOXD4L1],HUMANGGP:006514[FOXN2],HUMANGGP:040868[FOXO6], 2-FACTA-related-disease->UMLS:C0016632[Fox],UMLS:C0026351[moderate mental retardation],
FOXQ1	VASH1	2-FACTA-related-disease->UMLS:C0154025[Conjunctiva],UMLS:C0153628[Conjunctiva],
FOXQ1	RAI1	3-FACTA-related-drug->DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
FOXQ1	NIPBL	1-GoPubMed-related-disease->mesh:1763[Blepharoptosis],
FOXQ1	TBX1	1-FACTA-related-disease->UMLS:C0016632[Fox], 2-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
FOXQ1	NSD1	1-FACTA-related-disease->UMLS:C0221355[macrocephaly], 3-FACTA-related-drug->DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
FOXQ1	NFIA	1-FACTA-related-disease->UMLS:C0221355[macrocephaly], 2-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
FOXQ1	F13A1	2-FACTA-related-drug->DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00017[Tretinoin],
FTSJ1	IL1RAPL1	3-GoPubMed-related-gene->7592[ZNF41],4983[OPHN1],9459[ARHGEF6], 2-GoPubMed-related-GO->GO:0005092[GDP-dissociation inhibitor activity],GO:0005083[small GTPase regulator activity], 4-GoPubMed-related-disease->mesh:38901[Mental Retardation, X-Linked],mesh:12729[Sex Chromosome Aberrations],mesh:5600[Fragile X Syndrome],mesh:8607[Mental Retardation], 8-FACTA-related-gene->HUMANGGP:013204[FRMPD4],HUMANGGP:007566[IL1RAPL1],HUMANGGP:040636[FTSJ1],HUMANGGP:022463[REPS2],HUMANGGP:015143[DLG3],HUMANGGP:027462[ZNF41],HUMANGGP:034035[PQBP1],HUMANGGP:007783[ARHGEF6], 6-FACTA-related-disease->UMLS:C1136249[Mental Retardation, X-Linked],UMLS:C1845055[ATRX],UMLS:C0917816[mental retardation],UMLS:C0016667[Fragile X Syndrome],UMLS:C0004352[autism],UMLS:C0036868[Sex Chromosome Aberrations],
FTSJ1	CACNA1H	1-GoPubMed-related-gene->8242[KDM5C], 2-FACTA-related-disease->UMLS:C0004352[autism],UMLS:C0338656[cognitive impairment],
FTSJ1	MECP2	3-GoPubMed-related-disease->mesh:38901[Mental Retardation, X-Linked],mesh:40181[Genetic Diseases, X-Linked],mesh:8607[Mental Retardation], 1-FACTA-related-gene->HUMANGGP:013204[FRMPD4], 3-FACTA-related-disease->UMLS:C1845055[ATRX],UMLS:C1136249[Mental Retardation, X-Linked],UMLS:C1859974[FGD1],
FTSJ1	ARX	4-GoPubMed-related-gene->11141[IL1RAPL1],7592[ZNF41],347344[ZNF81],4983[OPHN1], 1-GoPubMed-related-GO->GO:0005092[GDP-dissociation inhibitor activity], 1-GoPubMed-related-disease->mesh:38901[Mental Retardation, X-Linked], 7-FACTA-related-gene->HUMANGGP:007783[ARHGEF6],HUMANGGP:039910[OPHN1],HUMANGGP:002027[RPS6KA3],HUMANGGP:020388[TM4SF2],HUMANGGP:040636[FTSJ1],HUMANGGP:028523[FACL4],HUMANGGP:015143[DLG3], 1-FACTA-related-disease->UMLS:C1136249[Mental Retardation, X-Linked],
FTSJ1	NLGN3	1-GoPubMed-related-gene->57502[NLGN4X], 3-GoPubMed-related-GO->GO:0005092[GDP-dissociation inhibitor activity],GO:0005083[small GTPase regulator activity],GO:0030695[GTPase regulator activity], 3-GoPubMed-related-disease->mesh:5600[Fragile X Syndrome],mesh:25064[Sex Chromosome Disorders],mesh:8607[Mental Retardation], 7-FACTA-related-gene->HUMANGGP:014727[NLGN3],HUMANGGP:040636[FTSJ1],HUMANGGP:015143[DLG3],HUMANGGP:027462[ZNF41],HUMANGGP:007783[ARHGEF6],HUMANGGP:020388[TM4SF2],HUMANGGP:039910[OPHN1], 4-FACTA-related-disease->UMLS:C1845055[ATRX],UMLS:C0004352[autism],UMLS:C0016667[Fragile X Syndrome],UMLS:C0917816[mental retardation],
FTSJ1	FGD1	5-GoPubMed-related-gene->7592[ZNF41],347344[ZNF81],57502[NLGN4X],11141[IL1RAPL1],8242[KDM5C], 3-GoPubMed-related-GO->GO:0005083[small GTPase regulator activity],GO:0030695[GTPase regulator activity],GO:0060589[nucleoside-triphosphatase regulator activity], 9-FACTA-related-gene->HUMANGGP:006914[ZNF81],HUMANGGP:040636[FTSJ1],HUMANGGP:015143[DLG3],HUMANGGP:027462[ZNF41],HUMANGGP:007783[ARHGEF6],HUMANGGP:020388[TM4SF2],HUMANGGP:039910[OPHN1],HUMANGGP:028523[FACL4],HUMANGGP:002027[RPS6KA3], 3-FACTA-related-disease->UMLS:C1859974[FGD1],UMLS:C1136249[Mental Retardation, X-Linked],UMLS:C0036857[severe mental retardation],
FTSJ1	DLGAP2	4-GoPubMed-related-disease->mesh:5600[Fragile X Syndrome],mesh:25064[Sex Chromosome Disorders],mesh:38901[Mental Retardation, X-Linked],mesh:8607[Mental Retardation], 3-FACTA-related-disease->UMLS:C0004352[autism],UMLS:C0917816[mental retardation],UMLS:C0025362[Mental Retardation],
FTSJ1	FRMPD4	2-GoPubMed-related-GO->GO:0030695[GTPase regulator activity],GO:0060589[nucleoside-triphosphatase regulator activity], 5-FACTA-related-gene->HUMANGGP:013204[FRMPD4],HUMANGGP:022463[REPS2],HUMANGGP:040636[FTSJ1],HUMANGGP:034035[PQBP1],HUMANGGP:007566[IL1RAPL1], 3-FACTA-related-disease->UMLS:C0796085[NHS],UMLS:C0917816[mental retardation],UMLS:C0025362[Mental Retardation],
FTSJ1	SYN1	3-GoPubMed-related-gene->54328[GPR173],347344[ZNF81],7592[ZNF41], 1-GoPubMed-related-GO->GO:0005092[GDP-dissociation inhibitor activity], 4-FACTA-related-gene->HUMANGGP:006914[ZNF81],HUMANGGP:027462[ZNF41],HUMANGGP:040636[FTSJ1],HUMANGGP:015143[DLG3], 3-FACTA-related-disease->UMLS:C1845055[ATRX],UMLS:C1136249[Mental Retardation, X-Linked],UMLS:C0016667[Fragile X Syndrome],
FTSJ1	OPHN1	4-GoPubMed-related-gene->9459[ARHGEF6],7592[ZNF41],11141[IL1RAPL1],57502[NLGN4X], 2-GoPubMed-related-GO->GO:0005092[GDP-dissociation inhibitor activity],GO:0005083[small GTPase regulator activity], 4-GoPubMed-related-disease->mesh:38901[Mental Retardation, X-Linked],mesh:5600[Fragile X Syndrome],mesh:8607[Mental Retardation],mesh:40181[Genetic Diseases, X-Linked], 8-FACTA-related-gene->HUMANGGP:039910[OPHN1],HUMANGGP:007783[ARHGEF6],HUMANGGP:020388[TM4SF2],HUMANGGP:002027[RPS6KA3],HUMANGGP:040636[FTSJ1],HUMANGGP:028523[FACL4],HUMANGGP:015143[DLG3],HUMANGGP:027462[ZNF41], 6-FACTA-related-disease->UMLS:C1136249[Mental Retardation, X-Linked],UMLS:C1845055[ATRX],UMLS:C1859974[FGD1],UMLS:C0917816[mental retardation],UMLS:C0036857[severe mental retardation],UMLS:C0016667[Fragile X Syndrome],
FTSJ1	NTNG1	5-GoPubMed-related-disease->mesh:38901[Mental Retardation, X-Linked],mesh:8607[Mental Retardation],mesh:40181[Genetic Diseases, X-Linked],mesh:20271[Heredodegenerative Disorders, Nervous System],mesh:19954[Neurobehavioral Manifestations], 3-FACTA-related-disease->UMLS:C0036857[severe mental retardation],UMLS:C0917816[mental retardation],UMLS:C0025362[Mental Retardation],
FTSJ1	TSPAN7	5-GoPubMed-related-gene->54328[GPR173],7592[ZNF41],9459[ARHGEF6],11141[IL1RAPL1],4983[OPHN1], 2-GoPubMed-related-GO->GO:0005092[GDP-dissociation inhibitor activity],GO:0005083[small GTPase regulator activity], 2-GoPubMed-related-disease->mesh:38901[Mental Retardation, X-Linked],mesh:5600[Fragile X Syndrome], 1-FACTA-related-gene->HUMANGGP:020388[TM4SF2], 4-FACTA-related-disease->UMLS:C1136249[Mental Retardation, X-Linked],UMLS:C0004352[autism],UMLS:C0917816[mental retardation],UMLS:C0025362[Mental Retardation],
FTSJ1	NLGN4X	1-GoPubMed-related-gene->7592[ZNF41], 4-GoPubMed-related-GO->GO:0005092[GDP-dissociation inhibitor activity],GO:0005083[small GTPase regulator activity],GO:0030695[GTPase regulator activity],GO:0060589[nucleoside-triphosphatase regulator activity], 10-FACTA-related-gene->HUMANGGP:014727[NLGN3],HUMANGGP:006914[ZNF81],HUMANGGP:040636[FTSJ1],HUMANGGP:015143[DLG3],HUMANGGP:027462[ZNF41],HUMANGGP:007783[ARHGEF6],HUMANGGP:020388[TM4SF2],HUMANGGP:028523[FACL4],HUMANGGP:039910[OPHN1],HUMANGGP:002027[RPS6KA3], 5-FACTA-related-disease->UMLS:C1859974[FGD1],UMLS:C1136249[Mental Retardation, X-Linked],UMLS:C0004352[autism],UMLS:C0917816[mental retardation],UMLS:C0025362[Mental Retardation],
FTSJ1	AGTR2	2-GoPubMed-related-gene->7592[ZNF41],57502[NLGN4X], 9-FACTA-related-gene->HUMANGGP:007783[ARHGEF6],HUMANGGP:020388[TM4SF2],HUMANGGP:040636[FTSJ1],HUMANGGP:039910[OPHN1],HUMANGGP:028523[FACL4],HUMANGGP:002027[RPS6KA3],HUMANGGP:015143[DLG3],HUMANGGP:027462[ZNF41],HUMANGGP:014727[NLGN3], 2-FACTA-related-disease->UMLS:C1845055[ATRX],UMLS:C1136249[Mental Retardation, X-Linked],
FTSJ1	SLC6A8	1-GoPubMed-related-gene->7592[ZNF41], 2-GoPubMed-related-GO->GO:0005092[GDP-dissociation inhibitor activity],GO:0005083[small GTPase regulator activity], 8-FACTA-related-gene->HUMANGGP:039910[OPHN1],HUMANGGP:002027[RPS6KA3],HUMANGGP:007783[ARHGEF6],HUMANGGP:020388[TM4SF2],HUMANGGP:040636[FTSJ1],HUMANGGP:028523[FACL4],HUMANGGP:015143[DLG3],HUMANGGP:027462[ZNF41], 5-FACTA-related-disease->UMLS:C1136249[Mental Retardation, X-Linked],UMLS:C1845055[ATRX],UMLS:C0036857[severe mental retardation],UMLS:C0917816[mental retardation],UMLS:C0016667[Fragile X Syndrome],
FTSJ1	NRXN1	1-GoPubMed-related-GO->GO:0016776[phosphotransferase activity, phosphate group as acceptor], 2-GoPubMed-related-disease->mesh:5600[Fragile X Syndrome],mesh:8607[Mental Retardation], 1-FACTA-related-gene->HUMANGGP:014727[NLGN3], 4-FACTA-related-disease->UMLS:C0036857[severe mental retardation],UMLS:C0004352[autism],UMLS:C1855900[HCG],UMLS:C0917816[mental retardation],
GABRA1	CHRNA7	1-GoPubMed-related-GO->GO:0022831[narrow pore, gated channel activity], 3-GoPubMed-related-disease->mesh:20190[Myoclonic Epilepsy, Juvenile],mesh:20936[Epilepsy, Benign Neonatal],mesh:4831[Epilepsies, Myoclonic], 2-FACTA-related-disease->UMLS:C0270853[juvenile myoclonic epilepsy],UMLS:C0014548[Epilepsy, Generalized], 2-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:BIOD00057[Fragment], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
GABRA1	SLC1A1	1-FACTA-related-gene->HUMANGGP:021476[SLC1A6], 1-FACTA-related-drug->DrugBank:APRD00280[Frontal],
GABRA1	FOXP2	2-FACTA-related-drug->DrugBank:APRD00280[Frontal],DrugBank:BIOD00057[Fragment],
GABRA1	SCN2A	1-GoPubMed-related-gene->2566[GABRG2], 3-GoPubMed-related-disease->mesh:20936[Epilepsy, Benign Neonatal],mesh:3294[Seizures, Febrile],mesh:53447[Channelopathies], 3-FACTA-related-gene->HUMANGGP:007992[GABRG2],HUMANGGP:033825[EFHC1],HUMANGGP:023447[GABRA1], 2-FACTA-related-disease->UMLS:C1858671[GEFS+],UMLS:C0270850[IGE], 2-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00256[Valproic Acid],
GABRA1	SCN1A	2-GoPubMed-related-gene->2566[GABRG2],80258[EFHC2], 2-GoPubMed-related-GO->GO:0022831[narrow pore, gated channel activity],GO:0022842[narrow pore channel activity], 7-GoPubMed-related-disease->mesh:3294[Seizures, Febrile],mesh:4831[Epilepsies, Myoclonic],mesh:20936[Epilepsy, Benign Neonatal],mesh:20190[Myoclonic Epilepsy, Juvenile],mesh:4829[Epilepsy, Generalized],mesh:53447[Channelopathies],mesh:4832[Epilepsy, Absence], 2-FACTA-related-gene->HUMANGGP:007992[GABRG2],HUMANGGP:015890[EFHC2], 1-FACTA-related-disease->UMLS:C1858671[GEFS+], 2-FACTA-related-drug->DrugBank:APRD00382[Pilocarpine],DrugBank:BIOD00057[Fragment],
GABRA1	MECP2	2-FACTA-related-drug->DrugBank:APRD00256[Valproic Acid],DrugBank:APRD00280[Frontal],
GABRA1	GABRB1	3-GoPubMed-related-gene->2570[GABRR2],2559[GABRA6],2568[GABRP], 1-GoPubMed-related-GO->GO:0071514[genetic imprinting], 5-FACTA-related-gene->HUMANGGP:004123[GABRB1],HUMANGGP:021907[GABRP],HUMANGGP:036164[GABRA6],HUMANGGP:023447[GABRA1],HUMANGGP:041448[GABRB2], 1-FACTA-related-disease->UMLS:C0043207[Wolfram syndrome], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
GABRA1	GABRA4	4-GoPubMed-related-gene->2560[GABRB1],2570[GABRR2],2561[GABRB2],2568[GABRP], 6-FACTA-related-gene->HUMANGGP:004123[GABRB1],HUMANGGP:021907[GABRP],HUMANGGP:041448[GABRB2],HUMANGGP:036164[GABRA6],HUMANGGP:023447[GABRA1],HUMANGGP:007992[GABRG2], 1-FACTA-related-disease->UMLS:C0043207[Wolfram syndrome], 1-FACTA-related-drug->DrugBank:APRD00631[Gel], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
GABRA1	KCNMA1	2-FACTA-related-drug->DrugBank:APRD00382[Pilocarpine],DrugBank:APRD00631[Gel],
GABRA1	CACNA1G	3-GoPubMed-related-disease->mesh:4832[Epilepsy, Absence],mesh:20190[Myoclonic Epilepsy, Juvenile],mesh:4829[Epilepsy, Generalized], 2-FACTA-related-disease->UMLS:C0270853[juvenile myoclonic epilepsy],UMLS:C0014553[Epilepsy, Absence],
GABRA1	OPRM1	2-GoPubMed-related-gene->80258[EFHC2],163175[LGI4], 1-FACTA-related-gene->HUMANGGP:015890[EFHC2], 1-FACTA-related-disease->UMLS:C0014548[Epilepsy, Generalized], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
GABRA1	GTF2I	3-FACTA-related-drug->DrugBank:APRD00256[Valproic Acid],DrugBank:BIOD00057[Fragment],DrugBank:APRD00631[Gel],
GABRA1	KCNJ10	2-GoPubMed-related-gene->80258[EFHC2],163175[LGI4], 2-GoPubMed-related-GO->GO:0005243[gap junction channel activity],GO:0022831[narrow pore, gated channel activity], 1-GoPubMed-related-disease->mesh:20190[Myoclonic Epilepsy, Juvenile], 1-FACTA-related-gene->HUMANGGP:015890[EFHC2], 3-FACTA-related-disease->UMLS:C0270850[IGE],UMLS:C0521785[unilateral deafness],UMLS:C0014548[Epilepsy, Generalized], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
GABRA1	ABAT	1-GoPubMed-related-gene->2570[GABRR2], 1-GoPubMed-related-disease->mesh:16750[Stiff-Person Syndrome], 1-FACTA-related-gene->HUMANGGP:041448[GABRB2], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
GABRA1	GRIN2B	3-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:BIOD00057[Fragment],DrugBank:APRD00631[Gel], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
GABRA1	MEF2C	2-FACTA-related-drug->DrugBank:APRD00382[Pilocarpine],DrugBank:APRD00256[Valproic Acid],
GABRA1	CACNA1H	7-GoPubMed-related-disease->mesh:4832[Epilepsy, Absence],mesh:4829[Epilepsy, Generalized],mesh:20936[Epilepsy, Benign Neonatal],mesh:20190[Myoclonic Epilepsy, Juvenile],mesh:53447[Channelopathies],mesh:3294[Seizures, Febrile],mesh:4831[Epilepsies, Myoclonic], 1-FACTA-related-gene->HUMANGGP:033825[EFHC1], 3-FACTA-related-disease->UMLS:C0014553[Epilepsy, Absence],UMLS:C0014548[Epilepsy, Generalized],UMLS:C0270853[juvenile myoclonic epilepsy],
GABRA1	ALDH5A1	1-GoPubMed-related-gene->2570[GABRR2], 2-GoPubMed-related-disease->mesh:4832[Epilepsy, Absence],mesh:20190[Myoclonic Epilepsy, Juvenile], 1-FACTA-related-gene->HUMANGGP:036718[SYN2], 2-FACTA-related-disease->UMLS:C0270853[juvenile myoclonic epilepsy],UMLS:C0014548[Epilepsy, Generalized], 2-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00631[Gel],
GABRA1	RELN	3-FACTA-related-drug->DrugBank:APRD00256[Valproic Acid],DrugBank:APRD00280[Frontal],DrugBank:APRD00631[Gel],
GABRA1	OXTR	1-FACTA-related-drug->DrugBank:APRD01072[HCH], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
GABRA2	HTR1B	2-FACTA-related-disease->UMLS:C0024517[major depressive episode],UMLS:C0001956[alcohol use disorder], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
GABRA2	CHRNA7	4-GoPubMed-related-GO->GO:0070238[activated T cell autonomous cell death],GO:0007417[central nervous system development],GO:0043029[T cell homeostasis],GO:0022831[narrow pore, gated channel activity], 1-GoPubMed-related-disease->mesh:14029[Tobacco Use Disorder], 1-FACTA-related-disease->UMLS:C0028043[nicotine addiction], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
GABRA2	FOXP2	1-FACTA-related-drug->DrugBank:APRD00280[Frontal],
GABRA2	TDO2	1-FACTA-related-disease->UMLS:C1510472[drug addiction], 2-FACTA-related-drug->DrugBank:APRD00280[Frontal],DrugBank:APRD00631[Gel],
GABRA2	BZRAP1	3-GoPubMed-related-disease->mesh:437[Alcoholism],mesh:19973[Alcohol-Related Disorders],mesh:19966[Substance-Related Disorders], 1-FACTA-related-disease->UMLS:C0233639[Autism],
GABRA2	RELN	1-FACTA-related-disease->UMLS:C0233639[Autism], 2-FACTA-related-drug->DrugBank:APRD00280[Frontal],DrugBank:APRD00631[Gel],
GABRA2	NLGN3	1-GoPubMed-related-disease->mesh:19970[Cocaine-Related Disorders], 2-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0600427[cocaine addiction],
GABRA2	NLGN1	1-GoPubMed-related-disease->mesh:19970[Cocaine-Related Disorders], 2-FACTA-related-disease->UMLS:C0600427[cocaine addiction],UMLS:C0233639[Autism],
GABRA2	OXTR	2-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0871388[social stress], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
GABRA2	OPRM1	1-GoPubMed-related-GO->GO:0016524[latrotoxin receptor activity], 1-GoPubMed-related-disease->mesh:6556[Heroin Dependence], 3-FACTA-related-gene->HUMANGGP:027640[ELTD1],HUMANGGP:016831[PDYN],HUMANGGP:021746[GRIK1], 4-FACTA-related-disease->UMLS:C0687132[heavy drinking],UMLS:C1510472[drug addiction],UMLS:C0600427[cocaine addiction],UMLS:C0038586[substance use disorders], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
GABRA2	SLC1A1	2-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0149654[conduct disorder], 1-FACTA-related-drug->DrugBank:APRD00280[Frontal],
GABRA2	TPH2	3-GoPubMed-related-disease->mesh:14029[Tobacco Use Disorder],mesh:6556[Heroin Dependence],mesh:19970[Cocaine-Related Disorders], 1-FACTA-related-drug->DrugBank:APRD00280[Frontal],
GABRA2	GABRB1	6-GoPubMed-related-gene->2565[GABRG1],2557[GABRA4],2570[GABRR2],2569[GABRR1],2559[GABRA6],2568[GABRP], 4-GoPubMed-related-GO->GO:0047636[alanopine dehydrogenase activity],GO:0004022[alcohol dehydrogenase (NAD) activity],GO:0016646[oxidoreductase activity, acting on the CH-NH group of donors, NAD or NADP as acceptor],GO:0016645[oxidoreductase activity, acting on the CH-NH group of donors], 3-GoPubMed-related-disease->mesh:14929[Wolfram Syndrome],mesh:437[Alcoholism],mesh:19973[Alcohol-Related Disorders], 7-FACTA-related-gene->HUMANGGP:004123[GABRB1],HUMANGGP:021907[GABRP],HUMANGGP:035315[GABRR1],HUMANGGP:036164[GABRA6],HUMANGGP:023025[GABRA2],HUMANGGP:023447[GABRA1],HUMANGGP:041448[GABRB2], 2-FACTA-related-disease->UMLS:C0043207[Wolfram syndrome],UMLS:C0233639[Autism], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
GABRA2	GABRA4	7-GoPubMed-related-gene->2565[GABRG1],2560[GABRB1],2564[GABRE],2570[GABRR2],2569[GABRR1],2567[GABRG3],2568[GABRP], 3-GoPubMed-related-disease->mesh:14029[Tobacco Use Disorder],mesh:19966[Substance-Related Disorders],mesh:437[Alcoholism], 9-FACTA-related-gene->HUMANGGP:004123[GABRB1],HUMANGGP:011821[GABRE],HUMANGGP:023025[GABRA2],HUMANGGP:021907[GABRP],HUMANGGP:035315[GABRR1],HUMANGGP:041448[GABRB2],HUMANGGP:036164[GABRA6],HUMANGGP:023447[GABRA1],HUMANGGP:007992[GABRG2], 4-FACTA-related-disease->UMLS:C0043207[Wolfram syndrome],UMLS:C0028043[nicotine addiction],UMLS:C0233639[Autism],UMLS:C1510472[drug addiction], 1-FACTA-related-drug->DrugBank:APRD00631[Gel], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
GABRA2	ABAT	3-GoPubMed-related-gene->2570[GABRR2],2569[GABRR1],2557[GABRA4], 2-FACTA-related-gene->HUMANGGP:035315[GABRR1],HUMANGGP:041448[GABRB2], 1-FACTA-related-disease->UMLS:C0233639[Autism],
GABRA2	DISC1	1-GoPubMed-related-disease->mesh:14929[Wolfram Syndrome], 1-FACTA-related-disease->UMLS:C0043207[Wolfram syndrome], 2-FACTA-related-drug->DrugBank:APRD00280[Frontal],DrugBank:APRD00631[Gel],
GABRA2	LAMB1	1-GoPubMed-related-GO->GO:0033780[taurochenodeoxycholate 6alpha-hydroxylase activity], 2-FACTA-related-disease->UMLS:C0600427[cocaine addiction],UMLS:C0233639[Autism], 1-FACTA-related-drug->DrugBank:APRD00631[Gel],
GABRA2	NRXN1	1-GoPubMed-related-GO->GO:0016524[latrotoxin receptor activity], 1-GoPubMed-related-disease->mesh:14029[Tobacco Use Disorder], 2-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0028043[nicotine addiction],
GABRA5	RPL10	2-GoPubMed-related-disease->mesh:24182[Uniparental Disomy],mesh:9630[Nondisjunction, Genetic], 2-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0004352[autism], 1-FACTA-related-drug->DrugBank:APRD00631[Gel],
GABRA5	CHRNA7	1-GoPubMed-related-GO->GO:0022831[narrow pore, gated channel activity], 1-GoPubMed-related-disease->mesh:20190[Myoclonic Epilepsy, Juvenile], 4-FACTA-related-disease->UMLS:C0270853[juvenile myoclonic epilepsy],UMLS:C0162635[Angelman syndrome],UMLS:C0036337[schizoaffective disorder],UMLS:C0014548[Epilepsy, Generalized], 2-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:BIOD00057[Fragment], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
GABRA5	GABRB1	2-GoPubMed-related-GO->GO:0071514[genetic imprinting],GO:0048532[anatomical structure arrangement], 6-FACTA-related-gene->HUMANGGP:004123[GABRB1],HUMANGGP:023013[GABRA5],HUMANGGP:021907[GABRP],HUMANGGP:035315[GABRR1],HUMANGGP:036164[GABRA6],HUMANGGP:023447[GABRA1], 3-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0036337[schizoaffective disorder],UMLS:C0004352[autism], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
GABRA5	FOXP2	2-FACTA-related-drug->DrugBank:APRD00280[Frontal],DrugBank:BIOD00057[Fragment],
GABRA5	OXTR	2-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0004352[autism], 2-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:APRD00627[Progesterone], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
GABRA5	SLC9A9	2-GoPubMed-related-disease->mesh:17204[Angelman Syndrome],mesh:25063[Chromosome Disorders], 1-FACTA-related-drug->DrugBank:APRD01072[HCH],
GABRA5	PLN	2-FACTA-related-drug->DrugBank:APRD00512[Phenytoin],DrugBank:APRD01072[HCH],
GABRA5	SLC25A12	3-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0004352[autism],UMLS:C0008074[Child Development Disorders, Pervasive],
GABRA5	AUTS2	1-GoPubMed-related-gene->2560[GABRB1], 2-GoPubMed-related-GO->GO:0007268[synaptic transmission],GO:0019226[transmission of nerve impulse], 1-FACTA-related-gene->HUMANGGP:004123[GABRB1], 3-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0004352[autism],UMLS:C0036337[schizoaffective disorder],
GABRA5	APBA2	1-GoPubMed-related-disease->mesh:17204[Angelman Syndrome], 2-FACTA-related-disease->UMLS:C0008074[Child Development Disorders, Pervasive],UMLS:C0004352[autism],
GABRA5	ASMT	4-FACTA-related-disease->UMLS:C0008074[Child Development Disorders, Pervasive],UMLS:C0014548[Epilepsy, Generalized],UMLS:C0079588[STS],UMLS:C0004352[autism], 1-FACTA-related-drug->DrugBank:APRD00627[Progesterone],
GABRA5	ATP10A	5-GoPubMed-related-disease->mesh:17204[Angelman Syndrome],mesh:11218[Prader-Willi Syndrome],mesh:24182[Uniparental Disomy],mesh:9630[Nondisjunction, Genetic],mesh:25063[Chromosome Disorders], 2-FACTA-related-disease->UMLS:C0162635[Angelman syndrome],UMLS:C0004352[autism],
GABRA5	TPH2	2-GoPubMed-related-gene->9145[SYNGR1],23316[CUX2], 4-FACTA-related-gene->HUMANGGP:036486[SYNGR1],HUMANGGP:014007[CUX2],HUMANGGP:022732[NAPG],HUMANGGP:010722[GRM4], 3-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:APRD00280[Frontal],DrugBank:APRD00627[Progesterone],
GABRA5	NDNL2	4-GoPubMed-related-GO->GO:0004066[asparagine synthase (glutamine-hydrolyzing) activity],GO:0016884[carbon-nitrogen ligase activity, with glutamine as amido-N-donor],GO:0016879[ligase activity, forming carbon-nitrogen bonds],GO:0016874[ligase activity], 3-GoPubMed-related-disease->mesh:17204[Angelman Syndrome],mesh:11218[Prader-Willi Syndrome],mesh:25063[Chromosome Disorders], 1-FACTA-related-disease->UMLS:C0004352[autism],
GABRA5	CACNA1G	3-GoPubMed-related-disease->mesh:4832[Epilepsy, Absence],mesh:20190[Myoclonic Epilepsy, Juvenile],mesh:4829[Epilepsy, Generalized], 3-FACTA-related-disease->UMLS:C0270853[juvenile myoclonic epilepsy],UMLS:C0014553[Epilepsy, Absence],UMLS:C0233639[Autism],
GABRA5	SYNGAP1	2-FACTA-related-disease->UMLS:C0008074[Child Development Disorders, Pervasive],UMLS:C0004352[autism],
GABRA5	HTR1B	1-FACTA-related-disease->UMLS:C0730321[PIC], 2-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:BIOD00057[Fragment], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
GABRA5	GABRA4	2-GoPubMed-related-gene->2560[GABRB1],2567[GABRG3], 2-GoPubMed-related-GO->GO:0007268[synaptic transmission],GO:0019226[transmission of nerve impulse], 1-GoPubMed-related-disease->mesh:11218[Prader-Willi Syndrome], 6-FACTA-related-gene->HUMANGGP:004123[GABRB1],HUMANGGP:021907[GABRP],HUMANGGP:035315[GABRR1],HUMANGGP:023013[GABRA5],HUMANGGP:036164[GABRA6],HUMANGGP:023447[GABRA1], 3-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0036337[schizoaffective disorder],UMLS:C0004352[autism], 1-FACTA-related-drug->DrugBank:APRD00631[Gel], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
GABRA5	GLO1	1-FACTA-related-disease->UMLS:C0016689[freckles], 2-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00631[Gel],
GABRA5	ABAT	1-GoPubMed-related-gene->9908[G3BP2], 2-FACTA-related-gene->HUMANGGP:032215[G3BP2],HUMANGGP:035315[GABRR1], 2-FACTA-related-disease->UMLS:C0342788[SCD],UMLS:C0233639[Autism], 2-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00627[Progesterone],
GABRA5	CACNA1H	3-GoPubMed-related-disease->mesh:4832[Epilepsy, Absence],mesh:4829[Epilepsy, Generalized],mesh:20190[Myoclonic Epilepsy, Juvenile], 5-FACTA-related-disease->UMLS:C0014553[Epilepsy, Absence],UMLS:C0014548[Epilepsy, Generalized],UMLS:C0270853[juvenile myoclonic epilepsy],UMLS:C0233639[Autism],UMLS:C0004352[autism],
GABRA5	SLC1A1	3-FACTA-related-disease->UMLS:C0008074[Child Development Disorders, Pervasive],UMLS:C0233639[Autism],UMLS:C0004352[autism], 2-FACTA-related-drug->DrugBank:APRD00280[Frontal],DrugBank:APRD00627[Progesterone],
GABRA5	SCN1A	2-GoPubMed-related-GO->GO:0022831[narrow pore, gated channel activity],GO:0022842[narrow pore channel activity], 3-GoPubMed-related-disease->mesh:20190[Myoclonic Epilepsy, Juvenile],mesh:4829[Epilepsy, Generalized],mesh:4832[Epilepsy, Absence], 2-FACTA-related-drug->DrugBank:APRD00512[Phenytoin],DrugBank:BIOD00057[Fragment],
GABRA5	DISC1	1-FACTA-related-gene->HUMANGGP:036486[SYNGR1], 1-FACTA-related-disease->UMLS:C0036337[schizoaffective disorder], 4-FACTA-related-drug->DrugBank:APRD00280[Frontal],DrugBank:BIOD00057[Fragment],DrugBank:APRD00627[Progesterone],DrugBank:APRD00631[Gel],
GABRA5	UBE2H	2-GoPubMed-related-disease->mesh:17204[Angelman Syndrome],mesh:25063[Chromosome Disorders], 2-FACTA-related-disease->UMLS:C0162635[Angelman syndrome],UMLS:C0004352[autism],
GABRA5	LRRC1	2-GoPubMed-related-disease->mesh:20190[Myoclonic Epilepsy, Juvenile],mesh:4829[Epilepsy, Generalized], 1-FACTA-related-disease->UMLS:C0270853[juvenile myoclonic epilepsy], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
GABRD	GPR139	1-GoPubMed-related-GO->GO:0005488[binding],
GABRD	GABRA4	3-GoPubMed-related-GO->GO:0007268[synaptic transmission],GO:0019226[transmission of nerve impulse],GO:0050877[neurological system process], 1-GoPubMed-related-disease->mesh:13226[Status Epilepticus], 3-FACTA-related-gene->HUMANGGP:023013[GABRA5],HUMANGGP:023447[GABRA1],HUMANGGP:007992[GABRG2], 1-FACTA-related-drug->DrugBank:APRD01322[Potassium Chloride], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
GABRD	NBEA	1-GoPubMed-related-GO->GO:0005488[binding],
GABRD	FMR1	1-GoPubMed-related-disease->mesh:5600[Fragile X Syndrome], 2-FACTA-related-gene->HUMANGGP:005638[PPP1R9B],HUMANGGP:002294[UNC13B], 1-FACTA-related-disease->UMLS:C0016667[Fragile X Syndrome], 2-FACTA-related-drug->DrugBank:APRD00280[Frontal],DrugBank:APRD01322[Potassium Chloride],
GABRD	SLC1A1	1-FACTA-related-drug->DrugBank:APRD00280[Frontal],
GABRD	ARX	3-GoPubMed-related-disease->mesh:13036[Spasms, Infantile],mesh:4829[Epilepsy, Generalized],mesh:4831[Epilepsies, Myoclonic],
GABRD	SCN1A	2-GoPubMed-related-gene->6324[SCN1B],2566[GABRG2], 5-GoPubMed-related-disease->mesh:3294[Seizures, Febrile],mesh:4831[Epilepsies, Myoclonic],mesh:20190[Myoclonic Epilepsy, Juvenile],mesh:4829[Epilepsy, Generalized],mesh:4832[Epilepsy, Absence], 3-FACTA-related-gene->HUMANGGP:014156[SCN1A],HUMANGGP:020586[SCN1B],HUMANGGP:007992[GABRG2], 1-FACTA-related-disease->UMLS:C1858671[GEFS+],
GABRD	ARNT2	1-GoPubMed-related-GO->GO:0005488[binding], 1-FACTA-related-disease->UMLS:C0020505[hyperphagia], 1-FACTA-related-drug->DrugBank:APRD00396[Estrogens],
GABRD	ALDH5A1	3-GoPubMed-related-disease->mesh:6948[Hyperkinesis],mesh:4832[Epilepsy, Absence],mesh:20190[Myoclonic Epilepsy, Juvenile], 3-FACTA-related-disease->UMLS:C0270853[juvenile myoclonic epilepsy],UMLS:C0014548[Epilepsy, Generalized],UMLS:C0424605[developmental delay],
GABRD	RELN	1-GoPubMed-related-disease->mesh:13036[Spasms, Infantile], 1-FACTA-related-drug->DrugBank:APRD00280[Frontal],
GABRD	ARHGAP15	1-GoPubMed-related-GO->GO:0005488[binding],
GABRD	LRRC1	1-GoPubMed-related-GO->GO:0005488[binding], 3-GoPubMed-related-disease->mesh:20190[Myoclonic Epilepsy, Juvenile],mesh:4831[Epilepsies, Myoclonic],mesh:4829[Epilepsy, Generalized], 2-FACTA-related-disease->UMLS:C0270853[juvenile myoclonic epilepsy],UMLS:C0014544[epilepsy],
GABRD	FOXP2	1-FACTA-related-drug->DrugBank:APRD00280[Frontal],
GABRD	ESRRB	1-FACTA-related-drug->DrugBank:APRD00396[Estrogens],
GABRD	NLGN1	1-GoPubMed-related-GO->GO:0005488[binding], 1-FACTA-related-disease->UMLS:C0917816[mental retardation],
GABRD	CDH8	1-GoPubMed-related-GO->GO:0005488[binding],
GABRD	TPH2	1-GoPubMed-related-disease->mesh:6948[Hyperkinesis], 2-FACTA-related-drug->DrugBank:APRD00280[Frontal],DrugBank:APRD00396[Estrogens],
GABRD	NLGN4Y	1-GoPubMed-related-GO->GO:0005488[binding], 1-FACTA-related-disease->UMLS:C0917816[mental retardation],
GABRD	RBMS3	1-GoPubMed-related-GO->GO:0005488[binding],
GABRD	CHRNA7	1-GoPubMed-related-GO->GO:0050890[cognition], 2-GoPubMed-related-disease->mesh:20190[Myoclonic Epilepsy, Juvenile],mesh:4831[Epilepsies, Myoclonic], 4-FACTA-related-disease->UMLS:C0270853[juvenile myoclonic epilepsy],UMLS:C0162635[Angelman syndrome],UMLS:C0424605[developmental delay],UMLS:C0014548[Epilepsy, Generalized], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
GABRD	GRIN2B	1-FACTA-related-drug->DrugBank:APRD01322[Potassium Chloride], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
GABRD	GRID2	1-GoPubMed-related-GO->GO:0005488[binding], 1-GoPubMed-related-disease->mesh:13226[Status Epilepticus],
GABRD	CDKL5	3-GoPubMed-related-disease->mesh:13036[Spasms, Infantile],mesh:4829[Epilepsy, Generalized],mesh:4831[Epilepsies, Myoclonic], 2-FACTA-related-disease->UMLS:C0036857[severe mental retardation],UMLS:C0162635[Angelman syndrome],
GARS	RFWD2	2-FACTA-related-disease->UMLS:C1510586[Autism spectrum disorder],UMLS:C0233639[Autism],
GARS	CHRNA7	2-FACTA-related-drug->DrugBank:EXPT02427[Atropine],DrugBank:BIOD00057[Fragment],
GARS	DPYD	1-GoPubMed-related-disease->mesh:20424[Ulnar Neuropathies], 1-FACTA-related-disease->UMLS:C1510586[Autism spectrum disorder], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
GARS	FBXO40	2-FACTA-related-disease->UMLS:C1510586[Autism spectrum disorder],UMLS:C0233639[Autism],
GARS	ASTN2	2-FACTA-related-disease->UMLS:C1510586[Autism spectrum disorder],UMLS:C0233639[Autism],
GARS	CNTNAP2	2-FACTA-related-disease->UMLS:C1510586[Autism spectrum disorder],UMLS:C0233639[Autism], 3-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
GARS	EGR2	2-GoPubMed-related-gene->57716[PRX],54332[GDAP1], 6-GoPubMed-related-disease->mesh:2607[Charcot-Marie-Tooth Disease],mesh:15417[Hereditary Motor and Sensory Neuropathies],mesh:20968[Brachial Plexus Neuritis],mesh:9477[Hereditary Sensory and Autonomic Neuropathies],mesh:1405[Reflex, Babinski],mesh:20516[Brachial Plexus Neuropathies], 6-FACTA-related-disease->UMLS:C1832274[CMT2D],UMLS:C1832399[CMT4B1],UMLS:C1858278[CMT4B2],UMLS:C1850386[GAN],UMLS:C1846574[SCAN1],UMLS:C1859198[CMT4A], 3-FACTA-related-drug->DrugBank:BIOD00082[IL-2],DrugBank:EXPT01467[Forskolin],DrugBank:BIOD00057[Fragment],
GARS	NTRK1	1-GoPubMed-related-disease->mesh:9477[Hereditary Sensory and Autonomic Neuropathies], 3-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00631[Gel],
GARS	MARK1	1-GoPubMed-related-gene->55699[IARS2], 2-FACTA-related-disease->UMLS:C1510586[Autism spectrum disorder],UMLS:C0233639[Autism], 1-FACTA-related-drug->DrugBank:APRD00631[Gel],
GARS	ADSL	2-FACTA-related-gene->HUMANGGP:021686[GARS-AIRS-GART],HUMANGGP:009042[GART], 1-FACTA-related-disease->UMLS:C0233639[Autism], 3-FACTA-related-drug->DrugBank:EXPT00512[Adenosine Monophosphate],DrugBank:APRD00080[Freeze],DrugBank:APRD00631[Gel],
GARS	HOXB1	1-GoPubMed-related-disease->mesh:2607[Charcot-Marie-Tooth Disease], 1-FACTA-related-disease->UMLS:C0007959[Charcot-Marie-Tooth Disease], 4-FACTA-related-drug->DrugBank:EXPT00494[Alanine],DrugBank:APRD00506[Spectrum],DrugBank:APRD00631[Gel],DrugBank:APRD00552[Spectrum],
GARS	NSD1	3-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00080[Freeze],
GARS	ADRB2	3-FACTA-related-drug->DrugBank:APRD00553[Albuterol],DrugBank:BIOD00057[Fragment],DrugBank:EXPT01467[Forskolin],
GARS	DHCR7	4-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00506[Spectrum],DrugBank:APRD00080[Freeze],DrugBank:APRD00552[Spectrum],
GARS	ALOX5AP	2-FACTA-related-drug->DrugBank:APRD00553[Albuterol],DrugBank:BIOD00057[Fragment],
GARS	EN2	2-FACTA-related-disease->UMLS:C1510586[Autism spectrum disorder],UMLS:C0233639[Autism], 3-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00450[Norepinephrine],DrugBank:APRD00631[Gel],
GDF3	HOXB1	1-GoPubMed-related-disease->mesh:18243[Teratocarcinoma], 3-FACTA-related-disease->UMLS:C0206664[Teratocarcinoma],UMLS:C0206659[embryonal carcinoma],UMLS:C0036631[seminoma], 2-FACTA-related-drug->DrugBank:APRD00017[Tretinoin],DrugBank:APRD00140[Tretinoin],
GDF3	DLX2	3-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:BIOD00001[DNase I],DrugBank:APRD00017[Tretinoin],
GDF3	MACROD2	1-FACTA-related-disease->UMLS:C0014175[endometriosis],
GDF3	DLX6	1-FACTA-related-disease->UMLS:C0206659[embryonal carcinoma], 2-FACTA-related-drug->DrugBank:BIOD00001[DNase I],DrugBank:APRD00140[Tretinoin],
GDF3	PINX1	1-FACTA-related-disease->UMLS:C1326912[tumorigenesis], 3-FACTA-related-drug->DrugBank:BIOD00001[DNase I],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
GDF3	SHANK3	1-GoPubMed-related-disease->mesh:3103[Coloboma],
GDF3	DLX1	5-GoPubMed-related-GO->GO:0005160[transforming growth factor beta receptor binding],GO:0004707[MAP kinase activity],GO:0004702[receptor signaling protein serine/threonine kinase activity],GO:0005057[receptor signaling protein activity],GO:0004674[protein serine/threonine kinase activity], 1-FACTA-related-disease->UMLS:C1855900[HCG], 3-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:BIOD00001[DNase I],DrugBank:APRD00017[Tretinoin],
GDF3	RELN	3-FACTA-related-drug->DrugBank:BIOD00001[DNase I],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
GDF3	GNAS	4-FACTA-related-drug->DrugBank:APRD00134[Activin],DrugBank:BIOD00001[DNase I],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
GDF3	PITX1	1-GoPubMed-related-GO->GO:0007369[gastrulation], 3-FACTA-related-drug->DrugBank:APRD00134[Activin],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
GDF3	ESRRB	1-GoPubMed-related-disease->mesh:18243[Teratocarcinoma], 1-FACTA-related-disease->UMLS:C0206659[embryonal carcinoma], 1-FACTA-related-drug->DrugBank:BIOD00001[DNase I],
GDF3	RAI1	2-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
GDF3	RAB39B	3-GoPubMed-related-disease->mesh:18236[Carcinoma, Embryonal],mesh:18239[Seminoma],mesh:18237[Germinoma], 4-FACTA-related-disease->UMLS:C0206659[embryonal carcinoma],UMLS:C0036631[seminoma],UMLS:C0027658[Neoplasms, Germ Cell and Embryonal],UMLS:C0039590[Testicular Neoplasms],
GDF3	CTNNA3	3-FACTA-related-disease->UMLS:C0206659[embryonal carcinoma],UMLS:C1855900[HCG],UMLS:C0014175[endometriosis],
GDF3	TBX1	2-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
GDF3	NFIA	1-GoPubMed-related-disease->mesh:2822[Choriocarcinoma], 1-FACTA-related-disease->UMLS:C1855900[HCG], 2-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
GDI1	NLGN4X	4-GoPubMed-related-GO->GO:0005092[GDP-dissociation inhibitor activity],GO:0005083[small GTPase regulator activity],GO:0030695[GTPase regulator activity],GO:0060589[nucleoside-triphosphatase regulator activity], 8-FACTA-related-gene->HUMANGGP:006914[ZNF81],HUMANGGP:040636[FTSJ1],HUMANGGP:015143[DLG3],HUMANGGP:007783[ARHGEF6],HUMANGGP:020388[TM4SF2],HUMANGGP:028523[FACL4],HUMANGGP:039910[OPHN1],HUMANGGP:002027[RPS6KA3], 4-FACTA-related-disease->UMLS:C1859974[FGD1],UMLS:C1136249[Mental Retardation, X-Linked],UMLS:C0917816[mental retardation],UMLS:C0025362[Mental Retardation],
GDI1	MECP2	3-GoPubMed-related-disease->mesh:38901[Mental Retardation, X-Linked],mesh:40181[Genetic Diseases, X-Linked],mesh:8607[Mental Retardation], 4-FACTA-related-disease->UMLS:C0035372[Rett syndrome],UMLS:C1845055[ATRX],UMLS:C1136249[Mental Retardation, X-Linked],UMLS:C1859974[FGD1], 1-FACTA-related-drug->DrugBank:APRD00495[VCR],
GDI1	ARX	2-GoPubMed-related-gene->11141[IL1RAPL1],4983[OPHN1], 1-GoPubMed-related-GO->GO:0005092[GDP-dissociation inhibitor activity], 1-GoPubMed-related-disease->mesh:38901[Mental Retardation, X-Linked], 7-FACTA-related-gene->HUMANGGP:007783[ARHGEF6],HUMANGGP:039910[OPHN1],HUMANGGP:002027[RPS6KA3],HUMANGGP:020388[TM4SF2],HUMANGGP:040636[FTSJ1],HUMANGGP:028523[FACL4],HUMANGGP:015143[DLG3], 1-FACTA-related-disease->UMLS:C1136249[Mental Retardation, X-Linked],
GDI1	PTGS2	1-pathway->nci_nature_pid:Signaling_mediated_by_p38-alpha_and_p38-beta[],
GDI1	ESR1	1-pathway->nci_nature_pid:Signaling_mediated_by_p38-alpha_and_p38-beta[],
GDI1	SLC6A8	2-GoPubMed-related-GO->GO:0005092[GDP-dissociation inhibitor activity],GO:0005083[small GTPase regulator activity], 7-FACTA-related-gene->HUMANGGP:039910[OPHN1],HUMANGGP:002027[RPS6KA3],HUMANGGP:007783[ARHGEF6],HUMANGGP:020388[TM4SF2],HUMANGGP:040636[FTSJ1],HUMANGGP:028523[FACL4],HUMANGGP:015143[DLG3], 5-FACTA-related-disease->UMLS:C1136249[Mental Retardation, X-Linked],UMLS:C1845055[ATRX],UMLS:C0917816[mental retardation],UMLS:C0021171[incontinentia pigmenti],UMLS:C0016667[Fragile X Syndrome],
GDI1	NLGN3	3-GoPubMed-related-GO->GO:0005092[GDP-dissociation inhibitor activity],GO:0005083[small GTPase regulator activity],GO:0030695[GTPase regulator activity], 2-GoPubMed-related-disease->mesh:19970[Cocaine-Related Disorders],mesh:8607[Mental Retardation], 5-FACTA-related-gene->HUMANGGP:040636[FTSJ1],HUMANGGP:015143[DLG3],HUMANGGP:007783[ARHGEF6],HUMANGGP:020388[TM4SF2],HUMANGGP:039910[OPHN1], 3-FACTA-related-disease->UMLS:C1845055[ATRX],UMLS:C0016667[Fragile X Syndrome],UMLS:C0917816[mental retardation],
GDI1	NLGN1	2-GoPubMed-related-disease->mesh:19970[Cocaine-Related Disorders],mesh:8607[Mental Retardation], 1-FACTA-related-disease->UMLS:C0917816[mental retardation],
GDI1	RPL10	2-FACTA-related-gene->HUMANGGP:004368[RPL10],HUMANGGP:027577[ATP6AP1], 2-FACTA-related-disease->UMLS:C1136249[Mental Retardation, X-Linked],UMLS:C0917816[mental retardation], 1-FACTA-related-drug->DrugBank:APRD00495[VCR],
GDI1	RAB39B	3-GoPubMed-related-disease->mesh:38901[Mental Retardation, X-Linked],mesh:40181[Genetic Diseases, X-Linked],mesh:8607[Mental Retardation], 3-FACTA-related-disease->UMLS:C1136249[Mental Retardation, X-Linked],UMLS:C0917816[mental retardation],UMLS:C0025362[Mental Retardation],
GDI1	OPHN1	4-GoPubMed-related-gene->9459[ARHGEF6],55998[NXF5],5063[PAK3],11141[IL1RAPL1], 2-GoPubMed-related-GO->GO:0005092[GDP-dissociation inhibitor activity],GO:0005083[small GTPase regulator activity], 3-GoPubMed-related-disease->mesh:38901[Mental Retardation, X-Linked],mesh:8607[Mental Retardation],mesh:40181[Genetic Diseases, X-Linked], 8-FACTA-related-gene->HUMANGGP:039910[OPHN1],HUMANGGP:007783[ARHGEF6],HUMANGGP:020388[TM4SF2],HUMANGGP:002027[RPS6KA3],HUMANGGP:024230[NXF5],HUMANGGP:040636[FTSJ1],HUMANGGP:028523[FACL4],HUMANGGP:015143[DLG3], 5-FACTA-related-disease->UMLS:C1136249[Mental Retardation, X-Linked],UMLS:C1845055[ATRX],UMLS:C1859974[FGD1],UMLS:C0917816[mental retardation],UMLS:C0016667[Fragile X Syndrome],
GDI1	CHRNA7	1-FACTA-related-drug->DrugBank:APRD00495[VCR],
GDI1	NTNG1	3-GoPubMed-related-disease->mesh:38901[Mental Retardation, X-Linked],mesh:8607[Mental Retardation],mesh:40181[Genetic Diseases, X-Linked], 3-FACTA-related-disease->UMLS:C0035372[Rett syndrome],UMLS:C0917816[mental retardation],UMLS:C0025362[Mental Retardation],
GDI1	IL1RAPL2	1-GoPubMed-related-gene->11141[IL1RAPL1], 4-GoPubMed-related-disease->mesh:12729[Sex Chromosome Aberrations],mesh:38901[Mental Retardation, X-Linked],mesh:8607[Mental Retardation],mesh:40181[Genetic Diseases, X-Linked], 1-FACTA-related-gene->HUMANGGP:007566[IL1RAPL1], 4-FACTA-related-disease->UMLS:C1136249[Mental Retardation, X-Linked],UMLS:C0917816[mental retardation],UMLS:C0036868[Sex Chromosome Aberrations],UMLS:C0025362[Mental Retardation],
GDI1	IL1RAPL1	2-GoPubMed-related-gene->4983[OPHN1],9459[ARHGEF6], 2-GoPubMed-related-GO->GO:0005092[GDP-dissociation inhibitor activity],GO:0005083[small GTPase regulator activity], 3-GoPubMed-related-disease->mesh:38901[Mental Retardation, X-Linked],mesh:12729[Sex Chromosome Aberrations],mesh:8607[Mental Retardation], 4-FACTA-related-gene->HUMANGGP:007566[IL1RAPL1],HUMANGGP:040636[FTSJ1],HUMANGGP:015143[DLG3],HUMANGGP:007783[ARHGEF6], 5-FACTA-related-disease->UMLS:C1136249[Mental Retardation, X-Linked],UMLS:C1845055[ATRX],UMLS:C0917816[mental retardation],UMLS:C0016667[Fragile X Syndrome],UMLS:C0036868[Sex Chromosome Aberrations],
GDI1	SYN1	1-GoPubMed-related-GO->GO:0005092[GDP-dissociation inhibitor activity], 3-FACTA-related-gene->HUMANGGP:006914[ZNF81],HUMANGGP:040636[FTSJ1],HUMANGGP:015143[DLG3], 3-FACTA-related-disease->UMLS:C1845055[ATRX],UMLS:C1136249[Mental Retardation, X-Linked],UMLS:C0016667[Fragile X Syndrome],
GDI1	HRAS	1-FACTA-related-drug->DrugBank:APRD00495[VCR],
GDI1	CDKL5	1-GoPubMed-related-gene->55998[NXF5], 1-GoPubMed-related-disease->mesh:38901[Mental Retardation, X-Linked], 4-FACTA-related-gene->HUMANGGP:024230[NXF5],HUMANGGP:020388[TM4SF2],HUMANGGP:039910[OPHN1],HUMANGGP:002027[RPS6KA3], 2-FACTA-related-disease->UMLS:C0035372[Rett syndrome],UMLS:C1136249[Mental Retardation, X-Linked],
GDI1	FGD1	1-GoPubMed-related-gene->11141[IL1RAPL1], 3-GoPubMed-related-GO->GO:0005083[small GTPase regulator activity],GO:0030695[GTPase regulator activity],GO:0060589[nucleoside-triphosphatase regulator activity], 8-FACTA-related-gene->HUMANGGP:006914[ZNF81],HUMANGGP:040636[FTSJ1],HUMANGGP:015143[DLG3],HUMANGGP:007783[ARHGEF6],HUMANGGP:020388[TM4SF2],HUMANGGP:039910[OPHN1],HUMANGGP:028523[FACL4],HUMANGGP:002027[RPS6KA3], 2-FACTA-related-disease->UMLS:C1859974[FGD1],UMLS:C1136249[Mental Retardation, X-Linked],
GDI1	TSPAN7	4-GoPubMed-related-gene->9459[ARHGEF6],11141[IL1RAPL1],4983[OPHN1],5063[PAK3], 2-GoPubMed-related-GO->GO:0005092[GDP-dissociation inhibitor activity],GO:0005083[small GTPase regulator activity], 1-GoPubMed-related-disease->mesh:38901[Mental Retardation, X-Linked], 1-FACTA-related-gene->HUMANGGP:020388[TM4SF2], 3-FACTA-related-disease->UMLS:C1136249[Mental Retardation, X-Linked],UMLS:C0917816[mental retardation],UMLS:C0025362[Mental Retardation],
GDI1	AGTR2	7-FACTA-related-gene->HUMANGGP:007783[ARHGEF6],HUMANGGP:020388[TM4SF2],HUMANGGP:040636[FTSJ1],HUMANGGP:039910[OPHN1],HUMANGGP:028523[FACL4],HUMANGGP:002027[RPS6KA3],HUMANGGP:015143[DLG3], 2-FACTA-related-disease->UMLS:C1845055[ATRX],UMLS:C1136249[Mental Retardation, X-Linked],
GDNF	MAP2	2-FACTA-related-drug->DrugBank:EXPT02758[Rasagiline],DrugBank:EXPT02391[Quinolinic Acid],
GDNF	MAOA	2-GoPubMed-related-disease->mesh:20267[MPTP Poisoning],mesh:10302[Parkinson Disease, Secondary], 1-FACTA-related-drug->DrugBank:APRD00304[AGG],
GDNF	DRD3	1-GoPubMed-related-GO->GO:0005127[ciliary neurotrophic factor receptor binding], 1-FACTA-related-disease->UMLS:C1860861[FET1], 1-FACTA-related-drug->DrugBank:APRD00531[Apomorphine],
GDNF	CACNA1C	1-pathway->reactome:REACT_18312[],
GDNF	DMD	1-FACTA-related-drug->DrugBank:APRD01085[Mazindol],
GDNF	CD44	1-GoPubMed-related-disease->mesh:15615[Cystic Adenomatoid Malformation of Lung, Congenital], 1-FACTA-related-disease->UMLS:C1333295[GCB-DLBCL], 1-FACTA-related-drug->DrugBank:BIOD00021[IL-11],
GDNF	TH	2-GoPubMed-related-disease->mesh:20267[MPTP Poisoning],mesh:10302[Parkinson Disease, Secondary],
GDNF	TDO2	1-FACTA-related-drug->DrugBank:EXPT02391[Quinolinic Acid],
GDNF	NF1	1-GoPubMed-related-gene->51575[ESF1], 1-FACTA-related-drug->DrugBank:BIOD00052[p75],
GDNF	GRIN2B	1-GoPubMed-related-gene->79846[C7orf63], 2-FACTA-related-disease->UMLS:C1333296[ABC-DLBCL],UMLS:C1333295[GCB-DLBCL], 1-FACTA-related-drug->DrugBank:APRD00705[NVP],
GDNF	CACNA1D	1-FACTA-related-drug->DrugBank:APRD00953[ETS], 1-pathway->reactome:REACT_18312[],
GDNF	NTRK3	3-GoPubMed-related-GO->GO:0005163[nerve growth factor receptor binding],GO:0005165[neurotrophin receptor binding],GO:0005123[death receptor binding], 1-GoPubMed-related-disease->mesh:18227[Sarcoma, Clear Cell], 1-FACTA-related-gene->HUMANGGP:029099[EDN3], 2-FACTA-related-drug->DrugBank:APRD00953[ETS],DrugBank:BIOD00052[p75],
GDNF	CACNA1F	1-pathway->reactome:REACT_18312[],
GDNF	GLO1	1-GoPubMed-related-disease->mesh:7691[Medullary Sponge Kidney],
GDNF	DCX	1-FACTA-related-drug->DrugBank:EXPT02391[Quinolinic Acid],
GDNF	CACNA1H	1-pathway->reactome:REACT_18312[],
GPR143	CAMTA1	1-GoPubMed-related-gene->83552[MFRP],
GPR143	SLC9A6	2-GoPubMed-related-disease->mesh:20417[Nystagmus, Congenital],mesh:9759[Nystagmus, Pathologic], 3-FACTA-related-disease->UMLS:C1138434[Genetic Diseases, X-Linked],UMLS:C0700501[Nystagmus],UMLS:C0028738[nystagmus],
GPR143	NSD1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
GPR143	TBL1X	3-GoPubMed-related-disease->mesh:16117[Albinism, Ocular],mesh:417[Albinism],mesh:17496[Hypopigmentation], 1-FACTA-related-disease->UMLS:C0027651[tumor],
GPR143	LAMB1	1-FACTA-related-disease->UMLS:C0700501[Nystagmus], 1-FACTA-related-drug->DrugBank:APRD00631[Gel],
GPR143	SND1	2-GoPubMed-related-disease->mesh:16117[Albinism, Ocular],mesh:417[Albinism],
GPR143	CACNA1F	3-GoPubMed-related-disease->mesh:16117[Albinism, Ocular],mesh:20417[Nystagmus, Congenital],mesh:9759[Nystagmus, Pathologic], 1-FACTA-related-disease->UMLS:C1138434[Genetic Diseases, X-Linked],
GPR143	AHI1	1-GoPubMed-related-GO->GO:0009881[photoreceptor activity], 3-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00631[Gel],
GPR143	SUCLG2	2-GoPubMed-related-disease->mesh:16117[Albinism, Ocular],mesh:417[Albinism], 1-FACTA-related-drug->DrugBank:APRD00631[Gel],
GPR143	CNTNAP2	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
GPR143	CA6	3-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00631[Gel],
GPR143	ASMT	1-GoPubMed-related-gene->51481[VCX3A], 2-GoPubMed-related-disease->mesh:20795[Photophobia],mesh:17436[Kallmann Syndrome],
GPR143	CADM1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
GPR143	BAIAP2	3-FACTA-related-disease->UMLS:C0024622[Retina],UMLS:C0154027[Retina],UMLS:C0027651[tumor], 1-FACTA-related-drug->DrugBank:APRD00631[Gel],
GPR143	CHD7	1-GoPubMed-related-disease->mesh:17436[Kallmann Syndrome], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
GPR143	NTRK1	3-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00631[Gel],
GPR143	NPAS2	3-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00631[Gel],
GPR143	CACNA1G	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
GPR143	NLGN4X	2-GoPubMed-related-gene->4412[MRX49],51481[VCX3A], 3-GoPubMed-related-disease->mesh:17436[Kallmann Syndrome],mesh:16117[Albinism, Ocular],mesh:417[Albinism], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
GRM6	CHD7	2-FACTA-related-drug->DrugBank:EXPT01447[Fluorescein],DrugBank:APRD00979[Fluorescein],
GRM6	MED12	2-FACTA-related-disease->UMLS:C1138434[Genetic Diseases, X-Linked],UMLS:C0338656[cognitive impairment], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
GRM6	ATP2B2	1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
GRM6	PLCD1	1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
GRM6	LRRC1	1-GoPubMed-related-disease->mesh:20190[Myoclonic Epilepsy, Juvenile], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
GRM6	SHANK3	1-GoPubMed-related-GO->GO:0007632[visual behavior], 3-FACTA-related-drug->DrugBank:EXPT01447[Fluorescein],DrugBank:APRD00979[Fluorescein],DrugBank:BIOD00057[Fragment],
GRM6	CNTN4	2-GoPubMed-related-disease->mesh:9216[Myopia],mesh:12030[Refractive Errors], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
GRM6	GABRA4	1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
GRM6	RGS7	3-FACTA-related-gene->HUMANGGP:018316[RAP1GAP],HUMANGGP:012556[RGSZ1],HUMANGGP:019578[GPSM2], 3-FACTA-related-disease->UMLS:C1835916[AGS3],UMLS:C0154027[Retina],UMLS:C0024622[Retina],
GRM6	CACNA1F	3-GoPubMed-related-gene->57010[CABP4],60506[NYX],93589[CACNA2D4], 1-GoPubMed-related-GO->GO:0007269[neurotransmitter secretion], 3-GoPubMed-related-disease->mesh:9755[Night Blindness],mesh:9216[Myopia],mesh:14786[Vision Disorders], 1-FACTA-related-gene->HUMANGGP:018114[CACNA2D4], 2-FACTA-related-disease->UMLS:C0028077[night blindness],UMLS:C1138434[Genetic Diseases, X-Linked], 2-FACTA-related-drug->DrugBank:EXPT01447[Fluorescein],DrugBank:APRD00979[Fluorescein],
GRM6	BAIAP2	3-GoPubMed-related-GO->GO:0004972[N-methyl-D-aspartate selective glutamate receptor activity],GO:0004970[ionotropic glutamate receptor activity],GO:0008066[glutamate receptor activity], 2-FACTA-related-disease->UMLS:C0024622[Retina],UMLS:C0154027[Retina],
GRM6	GABRB1	1-FACTA-related-drug->DrugBank:BIOD00057[Fragment], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
GRM6	SLC9A6	2-FACTA-related-disease->UMLS:C1138434[Genetic Diseases, X-Linked],UMLS:C0028738[nystagmus],
GRM6	PDZD4	3-GoPubMed-related-gene->116444[GRIN3B],2918[GRM8],2917[GRM7],
GRM6	GRIN2B	2-GoPubMed-related-gene->2906[GRIN2D],116444[GRIN3B], 4-GoPubMed-related-GO->GO:0004972[N-methyl-D-aspartate selective glutamate receptor activity],GO:0004970[ionotropic glutamate receptor activity],GO:0008066[glutamate receptor activity],GO:0016595[glutamate binding], 4-FACTA-related-gene->HUMANGGP:010722[GRM4],HUMANGGP:039570[GRIN2A],HUMANGGP:010796[GRIN1],HUMANGGP:010297[GRM5], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
GRM6	SCN2A	1-GoPubMed-related-GO->GO:0042551[neuron maturation], 3-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:EXPT01447[Fluorescein],DrugBank:APRD00979[Fluorescein],
GRM7	HTR3A	2-GoPubMed-related-GO->GO:0022831[narrow pore, gated channel activity],GO:0022842[narrow pore channel activity], 2-FACTA-related-disease->UMLS:C0278080[physical dependence],UMLS:C1510472[drug addiction], 1-FACTA-related-drug->DrugBank:APRD00450[Norepinephrine],
GRM7	FABP7	2-GoPubMed-related-disease->mesh:20362[Paraneoplastic Cerebellar Degeneration],mesh:20361[Paraneoplastic Syndromes, Nervous System],
GRM7	ASTN2	4-FACTA-related-disease->UMLS:C0085281[addiction],UMLS:C1263846[Attention Deficit Disorder with Hyperactivity],UMLS:C0005586[Bipolar Disorder],UMLS:C0036341[schizophrenia],
GRM7	GABRA4	1-FACTA-related-disease->UMLS:C1510472[drug addiction], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
GRM7	CTNNA3	1-FACTA-related-gene->HUMANGGP:003801[LRP1B], 2-FACTA-related-disease->UMLS:C1855900[HCG],UMLS:C1263846[Attention Deficit Disorder with Hyperactivity],
GRM7	TDO2	5-FACTA-related-disease->UMLS:C1263846[Attention Deficit Disorder with Hyperactivity],UMLS:C1510472[drug addiction],UMLS:C0005586[Bipolar Disorder],UMLS:C0036341[schizophrenia],UMLS:C1269683[major depression],
GRM7	BAIAP2	3-GoPubMed-related-GO->GO:0004972[N-methyl-D-aspartate selective glutamate receptor activity],GO:0004970[ionotropic glutamate receptor activity],GO:0008066[glutamate receptor activity], 1-FACTA-related-disease->UMLS:C1263846[Attention Deficit Disorder with Hyperactivity],
GRM7	GABRB1	1-FACTA-related-gene->HUMANGGP:001560[PTPRG], 1-FACTA-related-disease->UMLS:C0005586[Bipolar Disorder], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
GRM7	NLGN3	1-FACTA-related-drug->DrugBank:APRD00256[Valproic Acid],
GRM7	NLGN1	1-FACTA-related-disease->UMLS:C1269683[major depression], 1-FACTA-related-drug->DrugBank:APRD00256[Valproic Acid],
GRM7	GTF2I	1-FACTA-related-drug->DrugBank:APRD00256[Valproic Acid],
GRM7	RELN	1-FACTA-related-drug->DrugBank:APRD00256[Valproic Acid],
GRM7	GRIN2B	2-GoPubMed-related-gene->2906[GRIN2D],116444[GRIN3B], 3-GoPubMed-related-GO->GO:0004972[N-methyl-D-aspartate selective glutamate receptor activity],GO:0004970[ionotropic glutamate receptor activity],GO:0008066[glutamate receptor activity], 2-GoPubMed-related-disease->mesh:20270[Alcohol Withdrawal Seizures],mesh:430[Alcohol Withdrawal Delirium], 2-FACTA-related-gene->HUMANGGP:010722[GRM4],HUMANGGP:010297[GRM5], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
GRM7	MACROD2	2-FACTA-related-disease->UMLS:C1263846[Attention Deficit Disorder with Hyperactivity],UMLS:C0036341[schizophrenia],
GRM7	EN2	1-FACTA-related-drug->DrugBank:APRD00450[Norepinephrine],
GRM7	PDZD4	2-GoPubMed-related-gene->116444[GRIN3B],2918[GRM8],
GRM7	RGS7	1-FACTA-related-disease->UMLS:C0278080[physical dependence], 1-FACTA-related-drug->DrugBank:APRD00450[Norepinephrine],
GRM7	SLC6A8	1-FACTA-related-gene->HUMANGGP:021476[SLC1A6], 1-FACTA-related-drug->DrugBank:APRD00679[ENT],
GRM7	NRXN2	1-FACTA-related-disease->UMLS:C0036341[schizophrenia], 1-FACTA-related-drug->DrugBank:APRD00256[Valproic Acid],
GRM7	NRXN1	1-FACTA-related-disease->UMLS:C1855900[HCG], 1-FACTA-related-drug->DrugBank:APRD00256[Valproic Acid],
HDAC5	SCN2A	7-FACTA-related-drug->DrugBank:APRD00104[Simvastatin],DrugBank:EXPT02079[lysine],DrugBank:APRD00256[Valproic Acid],DrugBank:APRD00423[Sterol],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD01142[Nitric Oxide],
HDAC5	MECP2	4-FACTA-related-drug->DrugBank:APRD00562[Ddc],DrugBank:EXPT02079[lysine],DrugBank:APRD00256[Valproic Acid],DrugBank:APRD00326[Factor II],
HDAC5	EGR2	3-GoPubMed-related-GO->GO:0008140[cAMP response element binding protein binding],GO:0003713[transcription coactivator activity],GO:0016563[transcription activator activity], 6-FACTA-related-drug->DrugBank:APRD00326[Factor II],DrugBank:APRD00256[Valproic Acid],DrugBank:APRD00423[Sterol],DrugBank:EXPT01467[Forskolin],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
HDAC5	HDAC4	1-GoPubMed-related-gene->63035[BCORL1], 2-GoPubMed-related-GO->GO:0048148[behavioral response to cocaine],GO:0019213[deacetylase activity], 2-FACTA-related-gene->HUMANGGP:016108[HDAC4],HUMANGGP:014337[HDAC9], 4-FACTA-related-disease->UMLS:C0242583[BLS],UMLS:C0023452[childhood acute lymphoblastic leukemia],UMLS:C0023493[T-cell acute lymphoblastic leukemia],UMLS:C0271510[Recruitment], 8-FACTA-related-drug->DrugBank:APRD00764[Orphan],DrugBank:EXPT02079[lysine],DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:EXPT01467[Forskolin],DrugBank:EXPT00573[Aspartic Acid],DrugBank:APRD00627[Progesterone], 2-pathway->nci_nature_pid:Signaling_events_mediated_by_HDAC_Class_I[],nci_nature_pid:Signaling_events_mediated_by_HDAC_Class_II[],
HDAC5	MBD3	1-GoPubMed-related-GO->GO:0019213[deacetylase activity], 4-FACTA-related-drug->DrugBank:APRD00326[Factor II],DrugBank:APRD00256[Valproic Acid],DrugBank:EXPT02079[lysine],DrugBank:APRD00140[Tretinoin], 1-pathway->nci_nature_pid:Signaling_events_mediated_by_HDAC_Class_I[],
HDAC5	MBD1	1-GoPubMed-related-gene->22893[BAHD1], 1-FACTA-related-disease->UMLS:C0268164[HP1], 3-FACTA-related-drug->DrugBank:EXPT02079[lysine],DrugBank:APRD00326[Factor II],DrugBank:APRD01142[Nitric Oxide],
HDAC5	ESR1	2-GoPubMed-related-GO->GO:0030284[estrogen receptor activity],GO:0003712[transcription cofactor activity], 3-FACTA-related-gene->HUMANGGP:034131[STARD3NL],HUMANGGP:007971[FLJ42280],HUMANGGP:038233[ZBTB40], 1-FACTA-related-drug->DrugBank:APRD00627[Progesterone], 1-pathway->nci_nature_pid:Signaling_events_mediated_by_HDAC_Class_II[],
HDAC5	CREBBP	4-GoPubMed-related-GO->GO:0008140[cAMP response element binding protein binding],GO:0003713[transcription coactivator activity],GO:0016563[transcription activator activity],GO:0003712[transcription cofactor activity], 4-FACTA-related-drug->DrugBank:APRD00562[Ddc],DrugBank:APRD00423[Sterol],DrugBank:EXPT02079[lysine],DrugBank:APRD00627[Progesterone], 1-pathway->nci_nature_pid:Signaling_events_mediated_by_HDAC_Class_I[],
HDAC5	HOXB1	7-FACTA-related-drug->DrugBank:APRD00017[Tretinoin],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00256[Valproic Acid],DrugBank:EXPT02079[lysine],DrugBank:EXPT00494[Alanine],DrugBank:APRD00627[Progesterone],
HDAC5	MKL2	2-GoPubMed-related-disease->mesh:6332[Cardiomegaly],mesh:6984[Hypertrophy],
HDAC5	MEF2C	5-FACTA-related-gene->HUMANGGP:034131[STARD3NL],HUMANGGP:007971[FLJ42280],HUMANGGP:019322[TADA3L],HUMANGGP:038233[ZBTB40],HUMANGGP:036470[DCDC5], 1-FACTA-related-disease->UMLS:C1863727[FHL2], 5-FACTA-related-drug->DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00627[Progesterone],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00256[Valproic Acid], 1-pathway->nci_nature_pid:Signaling_events_mediated_by_HDAC_Class_II[],
HDAC5	SLC1A1	5-FACTA-related-drug->DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:EXPT00573[Aspartic Acid],DrugBank:APRD00627[Progesterone],
HDAC5	GTF2I	1-GoPubMed-related-GO->GO:0016563[transcription activator activity], 1-FACTA-related-drug->DrugBank:APRD00256[Valproic Acid], 1-pathway->netpath:BCR[],
HDAC5	RELN	3-FACTA-related-drug->DrugBank:APRD00256[Valproic Acid],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
HDAC5	CAMTA1	1-GoPubMed-related-gene->23125[CAMTA2], 1-FACTA-related-gene->HUMANGGP:034488[CAMTA2],
HDAC5	TSPAN7	2-GoPubMed-related-disease->mesh:7877[Legionnaires' Disease],mesh:7876[Legionellosis], 1-FACTA-related-disease->UMLS:C0023493[T-cell acute lymphoblastic leukemia],
HDAC5	CHD7	2-GoPubMed-related-gene->221400[TDRD6],55544[RBM38], 1-FACTA-related-drug->DrugBank:EXPT02079[lysine],
HOMER1	LAMB1	1-FACTA-related-gene->HUMANGGP:027101[LRRN3], 1-FACTA-related-disease->UMLS:C0236736[Cocaine-Related Disorders],
HOMER1	GRIN2B	1-GoPubMed-related-GO->GO:0060074[synapse maturation], 1-FACTA-related-disease->UMLS:C0178417[anhedonia], 2-FACTA-related-drug->DrugBank:APRD01322[Potassium Chloride],DrugBank:APRD00627[Progesterone],
HOMER1	SLC1A1	2-FACTA-related-drug->DrugBank:APRD00280[Frontal],DrugBank:APRD00627[Progesterone],
HOMER1	ADRB2	1-FACTA-related-drug->DrugBank:APRD00616[Scopolamine],
HOMER1	SHANK3	1-GoPubMed-related-gene->22941[SHANK2], 3-GoPubMed-related-GO->GO:0051015[actin filament binding],GO:0050808[synapse organization],GO:0043062[extracellular structure organization], 1-FACTA-related-gene->HUMANGGP:023831[ProSAP1], 2-FACTA-related-drug->DrugBank:APRD00280[Frontal],DrugBank:APRD00627[Progesterone],
HOMER1	SHANK2	1-GoPubMed-related-gene->1627[DBN1], 2-GoPubMed-related-GO->GO:0001639[PLC activating metabotropic glutamate receptor activity],GO:0051015[actin filament binding], 1-FACTA-related-gene->HUMANGGP:023831[ProSAP1], 1-FACTA-related-disease->UMLS:C0265341[RGS], 1-FACTA-related-drug->DrugBank:APRD00280[Frontal],
HOMER1	GABRA4	2-FACTA-related-disease->UMLS:C1510472[drug addiction],UMLS:C0002622[amnesia], 1-FACTA-related-drug->DrugBank:APRD01322[Potassium Chloride],
HOMER1	WNK3	2-FACTA-related-drug->DrugBank:APRD01322[Potassium Chloride],DrugBank:APRD00627[Progesterone],
HOMER1	DISC1	1-GoPubMed-related-GO->GO:0034007[S-linalool synthase activity], 1-FACTA-related-disease->UMLS:C0265341[RGS], 2-FACTA-related-drug->DrugBank:APRD00280[Frontal],DrugBank:APRD00627[Progesterone],
HOMER1	MECP2	2-FACTA-related-drug->DrugBank:APRD00280[Frontal],DrugBank:APRD01322[Potassium Chloride],
HOMER1	DCX	2-GoPubMed-related-GO->GO:0034007[S-linalool synthase activity],GO:0051015[actin filament binding], 1-FACTA-related-drug->DrugBank:APRD00616[Scopolamine],
HOMER1	RELN	1-FACTA-related-drug->DrugBank:APRD00280[Frontal],
HOMER1	NLGN3	2-GoPubMed-related-GO->GO:0050808[synapse organization],GO:0043062[extracellular structure organization], 2-FACTA-related-disease->UMLS:C0236736[Cocaine-Related Disorders],UMLS:C0017650[Globus],
HOMER1	NLGN1	2-GoPubMed-related-GO->GO:0050808[synapse organization],GO:0043062[extracellular structure organization], 2-FACTA-related-disease->UMLS:C0236736[Cocaine-Related Disorders],UMLS:C0017650[Globus],
HOMER1	MARK1	1-GoPubMed-related-GO->GO:0034007[S-linalool synthase activity], 1-FACTA-related-drug->DrugBank:APRD01322[Potassium Chloride],
HOMER1	NRCAM	1-FACTA-related-gene->HUMANGGP:027101[LRRN3], 2-FACTA-related-disease->UMLS:C0265341[RGS],UMLS:C1510472[drug addiction], 1-FACTA-related-drug->DrugBank:APRD00627[Progesterone],
HOMER1	FOXP2	1-FACTA-related-drug->DrugBank:APRD00280[Frontal],
HOMER1	HMGN1	1-FACTA-related-disease->UMLS:C0002622[amnesia], 1-FACTA-related-drug->DrugBank:APRD00627[Progesterone],
HOMER1	RGS7	2-FACTA-related-disease->UMLS:C0265341[RGS],UMLS:C0027412[Opioid-Related Disorders], 2-FACTA-related-drug->DrugBank:APRD00280[Frontal],DrugBank:APRD00627[Progesterone],
HOXA2	DLX2	1-GoPubMed-related-gene->56033[BARX1], 1-GoPubMed-related-GO->GO:0003677[DNA binding], 1-FACTA-related-gene->HUMANGGP:036505[HOXD8], 1-FACTA-related-disease->UMLS:C0016632[Fox], 3-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:EXPT02079[lysine],
HOXA2	DLX1	1-GoPubMed-related-gene->56033[BARX1], 1-FACTA-related-gene->HUMANGGP:036505[HOXD8], 1-FACTA-related-disease->UMLS:C0017589[Equina], 2-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
HOXA2	SCN2A	4-FACTA-related-drug->DrugBank:EXPT02079[lysine],DrugBank:APRD00256[Valproic Acid],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
HOXA2	ALDH5A1	1-FACTA-related-drug->DrugBank:APRD00512[Phenytoin],
HOXA2	CHD7	3-GoPubMed-related-disease->mesh:2754[Choanal Atresia],mesh:3103[Coloboma],mesh:15619[Respiratory System Abnormalities], 2-FACTA-related-disease->UMLS:C1535927[HHS],UMLS:C0158646[cleft lip/palate], 1-FACTA-related-drug->DrugBank:EXPT02079[lysine],
HOXA2	FOXG1	3-FACTA-related-disease->UMLS:C0035372[Rett syndrome],UMLS:C0016632[Fox],UMLS:C1535927[HHS], 1-FACTA-related-drug->DrugBank:EXPT02079[lysine],
HOXA2	SHANK3	1-GoPubMed-related-disease->mesh:3103[Coloboma],
HOXA2	SHANK2	1-FACTA-related-disease->UMLS:C0018775[Hearing Loss, Bilateral], 1-FACTA-related-drug->DrugBank:EXPT02079[lysine],
HOXA2	RELN	3-FACTA-related-drug->DrugBank:APRD00256[Valproic Acid],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
HOXA2	ATP2B2	1-FACTA-related-disease->UMLS:C0018775[Hearing Loss, Bilateral],
HOXA2	HOXB1	2-GoPubMed-related-gene->3198[HOXA1],3225[HOXC9], 2-FACTA-related-gene->HUMANGGP:025411[HOXA1],HUMANGGP:010763[HOXB9], 5-FACTA-related-drug->DrugBank:APRD00017[Tretinoin],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00256[Valproic Acid],DrugBank:EXPT02079[lysine],
HOXA2	HOXA1	1-GoPubMed-related-gene->100302299[HOTAIRM1], 1-GoPubMed-related-GO->GO:0043583[ear development], 2-GoPubMed-related-disease->mesh:2754[Choanal Atresia],mesh:6312[Hearing Loss, Bilateral], 5-FACTA-related-gene->HUMANGGP:025411[HOXA1],HUMANGGP:022632[HOXA4],HUMANGGP:019548[HOXC9],HUMANGGP:000356[HOXA6],HUMANGGP:015778[HOXC6], 5-FACTA-related-drug->DrugBank:APRD00017[Tretinoin],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00256[Valproic Acid],DrugBank:EXPT02079[lysine],
HOXA2	RAI1	3-FACTA-related-drug->DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
HOXA2	TBX1	1-FACTA-related-disease->UMLS:C0016632[Fox], 3-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:EXPT02079[lysine],
HOXA2	GTF2I	1-FACTA-related-disease->UMLS:C0035372[Rett syndrome], 1-FACTA-related-drug->DrugBank:APRD00256[Valproic Acid],
HOXA2	DAB1	2-GoPubMed-related-disease->mesh:3394[Craniofacial Dysostosis],mesh:2972[Cleft Palate],
HOXA2	PITX1	4-FACTA-related-drug->DrugBank:APRD00134[Activin],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:EXPT02079[lysine],
HOXA2	EN2	1-FACTA-related-disease->UMLS:C0431399[Joubert syndrome], 3-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00362[Retinoic Acid],
HOXA4	DLX2	1-GoPubMed-related-disease->mesh:13576[Syndactyly], 1-FACTA-related-disease->UMLS:C0700039[external genitalia], 4-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:BIOD00001[DNase I],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00631[Gel],
HOXA4	DLX1	1-GoPubMed-related-disease->mesh:13576[Syndactyly], 1-FACTA-related-disease->UMLS:C0700039[external genitalia], 3-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:BIOD00001[DNase I],DrugBank:APRD00017[Tretinoin],
HOXA4	FGD1	2-GoPubMed-related-disease->mesh:6972[Hypertelorism],mesh:3394[Craniofacial Dysostosis],
HOXA4	SEMA5A	4-GoPubMed-related-disease->mesh:7021[Hypospadias],mesh:13576[Syndactyly],mesh:13580[Synostosis],mesh:10409[Penile Diseases],
HOXA4	RELN	5-FACTA-related-drug->DrugBank:APRD00181[CAM],DrugBank:BIOD00001[DNase I],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00631[Gel],
HOXA4	HOXA1	1-GoPubMed-related-gene->100302299[HOTAIRM1], 2-GoPubMed-related-GO->GO:0032526[response to retinoic acid],GO:0033189[response to vitamin A], 5-FACTA-related-gene->HUMANGGP:022632[HOXA4],HUMANGGP:019548[HOXC9],HUMANGGP:023475[EVX1],HUMANGGP:000356[HOXA6],HUMANGGP:015778[HOXC6], 1-FACTA-related-disease->UMLS:C0206659[embryonal carcinoma], 3-FACTA-related-drug->DrugBank:APRD00017[Tretinoin],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00631[Gel],
HOXA4	DLX6	1-FACTA-related-gene->HUMANGGP:008320[HOX4], 2-FACTA-related-disease->UMLS:C0700039[external genitalia],UMLS:C0206659[embryonal carcinoma], 2-FACTA-related-drug->DrugBank:BIOD00001[DNase I],DrugBank:APRD00140[Tretinoin],
HOXA4	IL1RAPL2	1-GoPubMed-related-disease->mesh:12729[Sex Chromosome Aberrations], 1-FACTA-related-disease->UMLS:C0036868[Sex Chromosome Aberrations],
HOXA4	RAI1	3-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00631[Gel],
HOXA4	FABP5	1-GoPubMed-related-GO->GO:0043588[skin development], 2-FACTA-related-disease->UMLS:C1861784[CAM],UMLS:C0206659[embryonal carcinoma], 4-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00181[CAM],DrugBank:APRD00631[Gel],
HOXA4	GNAS	4-FACTA-related-drug->DrugBank:APRD00181[CAM],DrugBank:BIOD00001[DNase I],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
HOXA4	NRCAM	1-FACTA-related-disease->UMLS:C1861784[CAM], 1-FACTA-related-drug->DrugBank:APRD00181[CAM],
HOXA4	DAB1	2-GoPubMed-related-disease->mesh:6972[Hypertelorism],mesh:3394[Craniofacial Dysostosis], 1-FACTA-related-drug->DrugBank:APRD00631[Gel],
HOXA4	TBX1	3-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00631[Gel],
HOXA4	MEF2C	1-GoPubMed-related-gene->100271849[MEF2B], 2-FACTA-related-drug->DrugBank:APRD00017[Tretinoin],DrugBank:APRD00140[Tretinoin],
HOXA4	EN2	2-GoPubMed-related-disease->mesh:13576[Syndactyly],mesh:13580[Synostosis], 3-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00631[Gel],
HOXA4	NFIA	2-GoPubMed-related-GO->GO:0004530[deoxyribonuclease I activity],GO:0016888[endodeoxyribonuclease activity, producing 5'-phosphomonoesters], 2-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
HOXA4	PINX1	2-FACTA-related-disease->UMLS:C0027660[Neoplasms, Glandular and Epithelial],UMLS:C0005699[blast crisis], 3-FACTA-related-drug->DrugBank:BIOD00001[DNase I],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
HOXB9	RAB39B	2-GoPubMed-related-disease->mesh:18239[Seminoma],mesh:18237[Germinoma],
HOXB9	GRIP1	1-GoPubMed-related-GO->GO:0003712[transcription cofactor activity], 3-FACTA-related-drug->DrugBank:APRD00196[Cefadroxil],DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00017[Tretinoin],
HOXB9	HDAC4	6-FACTA-related-drug->DrugBank:EXPT02079[lysine],DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00649[Etoposide],DrugBank:APRD00627[Progesterone],
HOXB9	HOXA1	2-FACTA-related-gene->HUMANGGP:022632[HOXA4],HUMANGGP:019548[HOXC9], 6-FACTA-related-drug->DrugBank:APRD00017[Tretinoin],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00256[Valproic Acid],DrugBank:EXPT02079[lysine],DrugBank:APRD00627[Progesterone],
HOXB9	SCN2A	5-FACTA-related-drug->DrugBank:EXPT02079[lysine],DrugBank:BIOD00057[Fragment],DrugBank:APRD00256[Valproic Acid],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
HOXB9	HOXB1	1-GoPubMed-related-gene->3225[HOXC9], 4-GoPubMed-related-GO->GO:0050254[rhodopsin kinase activity],GO:0005095[GTPase inhibitor activity],GO:0030695[GTPase regulator activity],GO:0060589[nucleoside-triphosphatase regulator activity], 4-FACTA-related-gene->HUMANGGP:018087[PREP1],HUMANGGP:002915[HOXB5],HUMANGGP:010763[HOXB9],HUMANGGP:004484[HOXB6], 1-FACTA-related-disease->UMLS:C0008312[primary biliary cirrhosis], 7-FACTA-related-drug->DrugBank:APRD00196[Cefadroxil],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00256[Valproic Acid],DrugBank:EXPT02079[lysine],DrugBank:APRD00627[Progesterone],
HOXB9	RELN	1-GoPubMed-related-GO->GO:0047152[methanol-5-hydroxybenzimidazolylcobamide Co-methyltransferase activity], 4-FACTA-related-drug->DrugBank:APRD00181[CAM],DrugBank:APRD00256[Valproic Acid],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
HOXB9	SHANK3	1-GoPubMed-related-disease->mesh:7593[Joint Instability], 2-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00627[Progesterone],
HOXB9	GNAS	6-FACTA-related-drug->DrugBank:APRD00181[CAM],DrugBank:BIOD00057[Fragment],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:EXPT02079[lysine],DrugBank:APRD00627[Progesterone],
HOXB9	SEMA5A	2-FACTA-related-disease->UMLS:C0751781[NOD],UMLS:C0020179[Huntington's disease], 2-FACTA-related-drug->DrugBank:APRD00649[Etoposide],DrugBank:BIOD00057[Fragment],
HOXB9	GTF2I	2-FACTA-related-drug->DrugBank:APRD00256[Valproic Acid],DrugBank:BIOD00057[Fragment],
HOXB9	NRCAM	1-FACTA-related-disease->UMLS:C1861784[CAM], 2-FACTA-related-drug->DrugBank:APRD00181[CAM],DrugBank:APRD00627[Progesterone],
HOXB9	RAI1	1-GoPubMed-related-gene->3215[HOXB5], 2-GoPubMed-related-GO->GO:0030695[GTPase regulator activity],GO:0060589[nucleoside-triphosphatase regulator activity], 1-FACTA-related-disease->UMLS:C0151491[Congenital anomalies], 3-FACTA-related-drug->DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
HOXB9	EN2	1-GoPubMed-related-gene->3218[HOXB8], 5-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:BIOD00057[Fragment],DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00450[Norepinephrine],
HOXB9	PINX1	4-FACTA-related-drug->DrugBank:APRD00649[Etoposide],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:EXPT02079[lysine],
HOXB9	TBX1	1-GoPubMed-related-GO->GO:0003712[transcription cofactor activity], 4-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:EXPT02079[lysine],DrugBank:APRD00627[Progesterone],
HOXC6	PITX1	1-GoPubMed-related-GO->GO:0007369[gastrulation], 1-FACTA-related-gene->HUMANGGP:023475[EVX1], 5-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:EXPT02079[lysine],DrugBank:APRD00396[Estrogens],DrugBank:APRD00627[Progesterone],
HOXC6	DLX2	1-GoPubMed-related-gene->3234[HOXD8], 1-GoPubMed-related-GO->GO:0033077[T cell differentiation in the thymus], 2-FACTA-related-gene->HUMANGGP:025156[HOXD1],HUMANGGP:036505[HOXD8], 5-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:BIOD00001[DNase I],DrugBank:APRD00017[Tretinoin],DrugBank:EXPT02079[lysine],DrugBank:APRD00631[Gel],
HOXC6	DLX1	1-GoPubMed-related-gene->3234[HOXD8], 2-FACTA-related-gene->HUMANGGP:025156[HOXD1],HUMANGGP:036505[HOXD8], 3-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:BIOD00001[DNase I],DrugBank:APRD00017[Tretinoin],
HOXC6	TSPAN7	2-FACTA-related-disease->UMLS:C0023493[T-cell acute lymphoblastic leukemia],UMLS:C0023435[B-ALL],
HOXC6	ARNT2	1-GoPubMed-related-disease->mesh:18442[Lymphoma, Mucosa-Associated Lymphoid Tissue], 2-FACTA-related-drug->DrugBank:APRD00396[Estrogens],DrugBank:APRD00631[Gel],
HOXC6	TBX1	5-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:EXPT02079[lysine],DrugBank:APRD00627[Progesterone],DrugBank:APRD00631[Gel],
HOXC6	ESRRB	2-FACTA-related-drug->DrugBank:BIOD00001[DNase I],DrugBank:APRD00396[Estrogens],
HOXC6	NFIA	1-FACTA-related-disease->UMLS:C0023465[Leukemia, Monocytic, Acute], 2-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
HOXC6	HOXA1	1-GoPubMed-related-gene->2636[GBX1], 4-FACTA-related-gene->HUMANGGP:022632[HOXA4],HUMANGGP:019548[HOXC9],HUMANGGP:023475[EVX1],HUMANGGP:015778[HOXC6], 5-FACTA-related-drug->DrugBank:APRD00017[Tretinoin],DrugBank:APRD00140[Tretinoin],DrugBank:EXPT02079[lysine],DrugBank:APRD00627[Progesterone],DrugBank:APRD00631[Gel],
HOXC6	HOXB1	1-GoPubMed-related-gene->3225[HOXC9], 3-FACTA-related-gene->HUMANGGP:002915[HOXB5],HUMANGGP:010763[HOXB9],HUMANGGP:039160[HOXD9], 5-FACTA-related-drug->DrugBank:APRD00017[Tretinoin],DrugBank:APRD00140[Tretinoin],DrugBank:EXPT02079[lysine],DrugBank:APRD00631[Gel],DrugBank:APRD00627[Progesterone],
HOXC6	DLX6	1-GoPubMed-related-GO->GO:0035282[segmentation], 2-FACTA-related-gene->HUMANGGP:002915[HOXB5],HUMANGGP:008320[HOX4], 1-FACTA-related-disease->UMLS:C1522128[T-cell lymphomas], 2-FACTA-related-drug->DrugBank:BIOD00001[DNase I],DrugBank:APRD00140[Tretinoin],
HOXC6	ITGB7	2-GoPubMed-related-disease->mesh:17254[Leukemic Infiltration],mesh:18442[Lymphoma, Mucosa-Associated Lymphoid Tissue],
HOXC6	HMGN1	1-GoPubMed-related-disease->mesh:5935[Glucagonoma], 6-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:EXPT02079[lysine],DrugBank:APRD00396[Estrogens],DrugBank:APRD00627[Progesterone],DrugBank:APRD00631[Gel],
HOXC6	ATRX	3-FACTA-related-drug->DrugBank:APRD00953[ETS],DrugBank:EXPT02079[lysine],DrugBank:APRD00631[Gel],
HOXC6	RELN	4-FACTA-related-drug->DrugBank:BIOD00001[DNase I],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00631[Gel],
HOXC6	PINX1	4-FACTA-related-drug->DrugBank:BIOD00001[DNase I],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:EXPT02079[lysine],
HOXD4	CASC4	1-GoPubMed-related-disease->mesh:8[Abdominal Neoplasms],
HOXD4	DLX1	1-GoPubMed-related-gene->3234[HOXD8], 2-FACTA-related-gene->HUMANGGP:025156[HOXD1],HUMANGGP:036505[HOXD8], 3-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:BIOD00001[DNase I],DrugBank:APRD00017[Tretinoin],
HOXD4	PINX1	4-FACTA-related-drug->DrugBank:BIOD00001[DNase I],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:EXPT02079[lysine],
HOXD4	GRIP1	3-FACTA-related-drug->DrugBank:APRD00196[Cefadroxil],DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00017[Tretinoin],
HOXD4	RAI1	4-FACTA-related-drug->DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00631[Gel],
HOXD4	HOXA1	2-FACTA-related-gene->HUMANGGP:022632[HOXA4],HUMANGGP:015778[HOXC6], 1-FACTA-related-disease->UMLS:C0206659[embryonal carcinoma], 6-FACTA-related-drug->DrugBank:APRD00017[Tretinoin],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00362[Retinoic Acid],DrugBank:EXPT02079[lysine],DrugBank:EXPT01468[Folic Acid],DrugBank:APRD00631[Gel],
HOXD4	TBX1	4-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:EXPT02079[lysine],DrugBank:APRD00631[Gel],
HOXD4	TSN	1-GoPubMed-related-disease->mesh:18232[Rhabdomyosarcoma, Alveolar], 1-FACTA-related-drug->DrugBank:EXPT02079[lysine],
HOXD4	HOXB1	2-FACTA-related-gene->HUMANGGP:004484[HOXB6],HUMANGGP:039160[HOXD9], 1-FACTA-related-disease->UMLS:C0206659[embryonal carcinoma], 6-FACTA-related-drug->DrugBank:APRD00196[Cefadroxil],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00362[Retinoic Acid],DrugBank:EXPT02079[lysine],DrugBank:APRD00631[Gel],
HOXD4	DLX6	1-FACTA-related-gene->HUMANGGP:008320[HOX4], 1-FACTA-related-disease->UMLS:C0206659[embryonal carcinoma], 2-FACTA-related-drug->DrugBank:BIOD00001[DNase I],DrugBank:APRD00140[Tretinoin],
HOXD4	MECP2	4-FACTA-related-drug->DrugBank:EXPT02079[lysine],DrugBank:APRD00698[Leucovorin],DrugBank:BIOD00001[DNase I],DrugBank:EXPT01468[Folic Acid],
HOXD4	CACNA1G	3-FACTA-related-drug->DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00698[Leucovorin],DrugBank:APRD00017[Tretinoin],
HOXD4	EN2	1-GoPubMed-related-disease->mesh:18232[Rhabdomyosarcoma, Alveolar], 4-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00631[Gel],
HOXD4	RELN	4-FACTA-related-drug->DrugBank:BIOD00001[DNase I],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00631[Gel],
HOXD4	MEF2C	1-GoPubMed-related-disease->mesh:18232[Rhabdomyosarcoma, Alveolar], 4-FACTA-related-drug->DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00698[Leucovorin],
HOXD4	DLX2	1-GoPubMed-related-gene->3234[HOXD8], 2-FACTA-related-gene->HUMANGGP:025156[HOXD1],HUMANGGP:036505[HOXD8], 5-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:BIOD00001[DNase I],DrugBank:APRD00017[Tretinoin],DrugBank:EXPT02079[lysine],DrugBank:APRD00631[Gel],
HSPG2	LAMB1	2-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00631[Gel], 1-pathway->kegg:path:hsa04512[ECM-receptor interaction],
HSPG2	CREBBP	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
HSPG2	NLGN4X	1-FACTA-related-disease->UMLS:C0343284[chondrodysplasia], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
HSPG2	ABAT	2-FACTA-related-disease->UMLS:C0686347[tardive dyskinesia],UMLS:C0013386[Dyskinesia, Drug-Induced], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
HSPG2	HTR2A	1-FACTA-related-disease->UMLS:C0686347[tardive dyskinesia], 2-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00340[Reserpine],
HSPG2	AHI1	3-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00631[Gel],
HSPG2	DMPK	1-GoPubMed-related-disease->mesh:9222[Myotonia], 1-FACTA-related-disease->UMLS:C0553604[Myotonic Disorders], 3-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00631[Gel],DrugBank:APRD00506[Spectrum],
HSPG2	GABRA4	2-FACTA-related-disease->UMLS:C0686347[tardive dyskinesia],UMLS:C0013386[Dyskinesia, Drug-Induced], 1-FACTA-related-drug->DrugBank:APRD00631[Gel],
HSPG2	DMD	2-FACTA-related-drug->DrugBank:APRD01221[Rocuronium],DrugBank:BIOD00057[Fragment],
HSPG2	CA6	3-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00631[Gel],
HSPG2	DHCR7	1-FACTA-related-disease->UMLS:C0343284[chondrodysplasia], 3-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
HSPG2	NTRK3	1-FACTA-related-drug->DrugBank:APRD00340[Reserpine],
HSPG2	NTRK1	3-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00631[Gel],
HSPG2	NPAS2	3-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00631[Gel],
HSPG2	NSD1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
HSPG2	CD44	2-GoPubMed-related-GO->GO:0015012[heparan sulfate proteoglycan biosynthetic process],GO:0030201[heparan sulfate proteoglycan metabolic process], 1-FACTA-related-drug->DrugBank:APRD00328[Selectin], 1-pathway->kegg:path:hsa04512[ECM-receptor interaction],
HSPG2	CNTNAP2	3-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
HTR1A	TPH2	1-GoPubMed-related-gene->3362[HTR6], 2-GoPubMed-related-GO->GO:0002121[inter-male aggressive behavior],GO:0004993[serotonin receptor activity], 2-FACTA-related-gene->HUMANGGP:008892[TPH2],HUMANGGP:034384[HTR1A], 1-FACTA-related-disease->UMLS:C1269683[major depression], 4-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:APRD00530[Portal],DrugBank:APRD00280[Frontal],DrugBank:APRD00450[Norepinephrine],
HTR1A	CHRNA7	1-FACTA-related-gene->HUMANGGP:034085[CHRM1], 2-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:BIOD00057[Fragment], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
HTR1A	HTR7	3-GoPubMed-related-gene->3362[HTR6],3361[HTR5A],3355[HTR1F], 5-GoPubMed-related-GO->GO:0004993[serotonin receptor activity],GO:0022410[circadian sleep/wake cycle process],GO:0045187[regulation of circadian sleep/wake cycle, sleep],GO:0008227[G-protein coupled amine receptor activity],GO:0004930[G-protein coupled receptor activity], 6-FACTA-related-gene->HUMANGGP:018979[HTR3],HUMANGGP:016972[HTR2B],HUMANGGP:023136[HTR4],HUMANGGP:018007[HTR1F],HUMANGGP:007621[HTR5A],HUMANGGP:034384[HTR1A], 2-FACTA-related-disease->UMLS:C1852438[CCL],UMLS:C0040517[Tourette Syndrome], 2-FACTA-related-drug->DrugBank:APRD00243[CCL],DrugBank:BIOD00057[Fragment], 2-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],reactome:REACT_17064[],
HTR1A	SLC1A1	1-FACTA-related-disease->UMLS:C0041696[unipolar depression], 1-FACTA-related-drug->DrugBank:APRD00280[Frontal],
HTR1A	HTR3A	3-GoPubMed-related-gene->3362[HTR6],3361[HTR5A],3355[HTR1F], 2-GoPubMed-related-GO->GO:0004993[serotonin receptor activity],GO:0051378[serotonin binding], 2-GoPubMed-related-disease->mesh:6606[Hiccup],mesh:9041[Motion Sickness], 6-FACTA-related-gene->HUMANGGP:014538[HTR3A],HUMANGGP:018979[HTR3],HUMANGGP:023136[HTR4],HUMANGGP:016972[HTR2B],HUMANGGP:007621[HTR5A],HUMANGGP:018007[HTR1F], 3-FACTA-related-disease->UMLS:C0236733[Amphetamine-Related Disorders],UMLS:C0040517[Tourette Syndrome],UMLS:C0030319[panic disorder], 2-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:APRD00450[Norepinephrine],
HTR1A	HTR2A	4-GoPubMed-related-gene->3362[HTR6],3361[HTR5A],3358[HTR2C],3355[HTR1F], 5-GoPubMed-related-GO->GO:0004993[serotonin receptor activity],GO:0051378[serotonin binding],GO:0004937[alpha1-adrenergic receptor activity],GO:0008227[G-protein coupled amine receptor activity],GO:0004930[G-protein coupled receptor activity], 2-GoPubMed-related-disease->mesh:17109[Akathisia, Drug-Induced],mesh:2375[Catalepsy], 9-FACTA-related-gene->HUMANGGP:009093[solute carrier family 6 member 4],HUMANGGP:009760[HTR2A],HUMANGGP:007621[HTR5A],HUMANGGP:018007[HTR1F],HUMANGGP:034384[HTR1A],HUMANGGP:023136[HTR4],HUMANGGP:016972[HTR2B],HUMANGGP:026553[HTR2C],HUMANGGP:018979[HTR3], 3-FACTA-related-disease->UMLS:C0018609[Hartnup Disease],UMLS:C0260653[behavior problem],UMLS:C1852438[CCL], 5-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:APRD00243[CCL],DrugBank:BIOD00057[Fragment],DrugBank:EXPT01530[Glyceraldehyde-3-Phosphate],DrugBank:APRD00530[Portal], 2-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],reactome:REACT_17064[],
HTR1A	HTR1B	5-GoPubMed-related-gene->3352[HTR1D],3355[HTR1F],3354[HTR1E],3362[HTR6],3361[HTR5A], 8-GoPubMed-related-GO->GO:0002121[inter-male aggressive behavior],GO:0004993[serotonin receptor activity],GO:0051378[serotonin binding],GO:0022410[circadian sleep/wake cycle process],GO:0045187[regulation of circadian sleep/wake cycle, sleep],GO:0008227[G-protein coupled amine receptor activity],GO:0047893[flavonol 3-O-glucosyltransferase activity],GO:0004930[G-protein coupled receptor activity], 9-FACTA-related-gene->HUMANGGP:018007[HTR1F],HUMANGGP:016972[HTR2B],HUMANGGP:023136[HTR4],HUMANGGP:007621[HTR5A],HUMANGGP:034384[HTR1A],HUMANGGP:028637[5-HT-2C],HUMANGGP:018979[HTR3],HUMANGGP:009760[HTR2A],HUMANGGP:026553[HTR2C], 3-FACTA-related-disease->UMLS:C0018609[Hartnup Disease],UMLS:C1852438[CCL],UMLS:C0024517[major depressive episode], 7-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:APRD00243[CCL],DrugBank:EXPT01530[Glyceraldehyde-3-Phosphate],DrugBank:BIOD00057[Fragment],DrugBank:APRD00530[Portal],DrugBank:EXPT00494[Alanine],DrugBank:APRD00450[Norepinephrine], 3-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],reactome:REACT_19231[],reactome:REACT_17064[],
HTR1A	TH	1-GoPubMed-related-disease->mesh:6610[High Pressure Neurological Syndrome], 1-FACTA-related-drug->DrugBank:BIOD00017[IFN-gamma],
HTR1A	EN2	1-FACTA-related-gene->HUMANGGP:007621[HTR5A], 2-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00450[Norepinephrine],
HTR1A	DRD3	7-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:BIOD00057[Fragment],DrugBank:APRD00679[ENT],DrugBank:APRD00530[Portal],DrugBank:APRD00280[Frontal],DrugBank:BIOD00017[IFN-gamma],DrugBank:APRD00450[Norepinephrine],
HTR1A	MAOA	2-GoPubMed-related-disease->mesh:20230[Serotonin Syndrome],mesh:17109[Akathisia, Drug-Induced], 2-FACTA-related-gene->HUMANGGP:016972[HTR2B],HUMANGGP:007621[HTR5A], 6-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:BIOD00057[Fragment],DrugBank:APRD00450[Norepinephrine],DrugBank:APRD00679[ENT],DrugBank:APRD00530[Portal],DrugBank:APRD00280[Frontal],
HTR1A	SLC6A8	1-FACTA-related-drug->DrugBank:APRD00679[ENT],
HTR1A	SLC6A4	3-GoPubMed-related-GO->GO:0002121[inter-male aggressive behavior],GO:0051378[serotonin binding],GO:0004993[serotonin receptor activity], 4-FACTA-related-gene->HUMANGGP:009093[solute carrier family 6 member 4],HUMANGGP:007621[HTR5A],HUMANGGP:034384[HTR1A],HUMANGGP:009760[HTR2A], 6-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:APRD00679[ENT],DrugBank:APRD00530[Portal],DrugBank:APRD00280[Frontal],DrugBank:APRD00450[Norepinephrine],DrugBank:BIOD00057[Fragment],
HTR1A	FOXG1	1-FACTA-related-drug->DrugBank:APRD00530[Portal],
HTR1A	FOXP2	3-FACTA-related-drug->DrugBank:APRD00280[Frontal],DrugBank:BIOD00057[Fragment],DrugBank:BIOD00017[IFN-gamma],
HTR1A	NPAS2	2-FACTA-related-drug->DrugBank:APRD00530[Portal],DrugBank:EXPT00494[Alanine],
HTR1A	DISC1	4-FACTA-related-drug->DrugBank:EXPT01530[Glyceraldehyde-3-Phosphate],DrugBank:APRD00280[Frontal],DrugBank:BIOD00057[Fragment],DrugBank:EXPT00494[Alanine],
HTR1A	OXTR	1-FACTA-related-gene->HUMANGGP:016972[HTR2B], 1-FACTA-related-disease->UMLS:C0041696[unipolar depression], 1-FACTA-related-drug->DrugBank:APRD01072[HCH], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
HTR1A	NRCAM	2-FACTA-related-disease->UMLS:C0236733[Amphetamine-Related Disorders],UMLS:C0040517[Tourette Syndrome],
HTR2C	OXTR	1-FACTA-related-gene->HUMANGGP:016972[HTR2B], 1-FACTA-related-disease->UMLS:C0233639[Autism], 1-FACTA-related-drug->DrugBank:APRD01072[HCH], 3-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],reactome:REACT_18283[],kegg:path:hsa04020[Calcium signaling pathway],
HTR2C	ADRB2	1-GoPubMed-related-disease->mesh:3655[Decerebrate State], 1-FACTA-related-gene->HUMANGGP:020893[ADRA1A], 3-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:BIOD00057[Fragment],DrugBank:APRD00140[Tretinoin],
HTR2C	CHRNA7	1-FACTA-related-disease->UMLS:C0036337[schizoaffective disorder], 2-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:BIOD00057[Fragment], 2-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],kegg:path:hsa04020[Calcium signaling pathway],
HTR2C	TPH2	1-GoPubMed-related-gene->3362[HTR6], 2-GoPubMed-related-GO->GO:0042427[serotonin biosynthetic process],GO:0004993[serotonin receptor activity], 1-FACTA-related-gene->HUMANGGP:034384[HTR1A], 4-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:APRD00530[Portal],DrugBank:APRD00280[Frontal],DrugBank:APRD00450[Norepinephrine],
HTR2C	HTR7	3-GoPubMed-related-gene->3362[HTR6],3361[HTR5A],3355[HTR1F], 3-GoPubMed-related-GO->GO:0004993[serotonin receptor activity],GO:0008227[G-protein coupled amine receptor activity],GO:0004930[G-protein coupled receptor activity], 6-FACTA-related-gene->HUMANGGP:016972[HTR2B],HUMANGGP:023136[HTR4],HUMANGGP:018007[HTR1F],HUMANGGP:007621[HTR5A],HUMANGGP:034384[HTR1A],HUMANGGP:015266[HTR3B], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment], 3-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],kegg:path:hsa04020[Calcium signaling pathway],reactome:REACT_17064[],
HTR2C	NPAS2	1-GoPubMed-related-disease->mesh:20178[Sleep Disorders, Circadian Rhythm], 2-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0036337[schizoaffective disorder], 1-FACTA-related-drug->DrugBank:APRD00530[Portal],
HTR2C	GABRA4	4-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0036337[schizoaffective disorder],UMLS:C0686347[tardive dyskinesia],UMLS:C0013386[Dyskinesia, Drug-Induced], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
HTR2C	HTR1B	5-GoPubMed-related-gene->3355[HTR1F],3354[HTR1E],3362[HTR6],3361[HTR5A],3363[HTR7], 6-GoPubMed-related-GO->GO:0004993[serotonin receptor activity],GO:0051378[serotonin binding],GO:0042427[serotonin biosynthetic process],GO:0008227[G-protein coupled amine receptor activity],GO:0047893[flavonol 3-O-glucosyltransferase activity],GO:0004930[G-protein coupled receptor activity], 7-FACTA-related-gene->HUMANGGP:018007[HTR1F],HUMANGGP:016972[HTR2B],HUMANGGP:023136[HTR4],HUMANGGP:007621[HTR5A],HUMANGGP:034384[HTR1A],HUMANGGP:009760[HTR2A],HUMANGGP:026553[HTR2C], 2-FACTA-related-disease->UMLS:C0018609[Hartnup Disease],UMLS:C0233523[antisocial behavior], 6-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:APRD00254[Ranitidine],DrugBank:EXPT01530[Glyceraldehyde-3-Phosphate],DrugBank:BIOD00057[Fragment],DrugBank:APRD00530[Portal],DrugBank:APRD00450[Norepinephrine], 2-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],reactome:REACT_17064[],
HTR2C	EN2	1-FACTA-related-gene->HUMANGGP:007621[HTR5A], 1-FACTA-related-disease->UMLS:C0233639[Autism], 4-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:BIOD00057[Fragment],DrugBank:APRD00450[Norepinephrine],
HTR2C	DRD3	2-GoPubMed-related-GO->GO:0032099[negative regulation of appetite],GO:0032096[negative regulation of response to food], 1-GoPubMed-related-disease->mesh:4409[Dyskinesia, Drug-Induced], 2-FACTA-related-gene->HUMANGGP:007874[DRD3],HUMANGGP:007875[dopamine receptor D3], 4-FACTA-related-disease->UMLS:C0392702[abnormal involuntary movements],UMLS:C0686347[tardive dyskinesia],UMLS:C0013386[Dyskinesia, Drug-Induced],UMLS:C0162550[Akathisia, Drug-Induced], 6-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:BIOD00057[Fragment],DrugBank:APRD00633[Perphenazine],DrugBank:APRD00530[Portal],DrugBank:APRD00280[Frontal],DrugBank:APRD00450[Norepinephrine],
HTR2C	MBD1	1-FACTA-related-disease->UMLS:C0233639[Autism], 1-FACTA-related-drug->DrugBank:APRD00530[Portal],
HTR2C	SLC1A1	1-FACTA-related-disease->UMLS:C0233639[Autism], 3-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00280[Frontal],
HTR2C	GRIN2B	1-GoPubMed-related-disease->mesh:4409[Dyskinesia, Drug-Induced], 1-FACTA-related-disease->UMLS:C0012734[Disruptive Behavior Disorders], 2-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:BIOD00057[Fragment], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
HTR2C	FOXG1	1-GoPubMed-related-GO->GO:0003725[double-stranded RNA binding], 1-FACTA-related-drug->DrugBank:APRD00530[Portal],
HTR2C	MAOA	1-GoPubMed-related-disease->mesh:17109[Akathisia, Drug-Induced], 3-FACTA-related-gene->HUMANGGP:001711[MAOA],HUMANGGP:016972[HTR2B],HUMANGGP:007621[HTR5A], 1-FACTA-related-disease->UMLS:C0233523[antisocial behavior], 5-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:BIOD00057[Fragment],DrugBank:APRD00450[Norepinephrine],DrugBank:APRD00530[Portal],DrugBank:APRD00280[Frontal],
HTR2C	FOXP2	2-FACTA-related-drug->DrugBank:APRD00280[Frontal],DrugBank:BIOD00057[Fragment],
HTR2C	DAPK1	1-GoPubMed-related-disease->mesh:16545[Choroid Plexus Neoplasms], 1-FACTA-related-disease->UMLS:C0205770[choroid plexus papilloma], 2-FACTA-related-drug->DrugBank:APRD00017[Tretinoin],DrugBank:APRD00140[Tretinoin],
HTR2C	HTR3A	3-GoPubMed-related-gene->3362[HTR6],3361[HTR5A],3355[HTR1F], 3-GoPubMed-related-GO->GO:0004993[serotonin receptor activity],GO:0051378[serotonin binding],GO:0042427[serotonin biosynthetic process], 7-FACTA-related-gene->HUMANGGP:014538[HTR3A],HUMANGGP:015266[HTR3B],HUMANGGP:023136[HTR4],HUMANGGP:016972[HTR2B],HUMANGGP:007621[HTR5A],HUMANGGP:018007[HTR1F],HUMANGGP:020893[ADRA1A], 2-FACTA-related-disease->UMLS:C0233523[antisocial behavior],UMLS:C0233639[Autism], 2-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:APRD00450[Norepinephrine],
HTR2C	HTR2A	4-GoPubMed-related-gene->3362[HTR6],3361[HTR5A],3355[HTR1F],3357[HTR2B], 4-GoPubMed-related-GO->GO:0004993[serotonin receptor activity],GO:0051378[serotonin binding],GO:0008227[G-protein coupled amine receptor activity],GO:0004930[G-protein coupled receptor activity], 3-GoPubMed-related-disease->mesh:17109[Akathisia, Drug-Induced],mesh:2375[Catalepsy],mesh:4409[Dyskinesia, Drug-Induced], 7-FACTA-related-gene->HUMANGGP:009760[HTR2A],HUMANGGP:007621[HTR5A],HUMANGGP:018007[HTR1F],HUMANGGP:034384[HTR1A],HUMANGGP:023136[HTR4],HUMANGGP:016972[HTR2B],HUMANGGP:026553[HTR2C], 4-FACTA-related-disease->UMLS:C0392702[abnormal involuntary movements],UMLS:C0018609[Hartnup Disease],UMLS:C0036337[schizoaffective disorder],UMLS:C0686347[tardive dyskinesia], 6-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:APRD00633[Perphenazine],DrugBank:BIOD00057[Fragment],DrugBank:APRD00254[Ranitidine],DrugBank:EXPT01530[Glyceraldehyde-3-Phosphate],DrugBank:APRD00530[Portal], 5-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],reactome:REACT_18283[],kegg:path:hsa04020[Calcium signaling pathway],reactome:REACT_17064[],kegg:path:hsa04540[Gap junction],
HTR2C	DISC1	2-FACTA-related-disease->UMLS:C0036337[schizoaffective disorder],UMLS:C0265341[RGS], 3-FACTA-related-drug->DrugBank:EXPT01530[Glyceraldehyde-3-Phosphate],DrugBank:APRD00280[Frontal],DrugBank:BIOD00057[Fragment],
HTR2C	RELN	1-GoPubMed-related-GO->GO:0047152[methanol-5-hydroxybenzimidazolylcobamide Co-methyltransferase activity], 1-FACTA-related-disease->UMLS:C0233639[Autism], 3-FACTA-related-drug->DrugBank:APRD00280[Frontal],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
HTR2C	ADORA2A	2-GoPubMed-related-disease->mesh:2375[Catalepsy],mesh:4409[Dyskinesia, Drug-Induced], 3-FACTA-related-disease->UMLS:C0023374[Lesch-Nyhan Syndrome],UMLS:C0149676[enzyme deficiency],UMLS:C0233639[Autism], 2-FACTA-related-drug->DrugBank:APRD00280[Frontal],DrugBank:BIOD00057[Fragment], 2-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],kegg:path:hsa04020[Calcium signaling pathway],
HTR2C	SLC6A4	2-GoPubMed-related-GO->GO:0051378[serotonin binding],GO:0004993[serotonin receptor activity], 4-FACTA-related-gene->HUMANGGP:007621[HTR5A],HUMANGGP:034384[HTR1A],HUMANGGP:009760[HTR2A],HUMANGGP:015266[HTR3B], 2-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0233523[antisocial behavior], 5-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:APRD00530[Portal],DrugBank:APRD00280[Frontal],DrugBank:APRD00450[Norepinephrine],DrugBank:BIOD00057[Fragment],
HTR2C	ABAT	2-GoPubMed-related-disease->mesh:4409[Dyskinesia, Drug-Induced],mesh:2375[Catalepsy], 3-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0686347[tardive dyskinesia],UMLS:C0013386[Dyskinesia, Drug-Induced], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
HTR4	KCNMA1	1-GoPubMed-related-disease->mesh:3112[Colonic Pseudo-Obstruction],
HTR4	MED12	1-FACTA-related-disease->UMLS:C0004930[Behavior Disorders], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
HTR4	SLC6A4	1-GoPubMed-related-GO->GO:0004993[serotonin receptor activity], 2-GoPubMed-related-disease->mesh:43183[Irritable Bowel Syndrome],mesh:3109[Colonic Diseases, Functional], 1-FACTA-related-gene->HUMANGGP:007621[HTR5A], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
HTR4	HTR2A	3-GoPubMed-related-gene->3362[HTR6],3361[HTR5A],3355[HTR1F], 5-GoPubMed-related-GO->GO:0004993[serotonin receptor activity],GO:0043271[negative regulation of ion transport],GO:0042045[epithelial fluid transport],GO:0008227[G-protein coupled amine receptor activity],GO:0004930[G-protein coupled receptor activity], 5-FACTA-related-gene->HUMANGGP:007621[HTR5A],HUMANGGP:018007[HTR1F],HUMANGGP:023136[HTR4],HUMANGGP:016972[HTR2B],HUMANGGP:018979[HTR3], 1-FACTA-related-disease->UMLS:C1852438[CCL], 3-FACTA-related-drug->DrugBank:APRD00243[CCL],DrugBank:BIOD00057[Fragment],DrugBank:EXPT01530[Glyceraldehyde-3-Phosphate], 3-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],kegg:path:hsa04020[Calcium signaling pathway],reactome:REACT_17064[],
HTR4	BAIAP2	1-FACTA-related-gene->HUMANGGP:006897[NEUROD6], 1-FACTA-related-disease->UMLS:C1263846[Attention Deficit Disorder with Hyperactivity],
HTR4	GABRB1	2-FACTA-related-disease->UMLS:C0004352[autism],UMLS:C0005586[Bipolar Disorder], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
HTR4	OPRM1	2-GoPubMed-related-disease->mesh:5414[Flatulence],mesh:3248[Constipation], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
HTR4	HTR3A	3-GoPubMed-related-gene->3362[HTR6],3361[HTR5A],3355[HTR1F], 6-GoPubMed-related-GO->GO:0004993[serotonin receptor activity],GO:0043271[negative regulation of ion transport],GO:0042045[epithelial fluid transport],GO:0030432[peristalsis],GO:0014821[phasic smooth muscle contraction],GO:0060079[regulation of excitatory postsynaptic membrane potential], 3-GoPubMed-related-disease->mesh:43183[Irritable Bowel Syndrome],mesh:3109[Colonic Diseases, Functional],mesh:17091[Colitis, Ischemic], 5-FACTA-related-gene->HUMANGGP:018979[HTR3],HUMANGGP:023136[HTR4],HUMANGGP:016972[HTR2B],HUMANGGP:007621[HTR5A],HUMANGGP:018007[HTR1F], 1-FACTA-related-disease->UMLS:C0015674[chronic fatigue syndrome],
HTR4	RIMS3	2-FACTA-related-disease->UMLS:C0004352[autism],UMLS:C0036341[schizophrenia],
HTR4	DISC1	2-FACTA-related-disease->UMLS:C0036341[schizophrenia],UMLS:C0005586[Bipolar Disorder], 2-FACTA-related-drug->DrugBank:EXPT01530[Glyceraldehyde-3-Phosphate],DrugBank:BIOD00057[Fragment],
HTR4	HTR3C	1-GoPubMed-related-gene->3359[HTR3A], 3-GoPubMed-related-GO->GO:0004993[serotonin receptor activity],GO:0008227[G-protein coupled amine receptor activity],GO:0004930[G-protein coupled receptor activity], 2-GoPubMed-related-disease->mesh:43183[Irritable Bowel Syndrome],mesh:3109[Colonic Diseases, Functional], 1-FACTA-related-gene->HUMANGGP:018979[HTR3], 2-FACTA-related-disease->UMLS:C0004352[autism],UMLS:C0036341[schizophrenia],
HTR4	TDO2	1-GoPubMed-related-disease->mesh:16603[Eosinophilia-Myalgia Syndrome], 4-FACTA-related-disease->UMLS:C1263846[Attention Deficit Disorder with Hyperactivity],UMLS:C0005586[Bipolar Disorder],UMLS:C0004352[autism],UMLS:C0036341[schizophrenia],
HTR4	CHRNA7	1-FACTA-related-drug->DrugBank:BIOD00057[Fragment], 2-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],kegg:path:hsa04020[Calcium signaling pathway],
HTR4	HTR1B	5-GoPubMed-related-gene->3355[HTR1F],3354[HTR1E],3362[HTR6],3361[HTR5A],3363[HTR7], 3-GoPubMed-related-GO->GO:0004993[serotonin receptor activity],GO:0008227[G-protein coupled amine receptor activity],GO:0004930[G-protein coupled receptor activity], 5-FACTA-related-gene->HUMANGGP:018007[HTR1F],HUMANGGP:016972[HTR2B],HUMANGGP:023136[HTR4],HUMANGGP:007621[HTR5A],HUMANGGP:018979[HTR3], 2-FACTA-related-disease->UMLS:C1852438[CCL],UMLS:C1263846[Attention Deficit Disorder with Hyperactivity], 3-FACTA-related-drug->DrugBank:APRD00243[CCL],DrugBank:EXPT01530[Glyceraldehyde-3-Phosphate],DrugBank:BIOD00057[Fragment], 2-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],reactome:REACT_17064[],
HTR4	FABP7	2-GoPubMed-related-gene->9293[GPR52],2844[GPR21],
HTR4	HTR7	3-GoPubMed-related-gene->3362[HTR6],3361[HTR5A],3355[HTR1F], 5-GoPubMed-related-GO->GO:0042432[indole biosynthetic process],GO:0042431[indole metabolic process],GO:0004993[serotonin receptor activity],GO:0008227[G-protein coupled amine receptor activity],GO:0004930[G-protein coupled receptor activity], 3-GoPubMed-related-disease->mesh:18589[Gastroparesis],mesh:43183[Irritable Bowel Syndrome],mesh:3109[Colonic Diseases, Functional], 5-FACTA-related-gene->HUMANGGP:018979[HTR3],HUMANGGP:016972[HTR2B],HUMANGGP:023136[HTR4],HUMANGGP:018007[HTR1F],HUMANGGP:007621[HTR5A], 7-FACTA-related-disease->UMLS:C1852438[CCL],UMLS:C0015674[chronic fatigue syndrome],UMLS:C0004352[autism],UMLS:C1263846[Attention Deficit Disorder with Hyperactivity],UMLS:C0036341[schizophrenia],UMLS:C0043167[pertussis],UMLS:C0005586[Bipolar Disorder], 3-FACTA-related-drug->DrugBank:APRD00243[CCL],DrugBank:BIOD00057[Fragment],DrugBank:APRD00691[Estradiol], 4-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],kegg:path:hsa04020[Calcium signaling pathway],reactome:REACT_19327[],reactome:REACT_17064[],
HTR5A	CHRNA7	1-GoPubMed-related-GO->GO:0022831[narrow pore, gated channel activity], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment], 2-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],kegg:path:hsa04020[Calcium signaling pathway],
HTR5A	MAOA	3-FACTA-related-gene->HUMANGGP:001711[MAOA],HUMANGGP:016972[HTR2B],HUMANGGP:007621[HTR5A], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
HTR5A	TDO2	1-GoPubMed-related-GO->GO:0042428[serotonin metabolic process], 1-GoPubMed-related-disease->mesh:5879[Tourette Syndrome], 1-FACTA-related-gene->HUMANGGP:034384[HTR1A], 6-FACTA-related-disease->UMLS:C0040517[Tourette Syndrome],UMLS:C1263846[Attention Deficit Disorder with Hyperactivity],UMLS:C0005586[Bipolar Disorder],UMLS:C0004352[autism],UMLS:C1269683[major depression],UMLS:C0812393[suicide],
HTR5A	MED12	1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
HTR5A	CNTN4	1-GoPubMed-related-GO->GO:0004872[receptor activity], 2-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0004352[autism], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
HTR5A	HTR1B	5-GoPubMed-related-gene->3352[HTR1D],3355[HTR1F],3354[HTR1E],3362[HTR6],3363[HTR7], 5-GoPubMed-related-GO->GO:0004993[serotonin receptor activity],GO:0042427[serotonin biosynthetic process],GO:0042428[serotonin metabolic process],GO:0008227[G-protein coupled amine receptor activity],GO:0004930[G-protein coupled receptor activity], 7-FACTA-related-gene->HUMANGGP:018007[HTR1F],HUMANGGP:016972[HTR2B],HUMANGGP:023136[HTR4],HUMANGGP:007621[HTR5A],HUMANGGP:034384[HTR1A],HUMANGGP:009760[HTR2A],HUMANGGP:026553[HTR2C], 1-FACTA-related-disease->UMLS:C1263846[Attention Deficit Disorder with Hyperactivity], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment], 3-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],reactome:REACT_19231[],reactome:REACT_17064[],
HTR5A	EN2	1-GoPubMed-related-disease->mesh:16142[Holoprosencephaly], 2-FACTA-related-gene->HUMANGGP:000357[HOX1],HUMANGGP:007621[HTR5A], 3-FACTA-related-disease->UMLS:C1840529[HPE3],UMLS:C0233639[Autism],UMLS:C0004352[autism], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
HTR5A	SLC6A4	1-GoPubMed-related-GO->GO:0004993[serotonin receptor activity], 5-FACTA-related-gene->HUMANGGP:009094[SLC6A4],HUMANGGP:007621[HTR5A],HUMANGGP:034384[HTR1A],HUMANGGP:009760[HTR2A],HUMANGGP:015266[HTR3B], 1-FACTA-related-disease->UMLS:C0233639[Autism], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
HTR5A	ASTN2	4-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0004352[autism],UMLS:C1263846[Attention Deficit Disorder with Hyperactivity],UMLS:C0005586[Bipolar Disorder],
HTR5A	GABRB1	3-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0004352[autism],UMLS:C0005586[Bipolar Disorder], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
HTR5A	TPH2	1-GoPubMed-related-gene->3362[HTR6], 5-GoPubMed-related-GO->GO:0042427[serotonin biosynthetic process],GO:0046219[indolalkylamine biosynthetic process],GO:0042435[indole derivative biosynthetic process],GO:0042428[serotonin metabolic process],GO:0004993[serotonin receptor activity], 3-FACTA-related-gene->HUMANGGP:008892[TPH2],HUMANGGP:002081[TPH1],HUMANGGP:034384[HTR1A], 4-FACTA-related-disease->UMLS:C1269683[major depression],UMLS:C1263846[Attention Deficit Disorder with Hyperactivity],UMLS:C0812393[suicide],UMLS:C0038663[Suicide, Attempted],
HTR5A	NRCAM	3-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0004352[autism],UMLS:C0040517[Tourette Syndrome],
HTR5A	RBMS3	1-FACTA-related-disease->UMLS:C0001807[aggression],
HTR5A	HTR7	2-GoPubMed-related-gene->3362[HTR6],3355[HTR1F], 5-GoPubMed-related-GO->GO:0042432[indole biosynthetic process],GO:0042431[indole metabolic process],GO:0004993[serotonin receptor activity],GO:0008227[G-protein coupled amine receptor activity],GO:0004930[G-protein coupled receptor activity], 6-FACTA-related-gene->HUMANGGP:016972[HTR2B],HUMANGGP:023136[HTR4],HUMANGGP:018007[HTR1F],HUMANGGP:007621[HTR5A],HUMANGGP:034384[HTR1A],HUMANGGP:015266[HTR3B], 5-FACTA-related-disease->UMLS:C0040517[Tourette Syndrome],UMLS:C0015674[chronic fatigue syndrome],UMLS:C0004352[autism],UMLS:C1263846[Attention Deficit Disorder with Hyperactivity],UMLS:C0005586[Bipolar Disorder], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment], 3-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],kegg:path:hsa04020[Calcium signaling pathway],reactome:REACT_17064[],
HTR5A	BAIAP2	1-FACTA-related-disease->UMLS:C1263846[Attention Deficit Disorder with Hyperactivity],
HTR5A	NOS1AP	2-GoPubMed-related-GO->GO:0022831[narrow pore, gated channel activity],GO:0022842[narrow pore channel activity], 2-FACTA-related-disease->UMLS:C0005586[Bipolar Disorder],UMLS:C0028768[obsessive-compulsive disorder], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
HTR5A	ATP2B2	1-FACTA-related-drug->DrugBank:BIOD00057[Fragment], 1-pathway->kegg:path:hsa04020[Calcium signaling pathway],
HTR5A	CNTNAP2	2-GoPubMed-related-GO->GO:0022831[narrow pore, gated channel activity],GO:0022842[narrow pore channel activity], 2-GoPubMed-related-disease->mesh:5879[Tourette Syndrome],mesh:13981[Tic Disorders], 3-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0004352[autism],UMLS:C0040517[Tourette Syndrome], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
HTR5A	HTR2A	4-GoPubMed-related-gene->3362[HTR6],3358[HTR2C],3355[HTR1F],3357[HTR2B], 3-GoPubMed-related-GO->GO:0004993[serotonin receptor activity],GO:0008227[G-protein coupled amine receptor activity],GO:0004930[G-protein coupled receptor activity], 2-GoPubMed-related-disease->mesh:11595[Psychomotor Agitation],mesh:7319[Sleep Initiation and Maintenance Disorders], 7-FACTA-related-gene->HUMANGGP:009760[HTR2A],HUMANGGP:007621[HTR5A],HUMANGGP:018007[HTR1F],HUMANGGP:034384[HTR1A],HUMANGGP:023136[HTR4],HUMANGGP:016972[HTR2B],HUMANGGP:026553[HTR2C], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment], 3-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],kegg:path:hsa04020[Calcium signaling pathway],reactome:REACT_17064[],
HTR5A	AUTS2	2-GoPubMed-related-disease->mesh:5879[Tourette Syndrome],mesh:13981[Tic Disorders], 3-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0004352[autism],UMLS:C0040517[Tourette Syndrome],
HTR5A	NRXN1	2-GoPubMed-related-disease->mesh:5879[Tourette Syndrome],mesh:13981[Tic Disorders], 2-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0004352[autism],
HTR5A	IMMP2L	2-GoPubMed-related-disease->mesh:5879[Tourette Syndrome],mesh:13981[Tic Disorders], 3-FACTA-related-disease->UMLS:C0040517[Tourette Syndrome],UMLS:C0233639[Autism],UMLS:C0004352[autism],
HTR5A	HTR3A	3-GoPubMed-related-gene->3360[HTR4],3362[HTR6],3355[HTR1F], 5-GoPubMed-related-GO->GO:0004993[serotonin receptor activity],GO:0042428[serotonin metabolic process],GO:0042427[serotonin biosynthetic process],GO:0022831[narrow pore, gated channel activity],GO:0022842[narrow pore channel activity], 6-FACTA-related-gene->HUMANGGP:014538[HTR3A],HUMANGGP:015266[HTR3B],HUMANGGP:023136[HTR4],HUMANGGP:016972[HTR2B],HUMANGGP:007621[HTR5A],HUMANGGP:018007[HTR1F], 3-FACTA-related-disease->UMLS:C0015674[chronic fatigue syndrome],UMLS:C0233639[Autism],UMLS:C0040517[Tourette Syndrome],
HTR6	SLC6A4	1-GoPubMed-related-GO->GO:0004993[serotonin receptor activity], 4-FACTA-related-gene->HUMANGGP:007621[HTR5A],HUMANGGP:034384[HTR1A],HUMANGGP:009760[HTR2A],HUMANGGP:015266[HTR3B], 1-FACTA-related-disease->UMLS:C0233639[Autism], 3-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:APRD00530[Portal],DrugBank:BIOD00057[Fragment],
HTR6	TPH2	5-GoPubMed-related-GO->GO:0042427[serotonin biosynthetic process],GO:0046219[indolalkylamine biosynthetic process],GO:0042435[indole derivative biosynthetic process],GO:0042428[serotonin metabolic process],GO:0004993[serotonin receptor activity], 2-GoPubMed-related-disease->mesh:15673[Fatigue Syndrome, Chronic],mesh:4679[Encephalomyelitis], 2-FACTA-related-gene->HUMANGGP:008892[TPH2],HUMANGGP:034384[HTR1A], 4-FACTA-related-disease->UMLS:C1269683[major depression],UMLS:C1263846[Attention Deficit Disorder with Hyperactivity],UMLS:C0812393[suicide],UMLS:C0525045[Mood Disorders], 4-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:APRD00530[Portal],DrugBank:APRD00396[Estrogens],DrugBank:APRD00691[Estradiol],
HTR6	HTR2A	4-GoPubMed-related-gene->3361[HTR5A],3358[HTR2C],3355[HTR1F],3357[HTR2B], 3-GoPubMed-related-GO->GO:0004993[serotonin receptor activity],GO:0008227[G-protein coupled amine receptor activity],GO:0004930[G-protein coupled receptor activity], 1-GoPubMed-related-disease->mesh:4409[Dyskinesia, Drug-Induced], 8-FACTA-related-gene->HUMANGGP:009760[HTR2A],HUMANGGP:007621[HTR5A],HUMANGGP:018007[HTR1F],HUMANGGP:034384[HTR1A],HUMANGGP:023136[HTR4],HUMANGGP:016972[HTR2B],HUMANGGP:026553[HTR2C],HUMANGGP:018979[HTR3], 4-FACTA-related-disease->UMLS:C0233469[blunted affect],UMLS:C0018609[Hartnup Disease],UMLS:C1852438[CCL],UMLS:C0686347[tardive dyskinesia], 4-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:APRD00243[CCL],DrugBank:BIOD00057[Fragment],DrugBank:APRD00530[Portal], 3-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],kegg:path:hsa04020[Calcium signaling pathway],reactome:REACT_17064[],
HTR6	BAIAP2	1-FACTA-related-disease->UMLS:C1263846[Attention Deficit Disorder with Hyperactivity],
HTR6	HTR7	2-GoPubMed-related-gene->3361[HTR5A],3355[HTR1F], 5-GoPubMed-related-GO->GO:0042432[indole biosynthetic process],GO:0042431[indole metabolic process],GO:0004993[serotonin receptor activity],GO:0008227[G-protein coupled amine receptor activity],GO:0004930[G-protein coupled receptor activity], 9-FACTA-related-gene->HUMANGGP:018979[HTR3],HUMANGGP:016972[HTR2B],HUMANGGP:004507[adenylate cyclase-coupled],HUMANGGP:023136[HTR4],HUMANGGP:018007[HTR1F],HUMANGGP:007621[HTR5A],HUMANGGP:034384[HTR1A],HUMANGGP:015266[HTR3B],HUMANGGP:035969[somatostatin receptor 3], 5-FACTA-related-disease->UMLS:C1852438[CCL],UMLS:C0015674[chronic fatigue syndrome],UMLS:C0004352[autism],UMLS:C1263846[Attention Deficit Disorder with Hyperactivity],UMLS:C0036341[schizophrenia], 3-FACTA-related-drug->DrugBank:APRD00243[CCL],DrugBank:BIOD00057[Fragment],DrugBank:APRD00691[Estradiol], 4-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],kegg:path:hsa04020[Calcium signaling pathway],reactome:REACT_19327[],reactome:REACT_17064[],
HTR6	ADORA2A	1-GoPubMed-related-disease->mesh:4409[Dyskinesia, Drug-Induced], 1-FACTA-related-disease->UMLS:C0233639[Autism], 2-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00691[Estradiol], 3-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],kegg:path:hsa04020[Calcium signaling pathway],reactome:REACT_19327[],
HTR6	ARNT2	2-FACTA-related-drug->DrugBank:APRD00396[Estrogens],DrugBank:APRD00691[Estradiol],
HTR6	GRIN2B	1-GoPubMed-related-disease->mesh:4409[Dyskinesia, Drug-Induced], 2-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:BIOD00057[Fragment], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
HTR6	DRD3	1-GoPubMed-related-disease->mesh:4409[Dyskinesia, Drug-Induced], 3-FACTA-related-disease->UMLS:C0686347[tardive dyskinesia],UMLS:C0233469[blunted affect],UMLS:C0013386[Dyskinesia, Drug-Induced], 3-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:BIOD00057[Fragment],DrugBank:APRD00530[Portal],
HTR6	HTR3A	3-GoPubMed-related-gene->3360[HTR4],3361[HTR5A],3355[HTR1F], 3-GoPubMed-related-GO->GO:0004993[serotonin receptor activity],GO:0042428[serotonin metabolic process],GO:0042427[serotonin biosynthetic process], 7-FACTA-related-gene->HUMANGGP:014538[HTR3A],HUMANGGP:015266[HTR3B],HUMANGGP:018979[HTR3],HUMANGGP:023136[HTR4],HUMANGGP:016972[HTR2B],HUMANGGP:007621[HTR5A],HUMANGGP:018007[HTR1F], 2-FACTA-related-disease->UMLS:C0015674[chronic fatigue syndrome],UMLS:C0233639[Autism], 1-FACTA-related-drug->DrugBank:APRD01072[HCH],
HTR6	MBD1	1-FACTA-related-disease->UMLS:C0233639[Autism], 1-FACTA-related-drug->DrugBank:APRD00530[Portal],
HTR6	NLGN1	1-GoPubMed-related-disease->mesh:8569[Memory Disorders], 3-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0004352[autism],UMLS:C1269683[major depression],
HTR6	DISC1	1-GoPubMed-related-disease->mesh:6212[Hallucinations], 1-FACTA-related-disease->UMLS:C0036341[schizophrenia], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
HTR6	NPAS2	1-FACTA-related-disease->UMLS:C0233639[Autism], 1-FACTA-related-drug->DrugBank:APRD00530[Portal],
HTR6	MAOA	2-FACTA-related-gene->HUMANGGP:016972[HTR2B],HUMANGGP:007621[HTR5A], 3-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:BIOD00057[Fragment],DrugBank:APRD00530[Portal],
HTR6	CHRNA7	2-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:BIOD00057[Fragment], 2-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],kegg:path:hsa04020[Calcium signaling pathway],
HTR6	HTR1B	4-GoPubMed-related-gene->3355[HTR1F],3354[HTR1E],3361[HTR5A],3363[HTR7], 5-GoPubMed-related-GO->GO:0004993[serotonin receptor activity],GO:0042427[serotonin biosynthetic process],GO:0042428[serotonin metabolic process],GO:0008227[G-protein coupled amine receptor activity],GO:0004930[G-protein coupled receptor activity], 8-FACTA-related-gene->HUMANGGP:018007[HTR1F],HUMANGGP:016972[HTR2B],HUMANGGP:023136[HTR4],HUMANGGP:007621[HTR5A],HUMANGGP:034384[HTR1A],HUMANGGP:018979[HTR3],HUMANGGP:009760[HTR2A],HUMANGGP:026553[HTR2C], 3-FACTA-related-disease->UMLS:C0018609[Hartnup Disease],UMLS:C1852438[CCL],UMLS:C1263846[Attention Deficit Disorder with Hyperactivity], 4-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:APRD00243[CCL],DrugBank:BIOD00057[Fragment],DrugBank:APRD00530[Portal], 2-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],reactome:REACT_17064[],
HTR6	ASTN2	4-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0004352[autism],UMLS:C1263846[Attention Deficit Disorder with Hyperactivity],UMLS:C0036341[schizophrenia],
HTR6	TDO2	2-GoPubMed-related-GO->GO:0042430[indole and derivative metabolic process],GO:0042428[serotonin metabolic process], 2-FACTA-related-gene->HUMANGGP:034384[HTR1A],HUMANGGP:004507[adenylate cyclase-coupled], 5-FACTA-related-disease->UMLS:C1263846[Attention Deficit Disorder with Hyperactivity],UMLS:C0004352[autism],UMLS:C0036341[schizophrenia],UMLS:C1269683[major depression],UMLS:C0812393[suicide],
HTR6	RIMS3	2-FACTA-related-disease->UMLS:C0004352[autism],UMLS:C0036341[schizophrenia],
HTR6	ABAT	1-GoPubMed-related-disease->mesh:4409[Dyskinesia, Drug-Induced], 3-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0686347[tardive dyskinesia],UMLS:C0013386[Dyskinesia, Drug-Induced], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
HTR6	GABRA4	5-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0686347[tardive dyskinesia],UMLS:C0004352[autism],UMLS:C0013386[Dyskinesia, Drug-Induced],UMLS:C0525045[Mood Disorders], 1-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],
HTR6	OXTR	1-FACTA-related-gene->HUMANGGP:016972[HTR2B], 2-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0004352[autism], 3-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:APRD00396[Estrogens],DrugBank:APRD00691[Estradiol], 2-pathway->kegg:path:hsa04080[Neuroactive ligand-receptor interaction],kegg:path:hsa04020[Calcium signaling pathway],
IMPA2	PLCD1	3-pathway->kegg:path:hsa01100[Metabolic pathways],kegg:path:hsa00562[Inositol phosphate metabolism],kegg:path:hsa04070[Phosphatidylinositol signaling system],
IMPA2	TPH2	3-GoPubMed-related-gene->9145[SYNGR1],23316[CUX2],57132[CHMP1B], 4-FACTA-related-gene->HUMANGGP:036486[SYNGR1],HUMANGGP:014007[CUX2],HUMANGGP:022732[NAPG],HUMANGGP:010722[GRM4], 2-FACTA-related-disease->UMLS:C0085633[mood swings],UMLS:C0525045[Mood Disorders], 1-FACTA-related-drug->DrugBank:APRD00280[Frontal], 1-pathway->kegg:path:hsa01100[Metabolic pathways],
IMPA2	NOS1AP	1-GoPubMed-related-gene->8890[EIF2B4], 9-GoPubMed-related-GO->GO:0060292[long term synaptic depression],GO:0051970[negative regulation of transmission of nerve impulse],GO:0050805[negative regulation of synaptic transmission],GO:0031645[negative regulation of neurological system process],GO:0010648[negative regulation of cell communication],GO:0022831[narrow pore, gated channel activity],GO:0004972[N-methyl-D-aspartate selective glutamate receptor activity],GO:0004970[ionotropic glutamate receptor activity],GO:0008066[glutamate receptor activity], 2-FACTA-related-gene->HUMANGGP:004111[DPYSL2],HUMANGGP:010722[GRM4], 2-FACTA-related-disease->UMLS:C0036341[schizophrenia],UMLS:C0005586[Bipolar Disorder],
IMPA2	GRIN2B	3-GoPubMed-related-GO->GO:0004972[N-methyl-D-aspartate selective glutamate receptor activity],GO:0004970[ionotropic glutamate receptor activity],GO:0008066[glutamate receptor activity], 7-FACTA-related-gene->HUMANGGP:010722[GRM4],HUMANGGP:036486[SYNGR1],HUMANGGP:004111[DPYSL2],HUMANGGP:004451[EIF2],HUMANGGP:014007[CUX2],HUMANGGP:022732[NAPG],HUMANGGP:010429[IMPA2],
IMPA2	FOXP2	1-FACTA-related-drug->DrugBank:APRD00280[Frontal],
IMPA2	RIMS3	2-FACTA-related-disease->UMLS:C0004352[autism],UMLS:C0036341[schizophrenia],
IMPA2	SLC1A1	2-GoPubMed-related-GO->GO:0004972[N-methyl-D-aspartate selective glutamate receptor activity],GO:0004970[ionotropic glutamate receptor activity], 1-FACTA-related-disease->UMLS:C0004352[autism], 1-FACTA-related-drug->DrugBank:APRD00280[Frontal],
IMPA2	DISC1	1-FACTA-related-gene->HUMANGGP:036486[SYNGR1], 2-FACTA-related-disease->UMLS:C0036341[schizophrenia],UMLS:C0005586[Bipolar Disorder], 1-FACTA-related-drug->DrugBank:APRD00280[Frontal],
IMPA2	ANKRD11	1-GoPubMed-related-GO->GO:0004047[aminomethyltransferase activity], 2-GoPubMed-related-disease->mesh:7169[Impetigo],mesh:13207[Staphylococcal Skin Infections], 1-FACTA-related-disease->UMLS:C0004352[autism],
IMPA2	PTEN	2-pathway->kegg:path:hsa00562[Inositol phosphate metabolism],kegg:path:hsa04070[Phosphatidylinositol signaling system],
IMPA2	REEP3	2-FACTA-related-disease->UMLS:C0004352[autism],UMLS:C0004936[Mental Disorders],
IMPA2	TDO2	3-FACTA-related-disease->UMLS:C0005586[Bipolar Disorder],UMLS:C0004352[autism],UMLS:C0036341[schizophrenia], 1-FACTA-related-drug->DrugBank:APRD00280[Frontal], 1-pathway->kegg:path:hsa01100[Metabolic pathways],
IMPA2	RELN	1-FACTA-related-drug->DrugBank:APRD00280[Frontal],
IMPA2	CACNA1H	2-GoPubMed-related-disease->mesh:4832[Epilepsy, Absence],mesh:3294[Seizures, Febrile], 2-FACTA-related-disease->UMLS:C0004352[autism],UMLS:C0014556[Epilepsy, Temporal Lobe],
IMPA2	HMGN1	1-GoPubMed-related-disease->mesh:17192[Skin Diseases, Bacterial],
IMPA2	CACNA1G	1-GoPubMed-related-disease->mesh:4832[Epilepsy, Absence],
KCNJ2	CACNA1G	2-GoPubMed-related-GO->GO:0022843[voltage-gated cation channel activity],GO:0005244[voltage-gated ion channel activity], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
KCNJ2	DMPK	1-GoPubMed-related-disease->mesh:20513[Paralysis, Hyperkalemic Periodic], 1-FACTA-related-drug->DrugBank:APRD00506[Spectrum],
KCNJ2	CA6	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
KCNJ2	DHCR7	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
KCNJ2	NTRK1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
KCNJ2	CHD7	2-GoPubMed-related-GO->GO:0022843[voltage-gated cation channel activity],GO:0005244[voltage-gated ion channel activity], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
KCNJ2	CACNA1C	5-GoPubMed-related-GO->GO:0005267[potassium channel activity],GO:0022843[voltage-gated cation channel activity],GO:0005244[voltage-gated ion channel activity],GO:0007520[myoblast fusion],GO:0014902[myotube differentiation], 3-GoPubMed-related-disease->mesh:29593[Jervell-Lange Nielsen Syndrome],mesh:53447[Channelopathies],mesh:8133[Long QT Syndrome], 2-FACTA-related-disease->UMLS:C1859062[LQT3],UMLS:C0035828[LQT1],
KCNJ2	KCNJ10	2-GoPubMed-related-GO->GO:0006813[potassium ion transport],GO:0022831[narrow pore, gated channel activity], 1-FACTA-related-gene->HUMANGGP:038452[KCNJ16], 1-pathway->kegg:path:hsa04971[Gastric acid secretion],
KCNJ2	CNTNAP2	2-GoPubMed-related-GO->GO:0022831[narrow pore, gated channel activity],GO:0022842[narrow pore channel activity], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
KCNJ2	NSD1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
KCNJ2	CACNA1D	2-GoPubMed-related-GO->GO:0022843[voltage-gated cation channel activity],GO:0005244[voltage-gated ion channel activity], 3-GoPubMed-related-disease->mesh:20514[Hypokalemic Periodic Paralysis],mesh:10245[Paralyses, Familial Periodic],mesh:8133[Long QT Syndrome],
KCNJ2	PLN	1-GoPubMed-related-gene->388591[RNF207], 2-FACTA-related-gene->HUMANGGP:017027[SETD6],HUMANGGP:015905[CNOT1],
KCNJ2	HOXB1	2-GoPubMed-related-disease->mesh:20513[Paralysis, Hyperkalemic Periodic],mesh:10245[Paralyses, Familial Periodic], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
KCNJ2	AHI1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
KCNJ2	ROBO1	1-GoPubMed-related-disease->mesh:6011[Glycogen Storage Disease Type IV],
KCNJ2	NOS1AP	2-GoPubMed-related-gene->388591[RNF207],144245[ALG10B], 2-GoPubMed-related-GO->GO:0022831[narrow pore, gated channel activity],GO:0022842[narrow pore channel activity], 1-GoPubMed-related-disease->mesh:8133[Long QT Syndrome], 4-FACTA-related-gene->HUMANGGP:017027[SETD6],HUMANGGP:015905[CNOT1],HUMANGGP:037602[ALG10],HUMANGGP:010047[SCN4B],
KCNJ9	CACNA1G	1-GoPubMed-related-disease->mesh:4829[Epilepsy, Generalized], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
KCNJ9	LRRC1	1-GoPubMed-related-GO->GO:0005488[binding], 2-GoPubMed-related-disease->mesh:4829[Epilepsy, Generalized],mesh:4827[Epilepsy], 1-FACTA-related-disease->UMLS:C0014544[epilepsy], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
KCNJ9	GABRA4	2-GoPubMed-related-disease->mesh:4833[Epilepsy, Temporal Lobe],mesh:4828[Epilepsies, Partial], 1-FACTA-related-disease->UMLS:C0014556[Epilepsy, Temporal Lobe],
KCNJ9	NTRK1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
KCNJ9	CA6	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
KCNJ9	DHCR7	3-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
KCNJ9	CHD7	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
KCNJ9	NLGN4X	1-GoPubMed-related-GO->GO:0005515[protein binding], 1-FACTA-related-disease->UMLS:C0014544[epilepsy], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
KCNJ9	RGS7	1-FACTA-related-disease->UMLS:C0038587[Substance Withdrawal Syndrome],
KCNJ9	FLT1	2-FACTA-related-drug->DrugBank:APRD00174[Clonidine],DrugBank:BIOD00057[Fragment],
KCNJ9	KCNJ10	2-GoPubMed-related-gene->3772[KCNJ15],89822[KCNK17], 1-GoPubMed-related-GO->GO:0022831[narrow pore, gated channel activity], 2-FACTA-related-gene->HUMANGGP:012779[KCNJ10],HUMANGGP:005512[H326], 1-FACTA-related-disease->UMLS:C0014548[Epilepsy, Generalized], 2-FACTA-related-drug->DrugBank:APRD00174[Clonidine],DrugBank:BIOD00057[Fragment],
KCNJ9	CNTNAP2	2-GoPubMed-related-GO->GO:0022831[narrow pore, gated channel activity],GO:0022842[narrow pore channel activity], 3-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
KCNJ9	CREBBP	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
KCNJ9	CACNA1D	4-FACTA-related-disease->UMLS:C0347284[Pancreas],UMLS:C0030286[Pancreas],UMLS:C0011860[type 2 diabetes],UMLS:C0011849[diabetes],
KCNJ9	SCN1A	2-GoPubMed-related-GO->GO:0022831[narrow pore, gated channel activity],GO:0022842[narrow pore channel activity], 2-GoPubMed-related-disease->mesh:3294[Seizures, Febrile],mesh:4829[Epilepsy, Generalized], 1-FACTA-related-gene->HUMANGGP:017114[ATP1A2], 3-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
KCNJ9	CACNA1H	3-GoPubMed-related-disease->mesh:4829[Epilepsy, Generalized],mesh:3294[Seizures, Febrile],mesh:4827[Epilepsy], 3-FACTA-related-disease->UMLS:C0014548[Epilepsy, Generalized],UMLS:C0014544[epilepsy],UMLS:C0014556[Epilepsy, Temporal Lobe],
LDB1	TNIP2	2-GoPubMed-related-disease->mesh:10580[Peutz-Jeghers Syndrome],mesh:7911[Lentigo],
LDB1	CNTNAP2	2-GoPubMed-related-GO->GO:0030274[LIM domain binding],GO:0019904[protein domain specific binding], 1-GoPubMed-related-disease->mesh:7805[Language Development Disorders], 1-FACTA-related-gene->HUMANGGP:034980[LIM domain only 4],
LDB1	RAI1	2-GoPubMed-related-disease->mesh:7805[Language Development Disorders],mesh:11596[Psychomotor Disorders], 3-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00631[Gel],
LDB1	TBX1	4-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:EXPT02079[lysine],DrugBank:APRD00631[Gel],
LDB1	GNAS	5-FACTA-related-drug->DrugBank:APRD00134[Activin],DrugBank:BIOD00001[DNase I],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:EXPT02079[lysine],
LDB1	MARK1	1-GoPubMed-related-GO->GO:0033868[Goodpasture-antigen-binding protein kinase activity], 2-GoPubMed-related-disease->mesh:10580[Peutz-Jeghers Syndrome],mesh:7911[Lentigo], 2-FACTA-related-disease->UMLS:C0031269[Peutz-Jeghers syndrome],UMLS:C1326912[tumorigenesis], 2-FACTA-related-drug->DrugBank:EXPT02079[lysine],DrugBank:APRD00631[Gel],
LDB1	NSD1	2-GoPubMed-related-disease->mesh:7805[Language Development Disorders],mesh:7859[Learning Disorders], 3-FACTA-related-drug->DrugBank:EXPT02079[lysine],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
LDB1	NFIA	2-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
LDB1	DLX2	2-GoPubMed-related-GO->GO:0030900[forebrain development],GO:0003677[DNA binding], 5-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:BIOD00001[DNase I],DrugBank:APRD00017[Tretinoin],DrugBank:EXPT02079[lysine],DrugBank:APRD00631[Gel],
LDB1	PINX1	1-GoPubMed-related-gene->51132[RLIM], 1-FACTA-related-disease->UMLS:C1326912[tumorigenesis], 4-FACTA-related-drug->DrugBank:BIOD00001[DNase I],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:EXPT02079[lysine],
LDB1	NLGN4Y	2-GoPubMed-related-disease->mesh:7859[Learning Disorders],mesh:3147[Communication Disorders],
LDB1	NDNL2	2-GoPubMed-related-disease->mesh:7805[Language Development Disorders],mesh:3147[Communication Disorders],
LDB1	DLX6	3-GoPubMed-related-GO->GO:0030900[forebrain development],GO:0003677[DNA binding],GO:0003676[nucleic acid binding], 2-FACTA-related-drug->DrugBank:BIOD00001[DNase I],DrugBank:APRD00140[Tretinoin],
LDB1	PITX1	4-FACTA-related-drug->DrugBank:APRD00134[Activin],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:EXPT02079[lysine],
LDB1	RELN	4-FACTA-related-drug->DrugBank:BIOD00001[DNase I],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00631[Gel],
LDB1	ROBO1	3-GoPubMed-related-disease->mesh:7859[Learning Disorders],mesh:7805[Language Development Disorders],mesh:3147[Communication Disorders],
LDB1	DLX1	1-FACTA-related-disease->UMLS:C0023440[erythroleukemia], 3-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:BIOD00001[DNase I],DrugBank:APRD00017[Tretinoin],
LRPAP1	AHI1	1-FACTA-related-drug->DrugBank:APRD00552[Spectrum],
LRPAP1	NTRK1	2-FACTA-related-drug->DrugBank:APRD00552[Spectrum],DrugBank:APRD00691[Estradiol],
LRPAP1	DAB1	3-GoPubMed-related-GO->GO:0030229[very-low-density lipoprotein receptor activity],GO:0034189[very-low-density lipoprotein binding],GO:0030228[lipoprotein receptor activity], 1-FACTA-related-disease->UMLS:C1704378[Heymann nephritis], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment], 1-pathway->nci_nature_pid:Reelin_signaling_pathway[],
LRPAP1	SLC30A5	1-FACTA-related-drug->DrugBank:APRD00691[Estradiol],
LRPAP1	SLC1A1	1-GoPubMed-related-disease->mesh:20201[Brain Hemorrhage, Traumatic],
LRPAP1	CNTNAP2	2-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00552[Spectrum],
LRPAP1	NBEA	1-FACTA-related-disease->UMLS:C0023015[Language Disorders],
LRPAP1	HSD11B1	6-FACTA-related-gene->HUMANGGP:034915[APBB2],HUMANGGP:014690[FE65L2],HUMANGGP:019767[SOAT1],HUMANGGP:037589[TFCP2],HUMANGGP:012295[cholesterol 25-hydroxylase],HUMANGGP:040363[LRP8], 2-FACTA-related-disease->UMLS:C1862639[APOA1],UMLS:C1847047[LDLR],
LRPAP1	GRIN2B	1-FACTA-related-drug->DrugBank:BIOD00057[Fragment], 1-pathway->nci_nature_pid:Reelin_signaling_pathway[],
LRPAP1	CNTNAP5	1-FACTA-related-disease->UMLS:C0023015[Language Disorders],
LRPAP1	RELN	3-GoPubMed-related-GO->GO:0047362[thiosulfate-dithiol sulfurtransferase activity],GO:0030229[very-low-density lipoprotein receptor activity],GO:0034189[very-low-density lipoprotein binding], 1-pathway->nci_nature_pid:Reelin_signaling_pathway[],
LRPAP1	ATP2B2	1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
LRPAP1	GABRB1	1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
LRPAP1	FEZF2	1-GoPubMed-related-disease->mesh:18785[Tricuspid Atresia],
LRPAP1	HTR2A	1-GoPubMed-related-disease->mesh:4489[Edema, Cardiac], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
LRPAP1	MED12	1-GoPubMed-related-gene->9440[MED17], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
LRPAP1	NSD1	1-FACTA-related-disease->UMLS:C0795810[Wolf-Hirschhorn syndrome], 1-FACTA-related-drug->DrugBank:APRD00552[Spectrum],
LRPAP1	PLCD1	1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
LRPAP1	LRRC1	1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
LRRN1	CDH8	1-GoPubMed-related-GO->GO:0005488[binding],
LRRN1	NRCAM	1-GoPubMed-related-gene->54674[LRRN3], 1-FACTA-related-gene->HUMANGGP:027101[LRRN3], 2-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0004352[autism],
LRRN1	RBMS3	1-GoPubMed-related-GO->GO:0005488[binding],
LRRN1	NLGN4Y	1-GoPubMed-related-GO->GO:0005488[binding], 3-FACTA-related-disease->UMLS:C0004352[autism],UMLS:C0917816[mental retardation],UMLS:C0025362[Mental Retardation],
LRRN1	FBXO33	5-GoPubMed-related-GO->GO:0012501[programmed cell death],GO:0008219[cell death],GO:0016265[death],GO:0009987[cellular process],GO:0005488[binding],
LRRN1	CDH9	1-GoPubMed-related-GO->GO:0005488[binding], 1-GoPubMed-related-disease->mesh:267[Adhesions], 2-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0004352[autism],
LRRN1	FBXO40	1-FACTA-related-gene->HUMANGGP:028761[CNTN4], 3-FACTA-related-disease->UMLS:C1510586[Autism spectrum disorder],UMLS:C0233639[Autism],UMLS:C0004352[autism],
LRRN1	DPP6	1-GoPubMed-related-GO->GO:0005488[binding], 4-FACTA-related-disease->UMLS:C1510586[Autism spectrum disorder],UMLS:C0233639[Autism],UMLS:C0004352[autism],UMLS:C0917816[mental retardation],
LRRN1	CNTN4	4-FACTA-related-gene->HUMANGGP:028761[CNTN4],HUMANGGP:016267[LRRN1],HUMANGGP:024523[ITPR1],HUMANGGP:035007[MEGAP], 8-FACTA-related-disease->UMLS:C0795806[3p- syndrome],UMLS:C1510586[Autism spectrum disorder],UMLS:C0152021[Congenital heart disease],UMLS:C0233639[Autism],UMLS:C0004352[autism],UMLS:C0917816[mental retardation],UMLS:C0018816[Heart Septal Defects],UMLS:C0033377[prolapse],
LRRN1	CAMTA1	1-GoPubMed-related-GO->GO:0005488[binding], 4-GoPubMed-related-disease->mesh:9447[Neuroblastoma],mesh:18241[Neuroectodermal Tumors, Primitive, Peripheral],mesh:18242[Neuroectodermal Tumors, Primitive],mesh:18302[Neoplasms, Neuroepithelial], 1-FACTA-related-disease->UMLS:C0917816[mental retardation],
LRRN1	ASTN2	1-GoPubMed-related-GO->GO:0009987[cellular process], 1-FACTA-related-gene->HUMANGGP:028761[CNTN4], 3-FACTA-related-disease->UMLS:C1510586[Autism spectrum disorder],UMLS:C0233639[Autism],UMLS:C0004352[autism],
LRRN1	NBEA	1-GoPubMed-related-GO->GO:0005488[binding], 2-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0004352[autism],
LRRN1	ARHGAP15	2-GoPubMed-related-GO->GO:0009987[cellular process],GO:0005488[binding], 2-FACTA-related-disease->UMLS:C0025362[Mental Retardation],UMLS:C0039082[Syndrome],
LRRN1	NLGN1	1-GoPubMed-related-GO->GO:0005488[binding], 1-GoPubMed-related-disease->mesh:267[Adhesions], 1-FACTA-related-gene->HUMANGGP:028761[CNTN4], 4-FACTA-related-disease->UMLS:C1510586[Autism spectrum disorder],UMLS:C0233639[Autism],UMLS:C0004352[autism],UMLS:C0917816[mental retardation],
LRRN1	MARK1	3-FACTA-related-disease->UMLS:C1510586[Autism spectrum disorder],UMLS:C0233639[Autism],UMLS:C0004352[autism],
LRRN1	GPR139	1-GoPubMed-related-GO->GO:0005488[binding],
LRRN1	GRID2	1-GoPubMed-related-GO->GO:0005488[binding],
LRRN3	NRCAM	2-FACTA-related-gene->HUMANGGP:035843[NRCAM],HUMANGGP:027101[LRRN3], 3-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0001511[Adhesion],UMLS:C0004352[autism],
LRRN3	CDH8	1-GoPubMed-related-GO->GO:0005488[binding], 2-FACTA-related-disease->UMLS:C0596263[carcinogenesis],UMLS:C0027651[tumor],
LRRN3	RBMS3	1-GoPubMed-related-GO->GO:0005488[binding], 1-FACTA-related-disease->UMLS:C0027651[tumor],
LRRN3	CDH10	3-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0004352[autism],UMLS:C0001511[Adhesion],
LRRN3	RHOXF1	1-GoPubMed-related-GO->GO:0005488[binding], 2-FACTA-related-disease->UMLS:C0596263[carcinogenesis],UMLS:C0027651[tumor],
LRRN3	FBXO33	5-GoPubMed-related-GO->GO:0012501[programmed cell death],GO:0008219[cell death],GO:0016265[death],GO:0009987[cellular process],GO:0005488[binding], 1-FACTA-related-gene->HUMANGGP:004403[Polymerase],
LRRN3	MACROD2	3-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0004352[autism],UMLS:C0027651[tumor],
LRRN3	CDH9	1-GoPubMed-related-GO->GO:0005488[binding], 1-GoPubMed-related-disease->mesh:267[Adhesions], 3-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0004352[autism],UMLS:C0001511[Adhesion],
LRRN3	FBXO40	1-GoPubMed-related-disease->mesh:20022[Genetic Predisposition to Disease], 1-FACTA-related-gene->HUMANGGP:004403[Polymerase], 4-FACTA-related-disease->UMLS:C1510586[Autism spectrum disorder],UMLS:C0233639[Autism],UMLS:C0004352[autism],UMLS:C0001511[Adhesion],
LRRN3	DPP6	1-GoPubMed-related-GO->GO:0005488[binding], 3-FACTA-related-disease->UMLS:C1510586[Autism spectrum disorder],UMLS:C0233639[Autism],UMLS:C0004352[autism],
LRRN3	BZRAP1	1-GoPubMed-related-GO->GO:0005488[binding], 2-GoPubMed-related-disease->mesh:20022[Genetic Predisposition to Disease],mesh:4198[Disease Susceptibility], 2-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0004352[autism],
LRRN3	CAMTA1	1-GoPubMed-related-GO->GO:0005488[binding], 4-GoPubMed-related-disease->mesh:9447[Neuroblastoma],mesh:18241[Neuroectodermal Tumors, Primitive, Peripheral],mesh:18242[Neuroectodermal Tumors, Primitive],mesh:18302[Neoplasms, Neuroepithelial],
LRRN3	ASTN2	1-GoPubMed-related-GO->GO:0009987[cellular process], 2-GoPubMed-related-disease->mesh:20022[Genetic Predisposition to Disease],mesh:4198[Disease Susceptibility], 5-FACTA-related-disease->UMLS:C1510586[Autism spectrum disorder],UMLS:C0233639[Autism],UMLS:C0004352[autism],UMLS:C0001511[Adhesion],UMLS:C0027651[tumor],
LRRN3	NLGN1	1-GoPubMed-related-GO->GO:0005488[binding], 1-GoPubMed-related-disease->mesh:267[Adhesions], 4-FACTA-related-disease->UMLS:C1510586[Autism spectrum disorder],UMLS:C0233639[Autism],UMLS:C0004352[autism],UMLS:C0001511[Adhesion],
LRRN3	ARHGAP15	2-GoPubMed-related-GO->GO:0009987[cellular process],GO:0005488[binding], 1-FACTA-related-disease->UMLS:C0596263[carcinogenesis],
LRRN3	MARK1	5-FACTA-related-disease->UMLS:C1510586[Autism spectrum disorder],UMLS:C0233639[Autism],UMLS:C0004352[autism],UMLS:C0031511[pheochromocytoma],UMLS:C0596263[carcinogenesis],
LRRN3	NLGN4Y	1-GoPubMed-related-GO->GO:0005488[binding], 1-FACTA-related-disease->UMLS:C0004352[autism],
LRRN3	GPR139	1-GoPubMed-related-GO->GO:0005488[binding],
LRRN3	NBEA	1-GoPubMed-related-GO->GO:0005488[binding], 2-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0004352[autism],
LRRN3	GRID2	1-GoPubMed-related-GO->GO:0005488[binding],
MAP1B	DAPK1	3-FACTA-related-drug->DrugBank:APRD00017[Tretinoin],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00627[Progesterone], 1-pathway->nci_nature_pid:Netrin-mediated_signaling_events[],
MAP1B	PITX1	5-FACTA-related-drug->DrugBank:APRD00134[Activin],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:EXPT02079[lysine],DrugBank:APRD00627[Progesterone],
MAP1B	DISC1	1-FACTA-related-disease->UMLS:C1843916[LIS1], 6-FACTA-related-drug->DrugBank:EXPT01530[Glyceraldehyde-3-Phosphate],DrugBank:APRD00280[Frontal],DrugBank:BIOD00057[Fragment],DrugBank:EXPT02079[lysine],DrugBank:APRD00627[Progesterone],DrugBank:APRD00631[Gel],
MAP1B	HDAC4	6-FACTA-related-drug->DrugBank:APRD00764[Orphan],DrugBank:EXPT02079[lysine],DrugBank:APRD00369[ROS],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00627[Progesterone],
MAP1B	CREBBP	1-GoPubMed-related-disease->mesh:12183[Retrograde Degeneration], 1-FACTA-related-disease->UMLS:C1861305[TCC], 3-FACTA-related-drug->DrugBank:BIOD00001[DNase I],DrugBank:EXPT02079[lysine],DrugBank:APRD00627[Progesterone],
MAP1B	NSD1	4-FACTA-related-drug->DrugBank:APRD00162[MRC],DrugBank:EXPT02079[lysine],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
MAP1B	SLC1A1	4-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00280[Frontal],DrugBank:APRD00627[Progesterone],
MAP1B	MAP2	2-GoPubMed-related-gene->23288[IQCE],4130[MAP1A], 6-GoPubMed-related-GO->GO:0032466[negative regulation of cytokinesis],GO:0008017[microtubule binding],GO:0015631[tubulin binding],GO:0043014[alpha-tubulin binding],GO:0043621[protein self-association],GO:0008092[cytoskeletal protein binding], 1-GoPubMed-related-disease->mesh:12183[Retrograde Degeneration], 2-FACTA-related-gene->HUMANGGP:011667[MAP1A],HUMANGGP:006474[MAP1B], 3-FACTA-related-disease->UMLS:C0431380[Cortical dysplasia],UMLS:C0018835[Heartwater Disease],UMLS:C0949664[Tauopathies], 3-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:EXPT02391[Quinolinic Acid],DrugBank:APRD00017[Tretinoin],
MAP1B	DAB1	1-FACTA-related-disease->UMLS:C1843916[LIS1], 4-FACTA-related-drug->DrugBank:APRD00764[Orphan],DrugBank:BIOD00057[Fragment],DrugBank:APRD00627[Progesterone],DrugBank:APRD00631[Gel], 1-pathway->nci_nature_pid:Reelin_signaling_pathway[],
MAP1B	TDO2	3-FACTA-related-drug->DrugBank:EXPT02391[Quinolinic Acid],DrugBank:APRD00280[Frontal],DrugBank:APRD00631[Gel],
MAP1B	LAMB1	1-GoPubMed-related-disease->mesh:20240[Apraxia, Ideomotor], 5-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:BIOD00001[DNase I],DrugBank:APRD00017[Tretinoin],DrugBank:BIOD00057[Fragment],DrugBank:APRD00631[Gel],
MAP1B	CA6	5-FACTA-related-drug->DrugBank:APRD00162[MRC],DrugBank:BIOD00001[DNase I],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00631[Gel],
MAP1B	FMR1	2-FACTA-related-gene->HUMANGGP:005638[PPP1R9B],HUMANGGP:002294[UNC13B], 6-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:EXPT01530[Glyceraldehyde-3-Phosphate],DrugBank:EXPT02079[lysine],DrugBank:BIOD00001[DNase I],DrugBank:APRD00631[Gel],DrugBank:APRD00280[Frontal],
MAP1B	RELN	1-FACTA-related-gene->HUMANGGP:007468[TBCB], 1-FACTA-related-disease->UMLS:C1843916[LIS1], 5-FACTA-related-drug->DrugBank:BIOD00001[DNase I],DrugBank:APRD00280[Frontal],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00631[Gel], 2-pathway->nci_nature_pid:Reelin_signaling_pathway[],nci_nature_pid:Lissencephaly_gene_(LIS1)_in_neuronal_migration_and_development[],
MAP1B	DCX	3-GoPubMed-related-GO->GO:0008017[microtubule binding],GO:0015631[tubulin binding],GO:0008092[cytoskeletal protein binding], 1-FACTA-related-disease->UMLS:C1843916[LIS1], 3-FACTA-related-drug->DrugBank:EXPT02391[Quinolinic Acid],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin], 1-pathway->nci_nature_pid:Lissencephaly_gene_(LIS1)_in_neuronal_migration_and_development[],
MAP1B	GRIN2B	4-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:EXPT02079[lysine],DrugBank:APRD00627[Progesterone],DrugBank:APRD00631[Gel], 1-pathway->nci_nature_pid:Reelin_signaling_pathway[],
MAP1B	CHD7	4-GoPubMed-related-disease->mesh:14138[Tracheoesophageal Fistula],mesh:4933[Esophageal Atresia],mesh:4937[Esophageal Fistula],mesh:16156[Respiratory Tract Fistula], 2-FACTA-related-drug->DrugBank:BIOD00001[DNase I],DrugBank:EXPT02079[lysine],
MAP1B	FOXG1	4-FACTA-related-drug->DrugBank:APRD00162[MRC],DrugBank:APRD00623[ROC],DrugBank:EXPT02079[lysine],DrugBank:APRD00627[Progesterone],
MAP2K2	CACNA1G	3-FACTA-related-drug->DrugBank:EXPT01467[Forskolin],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum], 1-pathway->kegg:path:hsa04010[MAPK signaling pathway],
MAP2K2	DHCR7	1-FACTA-related-disease->UMLS:C0917816[mental retardation], 3-FACTA-related-drug->DrugBank:APRD00627[Progesterone],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
MAP2K2	HOXB1	3-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00627[Progesterone],
MAP2K2	NLGN4X	2-FACTA-related-disease->UMLS:C0917816[mental retardation],UMLS:C0025362[Mental Retardation], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
MAP2K2	NTRK1	3-FACTA-related-drug->DrugBank:APRD00627[Progesterone],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum], 4-pathway->kegg:path:hsa05200[Pathways in cancer],kegg:path:hsa05216[Thyroid cancer],kegg:path:hsa04010[MAPK signaling pathway],kegg:path:hsa04722[Neurotrophin signaling pathway],
MAP2K2	PTEN	7-pathway->kegg:path:hsa05200[Pathways in cancer],nci_nature_pid:Signaling_events_mediated_by_Stem_cell_factor_receptor_(c-Kit)[],kegg:path:hsa05218[Melanoma],kegg:path:hsa05215[Prostate cancer],kegg:path:hsa05214[Glioma],nci_nature_pid:PDGFR-beta_signaling_pathway[],kegg:path:hsa05213[Endometrial cancer],
MAP2K2	NLGN3	2-FACTA-related-disease->UMLS:C0917816[mental retardation],UMLS:C0162678[neurofibromatosis],
MAP2K2	CADM1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
MAP2K2	NPAS2	3-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD01142[Nitric Oxide],
MAP2K2	CREBBP	3-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00627[Progesterone], 6-pathway->kegg:path:hsa04916[Melanogenesis],kegg:path:hsa05200[Pathways in cancer],nci_nature_pid:Signaling_events_mediated_by_Stem_cell_factor_receptor_(c-Kit)[],kegg:path:hsa04720[Long-term potentiation],kegg:path:hsa05215[Prostate cancer],kegg:path:hsa05211[Renal cell carcinoma],
MAP2K2	AHI1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
MAP2K2	FOXG1	1-GoPubMed-related-disease->mesh:11666[Pulmonary Valve Stenosis], 1-FACTA-related-disease->UMLS:C1521943[Medulloblastoma], 1-FACTA-related-drug->DrugBank:APRD00627[Progesterone],
MAP2K2	HRAS	2-GoPubMed-related-disease->mesh:9634[Noonan Syndrome],mesh:21441[Carcinoma, Pancreatic Ductal], 2-FACTA-related-gene->HUMANGGP:022403[HRAS],HUMANGGP:022616[MAP2K2], 3-FACTA-related-disease->UMLS:C0587248[Costello syndrome],UMLS:C1275081[Cardio-facio-cutaneous syndrome],UMLS:C0037268[Skin Abnormalities], 1-FACTA-related-drug->DrugBank:APRD00627[Progesterone], 27-pathway->kegg:path:hsa04910[Insulin signaling pathway],kegg:path:hsa04916[Melanogenesis],kegg:path:hsa05200[Pathways in cancer],kegg:path:hsa04660[T cell receptor signaling pathway],kegg:path:hsa04650[Natural killer cell mediated cytotoxicity],nci_nature_pid:Signaling_events_mediated_by_Stem_cell_factor_receptor_(c-Kit)[],kegg:path:hsa05218[Melanoma],kegg:path:hsa05216[Thyroid cancer],kegg:path:hsa04010[MAPK signaling pathway],kegg:path:hsa04810[Regulation of actin cytoskeleton],kegg:path:hsa05219[Bladder cancer],kegg:path:hsa04540[Gap junction],kegg:path:hsa04722[Neurotrophin signaling pathway],kegg:path:hsa04720[Long-term potentiation],kegg:path:hsa04662[B cell receptor signaling pathway],kegg:path:hsa04370[VEGF signaling pathway],kegg:path:hsa04912[GnRH signaling pathway],kegg:path:hsa04730[Long-term depression],kegg:path:hsa05215[Prostate cancer],kegg:path:hsa05220[Chronic myeloid leukemia],kegg:path:hsa04012[ErbB signaling pathway],kegg:path:hsa05214[Glioma],kegg:path:hsa05211[Renal cell carcinoma],kegg:path:hsa05221[Acute myeloid leukemia],kegg:path:hsa04664[Fc epsilon RI signaling pathway],kegg:path:hsa05223[Non-small cell lung cancer],kegg:path:hsa05213[Endometrial cancer],
MAP2K2	MAPK3	4-GoPubMed-related-GO->GO:0008338[MAP kinase 1 activity],GO:0016908[MAP kinase 2 activity],GO:0004708[MAP kinase kinase activity],GO:0004712[protein serine/threonine/tyrosine kinase activity], 4-FACTA-related-gene->HUMANGGP:000307[MAPK3],HUMANGGP:012539[mitogen-activated protein kinase 3],HUMANGGP:022616[MAP2K2],HUMANGGP:019460[MAPK1], 3-FACTA-related-disease->UMLS:C0587248[Costello syndrome],UMLS:C0037268[Skin Abnormalities],UMLS:C1521943[Medulloblastoma], 3-FACTA-related-drug->DrugBank:APRD00627[Progesterone],DrugBank:EXPT01467[Forskolin],DrugBank:APRD01142[Nitric Oxide], 45-pathway->kegg:path:hsa04910[Insulin signaling pathway],kegg:path:hsa04916[Melanogenesis],kegg:path:hsa05200[Pathways in cancer],kegg:path:hsa04660[T cell receptor signaling pathway],nci_nature_pid:Fc-epsilon_receptor_I_signaling_in_mast_cells[],kegg:path:hsa04650[Natural killer cell mediated cytotoxicity],kegg:path:hsa04620[Toll-like receptor signaling pathway],nci_nature_pid:Signaling_events_mediated_by_Stem_cell_factor_receptor_(c-Kit)[],kegg:path:hsa05218[Melanoma],nci_nature_pid:Cellular_roles_of_Anthrax_toxin[],kegg:path:hsa05216[Thyroid cancer],nci_nature_pid:IL2-mediated_signaling_events[],nci_nature_pid:Downstream_signaling_in_naïve_CD8+_T_cells[],kegg:path:hsa04010[MAPK signaling pathway],kegg:path:hsa05020[Prion diseases],kegg:path:hsa04810[Regulation of actin cytoskeleton],kegg:path:hsa05219[Bladder cancer],nci_nature_pid:Endothelins[],kegg:path:hsa04270[Vascular smooth muscle contraction],nci_nature_pid:ErbB2/ErbB3_signaling_events[],kegg:path:hsa04540[Gap junction],kegg:path:hsa04722[Neurotrophin signaling pathway],nci_nature_pid:mTOR_signaling_pathway[],nci_nature_pid:ErbB1_downstream_signaling[],nci_nature_pid:CXCR3-mediated_signaling_events[],kegg:path:hsa04720[Long-term potentiation],kegg:path:hsa04662[B cell receptor signaling pathway],kegg:path:hsa04370[VEGF signaling pathway],nci_nature_pid:Ceramide_signaling_pathway[],kegg:path:hsa04912[GnRH signaling pathway],nci_nature_pid:GMCSF-mediated_signaling_events[],kegg:path:hsa04730[Long-term depression],nci_nature_pid:Netrin-mediated_signaling_events[],kegg:path:hsa05215[Prostate cancer],kegg:path:hsa05220[Chronic myeloid leukemia],kegg:path:hsa04012[ErbB signaling pathway],kegg:path:hsa05214[Glioma],kegg:path:hsa05211[Renal cell carcinoma],kegg:path:hsa05221[Acute myeloid leukemia],kegg:path:hsa04664[Fc epsilon RI signaling pathway],nci_nature_pid:PDGFR-beta_signaling_pathway[],nci_nature_pid:Signaling_events_mediated_by_Hepatocyte_Growth_Factor_Receptor_(c-Met)[],kegg:path:hsa05223[Non-small cell lung cancer],kegg:path:hsa05213[Endometrial cancer],nci_nature_pid:Nongenotropic_Androgen_signaling[],
MAP2K2	CA6	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
MAP2K2	NSD1	1-FACTA-related-disease->UMLS:C0424605[developmental delay], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
MAP2K2	CHD7	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
MAPT	NTRK3	2-FACTA-related-drug->DrugBank:APRD00340[Reserpine],DrugBank:EXPT02079[lysine],
MAPT	RELN	3-FACTA-related-drug->DrugBank:APRD00280[Frontal],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin], 1-pathway->nci_nature_pid:Reelin_signaling_pathway[],
MAPT	CNTNAP2	1-FACTA-related-disease->UMLS:C1868675[PARK2], 2-FACTA-related-drug->DrugBank:APRD00729[Parkin],DrugBank:BIOD00057[Fragment],
MAPT	HSD11B1	4-FACTA-related-gene->HUMANGGP:034915[APBB2],HUMANGGP:014690[FE65L2],HUMANGGP:019767[SOAT1],HUMANGGP:037589[TFCP2],
MAPT	RAI1	1-GoPubMed-related-disease->mesh:1072[Apraxias], 2-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
MAPT	HTR2A	4-FACTA-related-drug->DrugBank:APRD00729[Parkin],DrugBank:BIOD00057[Fragment],DrugBank:APRD00340[Reserpine],DrugBank:APRD00623[ROC],
MAPT	FOXP2	1-GoPubMed-related-disease->mesh:1072[Apraxias], 2-FACTA-related-drug->DrugBank:APRD00280[Frontal],DrugBank:BIOD00057[Fragment],
MAPT	GRIN2B	1-GoPubMed-related-gene->84630[TTBK1], 1-GoPubMed-related-GO->GO:0001661[conditioned taste aversion], 2-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:EXPT02079[lysine], 2-pathway->kegg:path:hsa05010[Alzheimer's disease],nci_nature_pid:Reelin_signaling_pathway[],
MAPT	SLC1A1	4-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:EXPT00573[Aspartic Acid],DrugBank:APRD00280[Frontal],
MAPT	NF1	1-FACTA-related-gene->HUMANGGP:038222[LRRC37B], 4-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00729[Parkin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00328[Selectin], 1-pathway->kegg:path:hsa04010[MAPK signaling pathway],
MAPT	IL1RAPL1	1-FACTA-related-disease->UMLS:C1868675[PARK2], 2-FACTA-related-drug->DrugBank:APRD00729[Parkin],DrugBank:APRD00017[Tretinoin],
MAPT	HDAC4	1-GoPubMed-related-gene->84830[C6orf105], 1-FACTA-related-gene->HUMANGGP:009990[C6orf105], 5-FACTA-related-drug->DrugBank:APRD00729[Parkin],DrugBank:EXPT02079[lysine],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:EXPT00573[Aspartic Acid],
MAPT	DAB1	1-FACTA-related-disease->UMLS:C1868675[PARK2], 2-FACTA-related-drug->DrugBank:APRD00729[Parkin],DrugBank:BIOD00057[Fragment], 1-pathway->nci_nature_pid:Reelin_signaling_pathway[],
MAPT	PARK2	6-FACTA-related-disease->UMLS:C1868675[PARK2],UMLS:C1868595[PARK1],UMLS:C1865581[PARK3],UMLS:C1858351[SCA11],UMLS:C1854488[SCA13],UMLS:C0752122[SCA4], 2-FACTA-related-drug->DrugBank:APRD00729[Parkin],DrugBank:BIOD00057[Fragment],
MAPT	PLCD1	2-GoPubMed-related-disease->mesh:20774[Pick Disease of the Brain],mesh:13494[Supranuclear Palsy, Progressive], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
MAPT	DAPK1	2-GoPubMed-related-gene->8735[MYH13],84547[PGBD1], 3-FACTA-related-gene->HUMANGGP:041779[SORCS1],HUMANGGP:022503[APH1B],HUMANGGP:002953[EIF2AK2], 2-FACTA-related-drug->DrugBank:APRD00017[Tretinoin],DrugBank:APRD00140[Tretinoin],
MAPT	LAMB1	1-GoPubMed-related-disease->mesh:20240[Apraxia, Ideomotor], 4-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:BIOD00057[Fragment],DrugBank:APRD00691[Estradiol],
MUS81	ESRRB	1-FACTA-related-drug->DrugBank:BIOD00001[DNase I],
MUS81	NTRK1	3-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00631[Gel],
MUS81	NLGN4X	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
MUS81	CREBBP	3-FACTA-related-drug->DrugBank:BIOD00001[DNase I],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
MUS81	DDX11	2-GoPubMed-related-GO->GO:0048256[flap endonuclease activity],GO:0004386[helicase activity], 2-GoPubMed-related-disease->mesh:5199[Fanconi Anemia],mesh:29502[Anemia, Hypoplastic, Congenital], 2-FACTA-related-disease->UMLS:C0015624[Fanconi],UMLS:C0043346[Xeroderma Pigmentosum],
MUS81	HOXB1	3-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00631[Gel],DrugBank:APRD00552[Spectrum],
MUS81	DLX6	1-FACTA-related-drug->DrugBank:BIOD00001[DNase I],
MUS81	AHI1	3-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00631[Gel],
MUS81	PINX1	3-GoPubMed-related-GO->GO:0042162[telomeric DNA binding],GO:0003697[single-stranded DNA binding],GO:0043566[structure-specific DNA binding], 4-GoPubMed-related-disease->mesh:53903[DNA Breaks, Double-Stranded],mesh:1260[Ataxia Telangiectasia],mesh:43171[Chromosomal Instability],mesh:42822[Genomic Instability], 3-FACTA-related-disease->UMLS:C1326912[tumorigenesis],UMLS:C0023487[acute promyelocytic leukemia],UMLS:C0004135[AT1], 1-FACTA-related-drug->DrugBank:BIOD00001[DNase I],
MUS81	MBD4	2-GoPubMed-related-gene->23583[SMUG1],27030[MLH3], 1-GoPubMed-related-disease->mesh:42822[Genomic Instability], 1-FACTA-related-disease->UMLS:C1326912[tumorigenesis],
MUS81	CACNA1G	2-GoPubMed-related-disease->mesh:42822[Genomic Instability],mesh:14898[Werner Syndrome], 1-FACTA-related-disease->UMLS:C0043119[WRN], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
MUS81	CADM1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
MUS81	CA6	4-FACTA-related-drug->DrugBank:BIOD00001[DNase I],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00631[Gel],
MUS81	DHCR7	3-FACTA-related-drug->DrugBank:BIOD00001[DNase I],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
MUS81	NSD1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
MUS81	CHD7	3-FACTA-related-drug->DrugBank:BIOD00001[DNase I],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
MYBL2	CADM1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
MYBL2	CHST5	1-FACTA-related-drug->DrugBank:APRD00396[Estrogens],
MYBL2	DHCR7	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
MYBL2	ARNT2	1-FACTA-related-drug->DrugBank:APRD00396[Estrogens],
MYBL2	CHD7	1-GoPubMed-related-GO->GO:0004683[calmodulin-dependent protein kinase activity], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
MYBL2	ESRRB	1-FACTA-related-drug->DrugBank:APRD00396[Estrogens],
MYBL2	CNTNAP2	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
MYBL2	CREBBP	2-GoPubMed-related-GO->GO:0004402[histone acetyltransferase activity],GO:0004468[lysine N-acetyltransferase activity], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum], 1-pathway->nci_nature_pid:E2F_transcription_factor_network[],
MYBL2	NLGN4X	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
MYBL2	HOXB1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
MYBL2	HRAS	1-FACTA-related-disease->UMLS:C1302772[Cutaneous Lymphoma],
MYBL2	AHI1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
MYBL2	NTRK1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
MYBL2	NPAS2	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
MYBL2	NSD1	1-GoPubMed-related-GO->GO:0004683[calmodulin-dependent protein kinase activity], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
MYBL2	CACNA1G	1-FACTA-related-gene->HUMANGGP:038143[SDC4], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
MYBPC3	CA6	3-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00631[Gel],
MYBPC3	AHI1	3-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00631[Gel],
MYBPC3	CHD7	3-FACTA-related-drug->DrugBank:EXPT02079[lysine],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
MYBPC3	DMD	1-FACTA-related-drug->DrugBank:BIOD00057[Fragment], 2-pathway->kegg:path:hsa05410[Hypertrophic cardiomyopathy (HCM)],kegg:path:hsa05414[Dilated cardiomyopathy],
MYBPC3	NLGN4X	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
MYBPC3	DHCR7	1-FACTA-related-disease->UMLS:C0263541[Founder], 3-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
MYBPC3	ITGB3	1-FACTA-related-gene->HUMANGGP:041910[ITGA8], 1-FACTA-related-disease->UMLS:C0263541[Founder], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment], 2-pathway->kegg:path:hsa05410[Hypertrophic cardiomyopathy (HCM)],kegg:path:hsa05414[Dilated cardiomyopathy],
MYBPC3	HOXB1	4-FACTA-related-drug->DrugBank:EXPT02079[lysine],DrugBank:APRD00506[Spectrum],DrugBank:APRD00631[Gel],DrugBank:APRD00552[Spectrum],
MYBPC3	SHANK3	2-GoPubMed-related-GO->GO:0003779[actin binding],GO:0008092[cytoskeletal protein binding], 3-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
MYBPC3	CADM1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
MYBPC3	NOS1AP	1-GoPubMed-related-GO->GO:0008016[regulation of heart contraction], 2-GoPubMed-related-disease->mesh:16757[Death, Sudden, Cardiac],mesh:3645[Death, Sudden], 2-FACTA-related-disease->UMLS:C0263541[Founder],UMLS:C0340279[ventricular hypertrophy], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
MYBPC3	CREBBP	3-FACTA-related-drug->DrugBank:EXPT02079[lysine],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
MYBPC3	NTRK1	4-FACTA-related-drug->DrugBank:EXPT02079[lysine],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00631[Gel],
MYBPC3	NSD1	3-FACTA-related-drug->DrugBank:EXPT02079[lysine],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
MYBPC3	ITGB7	2-pathway->kegg:path:hsa05410[Hypertrophic cardiomyopathy (HCM)],kegg:path:hsa05414[Dilated cardiomyopathy],
MYBPC3	CNTNAP2	3-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
NCOA1	GRIP1	4-GoPubMed-related-GO->GO:0008140[cAMP response element binding protein binding],GO:0003713[transcription coactivator activity],GO:0016563[transcription activator activity],GO:0003712[transcription cofactor activity], 1-GoPubMed-related-disease->mesh:13734[Androgen-Insensitivity Syndrome], 2-FACTA-related-gene->HUMANGGP:041085[NCOA1],HUMANGGP:041086[NCoA-1], 1-FACTA-related-disease->UMLS:C0242604[Thyroid Hormone Resistance Syndrome], 4-FACTA-related-drug->DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00396[Estrogens],DrugBank:APRD00691[Estradiol],
NCOA1	PITX1	5-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:EXPT02079[lysine],DrugBank:APRD00396[Estrogens],DrugBank:APRD00627[Progesterone],
NCOA1	ESR1	1-GoPubMed-related-gene->84612[PARD6B], 4-GoPubMed-related-GO->GO:0035066[positive regulation of histone acetylation],GO:0031058[positive regulation of histone modification],GO:0000773[phosphatidyl-N-methylethanolamine N-methyltransferase activity],GO:0003712[transcription cofactor activity], 2-GoPubMed-related-disease->mesh:9376[Neoplasms, Hormone-Dependent],mesh:4714[Endometrial Hyperplasia], 3-FACTA-related-drug->DrugBank:APRD00396[Estrogens],DrugBank:APRD00691[Estradiol],DrugBank:APRD00627[Progesterone], 1-pathway->netpath:TGF_beta_Receptor[],
NCOA1	CREBBP	8-GoPubMed-related-GO->GO:0034971[histone H3-R17 methylation],GO:0008140[cAMP response element binding protein binding],GO:0003713[transcription coactivator activity],GO:0035066[positive regulation of histone acetylation],GO:0016563[transcription activator activity],GO:0035035[histone acetyltransferase binding],GO:0031058[positive regulation of histone modification],GO:0003712[transcription cofactor activity], 4-FACTA-related-gene->HUMANGGP:036015[EP300],HUMANGGP:041085[NCOA1],HUMANGGP:022816[NCOA2],HUMANGGP:010959[MYST4], 1-FACTA-related-disease->UMLS:C1861305[TCC], 3-FACTA-related-drug->DrugBank:EXPT02079[lysine],DrugBank:EXPT01027[Glycerol],DrugBank:APRD00627[Progesterone], 4-pathway->nci_nature_pid:Glucocorticoid_receptor_regulatory_network[],nci_nature_pid:HIF-1-alpha_transcription_factor_network[],reactome:REACT_27161[],nci_nature_pid:Regulation_of_Androgen_receptor_activity[],
NCOA1	MEF2C	2-GoPubMed-related-disease->mesh:18233[Rhabdomyosarcoma, Embryonal],mesh:18232[Rhabdomyosarcoma, Alveolar], 4-FACTA-related-drug->DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00627[Progesterone],DrugBank:APRD00140[Tretinoin], 1-pathway->netpath:TGF_beta_Receptor[],
NCOA1	TSN	1-GoPubMed-related-disease->mesh:18232[Rhabdomyosarcoma, Alveolar], 1-FACTA-related-drug->DrugBank:EXPT02079[lysine],
NCOA1	RAI1	2-GoPubMed-related-disease->mesh:53098[Hypophosphatemic Rickets, X-Linked Dominant],mesh:7015[Hypophosphatemia, Familial], 3-FACTA-related-drug->DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
NCOA1	TBX1	4-GoPubMed-related-GO->GO:0008140[cAMP response element binding protein binding],GO:0003713[transcription coactivator activity],GO:0016563[transcription activator activity],GO:0003712[transcription cofactor activity], 4-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:EXPT02079[lysine],DrugBank:APRD00627[Progesterone],
NCOA1	GNAS	1-FACTA-related-disease->UMLS:C0242604[Thyroid Hormone Resistance Syndrome], 5-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:EXPT01027[Glycerol],DrugBank:APRD00017[Tretinoin],DrugBank:EXPT02079[lysine],DrugBank:APRD00627[Progesterone],
NCOA1	NSD1	4-FACTA-related-drug->DrugBank:EXPT02079[lysine],DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin], 1-pathway->netpath:AndrogenReceptor[],
NCOA1	EN2	1-GoPubMed-related-disease->mesh:18232[Rhabdomyosarcoma, Alveolar], 1-FACTA-related-disease->UMLS:C0206655[Rhabdomyosarcoma, Alveolar], 3-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00362[Retinoic Acid],
NCOA1	SLC1A1	4-FACTA-related-drug->DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00627[Progesterone],
NCOA1	IL1RAPL1	3-FACTA-related-drug->DrugBank:APRD00362[Retinoic Acid],DrugBank:EXPT01027[Glycerol],DrugBank:APRD00017[Tretinoin],
NCOA1	CTNNA3	1-FACTA-related-disease->UMLS:C0699885[carcinoma of the bladder],
NCOA1	ARNT2	2-FACTA-related-drug->DrugBank:APRD00396[Estrogens],DrugBank:APRD00691[Estradiol],
NCOA1	NRCAM	2-FACTA-related-disease->UMLS:C0206655[Rhabdomyosarcoma, Alveolar],UMLS:C0206656[embryonal rhabdomyosarcoma], 1-FACTA-related-drug->DrugBank:APRD00627[Progesterone],
NIPA1	NRXN1	3-GoPubMed-related-GO->GO:0007416[synapse assembly],GO:0050808[synapse organization],GO:0043062[extracellular structure organization], 3-FACTA-related-disease->UMLS:C0008074[Child Development Disorders, Pervasive],UMLS:C0036857[severe mental retardation],UMLS:C1855900[HCG],
NIPA1	APBA2	1-GoPubMed-related-disease->mesh:17204[Angelman Syndrome], 2-FACTA-related-disease->UMLS:C0008074[Child Development Disorders, Pervasive],UMLS:C1855900[HCG],
NIPA1	CNTN4	2-GoPubMed-related-GO->GO:0007409[axonogenesis],GO:0048667[cell morphogenesis involved in neuron differentiation], 1-FACTA-related-disease->UMLS:C1855900[HCG], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
NIPA1	NLGN4X	3-GoPubMed-related-GO->GO:0007416[synapse assembly],GO:0050808[synapse organization],GO:0043062[extracellular structure organization], 2-FACTA-related-disease->UMLS:C0020758[ichthyosis],UMLS:C0020757[ichthyosis],
NIPA1	SLC9A9	1-GoPubMed-related-GO->GO:0001764[neuron migration], 1-GoPubMed-related-disease->mesh:17204[Angelman Syndrome],
NIPA1	GABRB1	1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
NIPA1	UBE3A	1-GoPubMed-related-gene->8926[SNURF], 2-GoPubMed-related-disease->mesh:17204[Angelman Syndrome],mesh:11218[Prader-Willi Syndrome], 1-FACTA-related-gene->HUMANGGP:004935[GCP5], 2-FACTA-related-disease->UMLS:C0162635[Angelman syndrome],UMLS:C0036857[severe mental retardation], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
NIPA1	UBE2H	1-GoPubMed-related-disease->mesh:17204[Angelman Syndrome], 1-FACTA-related-disease->UMLS:C0162635[Angelman syndrome],
NIPA1	PLCD1	1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
NIPA1	LRRC1	1-GoPubMed-related-GO->GO:0003774[motor activity], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
NIPA1	NOS1AP	1-FACTA-related-disease->UMLS:C0008074[Child Development Disorders, Pervasive], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
NIPA1	ATP2B2	1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
NIPA1	NDNL2	2-GoPubMed-related-GO->GO:0004066[asparagine synthase (glutamine-hydrolyzing) activity],GO:0016884[carbon-nitrogen ligase activity, with glutamine as amido-N-donor], 2-GoPubMed-related-disease->mesh:17204[Angelman Syndrome],mesh:11218[Prader-Willi Syndrome],
NIPA1	MED12	1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
NIPA1	CDH9	1-GoPubMed-related-gene->51062[ATL1],
NIPA1	SHANK2	1-GoPubMed-related-GO->GO:0007416[synapse assembly], 2-GoPubMed-related-disease->mesh:20336[Paraparesis, Spastic],mesh:20335[Paraparesis], 2-FACTA-related-disease->UMLS:C0008074[Child Development Disorders, Pervasive],UMLS:C1855900[HCG],
NIPA1	ATP10A	2-GoPubMed-related-disease->mesh:17204[Angelman Syndrome],mesh:11218[Prader-Willi Syndrome], 1-FACTA-related-disease->UMLS:C0162635[Angelman syndrome],
NLGN2	NRXN2	7-FACTA-related-gene->HUMANGGP:038951[NRXN2],HUMANGGP:021925[NRXN3],HUMANGGP:022666[NLGN1],HUMANGGP:010914[NRXN1],HUMANGGP:014728[neuroligin 3],HUMANGGP:014727[NLGN3],HUMANGGP:030076[olfactory], 2-FACTA-related-disease->UMLS:C0004352[autism],UMLS:C0001511[Adhesion], 1-FACTA-related-drug->DrugBank:APRD00256[Valproic Acid], 1-pathway->kegg:path:hsa04514[Cell adhesion molecules (CAMs)],
NLGN2	NRXN1	1-GoPubMed-related-GO->GO:0042043[neurexin binding], 5-FACTA-related-gene->HUMANGGP:010914[NRXN1],HUMANGGP:038951[NRXN2],HUMANGGP:021925[NRXN3],HUMANGGP:022666[NLGN1],HUMANGGP:014727[NLGN3], 1-FACTA-related-disease->UMLS:C0004352[autism], 1-FACTA-related-drug->DrugBank:APRD00256[Valproic Acid], 1-pathway->kegg:path:hsa04514[Cell adhesion molecules (CAMs)],
NLGN2	GPR139	3-GoPubMed-related-GO->GO:0005102[receptor binding],GO:0005515[protein binding],GO:0005488[binding],
NLGN2	CNTNAP2	1-FACTA-related-disease->UMLS:C0004352[autism], 1-pathway->kegg:path:hsa04514[Cell adhesion molecules (CAMs)],
NLGN2	NDNL2	1-GoPubMed-related-GO->GO:0007399[nervous system development], 1-FACTA-related-disease->UMLS:C0004352[autism],
NLGN2	MDGA2	1-GoPubMed-related-GO->GO:0007399[nervous system development], 2-FACTA-related-gene->HUMANGGP:010914[NRXN1],HUMANGGP:030076[olfactory], 2-FACTA-related-disease->UMLS:C0004352[autism],UMLS:C0001511[Adhesion],
NLGN2	CDH10	1-GoPubMed-related-GO->GO:0032502[developmental process], 1-FACTA-related-gene->HUMANGGP:030076[olfactory], 2-FACTA-related-disease->UMLS:C0004352[autism],UMLS:C0001511[Adhesion],
NLGN2	RELN	1-GoPubMed-related-GO->GO:0042043[neurexin binding], 1-FACTA-related-drug->DrugBank:APRD00256[Valproic Acid],
NLGN2	SHANK3	1-GoPubMed-related-gene->54413[NLGN3], 1-GoPubMed-related-GO->GO:0042043[neurexin binding], 3-FACTA-related-gene->HUMANGGP:014727[NLGN3],HUMANGGP:010914[NRXN1],HUMANGGP:014728[neuroligin 3], 1-FACTA-related-disease->UMLS:C0004352[autism],
NLGN2	SHANK2	1-GoPubMed-related-gene->54413[NLGN3], 1-GoPubMed-related-GO->GO:0042043[neurexin binding], 1-FACTA-related-disease->UMLS:C0004352[autism],
NLGN2	HOXB1	1-FACTA-related-disease->UMLS:C0004352[autism], 1-FACTA-related-drug->DrugBank:APRD00256[Valproic Acid],
NLGN2	CDH9	3-GoPubMed-related-GO->GO:0005102[receptor binding],GO:0005515[protein binding],GO:0005488[binding], 1-GoPubMed-related-disease->mesh:267[Adhesions], 2-FACTA-related-disease->UMLS:C0004352[autism],UMLS:C0001511[Adhesion],
NLGN2	NLGN3	1-GoPubMed-related-GO->GO:0042043[neurexin binding], 7-FACTA-related-gene->HUMANGGP:014727[NLGN3],HUMANGGP:018904[NLGN4Y],HUMANGGP:022666[NLGN1],HUMANGGP:014728[neuroligin 3],HUMANGGP:021925[NRXN3],HUMANGGP:038951[NRXN2],HUMANGGP:010914[NRXN1], 1-FACTA-related-disease->UMLS:C0004352[autism], 1-FACTA-related-drug->DrugBank:APRD00256[Valproic Acid], 1-pathway->kegg:path:hsa04514[Cell adhesion molecules (CAMs)],
NLGN2	NLGN1	1-GoPubMed-related-gene->54413[NLGN3], 3-GoPubMed-related-GO->GO:0042043[neurexin binding],GO:0005515[protein binding],GO:0005488[binding], 1-GoPubMed-related-disease->mesh:267[Adhesions], 7-FACTA-related-gene->HUMANGGP:022666[NLGN1],HUMANGGP:018904[NLGN4Y],HUMANGGP:021925[NRXN3],HUMANGGP:038951[NRXN2],HUMANGGP:014727[NLGN3],HUMANGGP:010914[NRXN1],HUMANGGP:014728[neuroligin 3], 2-FACTA-related-disease->UMLS:C0004352[autism],UMLS:C0001511[Adhesion], 1-FACTA-related-drug->DrugBank:APRD00256[Valproic Acid], 1-pathway->kegg:path:hsa04514[Cell adhesion molecules (CAMs)],
NLGN2	NLGN4Y	1-GoPubMed-related-gene->54413[NLGN3], 3-GoPubMed-related-GO->GO:0042043[neurexin binding],GO:0005515[protein binding],GO:0005488[binding], 1-GoPubMed-related-disease->mesh:13568[Pathological Conditions, Signs and Symptoms], 4-FACTA-related-gene->HUMANGGP:018904[NLGN4Y],HUMANGGP:022666[NLGN1],HUMANGGP:014727[NLGN3],HUMANGGP:014728[neuroligin 3], 1-FACTA-related-disease->UMLS:C0004352[autism],
NLGN2	NLGN4X	1-GoPubMed-related-gene->54413[NLGN3], 2-GoPubMed-related-GO->GO:0042043[neurexin binding],GO:0005515[protein binding], 3-FACTA-related-gene->HUMANGGP:022666[NLGN1],HUMANGGP:014728[neuroligin 3],HUMANGGP:014727[NLGN3], 1-FACTA-related-disease->UMLS:C0004352[autism], 1-pathway->kegg:path:hsa04514[Cell adhesion molecules (CAMs)],
NLGN2	FBXO40	2-GoPubMed-related-GO->GO:0005102[receptor binding],GO:0005515[protein binding], 2-FACTA-related-gene->HUMANGGP:022666[NLGN1],HUMANGGP:010914[NRXN1], 2-FACTA-related-disease->UMLS:C0004352[autism],UMLS:C0001511[Adhesion],
NLGN2	GTF2I	1-FACTA-related-drug->DrugBank:APRD00256[Valproic Acid],
NLGN2	BZRAP1	1-GoPubMed-related-GO->GO:0005488[binding], 1-FACTA-related-gene->HUMANGGP:010914[NRXN1], 1-FACTA-related-disease->UMLS:C0004352[autism],
NLGN2	ASTN2	2-GoPubMed-related-GO->GO:0007155[cell adhesion],GO:0022610[biological adhesion], 2-FACTA-related-gene->HUMANGGP:022666[NLGN1],HUMANGGP:010914[NRXN1], 2-FACTA-related-disease->UMLS:C0004352[autism],UMLS:C0001511[Adhesion],
NLGN2	RFWD2	2-FACTA-related-gene->HUMANGGP:022666[NLGN1],HUMANGGP:010914[NRXN1], 2-FACTA-related-disease->UMLS:C0004352[autism],UMLS:C0001511[Adhesion],
NRXN3	NLGN1	2-GoPubMed-related-gene->9378[NRXN1],54413[NLGN3], 6-GoPubMed-related-GO->GO:0042043[neurexin binding],GO:0007416[synapse assembly],GO:0050808[synapse organization],GO:0043062[extracellular structure organization],GO:0005515[protein binding],GO:0005488[binding], 1-GoPubMed-related-disease->mesh:19970[Cocaine-Related Disorders], 6-FACTA-related-gene->HUMANGGP:022666[NLGN1],HUMANGGP:021925[NRXN3],HUMANGGP:038951[NRXN2],HUMANGGP:014727[NLGN3],HUMANGGP:010914[NRXN1],HUMANGGP:014728[neuroligin 3], 5-FACTA-related-disease->UMLS:C0600427[cocaine addiction],UMLS:C0004352[autism],UMLS:C0236736[Cocaine-Related Disorders],UMLS:C0017650[Globus],UMLS:C0001511[Adhesion], 1-FACTA-related-drug->DrugBank:APRD00256[Valproic Acid],
NRXN3	FBXO40	2-GoPubMed-related-gene->22871[NLGN1],9378[NRXN1], 1-GoPubMed-related-GO->GO:0005515[protein binding], 2-FACTA-related-gene->HUMANGGP:022666[NLGN1],HUMANGGP:010914[NRXN1], 2-FACTA-related-disease->UMLS:C0004352[autism],UMLS:C0001511[Adhesion],
NRXN3	GTF2I	1-FACTA-related-drug->DrugBank:APRD00256[Valproic Acid],
NRXN3	GABRA4	2-GoPubMed-related-GO->GO:0004871[signal transducer activity],GO:0060089[molecular transducer activity], 1-GoPubMed-related-disease->mesh:14029[Tobacco Use Disorder], 4-FACTA-related-disease->UMLS:C0028043[nicotine addiction],UMLS:C0040336[Tobacco Use Disorder],UMLS:C0004352[autism],UMLS:C1510472[drug addiction],
NRXN3	CADM1	1-GoPubMed-related-GO->GO:0042043[neurexin binding], 5-FACTA-related-gene->HUMANGGP:017997[CADM1],HUMANGGP:012357[C11orf70],HUMANGGP:013420[JUB],HUMANGGP:021925[NRXN3],HUMANGGP:020913[TPD52],
NRXN3	NLGN3	2-GoPubMed-related-gene->22871[NLGN1],9378[NRXN1], 4-GoPubMed-related-GO->GO:0042043[neurexin binding],GO:0007416[synapse assembly],GO:0050808[synapse organization],GO:0043062[extracellular structure organization], 1-GoPubMed-related-disease->mesh:19970[Cocaine-Related Disorders], 6-FACTA-related-gene->HUMANGGP:014727[NLGN3],HUMANGGP:022666[NLGN1],HUMANGGP:014728[neuroligin 3],HUMANGGP:021925[NRXN3],HUMANGGP:038951[NRXN2],HUMANGGP:010914[NRXN1], 4-FACTA-related-disease->UMLS:C0600427[cocaine addiction],UMLS:C0004352[autism],UMLS:C0236736[Cocaine-Related Disorders],UMLS:C0017650[Globus], 1-FACTA-related-drug->DrugBank:APRD00256[Valproic Acid],
NRXN3	NRXN2	1-GoPubMed-related-gene->9378[NRXN1], 3-GoPubMed-related-GO->GO:0007416[synapse assembly],GO:0050808[synapse organization],GO:0043062[extracellular structure organization], 7-FACTA-related-gene->HUMANGGP:038951[NRXN2],HUMANGGP:021925[NRXN3],HUMANGGP:022666[NLGN1],HUMANGGP:010914[NRXN1],HUMANGGP:014728[neuroligin 3],HUMANGGP:014727[NLGN3],HUMANGGP:010912[neurexin 1], 3-FACTA-related-disease->UMLS:C0004352[autism],UMLS:C0001511[Adhesion],UMLS:C0036341[schizophrenia], 1-FACTA-related-drug->DrugBank:APRD00256[Valproic Acid],
NRXN3	NRXN1	2-GoPubMed-related-gene->9379[NRXN2],22871[NLGN1], 4-GoPubMed-related-GO->GO:0042043[neurexin binding],GO:0007416[synapse assembly],GO:0050808[synapse organization],GO:0043062[extracellular structure organization], 1-GoPubMed-related-disease->mesh:14029[Tobacco Use Disorder], 5-FACTA-related-gene->HUMANGGP:010914[NRXN1],HUMANGGP:038951[NRXN2],HUMANGGP:021925[NRXN3],HUMANGGP:022666[NLGN1],HUMANGGP:014727[NLGN3], 3-FACTA-related-disease->UMLS:C0004352[autism],UMLS:C0028043[nicotine addiction],UMLS:C0040336[Tobacco Use Disorder], 1-FACTA-related-drug->DrugBank:APRD00256[Valproic Acid],
NRXN3	NLGN4Y	1-GoPubMed-related-gene->54413[NLGN3], 3-GoPubMed-related-GO->GO:0042043[neurexin binding],GO:0005515[protein binding],GO:0005488[binding], 3-FACTA-related-gene->HUMANGGP:022666[NLGN1],HUMANGGP:014727[NLGN3],HUMANGGP:014728[neuroligin 3], 1-FACTA-related-disease->UMLS:C0004352[autism],
NRXN3	ASTN2	2-GoPubMed-related-gene->22871[NLGN1],9378[NRXN1], 2-FACTA-related-gene->HUMANGGP:022666[NLGN1],HUMANGGP:010914[NRXN1], 4-FACTA-related-disease->UMLS:C0085281[addiction],UMLS:C0004352[autism],UMLS:C0036341[schizophrenia],UMLS:C0001511[Adhesion],
NRXN3	NLGN4X	1-GoPubMed-related-gene->54413[NLGN3], 5-GoPubMed-related-GO->GO:0042043[neurexin binding],GO:0007416[synapse assembly],GO:0050808[synapse organization],GO:0043062[extracellular structure organization],GO:0005515[protein binding], 3-FACTA-related-gene->HUMANGGP:022666[NLGN1],HUMANGGP:014728[neuroligin 3],HUMANGGP:014727[NLGN3], 1-FACTA-related-disease->UMLS:C0004352[autism],
NRXN3	DLX1	1-GoPubMed-related-disease->mesh:14096[Tooth, Supernumerary], 2-FACTA-related-disease->UMLS:C0004352[autism],UMLS:C0017650[Globus],
NRXN3	SHANK3	2-GoPubMed-related-gene->9378[NRXN1],54413[NLGN3], 4-GoPubMed-related-GO->GO:0042043[neurexin binding],GO:0007416[synapse assembly],GO:0050808[synapse organization],GO:0043062[extracellular structure organization], 3-FACTA-related-gene->HUMANGGP:014727[NLGN3],HUMANGGP:010914[NRXN1],HUMANGGP:014728[neuroligin 3], 1-FACTA-related-disease->UMLS:C0004352[autism],
NRXN3	ARNT2	2-GoPubMed-related-GO->GO:0005515[protein binding],GO:0005488[binding], 3-GoPubMed-related-disease->mesh:2971[Cleft Lip],mesh:8047[Lip Diseases],mesh:9056[Mouth Abnormalities],
NRXN3	RIMS3	2-FACTA-related-disease->UMLS:C0004352[autism],UMLS:C0036341[schizophrenia],
NRXN3	MARK1	3-FACTA-related-disease->UMLS:C0040336[Tobacco Use Disorder],UMLS:C0004352[autism],UMLS:C1326912[tumorigenesis],
NRXN3	TDO2	5-FACTA-related-disease->UMLS:C0040336[Tobacco Use Disorder],UMLS:C1510472[drug addiction],UMLS:C0004352[autism],UMLS:C0036341[schizophrenia],UMLS:C0001973[Alcoholism],
NRXN3	RAB39B	2-GoPubMed-related-disease->mesh:18236[Carcinoma, Embryonal],mesh:18239[Seminoma], 3-FACTA-related-disease->UMLS:C0027658[Neoplasms, Germ Cell and Embryonal],UMLS:C0004352[autism],UMLS:C0039590[Testicular Neoplasms],
NRXN3	RELN	1-GoPubMed-related-GO->GO:0042043[neurexin binding], 1-FACTA-related-drug->DrugBank:APRD00256[Valproic Acid],
OTX1	NFIA	4-GoPubMed-related-GO->GO:0004530[deoxyribonuclease I activity],GO:0016888[endodeoxyribonuclease activity, producing 5'-phosphomonoesters],GO:0004520[endodeoxyribonuclease activity],GO:0004536[deoxyribonuclease activity], 1-FACTA-related-disease->UMLS:C0497552[Nervous System Malformations], 2-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
OTX1	DLX2	1-GoPubMed-related-GO->GO:0030900[forebrain development], 3-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0497552[Nervous System Malformations],UMLS:C0022360[Jaw Abnormalities], 3-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:BIOD00001[DNase I],DrugBank:APRD00017[Tretinoin],
OTX1	FOXP2	3-GoPubMed-related-disease->mesh:7806[Language Disorders],mesh:3147[Communication Disorders],mesh:4410[Dyslexia], 1-FACTA-related-drug->DrugBank:APRD00280[Frontal],
OTX1	NDNL2	2-GoPubMed-related-GO->GO:0007420[brain development],GO:0007417[central nervous system development], 2-GoPubMed-related-disease->mesh:7806[Language Disorders],mesh:3147[Communication Disorders],
OTX1	CTTNBP2	3-GoPubMed-related-GO->GO:0004530[deoxyribonuclease I activity],GO:0016888[endodeoxyribonuclease activity, producing 5'-phosphomonoesters],GO:0004520[endodeoxyribonuclease activity], 2-GoPubMed-related-disease->mesh:7806[Language Disorders],mesh:3147[Communication Disorders], 1-FACTA-related-drug->DrugBank:BIOD00001[DNase I],
OTX1	NLGN4Y	2-GoPubMed-related-disease->mesh:7859[Learning Disorders],mesh:3147[Communication Disorders],
OTX1	ROBO1	4-GoPubMed-related-disease->mesh:4410[Dyslexia],mesh:7859[Learning Disorders],mesh:7806[Language Disorders],mesh:3147[Communication Disorders],
OTX1	EN2	1-FACTA-related-gene->HUMANGGP:037747[GBX2], 2-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0497552[Nervous System Malformations], 4-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00450[Norepinephrine],
OTX1	RELN	1-GoPubMed-related-GO->GO:0001764[neuron migration], 2-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0497552[Nervous System Malformations], 4-FACTA-related-drug->DrugBank:BIOD00001[DNase I],DrugBank:APRD00280[Frontal],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
OTX1	SHANK3	1-FACTA-related-disease->UMLS:C0233639[Autism], 3-FACTA-related-drug->DrugBank:APRD00280[Frontal],DrugBank:EXPT01447[Fluorescein],DrugBank:APRD00979[Fluorescein],
OTX1	SCN2A	4-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:EXPT01447[Fluorescein],DrugBank:APRD00979[Fluorescein],
OTX1	CNTNAP5	2-GoPubMed-related-disease->mesh:7806[Language Disorders],mesh:3147[Communication Disorders], 1-FACTA-related-disease->UMLS:C0233639[Autism],
OTX1	DLX6	2-GoPubMed-related-GO->GO:0030900[forebrain development],GO:0007420[brain development], 1-FACTA-related-disease->UMLS:C0497552[Nervous System Malformations], 2-FACTA-related-drug->DrugBank:BIOD00001[DNase I],DrugBank:APRD00140[Tretinoin],
OTX1	FOXG1	1-GoPubMed-related-GO->GO:0030900[forebrain development], 2-FACTA-related-disease->UMLS:C0038273[stereotypies],UMLS:C0012236[DiGeorge Syndrome],
OTX1	TPH2	1-FACTA-related-disease->UMLS:C0038273[stereotypies], 2-FACTA-related-drug->DrugBank:APRD00280[Frontal],DrugBank:APRD00450[Norepinephrine],
OTX1	ASMT	3-FACTA-related-disease->UMLS:C0265234[Branchio-Oto-Renal Syndrome],UMLS:C0012236[DiGeorge Syndrome],UMLS:C0079588[STS],
OTX1	DLX1	1-GoPubMed-related-GO->GO:0001764[neuron migration], 1-FACTA-related-disease->UMLS:C0497552[Nervous System Malformations], 3-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:BIOD00001[DNase I],DrugBank:APRD00017[Tretinoin],
OTX1	CHD7	1-FACTA-related-disease->UMLS:C0012236[DiGeorge Syndrome], 3-FACTA-related-drug->DrugBank:BIOD00001[DNase I],DrugBank:EXPT01447[Fluorescein],DrugBank:APRD00979[Fluorescein],
OTX1	RAI1	3-FACTA-related-drug->DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
OTX1	TBX1	3-FACTA-related-disease->UMLS:C0012236[DiGeorge Syndrome],UMLS:C0220704[velocardiofacial syndrome],UMLS:C0265234[Branchio-Oto-Renal Syndrome], 2-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
OTX1	NBEA	2-GoPubMed-related-GO->GO:0007420[brain development],GO:0007417[central nervous system development], 2-GoPubMed-related-disease->mesh:7806[Language Disorders],mesh:3147[Communication Disorders], 1-FACTA-related-disease->UMLS:C0233639[Autism],
OTX2	GNAS	7-FACTA-related-drug->DrugBank:APRD00134[Activin],DrugBank:APRD00181[CAM],DrugBank:BIOD00001[DNase I],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:EXPT02079[lysine],DrugBank:APRD00627[Progesterone],
OTX2	PSMD10	2-GoPubMed-related-disease->mesh:853[Anophthalmos],mesh:5124[Eye Abnormalities],
OTX2	OPHN1	1-GoPubMed-related-disease->mesh:5146[Facial Asymmetry],
OTX2	HOXB1	1-GoPubMed-related-gene->30062[RAX], 1-GoPubMed-related-GO->GO:0050254[rhodopsin kinase activity], 2-FACTA-related-disease->UMLS:C1863793[SCP],UMLS:C0206664[Teratocarcinoma], 6-FACTA-related-drug->DrugBank:APRD00017[Tretinoin],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00362[Retinoic Acid],DrugBank:EXPT02079[lysine],DrugBank:APRD00631[Gel],DrugBank:APRD00627[Progesterone],
OTX2	PITX1	1-GoPubMed-related-disease->mesh:25962[Septo-Optic Dysplasia], 6-FACTA-related-drug->DrugBank:APRD00201[GEO],DrugBank:APRD00134[Activin],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:EXPT02079[lysine],DrugBank:APRD00627[Progesterone],
OTX2	DLX2	2-FACTA-related-gene->HUMANGGP:015295[GSX2],HUMANGGP:028761[CNTN4], 6-FACTA-related-drug->DrugBank:BIOD00052[p75],DrugBank:APRD00140[Tretinoin],DrugBank:BIOD00001[DNase I],DrugBank:APRD00017[Tretinoin],DrugBank:EXPT02079[lysine],DrugBank:APRD00631[Gel],
OTX2	FOXP2	1-GoPubMed-related-gene->2016[EMX1], 1-FACTA-related-disease->UMLS:C1838601[RP11],
OTX2	RAI1	4-FACTA-related-drug->DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00631[Gel],
OTX2	DHCR7	1-GoPubMed-related-disease->mesh:16142[Holoprosencephaly], 1-FACTA-related-disease->UMLS:C0175694[Smith-Lemli-Opitz syndrome], 3-FACTA-related-drug->DrugBank:BIOD00052[p75],DrugBank:BIOD00001[DNase I],DrugBank:APRD00627[Progesterone],
OTX2	CACNA1C	1-GoPubMed-related-disease->mesh:5146[Facial Asymmetry], 1-FACTA-related-disease->UMLS:C0265240[Goldenhar Syndrome], 2-FACTA-related-drug->DrugBank:APRD00450[Norepinephrine],DrugBank:APRD00627[Progesterone],
OTX2	EN2	2-GoPubMed-related-gene->2637[GBX2],85416[ZIC5], 4-GoPubMed-related-GO->GO:0021903[rostrocaudal neural tube patterning],GO:0030917[midbrain-hindbrain boundary development],GO:0021532[neural tube patterning],GO:0021549[cerebellum development], 1-GoPubMed-related-disease->mesh:16142[Holoprosencephaly], 2-FACTA-related-gene->HUMANGGP:002869[BARHL1],HUMANGGP:037747[GBX2], 2-FACTA-related-disease->UMLS:C0236970[Alcohol-Induced Disorders],UMLS:C0220603[pediatric brain tumor], 5-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00450[Norepinephrine],DrugBank:APRD00631[Gel],
OTX2	TBX1	2-FACTA-related-disease->UMLS:C1838601[RP11],UMLS:C0265234[Branchio-Oto-Renal Syndrome], 5-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:EXPT02079[lysine],DrugBank:APRD00627[Progesterone],DrugBank:APRD00631[Gel],
OTX2	HDAC4	1-FACTA-related-disease->UMLS:C1838601[RP11], 6-FACTA-related-drug->DrugBank:APRD00764[Orphan],DrugBank:EXPT02079[lysine],DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00627[Progesterone],
OTX2	DISC1	5-FACTA-related-drug->DrugBank:BIOD00052[p75],DrugBank:EXPT01530[Glyceraldehyde-3-Phosphate],DrugBank:EXPT02079[lysine],DrugBank:APRD00627[Progesterone],DrugBank:APRD00631[Gel],
OTX2	ASMT	1-FACTA-related-disease->UMLS:C0265234[Branchio-Oto-Renal Syndrome], 2-FACTA-related-drug->DrugBank:APRD00181[CAM],DrugBank:APRD00627[Progesterone],
OTX2	DCTN5	2-GoPubMed-related-disease->mesh:8850[Microphthalmos],mesh:5124[Eye Abnormalities],
OTX2	SHANK3	1-GoPubMed-related-disease->mesh:3103[Coloboma], 1-FACTA-related-disease->UMLS:C1838601[RP11], 1-FACTA-related-drug->DrugBank:APRD00627[Progesterone],
OTX2	RELN	1-GoPubMed-related-disease->mesh:16142[Holoprosencephaly], 5-FACTA-related-drug->DrugBank:APRD00181[CAM],DrugBank:BIOD00001[DNase I],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00631[Gel],
PCDH17	CDH8	1-GoPubMed-related-GO->GO:0005488[binding], 12-FACTA-related-gene->HUMANGGP:040101[CDH8],HUMANGGP:014632[CDH14],HUMANGGP:006733[PCDH18],HUMANGGP:005855[CDH6],HUMANGGP:039315[CDH20],HUMANGGP:001536[CDH11],HUMANGGP:016747[CDH7],HUMANGGP:039193[PCDH17],HUMANGGP:001995[PCDH11],HUMANGGP:033673[PCDH8],HUMANGGP:024970[PCDH9],HUMANGGP:028535[PCDH10], 2-FACTA-related-disease->UMLS:C0154027[Retina],UMLS:C0024622[Retina],
PCDH17	LRRC1	2-GoPubMed-related-GO->GO:0007275[multicellular organismal development],GO:0005488[binding], 1-GoPubMed-related-disease->mesh:5317[Fetal Growth Retardation], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
PCDH17	PCDH19	2-GoPubMed-related-GO->GO:0007155[cell adhesion],GO:0022610[biological adhesion], 2-GoPubMed-related-disease->mesh:7805[Language Development Disorders],mesh:7806[Language Disorders], 8-FACTA-related-gene->HUMANGGP:028534[PCDH19],HUMANGGP:006733[PCDH18],HUMANGGP:008727[PCDH20],HUMANGGP:001995[PCDH11],HUMANGGP:039193[PCDH17],HUMANGGP:033673[PCDH8],HUMANGGP:024970[PCDH9],HUMANGGP:028535[PCDH10], 4-FACTA-related-disease->UMLS:C0917816[mental retardation],UMLS:C0424605[developmental delay],UMLS:C0004352[autism],UMLS:C0025362[Mental Retardation],
PCDH17	NBEA	2-GoPubMed-related-GO->GO:0005515[protein binding],GO:0005488[binding], 2-GoPubMed-related-disease->mesh:7806[Language Disorders],mesh:3147[Communication Disorders], 2-FACTA-related-disease->UMLS:C0004352[autism],UMLS:C0035335[retinoblastoma],
PCDH17	ATP2B2	1-FACTA-related-disease->UMLS:C0424605[developmental delay], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
PCDH17	MED12	2-FACTA-related-disease->UMLS:C0917816[mental retardation],UMLS:C0025362[Mental Retardation], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
PCDH17	PCDH10	10-FACTA-related-gene->HUMANGGP:006733[PCDH18],HUMANGGP:028535[PCDH10],HUMANGGP:014632[CDH14],HUMANGGP:001995[PCDH11],HUMANGGP:039193[PCDH17],HUMANGGP:028534[PCDH19],HUMANGGP:008727[PCDH20],HUMANGGP:024970[PCDH9],HUMANGGP:033673[PCDH8],HUMANGGP:039315[CDH20], 2-FACTA-related-disease->UMLS:C0004509[azoospermia],UMLS:C0004352[autism],
PCDH17	CTNNA3	1-GoPubMed-related-gene->26047[CNTNAP2], 2-GoPubMed-related-GO->GO:0007155[cell adhesion],GO:0022610[biological adhesion], 2-FACTA-related-disease->UMLS:C0014175[endometriosis],UMLS:C0917816[mental retardation],
PCDH17	NRXN1	2-GoPubMed-related-disease->mesh:7805[Language Development Disorders],mesh:7806[Language Disorders], 2-FACTA-related-disease->UMLS:C0004352[autism],UMLS:C0917816[mental retardation],
PCDH17	GABRB1	2-FACTA-related-disease->UMLS:C0004352[autism],UMLS:C0005586[Bipolar Disorder], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
PCDH17	MCPH1	3-GoPubMed-related-disease->mesh:8831[Microcephaly],mesh:19465[Craniofacial Abnormalities],mesh:7805[Language Development Disorders],
PCDH17	SLC6A8	3-GoPubMed-related-disease->mesh:7805[Language Development Disorders],mesh:7806[Language Disorders],mesh:3147[Communication Disorders], 2-FACTA-related-disease->UMLS:C0917816[mental retardation],UMLS:C0424605[developmental delay],
PCDH17	FOXG1	1-GoPubMed-related-disease->mesh:8831[Microcephaly], 1-FACTA-related-drug->DrugBank:APRD00162[MRC],
PCDH17	PCDH9	1-GoPubMed-related-gene->5100[PCDH8], 5-GoPubMed-related-GO->GO:0007155[cell adhesion],GO:0022610[biological adhesion],GO:0010467[gene expression],GO:0043170[macromolecule metabolic process],GO:0008152[metabolic process], 12-FACTA-related-gene->HUMANGGP:024970[PCDH9],HUMANGGP:014632[CDH14],HUMANGGP:006733[PCDH18],HUMANGGP:001995[PCDH11],HUMANGGP:039193[PCDH17],HUMANGGP:033673[PCDH8],HUMANGGP:008727[PCDH20],HUMANGGP:040101[CDH8],HUMANGGP:039315[CDH20],HUMANGGP:028535[PCDH10],HUMANGGP:028534[PCDH19],HUMANGGP:016747[CDH7], 5-FACTA-related-disease->UMLS:C0004352[autism],UMLS:C0917816[mental retardation],UMLS:C0025362[Mental Retardation],UMLS:C0154027[Retina],UMLS:C0024622[Retina],
PCDH17	DPP10	1-FACTA-related-drug->DrugBank:APRD00162[MRC],
PCDH17	NLGN4Y	2-GoPubMed-related-GO->GO:0005515[protein binding],GO:0005488[binding], 1-GoPubMed-related-disease->mesh:3147[Communication Disorders], 3-FACTA-related-disease->UMLS:C0004352[autism],UMLS:C0917816[mental retardation],UMLS:C0025362[Mental Retardation],
PCDH17	PLCD1	1-FACTA-related-disease->UMLS:C0014859[Esophageal Neoplasms], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
PCDH17	MACROD2	1-GoPubMed-related-GO->GO:0032502[developmental process], 2-FACTA-related-disease->UMLS:C0004352[autism],UMLS:C0014175[endometriosis],
PCDH17	CNTNAP2	4-GoPubMed-related-GO->GO:0030274[LIM domain binding],GO:0019904[protein domain specific binding],GO:0003002[regionalization],GO:0007389[pattern specification process], 2-GoPubMed-related-disease->mesh:7805[Language Development Disorders],mesh:7806[Language Disorders], 1-FACTA-related-gene->HUMANGGP:034980[LIM domain only 4], 1-FACTA-related-disease->UMLS:C0004352[autism], 2-FACTA-related-drug->DrugBank:APRD00162[MRC],DrugBank:BIOD00057[Fragment],
PCDH17	CNTN4	1-GoPubMed-related-disease->mesh:8831[Microcephaly], 4-FACTA-related-disease->UMLS:C0424605[developmental delay],UMLS:C0008073[Developmental Disabilities],UMLS:C0004352[autism],UMLS:C0917816[mental retardation], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
PCDH17	CA6	1-FACTA-related-drug->DrugBank:APRD00162[MRC],
PDYN	TPH2	6-FACTA-related-drug->DrugBank:APRD00530[Portal],DrugBank:APRD00280[Frontal],DrugBank:APRD00396[Estrogens],DrugBank:APRD00691[Estradiol],DrugBank:APRD01142[Nitric Oxide],DrugBank:APRD00627[Progesterone],
PDYN	MBD1	2-FACTA-related-drug->DrugBank:APRD00530[Portal],DrugBank:APRD01142[Nitric Oxide],
PDYN	GABRA4	1-FACTA-related-gene->HUMANGGP:023025[GABRA2], 2-FACTA-related-disease->UMLS:C0013386[Dyskinesia, Drug-Induced],UMLS:C1510472[drug addiction], 1-FACTA-related-drug->DrugBank:APRD01322[Potassium Chloride],
PDYN	HOXA1	1-GoPubMed-related-disease->mesh:4370[Duane Retraction Syndrome], 2-FACTA-related-drug->DrugBank:APRD00627[Progesterone],DrugBank:APRD00691[Estradiol],
PDYN	NRCAM	2-FACTA-related-disease->UMLS:C0236733[Amphetamine-Related Disorders],UMLS:C1510472[drug addiction], 1-FACTA-related-drug->DrugBank:APRD00627[Progesterone],
PDYN	SLC9A9	1-FACTA-related-gene->HUMANGGP:035830[ARRB2], 1-FACTA-related-disease->UMLS:C0038586[substance use disorders],
PDYN	HTR2A	1-GoPubMed-related-disease->mesh:19969[Amphetamine-Related Disorders], 2-FACTA-related-disease->UMLS:C0392702[abnormal involuntary movements],UMLS:C0600241[heroin abuse], 2-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00530[Portal],
PDYN	AGTR2	1-GoPubMed-related-GO->GO:0030325[adrenal gland development], 5-FACTA-related-drug->DrugBank:APRD01142[Nitric Oxide],DrugBank:BIOD00057[Fragment],DrugBank:APRD00396[Estrogens],DrugBank:APRD00691[Estradiol],DrugBank:APRD00627[Progesterone], 2-pathway->reactome:REACT_14819[],reactome:REACT_19231[],
PDYN	FOXP2	2-FACTA-related-drug->DrugBank:APRD00280[Frontal],DrugBank:BIOD00057[Fragment],
PDYN	GRIN2B	1-GoPubMed-related-disease->mesh:19969[Amphetamine-Related Disorders], 3-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD01322[Potassium Chloride],DrugBank:APRD00627[Progesterone],
PDYN	NLGN3	2-FACTA-related-disease->UMLS:C0600427[cocaine addiction],UMLS:C0236736[Cocaine-Related Disorders],
PDYN	ALDH5A1	2-FACTA-related-drug->DrugBank:APRD00512[Phenytoin],DrugBank:BIOD00057[Fragment],
PDYN	DRD3	2-FACTA-related-disease->UMLS:C0392702[abnormal involuntary movements],UMLS:C0013386[Dyskinesia, Drug-Induced], 3-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00530[Portal],DrugBank:APRD00280[Frontal],
PDYN	WNK3	2-FACTA-related-drug->DrugBank:APRD01322[Potassium Chloride],DrugBank:APRD00627[Progesterone],
PDYN	NPAS2	1-FACTA-related-disease->UMLS:C1510472[drug addiction], 2-FACTA-related-drug->DrugBank:APRD00530[Portal],DrugBank:APRD01142[Nitric Oxide],
PDYN	OPRM1	1-GoPubMed-related-gene->4986[OPRK1], 4-GoPubMed-related-GO->GO:0031626[beta-endorphin binding],GO:0031628[opioid receptor binding],GO:0043278[response to morphine],GO:0004985[opioid receptor activity], 2-GoPubMed-related-disease->mesh:9021[Morphine Dependence],mesh:19969[Amphetamine-Related Disorders], 5-FACTA-related-gene->HUMANGGP:006210[OPRM1],HUMANGGP:016831[PDYN],HUMANGGP:029837[OPRL1],HUMANGGP:035830[ARRB2],HUMANGGP:027681[PNOC], 5-FACTA-related-disease->UMLS:C0600241[heroin abuse],UMLS:C1510472[drug addiction],UMLS:C0236733[Amphetamine-Related Disorders],UMLS:C0600427[cocaine addiction],UMLS:C0038586[substance use disorders], 3-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD01142[Nitric Oxide],DrugBank:APRD00627[Progesterone], 3-pathway->reactome:REACT_14819[],reactome:REACT_19231[],reactome:REACT_15295[],
PDYN	LAMB1	2-FACTA-related-disease->UMLS:C0600427[cocaine addiction],UMLS:C0236736[Cocaine-Related Disorders], 2-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00691[Estradiol],
PDYN	FOXG1	2-FACTA-related-drug->DrugBank:APRD00530[Portal],DrugBank:APRD00627[Progesterone],
PDYN	HTR1B	2-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00530[Portal], 1-pathway->reactome:REACT_19231[],
PEG3	UBE2H	1-GoPubMed-related-gene->317751[MESTIT1], 1-GoPubMed-related-GO->GO:0031386[protein tag], 1-GoPubMed-related-disease->mesh:17204[Angelman Syndrome], 2-FACTA-related-disease->UMLS:C1272677[MEST],UMLS:C0162635[Angelman syndrome],
PEG3	MBD1	4-GoPubMed-related-GO->GO:0031507[heterochromatin formation],GO:0070828[heterochromatin organization],GO:0003677[DNA binding],GO:0003676[nucleic acid binding], 1-FACTA-related-disease->UMLS:C0035372[Rett syndrome], 3-FACTA-related-drug->DrugBank:EXPT02079[lysine],DrugBank:APRD00326[Factor II],DrugBank:APRD00631[Gel],
PEG3	NTRK1	4-FACTA-related-drug->DrugBank:EXPT02079[lysine],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00631[Gel],
PEG3	ATRX	3-FACTA-related-drug->DrugBank:APRD00326[Factor II],DrugBank:EXPT02079[lysine],DrugBank:APRD00631[Gel],
PEG3	AHI1	3-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00631[Gel],
PEG3	RPS6KA2	3-FACTA-related-disease->UMLS:C0206687[Carcinoma, Endometrioid],UMLS:C0206701[Cystadenocarcinoma, Serous],UMLS:C0206681[Adenocarcinoma, Clear Cell],
PEG3	CTNNA3	4-GoPubMed-related-disease->mesh:6828[Hydatidiform Mole],mesh:31901[Gestational Trophoblastic Neoplasms],mesh:14328[Trophoblastic Neoplasms],mesh:11252[Pregnancy Complications, Neoplastic], 2-FACTA-related-disease->UMLS:C0020217[Hydatidiform Mole],UMLS:C0206659[embryonal carcinoma],
PEG3	ATP10A	1-GoPubMed-related-GO->GO:0031386[protein tag], 3-GoPubMed-related-disease->mesh:17204[Angelman Syndrome],mesh:24182[Uniparental Disomy],mesh:9630[Nondisjunction, Genetic], 1-FACTA-related-gene->HUMANGGP:013733[PEG3], 3-FACTA-related-disease->UMLS:C1272677[MEST],UMLS:C0162635[Angelman syndrome],UMLS:C0206659[embryonal carcinoma],
PEG3	CREBBP	3-FACTA-related-drug->DrugBank:EXPT02079[lysine],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
PEG3	APBA2	7-GoPubMed-related-GO->GO:0044027[hypermethylation of CpG island],GO:0044026[DNA hypermethylation],GO:0044030[regulation of DNA methylation],GO:0008168[methyltransferase activity],GO:0016741[transferase activity, transferring one-carbon groups],GO:0006306[DNA methylation],GO:0006305[DNA alkylation], 1-GoPubMed-related-disease->mesh:17204[Angelman Syndrome], 1-FACTA-related-disease->UMLS:C0206687[Carcinoma, Endometrioid],
PEG3	HOXB1	1-FACTA-related-disease->UMLS:C0206659[embryonal carcinoma], 5-FACTA-related-drug->DrugBank:BIOD00030[Urokinase],DrugBank:EXPT02079[lysine],DrugBank:APRD00506[Spectrum],DrugBank:APRD00631[Gel],DrugBank:APRD00552[Spectrum],
PEG3	ST7	1-GoPubMed-related-gene->400410[ST20], 1-FACTA-related-disease->UMLS:C0035372[Rett syndrome], 1-FACTA-related-drug->DrugBank:APRD00631[Gel],
PEG3	DHCR7	2-FACTA-related-gene->HUMANGGP:023430[ASB4],HUMANGGP:025433[OSBPL1A], 1-FACTA-related-disease->UMLS:C1272677[MEST], 4-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00506[Spectrum],DrugBank:APRD00080[Freeze],DrugBank:APRD00552[Spectrum],
PEG3	F13A1	3-FACTA-related-drug->DrugBank:BIOD00030[Urokinase],DrugBank:BIOD00057[Fragment],DrugBank:APRD00631[Gel],
PEG3	CA6	1-FACTA-related-disease->UMLS:C0206701[Cystadenocarcinoma, Serous], 3-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00631[Gel],
PEG3	NPAS2	4-FACTA-related-drug->DrugBank:APRD00326[Factor II],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00631[Gel],
PEG3	CACNA1G	4-GoPubMed-related-GO->GO:0044027[hypermethylation of CpG island],GO:0044026[DNA hypermethylation],GO:0006306[DNA methylation],GO:0006305[DNA alkylation], 3-FACTA-related-drug->DrugBank:APRD00326[Factor II],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
PEG3	NSD1	5-FACTA-related-drug->DrugBank:EXPT02079[lysine],DrugBank:APRD00326[Factor II],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00080[Freeze],
PEG3	GTF2I	3-FACTA-related-disease->UMLS:C0004903[Beckwith-Wiedemann syndrome],UMLS:C0035372[Rett syndrome],UMLS:C0206659[embryonal carcinoma], 2-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00631[Gel], 1-pathway->netpath:TNFalpha[],
PERP	PLCD1	2-GoPubMed-related-disease->mesh:9128[Muscle Spasticity],mesh:9122[Muscle Hypertonia],
PERP	CREBBP	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum], 1-pathway->nci_nature_pid:Direct_p53_effectors[],
PERP	HOXB1	1-FACTA-related-disease->UMLS:C0007959[Charcot-Marie-Tooth Disease], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
PERP	DHCR7	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
PERP	NPAS2	3-FACTA-related-drug->DrugBank:EXPT01713[Heme],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
PERP	WNK3	1-GoPubMed-related-GO->GO:0009628[response to abiotic stimulus], 1-FACTA-related-drug->DrugBank:APRD01322[Potassium Chloride],
PERP	CADM1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
PERP	PTEN	2-pathway->nci_nature_pid:Direct_p53_effectors[],kegg:path:hsa04115[p53 signaling pathway],
PERP	RFWD2	2-pathway->nci_nature_pid:Direct_p53_effectors[],kegg:path:hsa04115[p53 signaling pathway],
PERP	CACNA1G	2-FACTA-related-disease->UMLS:C0264490[acute respiratory failure],UMLS:C0220633[uveal melanoma], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
PERP	CHD7	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
PERP	NSD1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
PERP	NLGN4X	1-GoPubMed-related-GO->GO:0005515[protein binding], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
PERP	MARK1	1-GoPubMed-related-disease->mesh:6617[Hip Dislocation], 1-FACTA-related-drug->DrugBank:APRD01322[Potassium Chloride],
PERP	GABRA4	4-GoPubMed-related-GO->GO:0004672[protein kinase activity],GO:0016773[phosphotransferase activity, alcohol group as acceptor],GO:0016301[kinase activity],GO:0016772[transferase activity, transferring phosphorus-containing groups], 1-FACTA-related-drug->DrugBank:APRD01322[Potassium Chloride],
PERP	NTRK1	1-GoPubMed-related-disease->mesh:6617[Hip Dislocation], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
PICK1	OPRM1	2-FACTA-related-gene->HUMANGGP:016831[PDYN],HUMANGGP:035830[ARRB2], 3-FACTA-related-disease->UMLS:C0236733[Amphetamine-Related Disorders],UMLS:C0600427[cocaine addiction],UMLS:C0038586[substance use disorders], 2-FACTA-related-drug->DrugBank:EXPT00494[Alanine],DrugBank:APRD01142[Nitric Oxide],
PICK1	GRIP1	7-GoPubMed-related-GO->GO:0030165[PDZ domain binding],GO:0060292[long term synaptic depression],GO:0051970[negative regulation of transmission of nerve impulse],GO:0050805[negative regulation of synaptic transmission],GO:0031645[negative regulation of neurological system process],GO:0010648[negative regulation of cell communication],GO:0019904[protein domain specific binding], 2-GoPubMed-related-disease->mesh:6562[Herpes Zoster],mesh:11180[Postmortem Changes], 3-FACTA-related-gene->HUMANGGP:012905[GRIP1],HUMANGGP:012906[glutamate receptor interacting protein 1],HUMANGGP:036374[ABP-L], 2-FACTA-related-disease->UMLS:C0271568[LTD],UMLS:C0600427[cocaine addiction], 1-FACTA-related-drug->DrugBank:EXPT02661[Propidium],
PICK1	GRID2	9-GoPubMed-related-GO->GO:0060292[long term synaptic depression],GO:0050805[negative regulation of synaptic transmission],GO:0051970[negative regulation of transmission of nerve impulse],GO:0031645[negative regulation of neurological system process],GO:0010648[negative regulation of cell communication],GO:0048167[regulation of synaptic plasticity],GO:0050804[regulation of synaptic transmission],GO:0031644[regulation of neurological system process],GO:0051969[regulation of transmission of nerve impulse], 1-FACTA-related-gene->HUMANGGP:006428[DLG2], 1-FACTA-related-drug->DrugBank:APRD00729[Parkin],
PICK1	PARK2	2-FACTA-related-drug->DrugBank:APRD00729[Parkin],DrugBank:APRD00450[Norepinephrine],
PICK1	CNTNAP2	1-GoPubMed-related-GO->GO:0019904[protein domain specific binding], 1-FACTA-related-drug->DrugBank:APRD00729[Parkin],
PICK1	HDAC4	2-FACTA-related-drug->DrugBank:APRD00729[Parkin],DrugBank:APRD00649[Etoposide],
PICK1	SLC30A5	1-GoPubMed-related-disease->mesh:169[Acrodermatitis],
PICK1	NRCAM	1-FACTA-related-disease->UMLS:C0236733[Amphetamine-Related Disorders],
PICK1	DAB1	3-GoPubMed-related-GO->GO:0001784[phosphotyrosine binding],GO:0045309[protein phosphorylated amino acid binding],GO:0051219[phosphoprotein binding], 1-FACTA-related-gene->HUMANGGP:006428[DLG2], 2-FACTA-related-drug->DrugBank:APRD00729[Parkin],DrugBank:APRD00081[Biopolymers],
PICK1	FRK	3-GoPubMed-related-GO->GO:0001784[phosphotyrosine binding],GO:0045309[protein phosphorylated amino acid binding],GO:0051219[phosphoprotein binding], 1-GoPubMed-related-disease->mesh:169[Acrodermatitis], 1-FACTA-related-drug->DrugBank:APRD00450[Norepinephrine],
PICK1	EN2	1-FACTA-related-drug->DrugBank:APRD00450[Norepinephrine],
PICK1	LAMB1	1-GoPubMed-related-GO->GO:0043495[protein anchor], 2-FACTA-related-disease->UMLS:C0600427[cocaine addiction],UMLS:C0236736[Cocaine-Related Disorders],
PICK1	NLGN3	4-GoPubMed-related-GO->GO:0060292[long term synaptic depression],GO:0051970[negative regulation of transmission of nerve impulse],GO:0050805[negative regulation of synaptic transmission],GO:0031645[negative regulation of neurological system process], 2-FACTA-related-disease->UMLS:C0600427[cocaine addiction],UMLS:C0236736[Cocaine-Related Disorders],
PICK1	TPH2	2-GoPubMed-related-GO->GO:0001512[dihydronicotinamide riboside quinone reductase activity],GO:0005484[SNAP receptor activity], 2-GoPubMed-related-disease->mesh:4679[Encephalomyelitis],mesh:11180[Postmortem Changes], 2-FACTA-related-drug->DrugBank:APRD00450[Norepinephrine],DrugBank:APRD01142[Nitric Oxide],
PICK1	SEMA5A	1-FACTA-related-drug->DrugBank:APRD00649[Etoposide],
PICK1	IL1RAPL1	1-FACTA-related-gene->HUMANGGP:006428[DLG2], 1-FACTA-related-drug->DrugBank:APRD00729[Parkin],
PRF1	NTRK1	5-FACTA-related-drug->DrugBank:APRD00627[Progesterone],DrugBank:EXPT02079[lysine],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00631[Gel],
PRF1	AHI1	3-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00631[Gel],
PRF1	PINX1	3-FACTA-related-drug->DrugBank:BIOD00001[DNase I],DrugBank:APRD00649[Etoposide],DrugBank:EXPT02079[lysine],
PRF1	CREBBP	5-FACTA-related-drug->DrugBank:BIOD00001[DNase I],DrugBank:EXPT02079[lysine],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00627[Progesterone],
PRF1	HOXB1	6-FACTA-related-drug->DrugBank:EXPT02079[lysine],DrugBank:EXPT00494[Alanine],DrugBank:APRD00506[Spectrum],DrugBank:APRD00631[Gel],DrugBank:APRD00552[Spectrum],DrugBank:APRD00627[Progesterone],
PRF1	DHCR7	4-FACTA-related-drug->DrugBank:BIOD00001[DNase I],DrugBank:APRD00627[Progesterone],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
PRF1	ICA1	2-GoPubMed-related-disease->mesh:18357[Respiratory Syncytial Virus Infections],mesh:18186[Pneumovirus Infections], 1-pathway->kegg:path:hsa04940[Type I diabetes mellitus],
PRF1	CA6	4-FACTA-related-drug->DrugBank:BIOD00001[DNase I],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00631[Gel],
PRF1	NPAS2	4-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:EXPT00494[Alanine],DrugBank:APRD00631[Gel],
PRF1	PLN	1-FACTA-related-gene->HUMANGGP:008371[TSF1], 1-FACTA-related-drug->DrugBank:BIOD00082[IL-2],
PRF1	DMPK	1-GoPubMed-related-disease->mesh:51346[Mobility Limitation], 3-FACTA-related-drug->DrugBank:APRD00631[Gel],DrugBank:EXPT02079[lysine],DrugBank:APRD00506[Spectrum],
PRF1	MBD4	2-GoPubMed-related-disease->mesh:18357[Respiratory Syncytial Virus Infections],mesh:18186[Pneumovirus Infections], 1-FACTA-related-drug->DrugBank:EXPT02079[lysine],
PRF1	CHD7	4-FACTA-related-drug->DrugBank:BIOD00001[DNase I],DrugBank:EXPT02079[lysine],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
PRF1	TNIP2	2-GoPubMed-related-disease->mesh:18357[Respiratory Syncytial Virus Infections],mesh:18186[Pneumovirus Infections],
PRF1	NSD1	3-FACTA-related-drug->DrugBank:EXPT02079[lysine],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
PRF1	CNTNAP2	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
PRKG1	SLC9A9	1-FACTA-related-disease->UMLS:C1263846[Attention Deficit Disorder with Hyperactivity], 1-FACTA-related-drug->DrugBank:APRD01072[HCH],
PRKG1	ITGA4	1-GoPubMed-related-disease->mesh:47708[Myofibroma], 1-FACTA-related-gene->HUMANGGP:023106[FLNC], 1-FACTA-related-disease->UMLS:C0023434[chronic lymphocytic leukemia],
PRKG1	GABRB1	1-GoPubMed-related-disease->mesh:37801[Hammer Toe Syndrome],
PRKG1	GRIN2B	2-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:APRD00627[Progesterone],
PRKG1	NOS1AP	1-FACTA-related-drug->DrugBank:APRD01142[Nitric Oxide],
PRKG1	FGD1	1-GoPubMed-related-disease->mesh:5146[Facial Asymmetry], 1-FACTA-related-drug->DrugBank:APRD00627[Progesterone],
PRKG1	IMMP2L	1-FACTA-related-drug->DrugBank:APRD01142[Nitric Oxide],
PRKG1	BAIAP2	1-FACTA-related-disease->UMLS:C1263846[Attention Deficit Disorder with Hyperactivity],
PRKG1	NXPH1	5-FACTA-related-gene->HUMANGGP:036656[NXPH1],HUMANGGP:019897[HKDC1],HUMANGGP:030713[PPM1H],HUMANGGP:023106[FLNC],HUMANGGP:030083[PRKG1], 2-FACTA-related-disease->UMLS:C0033975[psychotic],UMLS:C0002395[Alzheimer's disease],
PRKG1	OXTR	2-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:APRD00627[Progesterone],
PRKG1	NTRK3	1-GoPubMed-related-disease->mesh:18224[Myofibromatosis], 1-FACTA-related-drug->DrugBank:APRD00627[Progesterone],
PRKG1	TPH2	1-FACTA-related-disease->UMLS:C1263846[Attention Deficit Disorder with Hyperactivity], 3-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:APRD01142[Nitric Oxide],DrugBank:APRD00627[Progesterone],
PRKG1	HTR3A	1-FACTA-related-drug->DrugBank:APRD01072[HCH],
PRKG1	CHRNA7	1-FACTA-related-gene->HUMANGGP:030083[PRKG1], 1-FACTA-related-drug->DrugBank:APRD01072[HCH],
PRKG1	OPHN1	1-GoPubMed-related-disease->mesh:5146[Facial Asymmetry],
PRKG1	DPP6	1-GoPubMed-related-disease->mesh:37801[Hammer Toe Syndrome],
PSEN1	FRK	1-FACTA-related-drug->DrugBank:APRD00248[AMC],
PSEN1	FMR1	5-FACTA-related-drug->DrugBank:APRD00729[Parkin],DrugBank:APRD00521[DM1],DrugBank:EXPT00572[Asn],DrugBank:BIOD00057[Fragment],DrugBank:APRD00280[Frontal],
PSEN1	DHCR7	1-FACTA-related-disease->UMLS:C1862639[APOA1], 3-FACTA-related-drug->DrugBank:APRD00521[DM1],DrugBank:BIOD00035[CSF],DrugBank:BIOD00057[Fragment],
PSEN1	CTNNA3	2-GoPubMed-related-disease->mesh:544[Alzheimer Disease],mesh:24801[Tauopathies], 1-FACTA-related-gene->HUMANGGP:002446[CTNNA2], 1-FACTA-related-disease->UMLS:C0002395[Alzheimer's disease], 2-FACTA-related-drug->DrugBank:APRD00729[Parkin],DrugBank:BIOD00035[CSF],
PSEN1	HSD11B1	4-FACTA-related-gene->HUMANGGP:034915[APBB2],HUMANGGP:014690[FE65L2],HUMANGGP:019767[SOAT1],HUMANGGP:012295[cholesterol 25-hydroxylase], 1-FACTA-related-disease->UMLS:C1862639[APOA1],
PSEN1	NTRK1	1-GoPubMed-related-gene->284114[TMEM102], 1-pathway->kegg:path:hsa04722[Neurotrophin signaling pathway],
PSEN1	TH	1-GoPubMed-related-gene->256364[EML3],
PSEN1	EML1	1-GoPubMed-related-gene->256364[EML3],
PSEN1	SHANK2	2-GoPubMed-related-disease->mesh:20336[Paraparesis, Spastic],mesh:20335[Paraparesis], 1-FACTA-related-drug->DrugBank:APRD00280[Frontal],
PSEN1	DAPK1	3-FACTA-related-gene->HUMANGGP:041779[SORCS1],HUMANGGP:022503[APH1B],HUMANGGP:002953[EIF2AK2],
PSEN1	DISC1	4-FACTA-related-drug->DrugBank:APRD00280[Frontal],DrugBank:EXPT00573[Aspartic Acid],DrugBank:BIOD00057[Fragment],DrugBank:EXPT00494[Alanine],
PSEN1	HDAC4	2-FACTA-related-drug->DrugBank:APRD00729[Parkin],DrugBank:EXPT00573[Aspartic Acid],
PSEN1	MAP2	1-GoPubMed-related-gene->23288[IQCE], 1-FACTA-related-disease->UMLS:C0949664[Tauopathies],
PSEN1	MEF2C	2-FACTA-related-drug->DrugBank:APRD00521[DM1],DrugBank:EXPT03226[vitamin E], 1-pathway->netpath:Notch[],
PSEN1	SLC6A4	1-FACTA-related-disease->UMLS:C0206042[FFI], 3-FACTA-related-drug->DrugBank:APRD00280[Frontal],DrugBank:BIOD00057[Fragment],DrugBank:EXPT00568[vitamin C],
PSEN1	NRCAM	1-GoPubMed-related-disease->mesh:3750[Dental Fissures],
PSEN1	GPX1	4-FACTA-related-drug->DrugBank:APRD00248[AMC],DrugBank:EXPT03226[vitamin E],DrugBank:EXPT00568[vitamin C],DrugBank:EXPT00494[Alanine],
PVRL1	NRXN1	1-GoPubMed-related-GO->GO:0004385[guanylate kinase activity], 1-pathway->kegg:path:hsa04514[Cell adhesion molecules (CAMs)],
PVRL1	NLGN4X	1-pathway->kegg:path:hsa04514[Cell adhesion molecules (CAMs)],
PVRL1	GABRB1	1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
PVRL1	ARNT2	1-GoPubMed-related-GO->GO:0008813[chorismate lyase activity], 6-GoPubMed-related-disease->mesh:2971[Cleft Lip],mesh:2972[Cleft Palate],mesh:8047[Lip Diseases],mesh:7569[Jaw Abnormalities],mesh:19767[Maxillofacial Abnormalities],mesh:9056[Mouth Abnormalities],
PVRL1	TTN	1-GoPubMed-related-gene->253559[CADM2], 4-FACTA-related-gene->HUMANGGP:006269[TMEM25],HUMANGGP:028664[nectin 4],HUMANGGP:009821[down-regulated in lung cancer],HUMANGGP:005972[CXADR], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
PVRL1	PLCD1	1-GoPubMed-related-GO->GO:0051015[actin filament binding], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
PVRL1	LRRC1	1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
PVRL1	MTHFR	1-GoPubMed-related-gene->4965[OFC3], 5-FACTA-related-disease->UMLS:C1837210[OFC5],UMLS:C1842143[OFC4],UMLS:C1835894[OFC9],UMLS:C1864323[OFC2],UMLS:C1833369[OFC3], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
PVRL1	ATP2B2	1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
PVRL1	CNTNAP2	1-FACTA-related-drug->DrugBank:BIOD00057[Fragment], 1-pathway->kegg:path:hsa04514[Cell adhesion molecules (CAMs)],
PVRL1	MED12	1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
PVRL1	NLGN1	1-pathway->kegg:path:hsa04514[Cell adhesion molecules (CAMs)],
PVRL1	F13A1	1-FACTA-related-gene->HUMANGGP:005972[CXADR], 2-FACTA-related-disease->UMLS:C0158646[cleft lip/palate],UMLS:C0175697[Van der Woude syndrome], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
PVRL1	JMJD1C	1-FACTA-related-drug->DrugBank:EXPT00494[Alanine],
PVRL1	REEP3	1-FACTA-related-drug->DrugBank:EXPT00494[Alanine],
PVRL1	CADM1	2-GoPubMed-related-gene->253559[CADM2],199731[CADM4], 1-GoPubMed-related-GO->GO:0004385[guanylate kinase activity], 1-pathway->kegg:path:hsa04514[Cell adhesion molecules (CAMs)],
PVRL1	NLGN3	1-pathway->kegg:path:hsa04514[Cell adhesion molecules (CAMs)],
RAB11FIP5	FBXO40	2-FACTA-related-disease->UMLS:C1510586[Autism spectrum disorder],UMLS:C0004352[autism],
RAB11FIP5	MARK1	2-FACTA-related-disease->UMLS:C1510586[Autism spectrum disorder],UMLS:C0004352[autism],
RAB11FIP5	ASTN2	2-FACTA-related-disease->UMLS:C1510586[Autism spectrum disorder],UMLS:C0004352[autism],
RAB11FIP5	TPH2	1-GoPubMed-related-gene->8774[NAPG], 1-FACTA-related-disease->UMLS:C1510586[Autism spectrum disorder],
RAB11FIP5	NRXN1	1-GoPubMed-related-GO->GO:0005543[phospholipid binding], 3-FACTA-related-disease->UMLS:C1510586[Autism spectrum disorder],UMLS:C0008074[Child Development Disorders, Pervasive],UMLS:C0004352[autism],
RAB11FIP5	SYNGAP1	2-FACTA-related-disease->UMLS:C0008074[Child Development Disorders, Pervasive],UMLS:C0004352[autism],
RAB11FIP5	DLGAP2	3-FACTA-related-disease->UMLS:C1510586[Autism spectrum disorder],UMLS:C0008074[Child Development Disorders, Pervasive],UMLS:C0004352[autism],
RAB11FIP5	SLC25A12	3-FACTA-related-disease->UMLS:C0004352[autism],UMLS:C0008074[Child Development Disorders, Pervasive],UMLS:C0008073[Developmental Disabilities],
RAB11FIP5	ASMT	2-FACTA-related-disease->UMLS:C0008074[Child Development Disorders, Pervasive],UMLS:C0004352[autism],
RAB11FIP5	SHANK2	2-GoPubMed-related-GO->GO:0032456[endocytic recycling],GO:0016197[endosome transport], 2-FACTA-related-disease->UMLS:C0008074[Child Development Disorders, Pervasive],UMLS:C0004352[autism],
RAB11FIP5	APBA2	2-FACTA-related-disease->UMLS:C0008074[Child Development Disorders, Pervasive],UMLS:C0004352[autism],
RAB11FIP5	RIMS3	1-FACTA-related-disease->UMLS:C0004352[autism],
RAB11FIP5	DPP6	2-FACTA-related-disease->UMLS:C1510586[Autism spectrum disorder],UMLS:C0004352[autism],
RAB11FIP5	IMMP2L	1-GoPubMed-related-GO->GO:0051020[GTPase binding], 3-FACTA-related-disease->UMLS:C1510586[Autism spectrum disorder],UMLS:C0524528[pervasive developmental disorder],UMLS:C0004352[autism],
RAB11FIP5	RFWD2	2-FACTA-related-disease->UMLS:C1510586[Autism spectrum disorder],UMLS:C0004352[autism],
RAB11FIP5	ERBB4	1-pathway->kegg:path:hsa04144[Endocytosis],
RBP1	HDAC4	3-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:BIOD00030[Urokinase],
RBP1	TGM3	1-GoPubMed-related-disease->mesh:16112[Ichthyosis Vulgaris], 1-FACTA-related-drug->DrugBank:EXPT00572[Asn],
RBP1	RELN	4-FACTA-related-drug->DrugBank:BIOD00001[DNase I],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00631[Gel],
RBP1	DAPK1	2-GoPubMed-related-GO->GO:0033871[[heparan sulfate]-glucosamine 3-sulfotransferase 2 activity],GO:0034483[heparan sulfate sulfotransferase activity], 1-FACTA-related-gene->HUMANGGP:033120[TNFRSF10C], 3-FACTA-related-disease->UMLS:C1334177[invasive cervical cancer],UMLS:C0033036[APC],UMLS:C0019562[Hippel], 3-FACTA-related-drug->DrugBank:APRD00017[Tretinoin],DrugBank:BIOD00030[Urokinase],DrugBank:APRD00140[Tretinoin],
RBP1	DLX6	2-FACTA-related-drug->DrugBank:BIOD00001[DNase I],DrugBank:APRD00140[Tretinoin],
RBP1	LAMB1	1-FACTA-related-gene->HUMANGGP:004234[synaptophysin-like protein], 4-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:BIOD00001[DNase I],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00631[Gel],
RBP1	DLX1	3-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:BIOD00001[DNase I],DrugBank:APRD00017[Tretinoin],
RBP1	FOXP1	1-GoPubMed-related-disease->mesh:16569[Blepharophimosis], 2-FACTA-related-drug->DrugBank:EXPT00572[Asn],DrugBank:BIOD00030[Urokinase],
RBP1	SEMA5A	1-GoPubMed-related-gene->5948[RBP2], 1-FACTA-related-gene->HUMANGGP:002792[RBP2],
RBP1	TBX1	3-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00631[Gel],
RBP1	PINX1	3-FACTA-related-drug->DrugBank:BIOD00001[DNase I],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
RBP1	NFIA	2-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
RBP1	RAI1	3-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00631[Gel],
RBP1	DLX2	4-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:BIOD00001[DNase I],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00631[Gel],
RBP1	ALOX5AP	2-FACTA-related-gene->HUMANGGP:014275[EIF4A2],HUMANGGP:004234[synaptophysin-like protein], 1-FACTA-related-disease->UMLS:C0345967[malignant mesothelioma],
RBP1	F13A1	3-FACTA-related-drug->DrugBank:BIOD00030[Urokinase],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00631[Gel],
SHANK1	GPR139	1-GoPubMed-related-GO->GO:0005488[binding],
SHANK1	NTNG1	1-GoPubMed-related-GO->GO:0005488[binding], 5-GoPubMed-related-disease->mesh:38901[Mental Retardation, X-Linked],mesh:8607[Mental Retardation],mesh:40181[Genetic Diseases, X-Linked],mesh:20271[Heredodegenerative Disorders, Nervous System],mesh:19954[Neurobehavioral Manifestations], 2-FACTA-related-disease->UMLS:C0917816[mental retardation],UMLS:C0025362[Mental Retardation],
SHANK1	ANKRD11	1-GoPubMed-related-gene->85358[SHANK3], 1-FACTA-related-gene->HUMANGGP:009024[SHANK3], 4-FACTA-related-disease->UMLS:C0004352[autism],UMLS:C0917816[mental retardation],UMLS:C0338656[cognitive impairment],UMLS:C0025362[Mental Retardation],
SHANK1	APBA2	3-GoPubMed-related-GO->GO:0006306[DNA methylation],GO:0006305[DNA alkylation],GO:0043414[macromolecule methylation], 5-FACTA-related-disease->UMLS:C0004352[autism],UMLS:C0917816[mental retardation],UMLS:C0002395[Alzheimer's disease],UMLS:C0007621[Cell Transformation, Neoplastic],UMLS:C0025362[Mental Retardation],
SHANK1	ARHGAP15	1-GoPubMed-related-GO->GO:0005488[binding], 2-FACTA-related-disease->UMLS:C1260899[DBA],UMLS:C0025362[Mental Retardation],
SHANK1	CDH8	1-GoPubMed-related-GO->GO:0005488[binding],
SHANK1	NBEA	1-GoPubMed-related-GO->GO:0005488[binding], 1-FACTA-related-disease->UMLS:C0004352[autism],
SHANK1	SHANK3	1-GoPubMed-related-gene->22941[SHANK2], 2-GoPubMed-related-GO->GO:0008542[visual learning],GO:0007632[visual behavior], 4-FACTA-related-gene->HUMANGGP:020266[SHANK1],HUMANGGP:009024[SHANK3],HUMANGGP:014095[CIRL1],HUMANGGP:023831[ProSAP1], 1-FACTA-related-disease->UMLS:C0004352[autism], 1-FACTA-related-drug->DrugBank:APRD00627[Progesterone],
SHANK1	SHANK2	2-GoPubMed-related-gene->85358[SHANK3],10458[BAIAP2], 1-GoPubMed-related-disease->mesh:5600[Fragile X Syndrome], 4-FACTA-related-gene->HUMANGGP:020266[SHANK1],HUMANGGP:023831[ProSAP1],HUMANGGP:014095[CIRL1],HUMANGGP:009024[SHANK3], 2-FACTA-related-disease->UMLS:C0004352[autism],UMLS:C0917816[mental retardation],
SHANK1	FGD1	1-FACTA-related-drug->DrugBank:APRD00627[Progesterone],
SHANK1	RBMS3	1-GoPubMed-related-GO->GO:0005488[binding],
SHANK1	OPHN1	4-GoPubMed-related-disease->mesh:38901[Mental Retardation, X-Linked],mesh:5600[Fragile X Syndrome],mesh:8607[Mental Retardation],mesh:40181[Genetic Diseases, X-Linked], 2-FACTA-related-disease->UMLS:C0917816[mental retardation],UMLS:C0016667[Fragile X Syndrome],
SHANK1	GRID2	1-GoPubMed-related-GO->GO:0005488[binding], 1-FACTA-related-disease->UMLS:C1260899[DBA],
SHANK1	NLGN4Y	1-GoPubMed-related-GO->GO:0005488[binding], 2-GoPubMed-related-disease->mesh:8607[Mental Retardation],mesh:19954[Neurobehavioral Manifestations], 3-FACTA-related-disease->UMLS:C0004352[autism],UMLS:C0917816[mental retardation],UMLS:C0025362[Mental Retardation],
SHANK1	MKL2	1-FACTA-related-gene->HUMANGGP:001635[SAP1], 1-FACTA-related-disease->UMLS:C0004352[autism],
SHANK1	NLGN1	1-GoPubMed-related-GO->GO:0005488[binding], 3-GoPubMed-related-disease->mesh:25063[Chromosome Disorders],mesh:19954[Neurobehavioral Manifestations],mesh:8607[Mental Retardation], 3-FACTA-related-disease->UMLS:C0004352[autism],UMLS:C0917816[mental retardation],UMLS:C1260899[DBA],
SHANK1	IL1RAPL2	4-GoPubMed-related-disease->mesh:38901[Mental Retardation, X-Linked],mesh:8607[Mental Retardation],mesh:19954[Neurobehavioral Manifestations],mesh:40181[Genetic Diseases, X-Linked], 3-FACTA-related-disease->UMLS:C0917816[mental retardation],UMLS:C0025362[Mental Retardation],UMLS:C0004352[autism],
SIN3A	UBE2H	1-GoPubMed-related-GO->GO:0060216[definitive hemopoiesis], 1-GoPubMed-related-disease->mesh:17204[Angelman Syndrome], 2-FACTA-related-disease->UMLS:C0162635[Angelman syndrome],UMLS:C0004352[autism],
SIN3A	NTNG1	4-GoPubMed-related-disease->mesh:15518[Rett Syndrome],mesh:38901[Mental Retardation, X-Linked],mesh:8607[Mental Retardation],mesh:40181[Genetic Diseases, X-Linked], 2-FACTA-related-disease->UMLS:C0035372[Rett syndrome],UMLS:C0751781[NOD],
SIN3A	SYN1	1-GoPubMed-related-GO->GO:0043336[site-specific telomere resolvase activity], 1-GoPubMed-related-disease->mesh:15518[Rett Syndrome], 1-FACTA-related-disease->UMLS:C1845055[ATRX], 3-FACTA-related-drug->DrugBank:EXPT02079[lysine],DrugBank:APRD00080[Freeze],DrugBank:APRD00631[Gel],
SIN3A	MBD3	4-GoPubMed-related-disease->mesh:15518[Rett Syndrome],mesh:7859[Learning Disorders],mesh:38901[Mental Retardation, X-Linked],mesh:15473[Leukemia, Promyelocytic, Acute], 2-FACTA-related-disease->UMLS:C1845055[ATRX],UMLS:C0035372[Rett syndrome], 5-FACTA-related-drug->DrugBank:APRD00326[Factor II],DrugBank:EXPT02079[lysine],DrugBank:BIOD00017[IFN-gamma],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00631[Gel], 1-pathway->nci_nature_pid:Signaling_events_mediated_by_HDAC_Class_I[],
SIN3A	ATRX	2-FACTA-related-disease->UMLS:C1845055[ATRX],UMLS:C0268164[HP1], 3-FACTA-related-drug->DrugBank:APRD00326[Factor II],DrugBank:EXPT02079[lysine],DrugBank:APRD00631[Gel],
SIN3A	NSD1	5-GoPubMed-related-GO->GO:0008469[histone-arginine N-methyltransferase activity],GO:0042054[histone methyltransferase activity],GO:0016273[arginine N-methyltransferase activity],GO:0016274[protein-arginine N-methyltransferase activity],GO:0008276[protein methyltransferase activity], 1-GoPubMed-related-disease->mesh:7859[Learning Disorders], 1-FACTA-related-disease->UMLS:C1845055[ATRX], 6-FACTA-related-drug->DrugBank:EXPT02079[lysine],DrugBank:APRD00326[Factor II],DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00080[Freeze], 1-pathway->netpath:AndrogenReceptor[],
SIN3A	SLC9A6	2-GoPubMed-related-disease->mesh:17204[Angelman Syndrome],mesh:8831[Microcephaly], 2-FACTA-related-disease->UMLS:C0162635[Angelman syndrome],UMLS:C0004352[autism],
SIN3A	PCDH19	2-GoPubMed-related-disease->mesh:15518[Rett Syndrome],mesh:38901[Mental Retardation, X-Linked], 2-FACTA-related-disease->UMLS:C0035372[Rett syndrome],UMLS:C0004352[autism],
SIN3A	IL1RAPL2	3-GoPubMed-related-disease->mesh:38901[Mental Retardation, X-Linked],mesh:8607[Mental Retardation],mesh:40181[Genetic Diseases, X-Linked], 1-FACTA-related-disease->UMLS:C0004352[autism],
SIN3A	DCX	1-GoPubMed-related-disease->mesh:8831[Microcephaly], 1-FACTA-related-gene->HUMANGGP:034613[TUBA3], 2-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
SIN3A	TBX1	4-GoPubMed-related-GO->GO:0008140[cAMP response element binding protein binding],GO:0003713[transcription coactivator activity],GO:0016563[transcription activator activity],GO:0003712[transcription cofactor activity], 5-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:EXPT02079[lysine],DrugBank:APRD00627[Progesterone],DrugBank:APRD00631[Gel],
SIN3A	RAB39B	3-GoPubMed-related-disease->mesh:38901[Mental Retardation, X-Linked],mesh:40181[Genetic Diseases, X-Linked],mesh:8607[Mental Retardation], 1-FACTA-related-disease->UMLS:C0004352[autism],
SIN3A	RAI1	4-FACTA-related-drug->DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00631[Gel],
SIN3A	HDAC4	1-GoPubMed-related-disease->mesh:15473[Leukemia, Promyelocytic, Acute], 1-FACTA-related-disease->UMLS:C0271510[Recruitment], 6-FACTA-related-drug->DrugBank:EXPT02079[lysine],DrugBank:APRD00362[Retinoic Acid],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD00627[Progesterone],DrugBank:BIOD00017[IFN-gamma], 1-pathway->nci_nature_pid:Signaling_events_mediated_by_HDAC_Class_I[],
SIN3A	MECP2	4-GoPubMed-related-GO->GO:0008469[histone-arginine N-methyltransferase activity],GO:0042054[histone methyltransferase activity],GO:0016273[arginine N-methyltransferase activity],GO:0016274[protein-arginine N-methyltransferase activity], 5-GoPubMed-related-disease->mesh:15518[Rett Syndrome],mesh:38901[Mental Retardation, X-Linked],mesh:17204[Angelman Syndrome],mesh:40181[Genetic Diseases, X-Linked],mesh:8607[Mental Retardation], 2-FACTA-related-gene->HUMANGGP:039791[TUBA1B],HUMANGGP:021077[transcriptional co-repressor Sin3A], 3-FACTA-related-disease->UMLS:C0035372[Rett syndrome],UMLS:C1845055[ATRX],UMLS:C0162635[Angelman syndrome], 2-FACTA-related-drug->DrugBank:EXPT02079[lysine],DrugBank:APRD00326[Factor II],
SIN3A	STK39	2-FACTA-related-disease->UMLS:C1522127[B-cell lymphomas],UMLS:C0004352[autism], 1-FACTA-related-drug->DrugBank:APRD00627[Progesterone],
SIN3A	MBD1	1-GoPubMed-related-GO->GO:0031507[heterochromatin formation], 1-GoPubMed-related-disease->mesh:15518[Rett Syndrome], 4-FACTA-related-disease->UMLS:C1845055[ATRX],UMLS:C0268164[HP1],UMLS:C0035372[Rett syndrome],UMLS:C0740302[MAR], 4-FACTA-related-drug->DrugBank:EXPT02079[lysine],DrugBank:APRD00326[Factor II],DrugBank:BIOD00017[IFN-gamma],DrugBank:APRD00631[Gel],
SLC6A1	DCX	2-GoPubMed-related-disease->mesh:13036[Spasms, Infantile],mesh:18303[Ganglioglioma],
SLC6A1	CACNA1H	3-GoPubMed-related-disease->mesh:4832[Epilepsy, Absence],mesh:13226[Status Epilepticus],mesh:4827[Epilepsy],
SLC6A1	HTR1B	1-FACTA-related-gene->HUMANGGP:031659[SLC6A2], 1-FACTA-related-disease->UMLS:C1263846[Attention Deficit Disorder with Hyperactivity], 3-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:APRD00530[Portal],DrugBank:APRD00450[Norepinephrine],
SLC6A1	FOXG1	1-GoPubMed-related-GO->GO:0031404[chloride ion binding], 1-FACTA-related-drug->DrugBank:APRD00530[Portal],
SLC6A1	EN2	1-FACTA-related-drug->DrugBank:APRD00450[Norepinephrine],
SLC6A1	CDKL5	2-GoPubMed-related-GO->GO:0022831[narrow pore, gated channel activity],GO:0022842[narrow pore channel activity], 1-GoPubMed-related-disease->mesh:13036[Spasms, Infantile],
SLC6A1	MAOA	4-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:APRD00450[Norepinephrine],DrugBank:APRD00679[ENT],DrugBank:APRD00530[Portal],
SLC6A1	SLC6A8	1-FACTA-related-drug->DrugBank:APRD00679[ENT],
SLC6A1	CHRNA7	1-GoPubMed-related-GO->GO:0022831[narrow pore, gated channel activity], 1-FACTA-related-drug->DrugBank:APRD01072[HCH],
SLC6A1	BAIAP2	1-FACTA-related-disease->UMLS:C1263846[Attention Deficit Disorder with Hyperactivity],
SLC6A1	SLC9A9	1-GoPubMed-related-GO->GO:0015291[secondary active transmembrane transporter activity], 4-FACTA-related-gene->HUMANGGP:012079[GFOD1],HUMANGGP:041797[SLC1A2],HUMANGGP:020893[ADRA1A],HUMANGGP:031659[SLC6A2], 2-FACTA-related-disease->UMLS:C0038586[substance use disorders],UMLS:C1263846[Attention Deficit Disorder with Hyperactivity], 1-FACTA-related-drug->DrugBank:APRD01072[HCH],
SLC6A1	DRD3	4-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:APRD00679[ENT],DrugBank:APRD00530[Portal],DrugBank:APRD00450[Norepinephrine],
SLC6A1	GRIN2B	1-FACTA-related-disease->UMLS:C0178417[anhedonia], 1-FACTA-related-drug->DrugBank:APRD01072[HCH],
SLC6A1	OXTR	1-GoPubMed-related-gene->6538[SLC6A11], 2-FACTA-related-disease->UMLS:C0241210[delayed speech],UMLS:C0524528[pervasive developmental disorder], 1-FACTA-related-drug->DrugBank:APRD01072[HCH],
SLC6A1	CACNA1G	1-GoPubMed-related-disease->mesh:4832[Epilepsy, Absence],
SLC6A1	SLC4A10	2-GoPubMed-related-GO->GO:0015291[secondary active transmembrane transporter activity],GO:0022838[substrate-specific channel activity], 1-GoPubMed-related-disease->mesh:17029[Epilepsy, Complex Partial],
SLC6A1	ADRB2	2-FACTA-related-gene->HUMANGGP:012079[GFOD1],HUMANGGP:020893[ADRA1A], 1-FACTA-related-drug->DrugBank:APRD01072[HCH],
SLC6A1	ASTN2	1-FACTA-related-gene->HUMANGGP:035315[GABRR1], 3-FACTA-related-disease->UMLS:C0038586[substance use disorders],UMLS:C0085281[addiction],UMLS:C1263846[Attention Deficit Disorder with Hyperactivity],
SLC6A1	TPH2	1-FACTA-related-gene->HUMANGGP:012079[GFOD1], 1-FACTA-related-disease->UMLS:C1263846[Attention Deficit Disorder with Hyperactivity], 3-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:APRD00530[Portal],DrugBank:APRD00450[Norepinephrine],
SLC6A1	HTR3A	2-GoPubMed-related-GO->GO:0022831[narrow pore, gated channel activity],GO:0022842[narrow pore channel activity], 1-FACTA-related-gene->HUMANGGP:020893[ADRA1A], 2-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:APRD00450[Norepinephrine],
SLC6A1	GABRA4	2-GoPubMed-related-gene->2570[GABRR2],2569[GABRR1], 2-GoPubMed-related-disease->mesh:11218[Prader-Willi Syndrome],mesh:13226[Status Epilepticus], 2-FACTA-related-gene->HUMANGGP:035315[GABRR1],HUMANGGP:026795[GAT-3],
SLC6A1	ABAT	2-GoPubMed-related-gene->2570[GABRR2],2569[GABRR1], 2-GoPubMed-related-GO->GO:0009450[gamma-aminobutyric acid catabolic process],GO:0051936[gamma-aminobutyric acid uptake during transmission of nerve impulse], 2-GoPubMed-related-disease->mesh:13036[Spasms, Infantile],mesh:17029[Epilepsy, Complex Partial], 2-FACTA-related-gene->HUMANGGP:023737[SLC6A13],HUMANGGP:035315[GABRR1],
SLC6A1	MBD1	1-FACTA-related-drug->DrugBank:APRD00530[Portal],
SLC6A1	NPAS2	1-FACTA-related-drug->DrugBank:APRD00530[Portal],
SLC6A1	GABRB1	2-GoPubMed-related-gene->2570[GABRR2],2569[GABRR1], 1-FACTA-related-gene->HUMANGGP:035315[GABRR1], 1-FACTA-related-disease->UMLS:C0086769[panic attacks],
SLC6A2	HTR2A	2-GoPubMed-related-GO->GO:0051378[serotonin binding],GO:0001504[neurotransmitter uptake], 1-GoPubMed-related-disease->mesh:19969[Amphetamine-Related Disorders], 1-FACTA-related-gene->HUMANGGP:012079[GFOD1], 2-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:APRD00530[Portal],
SLC6A2	HTR1B	1-GoPubMed-related-GO->GO:0051378[serotonin binding], 1-FACTA-related-gene->HUMANGGP:031659[SLC6A2], 1-FACTA-related-disease->UMLS:C1263846[Attention Deficit Disorder with Hyperactivity], 3-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:APRD00530[Portal],DrugBank:APRD00450[Norepinephrine],
SLC6A2	FOXG1	1-FACTA-related-drug->DrugBank:APRD00530[Portal],
SLC6A2	TPH2	1-GoPubMed-related-GO->GO:0004511[tyrosine 3-monooxygenase activity], 1-GoPubMed-related-disease->mesh:19970[Cocaine-Related Disorders], 1-FACTA-related-gene->HUMANGGP:012079[GFOD1], 2-FACTA-related-disease->UMLS:C1269683[major depression],UMLS:C1263846[Attention Deficit Disorder with Hyperactivity], 3-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:APRD00530[Portal],DrugBank:APRD00450[Norepinephrine],
SLC6A2	EN2	1-FACTA-related-drug->DrugBank:APRD00450[Norepinephrine],
SLC6A2	MAOA	4-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:APRD00450[Norepinephrine],DrugBank:APRD00679[ENT],DrugBank:APRD00530[Portal],
SLC6A2	DRD3	4-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:APRD00679[ENT],DrugBank:APRD00530[Portal],DrugBank:APRD00450[Norepinephrine],
SLC6A2	GRIN2B	1-GoPubMed-related-GO->GO:0001661[conditioned taste aversion], 1-GoPubMed-related-disease->mesh:19969[Amphetamine-Related Disorders], 2-FACTA-related-disease->UMLS:C0178417[anhedonia],UMLS:C0012734[Disruptive Behavior Disorders], 1-FACTA-related-drug->DrugBank:APRD01072[HCH],
SLC6A2	HTR7	2-FACTA-related-disease->UMLS:C0040517[Tourette Syndrome],UMLS:C1263846[Attention Deficit Disorder with Hyperactivity],
SLC6A2	OXTR	1-FACTA-related-disease->UMLS:C0031572[social phobia], 1-FACTA-related-drug->DrugBank:APRD01072[HCH],
SLC6A2	SLC6A8	1-FACTA-related-drug->DrugBank:APRD00679[ENT],
SLC6A2	SLC6A4	2-GoPubMed-related-gene->222962[SLC29A4],91179[SCARF2], 3-GoPubMed-related-GO->GO:0019811[cocaine binding],GO:0070728[leucine binding],GO:0051378[serotonin binding], 2-GoPubMed-related-disease->mesh:19969[Amphetamine-Related Disorders],mesh:19970[Cocaine-Related Disorders], 1-FACTA-related-gene->HUMANGGP:031659[SLC6A2], 4-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:APRD00679[ENT],DrugBank:APRD00530[Portal],DrugBank:APRD00450[Norepinephrine],
SLC6A2	SLC9A9	2-FACTA-related-gene->HUMANGGP:012079[GFOD1],HUMANGGP:031659[SLC6A2], 2-FACTA-related-disease->UMLS:C0038586[substance use disorders],UMLS:C1263846[Attention Deficit Disorder with Hyperactivity], 1-FACTA-related-drug->DrugBank:APRD01072[HCH],
SLC6A2	HTR3A	2-GoPubMed-related-GO->GO:0051378[serotonin binding],GO:0001975[response to amphetamine], 1-FACTA-related-disease->UMLS:C0040517[Tourette Syndrome], 2-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:APRD00450[Norepinephrine],
SLC6A2	NPAS2	1-FACTA-related-drug->DrugBank:APRD00530[Portal],
SLC6A2	TDO2	3-FACTA-related-disease->UMLS:C0040517[Tourette Syndrome],UMLS:C1263846[Attention Deficit Disorder with Hyperactivity],UMLS:C1269683[major depression],
SLC6A2	CACNA1C	4-FACTA-related-gene->HUMANGGP:014986[CAMKK2],HUMANGGP:012092[CAMK2B],HUMANGGP:009938[ITPR3],HUMANGGP:028295[GNAO1], 1-FACTA-related-disease->UMLS:C0023976[Long QT Syndrome], 1-FACTA-related-drug->DrugBank:APRD00450[Norepinephrine],
SLC6A2	PLN	1-GoPubMed-related-disease->mesh:11665[Pulmonary Valve Insufficiency], 1-FACTA-related-drug->DrugBank:APRD01072[HCH],
SLC6A3	HTR2A	1-GoPubMed-related-disease->mesh:19969[Amphetamine-Related Disorders], 4-FACTA-related-drug->DrugBank:APRD00729[Parkin],DrugBank:APRD01072[HCH],DrugBank:BIOD00057[Fragment],DrugBank:APRD00530[Portal],
SLC6A3	SLC1A1	1-GoPubMed-related-GO->GO:0016413[O-acetyltransferase activity], 2-FACTA-related-drug->DrugBank:EXPT00573[Aspartic Acid],DrugBank:APRD00280[Frontal],
SLC6A3	SLC6A8	3-FACTA-related-drug->DrugBank:APRD00679[ENT],DrugBank:EXPT00573[Aspartic Acid],DrugBank:BIOD00035[CSF],
SLC6A3	SLC6A4	1-GoPubMed-related-gene->1815[DRD4], 1-GoPubMed-related-GO->GO:0019811[cocaine binding], 3-GoPubMed-related-disease->mesh:20270[Alcohol Withdrawal Seizures],mesh:19969[Amphetamine-Related Disorders],mesh:19970[Cocaine-Related Disorders], 4-FACTA-related-gene->HUMANGGP:004451[EIF2],HUMANGGP:031659[SLC6A2],HUMANGGP:024278[SYNJ1],HUMANGGP:032072[SLC6A3], 1-FACTA-related-disease->UMLS:C1851920[DRD], 6-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:APRD00679[ENT],DrugBank:APRD00530[Portal],DrugBank:APRD00280[Frontal],DrugBank:APRD00450[Norepinephrine],DrugBank:BIOD00057[Fragment],
SLC6A3	HTR1B	1-GoPubMed-related-gene->1816[DRD5], 1-GoPubMed-related-GO->GO:0005484[SNAP receptor activity], 1-FACTA-related-gene->HUMANGGP:031659[SLC6A2], 2-FACTA-related-disease->UMLS:C1851920[DRD],UMLS:C1263846[Attention Deficit Disorder with Hyperactivity], 6-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:BIOD00057[Fragment],DrugBank:APRD00530[Portal],DrugBank:BIOD00035[CSF],DrugBank:EXPT00494[Alanine],DrugBank:APRD00450[Norepinephrine],
SLC6A3	FOXG1	1-FACTA-related-drug->DrugBank:APRD00530[Portal],
SLC6A3	NLGN3	1-GoPubMed-related-disease->mesh:19970[Cocaine-Related Disorders], 1-FACTA-related-disease->UMLS:C0600427[cocaine addiction],
SLC6A3	EN2	3-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00450[Norepinephrine],DrugBank:APRD00631[Gel],
SLC6A3	CNTNAP2	1-FACTA-related-disease->UMLS:C1868675[PARK2], 2-FACTA-related-drug->DrugBank:APRD00729[Parkin],DrugBank:BIOD00057[Fragment],
SLC6A3	MAOA	1-FACTA-related-disease->UMLS:C1851920[DRD], 7-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:BIOD00057[Fragment],DrugBank:APRD00450[Norepinephrine],DrugBank:APRD00679[ENT],DrugBank:APRD00530[Portal],DrugBank:APRD00280[Frontal],DrugBank:BIOD00035[CSF],
SLC6A3	BAIAP2	1-FACTA-related-disease->UMLS:C1263846[Attention Deficit Disorder with Hyperactivity], 1-FACTA-related-drug->DrugBank:APRD00631[Gel],
SLC6A3	DRD3	2-GoPubMed-related-gene->1816[DRD5],1815[DRD4], 5-GoPubMed-related-GO->GO:0035240[dopamine binding],GO:0043178[alcohol binding],GO:0016890[site-specific endodeoxyribonuclease activity, specific for altered base],GO:0043848[excinuclease cho activity],GO:0005484[SNAP receptor activity], 2-FACTA-related-gene->HUMANGGP:004451[EIF2],HUMANGGP:024278[SYNJ1], 1-FACTA-related-disease->UMLS:C1851920[DRD], 8-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:APRD00729[Parkin],DrugBank:BIOD00057[Fragment],DrugBank:APRD00679[ENT],DrugBank:APRD00530[Portal],DrugBank:APRD00280[Frontal],DrugBank:APRD00450[Norepinephrine],DrugBank:APRD00631[Gel],
SLC6A3	LAMB1	1-FACTA-related-disease->UMLS:C0600427[cocaine addiction], 2-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00631[Gel],
SLC6A3	GRIN2B	3-GoPubMed-related-disease->mesh:20270[Alcohol Withdrawal Seizures],mesh:19969[Amphetamine-Related Disorders],mesh:430[Alcohol Withdrawal Delirium], 2-FACTA-related-gene->HUMANGGP:004111[DPYSL2],HUMANGGP:004451[EIF2], 2-FACTA-related-disease->UMLS:C1851920[DRD],UMLS:C1861537[OFC], 3-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:BIOD00057[Fragment],DrugBank:APRD00631[Gel],
SLC6A3	FOXP2	1-GoPubMed-related-disease->mesh:13342[Stuttering], 2-FACTA-related-drug->DrugBank:APRD00280[Frontal],DrugBank:BIOD00057[Fragment],
SLC6A3	OPRM1	3-GoPubMed-related-disease->mesh:6556[Heroin Dependence],mesh:20270[Alcohol Withdrawal Seizures],mesh:19969[Amphetamine-Related Disorders], 1-FACTA-related-disease->UMLS:C0600427[cocaine addiction], 3-FACTA-related-drug->DrugBank:EXPT00573[Aspartic Acid],DrugBank:BIOD00057[Fragment],DrugBank:EXPT00494[Alanine],
SLC6A3	IL1RAPL1	1-FACTA-related-disease->UMLS:C1868675[PARK2], 1-FACTA-related-drug->DrugBank:APRD00729[Parkin],
SLC6A3	PARK2	1-FACTA-related-gene->HUMANGGP:008036[FBXO7], 2-FACTA-related-disease->UMLS:C1868675[PARK2],UMLS:C1847640[KRS], 4-FACTA-related-drug->DrugBank:APRD00729[Parkin],DrugBank:BIOD00057[Fragment],DrugBank:APRD00450[Norepinephrine],DrugBank:APRD00631[Gel], 2-pathway->kegg:path:hsa05012[Parkinson's disease],nci_nature_pid:Alpha-synuclein_signaling[],
SLC6A3	MBD1	1-GoPubMed-related-GO->GO:0009008[DNA-methyltransferase activity], 2-FACTA-related-drug->DrugBank:APRD00530[Portal],DrugBank:APRD00631[Gel],
SLC6A3	HDAC4	2-FACTA-related-drug->DrugBank:APRD00729[Parkin],DrugBank:EXPT00573[Aspartic Acid],
SLC6A3	TPH2	2-GoPubMed-related-GO->GO:0004511[tyrosine 3-monooxygenase activity],GO:0005484[SNAP receptor activity], 3-GoPubMed-related-disease->mesh:14029[Tobacco Use Disorder],mesh:6556[Heroin Dependence],mesh:19970[Cocaine-Related Disorders], 1-FACTA-related-disease->UMLS:C1263846[Attention Deficit Disorder with Hyperactivity], 5-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:APRD00530[Portal],DrugBank:APRD00280[Frontal],DrugBank:APRD00450[Norepinephrine],DrugBank:BIOD00035[CSF],
SLC6A3	NPAS2	3-FACTA-related-drug->DrugBank:APRD00530[Portal],DrugBank:EXPT00494[Alanine],DrugBank:APRD00631[Gel],
SLC6A3	DISC1	5-FACTA-related-drug->DrugBank:APRD00280[Frontal],DrugBank:EXPT00573[Aspartic Acid],DrugBank:BIOD00057[Fragment],DrugBank:EXPT00494[Alanine],DrugBank:APRD00631[Gel],
SNAP29	SLC1A1	1-FACTA-related-disease->UMLS:C0004352[autism], 1-FACTA-related-drug->DrugBank:APRD00280[Frontal],
SNAP29	TDO2	3-FACTA-related-disease->UMLS:C0005586[Bipolar Disorder],UMLS:C0004352[autism],UMLS:C0036341[schizophrenia], 1-FACTA-related-drug->DrugBank:APRD00280[Frontal],
SNAP29	PLCD1	1-GoPubMed-related-GO->GO:0022406[membrane docking], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
SNAP29	CNTN4	1-FACTA-related-disease->UMLS:C0004352[autism], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
SNAP29	SEMA5A	3-GoPubMed-related-disease->mesh:7021[Hypospadias],mesh:10409[Penile Diseases],mesh:3456[Cryptorchidism], 1-FACTA-related-disease->UMLS:C0004352[autism], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
SNAP29	RIMS3	1-GoPubMed-related-GO->GO:0007269[neurotransmitter secretion], 2-FACTA-related-disease->UMLS:C0004352[autism],UMLS:C0036341[schizophrenia],
SNAP29	DRD3	1-GoPubMed-related-gene->8677[STX10], 1-GoPubMed-related-GO->GO:0005484[SNAP receptor activity], 2-GoPubMed-related-disease->mesh:14103[Torticollis],mesh:20821[Dystonic Disorders], 2-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00280[Frontal],
SNAP29	LRRC1	1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
SNAP29	FOXP2	2-FACTA-related-drug->DrugBank:APRD00280[Frontal],DrugBank:BIOD00057[Fragment],
SNAP29	NLGN4X	3-FACTA-related-disease->UMLS:C0004352[autism],UMLS:C0020758[ichthyosis],UMLS:C0020757[ichthyosis],
SNAP29	ATP2B2	1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
SNAP29	RELN	1-FACTA-related-disease->UMLS:C0497552[Nervous System Malformations], 1-FACTA-related-drug->DrugBank:APRD00280[Frontal],
SNAP29	MED12	1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
SNAP29	SHANK3	1-GoPubMed-related-disease->mesh:4062[DiGeorge Syndrome], 1-FACTA-related-gene->HUMANGGP:024970[PCDH9], 1-FACTA-related-disease->UMLS:C0004352[autism], 2-FACTA-related-drug->DrugBank:APRD00280[Frontal],DrugBank:BIOD00057[Fragment],
SNAP29	DISC1	2-FACTA-related-disease->UMLS:C0036341[schizophrenia],UMLS:C0005586[Bipolar Disorder], 2-FACTA-related-drug->DrugBank:APRD00280[Frontal],DrugBank:BIOD00057[Fragment],
SNAP29	GABRB1	2-FACTA-related-disease->UMLS:C0004352[autism],UMLS:C0005586[Bipolar Disorder], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
SNX27	GPR139	1-GoPubMed-related-GO->GO:0005488[binding],
SNX27	GRID2	1-GoPubMed-related-GO->GO:0005488[binding],
SNX27	RB1CC1	1-FACTA-related-drug->DrugBank:APRD00631[Gel],
SNX27	CDH8	1-GoPubMed-related-GO->GO:0005488[binding], 1-FACTA-related-disease->UMLS:C0027651[tumor],
SNX27	RBMS3	1-GoPubMed-related-GO->GO:0005488[binding], 1-FACTA-related-disease->UMLS:C0027651[tumor],
SNX27	LZTS2	5-GoPubMed-related-disease->mesh:11471[Prostatic Neoplasms],mesh:11469[Prostatic Diseases],mesh:5834[Genital Neoplasms, Male],mesh:14565[Urogenital Neoplasms],mesh:5832[Genital Diseases, Male], 1-FACTA-related-disease->UMLS:C1526991[Neoplasms],
SNX27	CDH10	8-GoPubMed-related-disease->mesh:11471[Prostatic Neoplasms],mesh:11469[Prostatic Diseases],mesh:5834[Genital Neoplasms, Male],mesh:14565[Urogenital Neoplasms],mesh:5832[Genital Diseases, Male],mesh:52801[Male Urogenital Diseases],mesh:52776[Female Urogenital Diseases],mesh:5261[Female Urogenital Diseases and Pregnancy Complications],
SNX27	NBEA	1-GoPubMed-related-GO->GO:0005488[binding],
SNX27	SEZ6L2	5-GoPubMed-related-disease->mesh:11471[Prostatic Neoplasms],mesh:11469[Prostatic Diseases],mesh:5834[Genital Neoplasms, Male],mesh:14565[Urogenital Neoplasms],mesh:5832[Genital Diseases, Male], 1-FACTA-related-disease->UMLS:C0027651[tumor],
SNX27	NLGN1	7-GoPubMed-related-GO->GO:0000394[RNA splicing, via endonucleolytic cleavage and ligation],GO:0000374[Group III intron splicing],GO:0000372[Group I intron splicing],GO:0000376[RNA splicing, via transesterification reactions with guanosine as nucleophile],GO:0000373[Group II intron splicing],GO:0000398[nuclear mRNA splicing, via spliceosome],GO:0005488[binding],
SNX27	BZRAP1	2-GoPubMed-related-GO->GO:0016197[endosome transport],GO:0005488[binding], 1-GoPubMed-related-disease->mesh:19966[Substance-Related Disorders],
SNX27	HNRNPH2	1-GoPubMed-related-GO->GO:0005488[binding], 7-GoPubMed-related-disease->mesh:11471[Prostatic Neoplasms],mesh:11469[Prostatic Diseases],mesh:5834[Genital Neoplasms, Male],mesh:14565[Urogenital Neoplasms],mesh:5832[Genital Diseases, Male],mesh:7280[Disorders of Environmental Origin],mesh:52801[Male Urogenital Diseases],
SNX27	TBC1D4	1-FACTA-related-disease->UMLS:C0027651[tumor], 1-FACTA-related-drug->DrugBank:APRD00631[Gel],
SNX27	NLGN4Y	1-GoPubMed-related-GO->GO:0005488[binding],
SNX27	SCFD2	1-GoPubMed-related-GO->GO:0005488[binding], 1-GoPubMed-related-disease->mesh:7280[Disorders of Environmental Origin], 1-FACTA-related-disease->UMLS:C0027651[tumor],
SNX27	MCPH1	1-FACTA-related-drug->DrugBank:APRD00631[Gel],
SNX27	ARHGAP15	1-GoPubMed-related-GO->GO:0005488[binding],
STK11	DISC1	5-FACTA-related-drug->DrugBank:APRD00280[Frontal],DrugBank:EXPT01467[Forskolin],DrugBank:EXPT02079[lysine],DrugBank:APRD00627[Progesterone],DrugBank:APRD00631[Gel],
STK11	MECP2	1-GoPubMed-related-gene->55663[ZNF446], 1-FACTA-related-gene->HUMANGGP:021056[zinc finger protein 446], 3-FACTA-related-drug->DrugBank:APRD00953[ETS],DrugBank:EXPT02079[lysine],DrugBank:APRD00280[Frontal],
STK11	MAPK3	1-GoPubMed-related-gene->55663[ZNF446], 1-FACTA-related-gene->HUMANGGP:021056[zinc finger protein 446], 3-FACTA-related-drug->DrugBank:APRD00627[Progesterone],DrugBank:EXPT01467[Forskolin],DrugBank:EXPT02079[lysine],
STK11	ESR1	1-GoPubMed-related-gene->55663[ZNF446], 1-FACTA-related-gene->HUMANGGP:021056[zinc finger protein 446], 2-FACTA-related-drug->DrugBank:APRD00953[ETS],DrugBank:APRD00627[Progesterone],
STK11	MEF2C	3-GoPubMed-related-GO->GO:0004683[calmodulin-dependent protein kinase activity],GO:0047322[[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase activity],GO:0050405[[acetyl-CoA carboxylase] kinase activity], 2-FACTA-related-drug->DrugBank:APRD00715[CTA],DrugBank:APRD00627[Progesterone],
STK11	RELN	1-GoPubMed-related-disease->mesh:6223[Hamartoma Syndrome, Multiple], 2-FACTA-related-drug->DrugBank:APRD00280[Frontal],DrugBank:APRD00631[Gel],
STK11	TNIP2	1-GoPubMed-related-gene->114790[STK11IP], 2-GoPubMed-related-disease->mesh:10580[Peutz-Jeghers Syndrome],mesh:7911[Lentigo],
STK11	HRAS	2-FACTA-related-drug->DrugBank:APRD00715[CTA],DrugBank:APRD00627[Progesterone],
STK11	FHIT	1-FACTA-related-gene->HUMANGGP:003800[LRPDIT], 1-FACTA-related-disease->UMLS:C1334455[Pulmonary Sclerosing Hemangioma],
STK11	PTEN	3-GoPubMed-related-disease->mesh:6223[Hamartoma Syndrome, Multiple],mesh:6222[Hamartoma],mesh:10580[Peutz-Jeghers Syndrome], 2-FACTA-related-disease->UMLS:C0265248[Ruvalcaba syndrome],UMLS:C0018553[Hamartoma Syndrome, Multiple],
STK11	ATRX	3-FACTA-related-drug->DrugBank:APRD00953[ETS],DrugBank:EXPT02079[lysine],DrugBank:APRD00631[Gel],
STK11	PIK3CG	1-GoPubMed-related-disease->mesh:6223[Hamartoma Syndrome, Multiple], 2-FACTA-related-gene->HUMANGGP:025566[PIK3CG],HUMANGGP:041811[RALB],
STK11	SLC1A1	2-FACTA-related-drug->DrugBank:APRD00280[Frontal],DrugBank:APRD00627[Progesterone],
STK11	MARK1	2-GoPubMed-related-gene->9024[BRSK2],57787[MARK4], 4-GoPubMed-related-GO->GO:0090162[establishment of epithelial cell polarity],GO:0047322[[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase activity],GO:0050405[[acetyl-CoA carboxylase] kinase activity],GO:0033868[Goodpasture-antigen-binding protein kinase activity], 2-GoPubMed-related-disease->mesh:10580[Peutz-Jeghers Syndrome],mesh:7911[Lentigo], 1-FACTA-related-disease->UMLS:C0031269[Peutz-Jeghers syndrome], 2-FACTA-related-drug->DrugBank:EXPT02079[lysine],DrugBank:APRD00631[Gel],
STK11	SYN1	1-GoPubMed-related-GO->GO:0004683[calmodulin-dependent protein kinase activity], 4-FACTA-related-drug->DrugBank:APRD00953[ETS],DrugBank:EXPT02079[lysine],DrugBank:APRD00080[Freeze],DrugBank:APRD00631[Gel],
STK11	FOXP2	1-FACTA-related-drug->DrugBank:APRD00280[Frontal],
TAF1C	BTAF1	1-GoPubMed-related-gene->129685[TAF8], 1-GoPubMed-related-GO->GO:0017025[TATA-binding protein binding], 1-FACTA-related-gene->HUMANGGP:010829[TFIID],
TAF1C	PLCD1	1-FACTA-related-disease->UMLS:C0027651[tumor], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
TAF1C	LRRC1	1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
TAF1C	FEZF2	2-FACTA-related-disease->UMLS:C0004352[autism],UMLS:C0027651[tumor],
TAF1C	ATP2B2	1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
TAF1C	NDNL2	2-GoPubMed-related-disease->mesh:7806[Language Disorders],mesh:3147[Communication Disorders], 1-FACTA-related-gene->HUMANGGP:024031[FISH], 1-FACTA-related-disease->UMLS:C0004352[autism],
TAF1C	MED12	1-GoPubMed-related-GO->GO:0006352[transcription initiation], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
TAF1C	CDH10	2-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0004352[autism],
TAF1C	RIMS3	2-FACTA-related-disease->UMLS:C0004352[autism],UMLS:C0027651[tumor],
TAF1C	NBEA	2-GoPubMed-related-disease->mesh:7806[Language Disorders],mesh:3147[Communication Disorders], 2-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0004352[autism],
TAF1C	BZRAP1	2-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0004352[autism],
TAF1C	REEP3	2-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0004352[autism],
TAF1C	CTNNA3	1-FACTA-related-gene->HUMANGGP:018678[MACROD2],
TAF1C	NRXN1	1-GoPubMed-related-disease->mesh:7806[Language Disorders], 1-FACTA-related-gene->HUMANGGP:018678[MACROD2], 2-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0004352[autism],
TAF1C	GABRB1	2-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0004352[autism], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
TAF1C	SCFD2	3-GoPubMed-related-GO->GO:0010843[promoter binding],GO:0044212[DNA regulatory region binding],GO:0043565[sequence-specific DNA binding], 1-FACTA-related-disease->UMLS:C0027651[tumor],
TBR1	TSPAN7	1-GoPubMed-related-disease->mesh:5600[Fragile X Syndrome], 1-FACTA-related-disease->UMLS:C1136249[Mental Retardation, X-Linked],
TBR1	EGR2	4-FACTA-related-drug->DrugBank:APRD00256[Valproic Acid],DrugBank:BIOD00001[DNase I],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
TBR1	PINX1	4-FACTA-related-drug->DrugBank:BIOD00001[DNase I],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:EXPT02079[lysine],
TBR1	NRXN1	4-GoPubMed-related-GO->GO:0004385[guanylate kinase activity],GO:0019201[nucleotide kinase activity],GO:0019205[nucleobase, nucleoside, nucleotide kinase activity],GO:0016776[phosphotransferase activity, phosphate group as acceptor], 1-GoPubMed-related-disease->mesh:5600[Fragile X Syndrome], 2-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0036857[severe mental retardation], 1-FACTA-related-drug->DrugBank:APRD00256[Valproic Acid],
TBR1	GNAS	5-FACTA-related-drug->DrugBank:APRD00134[Activin],DrugBank:BIOD00001[DNase I],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:EXPT02079[lysine],
TBR1	TPH2	1-GoPubMed-related-disease->mesh:6948[Hyperkinesis], 2-FACTA-related-drug->DrugBank:BIOD00035[CSF],DrugBank:APRD01142[Nitric Oxide],
TBR1	RELN	1-FACTA-related-gene->HUMANGGP:014919[RELN], 3-FACTA-related-disease->UMLS:C0233639[Autism],UMLS:C0497552[Nervous System Malformations],UMLS:C1136249[Mental Retardation, X-Linked], 4-FACTA-related-drug->DrugBank:APRD00256[Valproic Acid],DrugBank:BIOD00001[DNase I],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
TBR1	HOXB1	1-FACTA-related-disease->UMLS:C1533172[INS], 4-FACTA-related-drug->DrugBank:APRD00017[Tretinoin],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00256[Valproic Acid],DrugBank:EXPT02079[lysine],
TBR1	DLX2	1-GoPubMed-related-gene->1745[DLX1], 1-FACTA-related-gene->HUMANGGP:002694[T-brain-1], 3-FACTA-related-disease->UMLS:C1136249[Mental Retardation, X-Linked],UMLS:C0233639[Autism],UMLS:C0497552[Nervous System Malformations], 4-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:BIOD00001[DNase I],DrugBank:APRD00017[Tretinoin],DrugBank:EXPT02079[lysine],
TBR1	ALDH5A1	1-GoPubMed-related-disease->mesh:6948[Hyperkinesis], 1-FACTA-related-drug->DrugBank:BIOD00035[CSF],
TBR1	TBX1	2-GoPubMed-related-gene->6913[TBX15],9096[TBX18], 3-GoPubMed-related-GO->GO:0048341[paraxial mesoderm formation],GO:0048340[paraxial mesoderm morphogenesis],GO:0048339[paraxial mesoderm development], 5-FACTA-related-gene->HUMANGGP:028643[TBX15],HUMANGGP:023660[TBX19],HUMANGGP:033879[TBX18],HUMANGGP:041357[TBX6],HUMANGGP:006197[eomesodermin], 1-FACTA-related-disease->UMLS:C0265264[HOS], 3-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:EXPT02079[lysine],
TBR1	DLX6	1-GoPubMed-related-gene->1745[DLX1], 2-FACTA-related-disease->UMLS:C0497552[Nervous System Malformations],UMLS:C0036857[severe mental retardation], 2-FACTA-related-drug->DrugBank:BIOD00001[DNase I],DrugBank:APRD00140[Tretinoin],
TBR1	MBD4	1-FACTA-related-disease->UMLS:C0270549[GAD], 1-FACTA-related-drug->DrugBank:EXPT02079[lysine],
TBR1	DLX1	1-FACTA-related-gene->HUMANGGP:002694[T-brain-1], 1-FACTA-related-disease->UMLS:C0497552[Nervous System Malformations], 3-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:BIOD00001[DNase I],DrugBank:APRD00017[Tretinoin],
TBR1	PITX1	1-GoPubMed-related-gene->9096[TBX18], 4-FACTA-related-drug->DrugBank:APRD00134[Activin],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:EXPT02079[lysine],
TBR1	SCN2A	5-FACTA-related-drug->DrugBank:EXPT02079[lysine],DrugBank:APRD00256[Valproic Acid],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],DrugBank:APRD01142[Nitric Oxide],
TFAP2B	HTR3A	1-FACTA-related-disease->UMLS:C0233523[antisocial behavior], 1-FACTA-related-drug->DrugBank:APRD01072[HCH],
TFAP2B	MARK1	2-GoPubMed-related-disease->mesh:17545[Aortic Aneurysm, Thoracic],mesh:784[Aneurysm, Dissecting],
TFAP2B	JMJD1C	1-FACTA-related-drug->DrugBank:EXPT00494[Alanine],
TFAP2B	SLC9A9	1-FACTA-related-drug->DrugBank:APRD01072[HCH],
TFAP2B	RBFOX1	1-GoPubMed-related-disease->mesh:20447[Parasomnias],
TFAP2B	HTR1B	3-GoPubMed-related-GO->GO:0042749[regulation of circadian sleep/wake cycle],GO:0022410[circadian sleep/wake cycle process],GO:0045187[regulation of circadian sleep/wake cycle, sleep], 1-FACTA-related-disease->UMLS:C0233523[antisocial behavior], 2-FACTA-related-drug->DrugBank:APRD01072[HCH],DrugBank:EXPT00494[Alanine],
TFAP2B	GPC6	1-FACTA-related-disease->UMLS:C0524801[Retinal Neoplasms], 1-FACTA-related-drug->DrugBank:EXPT00573[Aspartic Acid],
TFAP2B	CNTNAP2	1-GoPubMed-related-disease->mesh:20447[Parasomnias], 3-FACTA-related-gene->HUMANGGP:000896[SLC35E2],HUMANGGP:026473[FUSIP1],HUMANGGP:040978[POU4F2],
TFAP2B	REEP3	1-FACTA-related-drug->DrugBank:EXPT00494[Alanine],
TFAP2B	CHRNA7	2-GoPubMed-related-GO->GO:0016641[oxidoreductase activity, acting on the CH-NH2 group of donors, oxygen as acceptor],GO:0016638[oxidoreductase activity, acting on the CH-NH2 group of donors], 1-GoPubMed-related-disease->mesh:20190[Myoclonic Epilepsy, Juvenile], 1-FACTA-related-disease->UMLS:C0270853[juvenile myoclonic epilepsy], 1-FACTA-related-drug->DrugBank:APRD01072[HCH],
TFAP2B	MYO1A	1-FACTA-related-drug->DrugBank:EXPT00573[Aspartic Acid],
TFAP2B	GRIN2B	1-FACTA-related-drug->DrugBank:APRD01072[HCH],
TFAP2B	OXTR	1-FACTA-related-drug->DrugBank:APRD01072[HCH],
TFAP2B	SLC6A4	1-FACTA-related-disease->UMLS:C0233523[antisocial behavior], 1-FACTA-related-drug->DrugBank:APRD01072[HCH],
TFAP2B	LRRC1	7-GoPubMed-related-gene->28978[TMEM14A],26268[FBXO9],26036[ZNF451],9697[TRAM2],85315[PAQR8],9589[WTAP],60481[ELOVL5], 1-GoPubMed-related-disease->mesh:20190[Myoclonic Epilepsy, Juvenile], 5-FACTA-related-gene->HUMANGGP:008674[LRRC1],HUMANGGP:000191[KIAA0936],HUMANGGP:027126[KIAA0576],HUMANGGP:042069[LMPB1],HUMANGGP:023029[KIAA0105], 3-FACTA-related-disease->UMLS:C1850778[EJM1],UMLS:C0270853[juvenile myoclonic epilepsy],UMLS:C0085548[Polycystic Kidney, Autosomal Recessive],
TFAP2B	CACNA1G	1-GoPubMed-related-disease->mesh:20190[Myoclonic Epilepsy, Juvenile], 1-FACTA-related-gene->HUMANGGP:018557[KCNA2], 2-FACTA-related-disease->UMLS:C0270853[juvenile myoclonic epilepsy],UMLS:C0524801[Retinal Neoplasms],
TNNI3	NOS1AP	2-GoPubMed-related-GO->GO:0004111[creatine kinase activity],GO:0016775[phosphotransferase activity, nitrogenous group as acceptor], 2-FACTA-related-disease->UMLS:C0037293[Tag],UMLS:C0340279[ventricular hypertrophy], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
TNNI3	PLCD1	1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
TNNI3	LRRC1	1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
TNNI3	FOXG1	1-GoPubMed-related-disease->mesh:6335[Heart Injuries], 1-FACTA-related-drug->DrugBank:APRD00627[Progesterone],
TNNI3	FGD1	1-FACTA-related-drug->DrugBank:APRD00627[Progesterone],
TNNI3	CACNA1C	2-GoPubMed-related-GO->GO:0060047[heart contraction],GO:0003015[heart process], 1-FACTA-related-drug->DrugBank:APRD00627[Progesterone], 3-pathway->kegg:path:hsa05410[Hypertrophic cardiomyopathy (HCM)],kegg:path:hsa05414[Dilated cardiomyopathy],kegg:path:hsa04260[Cardiac muscle contraction],
TNNI3	ITGB3	2-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00627[Progesterone], 2-pathway->kegg:path:hsa05410[Hypertrophic cardiomyopathy (HCM)],kegg:path:hsa05414[Dilated cardiomyopathy],
TNNI3	ATP2B2	1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
TNNI3	MED12	1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
TNNI3	AGTR2	1-GoPubMed-related-disease->mesh:2313[Cardiomyopathy, Restrictive], 1-FACTA-related-disease->UMLS:C0277558[familial disorder], 2-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00627[Progesterone],
TNNI3	MAOA	1-GoPubMed-related-disease->mesh:6557[Herpangina], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
TNNI3	CACNA1D	2-GoPubMed-related-GO->GO:0060047[heart contraction],GO:0003015[heart process], 3-pathway->kegg:path:hsa05410[Hypertrophic cardiomyopathy (HCM)],kegg:path:hsa05414[Dilated cardiomyopathy],kegg:path:hsa04260[Cardiac muscle contraction],
TNNI3	SLC9A6	1-pathway->kegg:path:hsa04260[Cardiac muscle contraction],
TNNI3	CACNA1F	3-pathway->kegg:path:hsa05410[Hypertrophic cardiomyopathy (HCM)],kegg:path:hsa05414[Dilated cardiomyopathy],kegg:path:hsa04260[Cardiac muscle contraction],
TNNI3	GPX1	1-GoPubMed-related-disease->mesh:14912[White Muscle Disease],
TNNI3	ITGB7	2-pathway->kegg:path:hsa05410[Hypertrophic cardiomyopathy (HCM)],kegg:path:hsa05414[Dilated cardiomyopathy],
TNNI3	PLN	5-GoPubMed-related-GO->GO:0055119[relaxation of cardiac muscle],GO:0055118[negative regulation of cardiac muscle contraction],GO:0045988[negative regulation of striated muscle contraction],GO:0060048[cardiac muscle contraction],GO:0006941[striated muscle contraction], 1-GoPubMed-related-disease->mesh:24741[Cardiomyopathy, Hypertrophic, Familial], 1-FACTA-related-gene->HUMANGGP:033470[biphenyl hydrolase-like], 1-FACTA-related-disease->UMLS:C0949658[Cardiomyopathy, Hypertrophic, Familial],
TNNI3	DMD	1-FACTA-related-drug->DrugBank:BIOD00057[Fragment], 2-pathway->kegg:path:hsa05410[Hypertrophic cardiomyopathy (HCM)],kegg:path:hsa05414[Dilated cardiomyopathy],
UNC13D	NBEA	1-GoPubMed-related-disease->mesh:2609[Chediak-Higashi Syndrome], 1-FACTA-related-disease->UMLS:C0007965[Chediak-Higashi syndrome],
UNC13D	NLGN4X	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
UNC13D	CADM1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
UNC13D	SH3KBP1	2-GoPubMed-related-gene->9050[PSTPIP2],26469[PTPN18], 1-GoPubMed-related-GO->GO:0047221[sn-glycerol-3-phosphate 2-alpha-galactosyltransferase activity], 1-GoPubMed-related-disease->mesh:7946[Leukemia, Mast-Cell],
UNC13D	NPAS2	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
UNC13D	DHCR7	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
UNC13D	NSD1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
UNC13D	CREBBP	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
UNC13D	SYN1	1-GoPubMed-related-GO->GO:0005484[SNAP receptor activity], 1-GoPubMed-related-disease->mesh:4673[Encephalomyelitis, Acute Disseminated],
UNC13D	NTRK1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
UNC13D	PINX1	1-FACTA-related-drug->DrugBank:APRD00649[Etoposide],
UNC13D	CNTNAP2	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
UNC13D	CA6	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
UNC13D	SEMA5A	1-FACTA-related-drug->DrugBank:APRD00649[Etoposide],
UNC13D	AHI1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
UNC13D	CHD7	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
USH2A	CHD7	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
USH2A	PLCD1	1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
USH2A	LRRC1	1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
USH2A	NTRK1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
USH2A	SHANK3	1-GoPubMed-related-GO->GO:0031386[protein tag], 3-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
USH2A	ATP2B2	1-GoPubMed-related-disease->mesh:34381[Hearing Loss], 1-FACTA-related-gene->HUMANGGP:022262[CDH23], 1-FACTA-related-disease->UMLS:C0271097[Usher syndrome], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
USH2A	CNTNAP2	1-GoPubMed-related-gene->51133[KCTD3], 1-FACTA-related-gene->HUMANGGP:009063[KCTD3], 1-FACTA-related-disease->UMLS:C1848634[USH2A], 3-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
USH2A	MED12	1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
USH2A	CREBBP	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
USH2A	CACNA1D	1-FACTA-related-disease->UMLS:C0271097[Usher syndrome],
USH2A	NPAS2	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
USH2A	AHI1	1-GoPubMed-related-GO->GO:0042384[cilium assembly], 1-GoPubMed-related-disease->mesh:16751[Hepatitis E], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
USH2A	NSD1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
USH2A	CADM1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
USH2A	CA6	1-GoPubMed-related-GO->GO:0000224[peptide-N4-(N-acetyl-beta-glucosaminyl)asparagine amidase activity], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
USH2A	DHCR7	3-FACTA-related-drug->DrugBank:BIOD00057[Fragment],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
USH2A	NLGN4X	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
USH2A	GABRB1	1-GoPubMed-related-GO->GO:0043495[protein anchor], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
USP33	AHI1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
USP33	CACNA1G	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
USP33	CADM1	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
USP33	CA6	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
USP33	DHCR7	3-FACTA-related-drug->DrugBank:APRD00627[Progesterone],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
USP33	AFF4	4-GoPubMed-related-disease->mesh:2051[Burkitt Lymphoma],mesh:16402[Lymphoma, Small Noncleaved-Cell],mesh:16395[Lymphoma, High-Grade],mesh:8226[Lymphoma, Small-Cell], 1-FACTA-related-disease->UMLS:C0023418[leukemia],
USP33	NLGN4X	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
USP33	CHD7	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
USP33	FGD1	1-FACTA-related-drug->DrugBank:APRD00627[Progesterone],
USP33	NTRK1	3-FACTA-related-drug->DrugBank:APRD00627[Progesterone],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
USP33	TSPAN7	4-FACTA-related-disease->UMLS:C0023493[T-cell acute lymphoblastic leukemia],UMLS:C0023435[B-ALL],UMLS:C0023449[acute lymphoblastic leukemia],UMLS:C0024299[lymphoma],
USP33	SHANK3	2-GoPubMed-related-GO->GO:0048532[anatomical structure arrangement],GO:0031386[protein tag], 3-FACTA-related-drug->DrugBank:APRD00627[Progesterone],DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
USP33	ATP2B2	2-GoPubMed-related-disease->mesh:6623[Hippel-Lindau Disease],mesh:798[Angiomatosis],
USP33	CNTNAP2	1-GoPubMed-related-GO->GO:0048532[anatomical structure arrangement], 2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
USP33	CREBBP	3-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00627[Progesterone],
USP33	STK39	4-FACTA-related-disease->UMLS:C0376358[prostate cancer],UMLS:C0033578[Prostatic Neoplasms],UMLS:C0024299[lymphoma],UMLS:C0006142[breast cancer], 1-FACTA-related-drug->DrugBank:APRD00627[Progesterone],
USP33	NPAS2	2-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],
USP33	HOXB1	3-FACTA-related-drug->DrugBank:APRD00506[Spectrum],DrugBank:APRD00552[Spectrum],DrugBank:APRD00627[Progesterone],
VBP1	PLCD1	1-FACTA-related-disease->UMLS:C0596263[carcinogenesis], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
VBP1	NLGN4Y	2-GoPubMed-related-GO->GO:0005515[protein binding],GO:0005488[binding],
VBP1	DHCR7	3-FACTA-related-drug->DrugBank:BIOD00052[p75],DrugBank:BIOD00057[Fragment],DrugBank:APRD00627[Progesterone],
VBP1	MED12	1-GoPubMed-related-disease->mesh:7446[Inversion, Chromosome], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
VBP1	ARHGAP15	2-GoPubMed-related-GO->GO:0005515[protein binding],GO:0005488[binding], 1-FACTA-related-disease->UMLS:C0596263[carcinogenesis],
VBP1	PCDH10	1-FACTA-related-drug->DrugBank:BIOD00052[p75],
VBP1	NXPH1	2-GoPubMed-related-disease->mesh:10673[Pheochromocytoma],mesh:10235[Paraganglioma],
VBP1	DISC1	3-FACTA-related-drug->DrugBank:BIOD00052[p75],DrugBank:BIOD00057[Fragment],DrugBank:APRD00627[Progesterone],
VBP1	LZTS2	3-FACTA-related-disease->UMLS:C0019562[Hippel],UMLS:C1326912[tumorigenesis],UMLS:C0596263[carcinogenesis],
VBP1	ATP2B2	2-GoPubMed-related-disease->mesh:6623[Hippel-Lindau Disease],mesh:798[Angiomatosis], 1-FACTA-related-disease->UMLS:C0019562[Hippel], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
VBP1	NBEA	2-GoPubMed-related-GO->GO:0005515[protein binding],GO:0005488[binding],
VBP1	SLC6A8	1-FACTA-related-gene->HUMANGGP:020388[TM4SF2], 1-FACTA-related-disease->UMLS:C0021171[incontinentia pigmenti],
VBP1	NTRK1	2-FACTA-related-drug->DrugBank:BIOD00052[p75],DrugBank:APRD00627[Progesterone],
VBP1	LRRC1	1-GoPubMed-related-GO->GO:0005488[binding], 1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
VBP1	NLGN1	2-GoPubMed-related-GO->GO:0005515[protein binding],GO:0005488[binding],
VBP1	FGD1	1-FACTA-related-gene->HUMANGGP:020388[TM4SF2], 1-FACTA-related-disease->UMLS:C0334044[dysplasia], 1-FACTA-related-drug->DrugBank:APRD00627[Progesterone],
VBP1	GABRB1	1-FACTA-related-drug->DrugBank:BIOD00057[Fragment],
VBP1	GPR139	2-GoPubMed-related-GO->GO:0005515[protein binding],GO:0005488[binding],
WNK1	NSD1	3-FACTA-related-drug->DrugBank:APRD00162[MRC],DrugBank:EXPT02079[lysine],DrugBank:APRD00326[Factor II],
WNK1	CNTNAP2	1-FACTA-related-drug->DrugBank:APRD00162[MRC],
WNK1	EIF4E	1-GoPubMed-related-disease->mesh:18188[Cardiovirus Infections], 2-FACTA-related-drug->DrugBank:BIOD00067[Pancrelipase],DrugBank:APRD00627[Progesterone],
WNK1	MARK1	3-FACTA-related-drug->DrugBank:APRD01322[Potassium Chloride],DrugBank:EXPT02079[lysine],DrugBank:APRD00631[Gel],
WNK1	NTRK1	1-GoPubMed-related-disease->mesh:9477[Hereditary Sensory and Autonomic Neuropathies], 1-FACTA-related-gene->HUMANGGP:017733[HSN2], 4-FACTA-related-disease->UMLS:C0003028[anhidrosis],UMLS:C0027889[Hereditary Sensory and Autonomic Neuropathies],UMLS:C0751540[Morvan],UMLS:C0699739[hereditary sensory neuropathy], 4-FACTA-related-drug->DrugBank:BIOD00052[p75],DrugBank:APRD00627[Progesterone],DrugBank:EXPT02079[lysine],DrugBank:APRD00631[Gel],
WNK1	ATRX	3-FACTA-related-drug->DrugBank:APRD00326[Factor II],DrugBank:EXPT02079[lysine],DrugBank:APRD00631[Gel],
WNK1	WNK3	3-GoPubMed-related-gene->65268[WNK2],65266[WNK4],9943[OXSR1], 4-GoPubMed-related-disease->mesh:11546[Pseudohypoaldosteronism],mesh:6947[Hyperkalemia],mesh:15499[Renal Tubular Transport, Inborn Errors],mesh:309[Adrenal Insufficiency], 7-FACTA-related-gene->HUMANGGP:030701[WNK3],HUMANGGP:001528[WNK2],HUMANGGP:015638[WNK4],HUMANGGP:017734[WNK1],HUMANGGP:012410[SPAK],HUMANGGP:009786[OSR1],HUMANGGP:009226[SPS1], 3-FACTA-related-disease->UMLS:C0033805[Pseudohypoaldosteronism],UMLS:C0598428[genetic hypertension],UMLS:C0004775[Bartter's syndrome], 4-FACTA-related-drug->DrugBank:EXPT02079[lysine],DrugBank:APRD01322[Potassium Chloride],DrugBank:APRD00627[Progesterone],DrugBank:APRD00631[Gel],
WNK1	STK39	3-GoPubMed-related-gene->9943[OXSR1],65266[WNK4],65267[WNK3], 4-GoPubMed-related-disease->mesh:11546[Pseudohypoaldosteronism],mesh:6947[Hyperkalemia],mesh:15499[Renal Tubular Transport, Inborn Errors],mesh:309[Adrenal Insufficiency], 1-FACTA-related-gene->HUMANGGP:012410[SPAK], 1-FACTA-related-drug->DrugBank:APRD00627[Progesterone],
WNK1	DLX2	1-GoPubMed-related-GO->GO:0004704[NF-kappaB-inducing kinase activity], 3-FACTA-related-drug->DrugBank:BIOD00052[p75],DrugBank:EXPT02079[lysine],DrugBank:APRD00631[Gel],
WNK1	ADRB2	2-FACTA-related-gene->HUMANGGP:039243[ADRA1B],HUMANGGP:016527[SLC8A1], 1-FACTA-related-drug->DrugBank:BIOD00067[Pancrelipase],
WNK1	MECP2	1-GoPubMed-related-gene->55663[ZNF446], 1-FACTA-related-gene->HUMANGGP:021056[zinc finger protein 446], 3-FACTA-related-drug->DrugBank:EXPT02079[lysine],DrugBank:APRD00326[Factor II],DrugBank:APRD01322[Potassium Chloride],
WNK1	ESR1	1-GoPubMed-related-gene->55663[ZNF446], 1-FACTA-related-gene->HUMANGGP:021056[zinc finger protein 446], 1-FACTA-related-drug->DrugBank:APRD00627[Progesterone],
WNK1	CA6	2-FACTA-related-drug->DrugBank:APRD00162[MRC],DrugBank:APRD00631[Gel],
WNK1	GRIP1	1-GoPubMed-related-disease->mesh:6947[Hyperkalemia],
WNK1	DISC1	5-FACTA-related-drug->DrugBank:BIOD00052[p75],DrugBank:EXPT02079[lysine],DrugBank:EXPT00494[Alanine],DrugBank:APRD00627[Progesterone],DrugBank:APRD00631[Gel],
WNK1	FOXG1	3-FACTA-related-drug->DrugBank:APRD00162[MRC],DrugBank:EXPT02079[lysine],DrugBank:APRD00627[Progesterone],
ZIC1	RAI1	2-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
ZIC1	NLGN1	1-FACTA-related-drug->DrugBank:APRD00256[Valproic Acid],
ZIC1	RELN	1-GoPubMed-related-disease->mesh:16142[Holoprosencephaly], 2-FACTA-related-disease->UMLS:C0266463[lissencephaly],UMLS:C0497552[Nervous System Malformations], 3-FACTA-related-drug->DrugBank:APRD00256[Valproic Acid],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
ZIC1	MEF2C	1-GoPubMed-related-gene->6474[SHOX2], 3-FACTA-related-drug->DrugBank:APRD00017[Tretinoin],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00256[Valproic Acid],
ZIC1	HOXB1	1-FACTA-related-disease->UMLS:C1863793[SCP], 3-FACTA-related-drug->DrugBank:APRD00017[Tretinoin],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00256[Valproic Acid],
ZIC1	DLX2	1-GoPubMed-related-GO->GO:0030900[forebrain development], 2-FACTA-related-disease->UMLS:C0266463[lissencephaly],UMLS:C0497552[Nervous System Malformations], 2-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
ZIC1	NLGN3	1-FACTA-related-drug->DrugBank:APRD00256[Valproic Acid],
ZIC1	DHCR7	2-GoPubMed-related-disease->mesh:16142[Holoprosencephaly],mesh:3616[Dandy-Walker Syndrome],
ZIC1	EN2	1-GoPubMed-related-gene->85416[ZIC5], 1-GoPubMed-related-disease->mesh:16142[Holoprosencephaly], 1-FACTA-related-gene->HUMANGGP:028228[SFMBT2], 5-FACTA-related-disease->UMLS:C0220603[pediatric brain tumor],UMLS:C0431399[Joubert syndrome],UMLS:C1861732[ACV],UMLS:C0497552[Nervous System Malformations],UMLS:C0026106[mild mental retardation], 2-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
ZIC1	NRXN2	1-FACTA-related-drug->DrugBank:APRD00256[Valproic Acid],
ZIC1	DLX1	1-FACTA-related-disease->UMLS:C0497552[Nervous System Malformations], 2-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
ZIC1	SCN2A	3-FACTA-related-drug->DrugBank:APRD00256[Valproic Acid],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
ZIC1	FABP7	2-GoPubMed-related-disease->mesh:20362[Paraneoplastic Cerebellar Degeneration],mesh:20361[Paraneoplastic Syndromes, Nervous System],
ZIC1	DCTN5	2-GoPubMed-related-disease->mesh:3616[Dandy-Walker Syndrome],mesh:16135[Spinal Dysraphism],
ZIC1	TBX1	2-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
ZIC1	EGR2	3-FACTA-related-drug->DrugBank:APRD00256[Valproic Acid],DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],
ZIC1	RFWD2	2-GoPubMed-related-disease->mesh:22861[Hermanski-Pudlak Syndrome],mesh:10981[Platelet Storage Pool Deficiency],
ZIC1	NFIA	1-FACTA-related-disease->UMLS:C0497552[Nervous System Malformations], 2-FACTA-related-drug->DrugBank:APRD00140[Tretinoin],DrugBank:APRD00017[Tretinoin],